Any feedback?
Information on EC 3.1.1.4 - phospholipase A2
for references in articles please use BRENDA:EC3.1.1.4Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
3.1.1.4 phospholipase A2IUBMB Comments
Also acts on phosphatidylethanolamine, choline plasmalogen and phosphatides, removing the fatty acid attached to the 2-position. Requires Ca2+.
Specify your search results
Word Map
- 3.1.1.4
-
arachidonic
- phospholipid
- prostaglandin
-
cyclooxygenase
-
eicosanoids
-
leukotriene
- necrosis
- indomethacin
- agonist
- lysophosphatidylcholine
- endothelial
- neutrophil
- bromide
- phosphatidylethanolamine
- crotalus
- lipoxygenase
- cox-2
-
phorbol
-
ionophore
- pkc
- inositol
- artery
-
neurotoxic
- quinacrine
-
thromboxane
- peroxiredoxins
-
platelet-activating
- diacylglycerols
- nephropathy
- lysophospholipids
-
bilayer
- phosphatidylinositol
-
prelabeled
- edema
-
prostanoids
- phosphatidylserine
- pertussis
-
interfacial
-
phosphatidic
-
envenom
- glycerophospholipids
-
nordihydroguaiaretic
-
presynaptic
- synovial
- prostacyclin
- viper
-
micelle
- pharmacology
- analysis
- food industry
- biotechnology
-
lipoprotein-associated
- ndga
- industry
- drug development
- zymosan
- medicine
- synthesis
The enzyme appears in viruses and cellular organisms
Synonyms
phospholipase a2, cpla2, spla2, spla(2), prdx6, cytosolic phospholipase a2, crotoxin, pla2s, ipla2, spla2-iia, 
more
topPlease wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYNONYM 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
14 kDa phospholipase A2
-
-
-
-
Agkistrotoxin
-
-
-
-
amdI1
-
-
-
-
Ammodytin I2
-
-
-
-
APLA
-
-
-
-
APP-D-49
-
-
-
-
ASPLA1
-
-
-
-
ASPLA10
-
-
-
-
ASPLA11
-
-
-
-
ASPLA12
-
-
-
-
ASPLA13
-
-
-
-
ASPLA14
-
-
-
-
ASPLA15
-
-
-
-
ASPLA16
-
-
-
-
ASPLA17
-
-
-
-
ASPLA2
-
-
-
-
ASPLA3
-
-
-
-
ASPLA4
-
-
-
-
ASPLA5
-
-
-
-
ASPLA6
-
-
-
-
ASPLA7
-
-
-
-
ASPLA8
-
-
-
-
ASPLA9
-
-
-
-
ATX
-
-
-
-
Basic protein I/II
-
-
-
-
BJ-PLA2
-
-
-
-
BJUPLA2
-
-
-
-
BPI/BPII
-
-
-
-
CaI-PLA2
-
-
-
-
Caudoxin
-
-
-
-
cPm09
-
-
-
-
Enhancing factor
-
-
-
-
GIIC sPLA2
-
-
-
-
GIID sPLA2
-
-
-
-
GIIE sPLA2
-
-
-
-
GIIF sPLA2
-
-
-
-
GIII sPLA2
-
-
-
-
Group IB phospholipase A2
-
-
-
-
Group IIA phospholipase A2
-
-
-
-
Group V phospholipase A2
-
-
-
-
Group VI phospholipase A2
-
-
-
-
GVI PLA2
-
-
-
-
GX sPLA2
-
-
-
-
GXII sPLA2
-
-
-
-
GXIII sPLA2
-
-
-
-
iPLA2
-
-
-
-
lecithinase A
-
-
-
-
MP-III 4R
-
-
-
-
Muscarinic inhibitor
-
-
-
-
Myotoxin
-
-
-
-
NAJPLA-2A
-
-
-
-
NAJPLA-2B
-
-
-
-
NAJPLA-2C
-
-
-
-
Nigexine
-
-
-
-
Non-pancreatic secretory phospholipase A2
-
-
-
-
Notechis 11'2
-
-
-
-
Notexin
-
-
-
-
NPLA
-
-
-
-
NPS-PLA2
-
-
-
-
OHV A-PLA2
-
-
-
-
OHV-APLA2
-
-
-
-
pgPLA 1a/pgPLA 2a
-
-
-
-
phosphatidase
-
-
-
-
phosphatide 2-acylhydrolase
-
-
-
-
phosphatidolipase
-
-
-
-
Phosphatidylcholine 2-acylhydrolase
-
-
-
-
Phosphatidylcholine 2-acylhydrolase GIIC
-
-
-
-
Phosphatidylcholine 2-acylhydrolase GIID
-
-
-
-
Phosphatidylcholine 2-acylhydrolase GIIE
-
-
-
-
Phosphatidylcholine 2-acylhydrolase GIIF
-
-
-
-
Phosphatidylcholine 2-acylhydrolase GIII
-
-
-
-
Phosphatidylcholine 2-acylhydrolase GX
-
-
-
-
Phosphatidylcholine 2-acylhydrolase GXII
-
-
-
-
Phosphatidylcholine 2-acylhydrolase GXIII
-
-
-
-
phospholipase A
-
-
-
-
Phospholipase A2 inhibitor
-
-
-
-
pkP5
-
-
-
-
PLA2-10
-
-
-
-
PLA2-VI
-
-
-
-
PLA2-VII
-
-
-
-
PLA2IID
-
-
-
-
platelet activating factor acetyl hydrolase
-
-
-
-
Pt-PLA1
-
-
-
-
Pt-PLA2
-
-
-
-
Secretory-type PLA, stroma-associated homolog
-
-
-
-
sPLA(2)-IID
-
-
-
-
sPLA(2)-IIE
-
-
-
-
sPLA(2)-IIF
-
-
-
-
TMV-K49
-
-
-
-
Toxin VI
-
-
-
-
Toxin VI:5
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
hydrolysis of carboxylic ester
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PATHWAY SOURCE
PATHWAYS
BRENDA
KEGG
-
-, -, -, -, -, -, -, -, -, -, -, -, -, -, -, -, -, -, -, -
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYSTEMATIC NAME
IUBMB Comments
phosphatidylcholine 2-acylhydrolase
Also acts on phosphatidylethanolamine, choline plasmalogen and phosphatides, removing the fatty acid attached to the 2-position. Requires Ca2+.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CAS REGISTRY NUMBER
COMMENTARY
9001-84-7
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Ca2+
activity increases from 0.2 mM up to 1.0 mM Ca2+. The structure of the calcium-bound domain is distinct from that without the ion
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Aberrant Crypt Foci
Effects of green tea and high-fat diet on arachidonic acid metabolism and aberrant crypt foci formation in an azoxymethane-induced colon carcinogenesis mouse model.
Aberrant Crypt Foci
The chemopreventive role of ursodeoxycholic acid in azoxymethane-treated rats: suppressive effects on enhanced group II phospholipase A2 expression in colonic tissue.
Abscess
[Research progress in the application of necrotic cavity lavage in the treatment of infected pancreatic necrosis].
Acalculous Cholecystitis
Experimental study on the pathogenesis of acute acalculous cholecystitis, with special reference to the roles of microcirculatory disturbances, free radicals and membrane-bound phospholipase A2.
Acidosis
Extracellular presence of IL-8 in the astrocyte-rich cultured cerebellar granule cells under acidosis.
Acidosis
Renal peroxiredoxin 6 interacts with anion exchanger 1 and plays a novel role in pH homeostasis.
Acidosis, Lactic
Progress in understanding the pathophysiology of cerebral ischemia: the almitrine-raubasine approach.
Acne Vulgaris
Decreased eicosapentaenoic acid levels in acne vulgaris reveals the presence of a proinflammatory state.
Acquired Immunodeficiency Syndrome
Exploration of associations between phospholipase A2 gene family polymorphisms and AIDS progression using the SNPlex method.
Acquired Immunodeficiency Syndrome
The crystal structure, mutagenesis, and activity studies reveal that patatin is a lipid acyl hydrolase with a Ser-Asp catalytic dyad.
Acquired Immunodeficiency Syndrome
The diversity of bioactive proteins in Australian snake venoms.
Acute Chest Syndrome
A two-event in vitro model of acute chest syndrome: The role of secretory phospholipase A(2) and neutrophils.
Acute Chest Syndrome
Phospholipase A2 levels in acute chest syndrome of sickle cell disease.
Acute Chest Syndrome
Refining the value of secretory phospholipase A2 as a predictor of acute chest syndrome in sickle cell disease: results of a feasibility study (PROACTIVE).
Acute Chest Syndrome
Secretory phospholipase A(2) predicts impending acute chest syndrome in sickle cell disease.
Acute Chest Syndrome
Secretory phospholipase A2 levels in patients with sickle cell disease and acute chest syndrome.
Acute Chest Syndrome
Serum C-reactive protein parallels secretory phospholipase A2 in sickle cell disease patients with vasoocclusive crisis or acute chest syndrome.
Acute Chest Syndrome
Transfusion prevents acute chest syndrome predicted by elevated secretory phospholipase A2.
Acute Coronary Syndrome
Acute coronary syndromes: targeting inflammation-what has the VISTA-16 trial taught us?
Acute Coronary Syndrome
After FRANCIS: next steps in the clinical evaluation of varespladib methyl.
Acute Coronary Syndrome
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Acute Coronary Syndrome
Anti-inflammatory effects of varespladib methyl in diabetic patients with acute coronary syndrome.
Acute Coronary Syndrome
Biomarkers and Bioassays for Cardiovascular Diseases: Present and Future.
Acute Coronary Syndrome
C-reactive protein, interleukin-6, secretory phospholipase A(2) group IIA and intercellular adhesion molecule-1 in the prediction of late outcome events after acute coronary syndromes.
Acute Coronary Syndrome
Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes.
Acute Coronary Syndrome
CRP, interleukin-6, secretory phospholipase A(2) group IIA, and intercellular adhesion molecule-1 during the early phase of acute coronary syndromes and long-term follow-up.
Acute Coronary Syndrome
Inhibition of Secretory Phospholipase A(2) in Patients with Acute Coronary Syndromes: Rationale and Design of the Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks (VISTA-16) Trial.
Acute Coronary Syndrome
Phospholipase A2 Enzymes, High-Dose Atorvastatin, and Prediction of Ischemic Events After Acute Coronary Syndromes.
Acute Coronary Syndrome
Relation of secretory phospholipase A(2) and high-sensitivity C-reactive protein to Chlamydia pneumoniae infection in acute coronary syndromes.
Acute Coronary Syndrome
Secretory Phospholipase A2 Is Associated with the Odds of Acute Coronary Syndromes through Elevation of Serum Amyloid-A Protein.
Acute Coronary Syndrome
Secretory phospholipase A2 modified HDL rapidly and potently suppresses platelet activation.
Acute Coronary Syndrome
Short- and long-term elevation of autoantibody titers against oxidized LDL in patients with acute coronary syndromes. Role of the lipoprotein-associated phospholipase A2 and the effect of atorvastatin treatment.
Acute Coronary Syndrome
The association of PLA2G2A single nucleotide polymorphisms with type IIa secretory phospholipase A2 level but not its activity in patients with stable coronary heart disease.
Acute Coronary Syndrome
Thrombin increases cardiomyocyte acute cell death after ischemia and reperfusion.
Acute Coronary Syndrome
Varespladib methyl, an oral phospholipase A2 inhibitor for the potential treatment of coronary artery disease.
Acute Kidney Injury
A Biochemical and Pharmacological Characterization of Phospholipase A2 and Metalloproteinase Fractions from Eastern Russell's Viper (Daboia siamensis) Venom: Two Major Components Associated with Acute Kidney Injury.
Acute Kidney Injury
Alterations in rabbit renal microvascular prostanoid synthesis in acute renal failure.
Acute Kidney Injury
Peroxiredoxin 6 overexpression attenuates lipopolysaccharide-induced acute kidney injury.
Acute Kidney Injury
Phospholipase A2 inhibits cisplatin-induced acute kidney injury by modulating regulatory T cells by the CD206 mannose receptor.
Acute Kidney Injury
Role of fatty acid beta-oxidation and calcium-independent phospholipase A2 in ischemic acute renal failure.
Acute Kidney Injury
Severe and fatal mass attacks by 'killer' bees (Africanized honey bees--Apis mellifera scutellata) in Brazil: clinicopathological studies with measurement of serum venom concentrations.
Acute Lung Injury
Acute lung injury by sepsis and acid aspiration: a key role for cytosolic phospholipase A2.
Acute Lung Injury
Acute lung injury in experimental pancreatitis in rats: pulmonary protective effects of crotapotin and N-acetylcysteine.
Acute Lung Injury
Acute lung injury induced by phospholipase A2. Structural and functional changes.
Acute Lung Injury
Changes of pulmonary glucocorticoid receptor and phospholipase A2 in sheep with acute lung injury after high dose endotoxin infusion.
Acute Lung Injury
Clinical and biological role of secretory phospholipase A2 in acute respiratory distress syndrome infants.
Acute Lung Injury
Correlation between sPLA2-IIA and phosgene-induced rat acute lung injury.
Acute Lung Injury
Crucial role of group IIA phospholipase A(2) in oleic acid-induced acute lung injury in rabbits.
Acute Lung Injury
Deletion of peroxiredoxin 6 is protective in lipopolysaccharide-induced acute lung injury in mice*
Acute Lung Injury
Endotoxin induces expression of type II phospholipase A2 in macrophages during acute lung injury in guinea pigs: involvement of TNF-alpha in lipopolysaccharide-induced type II phospholipase A2 synthesis.
Acute Lung Injury
Generation of lyso-phospholipids from surfactant in acute lung injury is mediated by type-II phospholipase A2 and inhibited by a direct surfactant protein A-phospholipase A2 protein interaction.
Acute Lung Injury
Genetic inactivation of the phospholipase A2 activity of peroxiredoxin 6 in mice protects against LPS-induced acute lung injury.
Acute Lung Injury
Group V Phospholipase A2 Mediates Endothelial Dysfunction and Acute Lung Injury Caused by Methicillin-Resistant Staphylococcus Aureus.
Acute Lung Injury
Induction of type-IIA secretory phospholipase A2 in animal models of acute lung injury.
Acute Lung Injury
Inhibition of calcium-independent phospholipase A2 prevents inflammatory mediator production in pulmonary microvascular endothelium.
Acute Lung Injury
Inhibition of secretory phospholipase A2 activity attenuates lipopolysaccharide-induced acute lung injury in a mouse model.
Acute Lung Injury
Inhibition of the phospholipase A2 activity of peroxiredoxin 6 prevents lung damage with exposure to hyperoxia.
Acute Lung Injury
Lidocaine attenuates acute lung injury induced by a combination of phospholipase A2 and trypsin.
Acute Lung Injury
Mechanical induction of Group V phospholipase A2 causes lung inflammation and acute lung injury.
Acute Lung Injury
Novel variants in the PRDX6 Gene and the risk of Acute Lung Injury following major trauma.
Acute Lung Injury
Peroxiredoxin 6 knockout aggravates cecal ligation and puncture-induced acute lung injury.
Acute Lung Injury
Phospholipase A2 mediates nitric oxide production by alveolar macrophages and acute lung injury in pancreatitis.
Acute Lung Injury
Potential role of Clara cell protein, an endogenous phospholipase A2 inhibitor, in acute lung injury.
Acute Lung Injury
Reductions of phospholipase A(2) inhibition of pulmonary surfactant with hyaluronan.
Acute Lung Injury
Secretory Group V Phospholipase A2 Regulates Acute Lung Injury and Neutrophilic Inflammation Caused by LPS in Mice.
Acute Lung Injury
Secretory phospholipase A2 pathway in various types of lung injury in neonates and infants: a multicentre translational study.
Acute Lung Injury
Secretory phospholipases A2 stimulate mucus secretion, induce airway inflammation, and produce secretory hyperresponsiveness to neutrophil elastase in ferret trachea.
Acute Lung Injury
Surfactant and Varespladib Co-Administration in Stimulated Rat Alveolar Macrophages Culture.
Acute Lung Injury
The serpentine path to a novel mechanism-based inhibitor of acute inflammatory lung injury.
Acute Lung Injury
Therapeutic time-window of a group IIA phospholipase A2 inhibitor in rabbit acute lung injury: correlation with lung surfactant protection.
Adenocarcinoma
Bothrops moojeni myotoxin-II, a Lys49-phospholipase A2 homologue: an example of function versatility of snake venom proteins.
Adenocarcinoma
COX-2, inflammatory secreted PLA2, and cytoplasmic PLA2 protein expression in small bowel adenocarcinomas compared with colorectal adenocarcinomas.
Adenocarcinoma
Cytokeratin 8 and 19 as antigens recognized by adenocarcinoma-reactive human monoclonal antibody AE6F4.
Adenocarcinoma
Differential expression and function of peroxiredoxin 1 and peroxiredoxin 6 in cancerous MCF-7 and noncancerous MCF-10A breast epithelial cells.
Adenocarcinoma
Distinct expression pattern of the full set of secreted phospholipases A2 in human colorectal adenocarcinomas: sPLA2-III as a biomarker candidate.
Adenocarcinoma
Expression of cytosolic and group X secretory phospholipase A(2) genes in human colorectal adenocarcinomas.
Adenocarcinoma
Expression of group IIa secretory phospholipase A2 increases with prostate tumor grade.
Adenocarcinoma
Expression of group IIA secretory phospholipase A2 is elevated in prostatic intraepithelial neoplasia and adenocarcinoma.
Adenocarcinoma
Expression of inflammatory secretory phospholipase A2 and cytosolic phospholipase A2 in premalignant and malignant Barrett's oesophagus.
Adenocarcinoma
Expression of secreted phospholipase A2-Group IIA correlates with prognosis of gastric adenocarcinoma.
Adenocarcinoma
In vivo and in vitro studies of cytosolic phospholipase A2 expression in Helicobacter pylori infection.
Adenocarcinoma
Modulation of growth in human esophageal adenocarcinoma cells by group IIa secretory phospholipase A(2).
Adenocarcinoma
Phospholipase A2 group IIA expression in gastric adenocarcinoma is associated with prolonged survival and less frequent metastasis.
Adenocarcinoma
Secretory Phospholipase A(2) Inhibition Attenuates Intercellular Adhesion Molecule-1 Expression in Human Esophageal Adenocarcinoma Cells.
Adenocarcinoma
Secretory Phospholipase A2 IIa Mediates Expression of Growth Factor Receptors in Esophageal Adenocarcinoma.
Adenocarcinoma
Secretory phospholipase A2 mediates human esophageal adenocarcinoma cell growth and proliferation via ERK 1/2 pathway.
Adenocarcinoma
Suppression of N-nitrosobis(2-oxopropyl)amine-induced pancreatic carcinogenesis in hamsters by pioglitazone, a ligand of peroxisome proliferator-activated receptor gamma.
Adenocarcinoma of Lung
Adrenergic receptors: possible mechanism of inverse regulation of alpha- and beta-receptors.
Adenocarcinoma of Lung
Anti-tumor activity of CrTX in human lung adenocarcinoma cell line A549.
Adenocarcinoma of Lung
Crotoxin suppresses the tumorigenic properties and enhances the antitumor activity of Iressa® (gefinitib) in human lung adenocarcinoma SPCA?1 cells.
Adenocarcinoma of Lung
Group IIa secretory phospholipase A2 (sPLA2IIa) and progression in patients with lung cancer.
Adenocarcinoma of Lung
Inhibition of secretory phospholipase A2 IIa attenuates prostaglandin E2-induced invasiveness in lung adenocarcinoma.
Adenocarcinoma of Lung
Keratinocyte Growth Factor and Glucocorticoid Induction of Human Peroxiredoxin 6 Gene Expression Occur by Independent Mechanisms That Are Synergistic.
Adenocarcinoma of Lung
Phospholipase A2-induced stimulation of A549 lung adenocarcinoma cell line proliferation.
Adenocarcinoma of Lung
Prognostic roles of mRNA expression of peroxiredoxins in lung cancer.
Adenocarcinoma of Lung
Triosephosphate isomerase and peroxiredoxin 6, two novel serum markers for human lung squamous cell carcinoma.
Adenoma
Diversity in secreted PLA2-IIA activity among inbred mouse strains that are resistant or susceptible to Apc Min/+ tumorigenesis.
Adenoma
Early gene expression differences in inbred mouse strains with susceptibility to pulmonary adenomas.
Adenoma
Examining the role of Paneth cells in the small intestine by lineage ablation in transgenic mice.
Adenoma
Expression of group II phospholipase A2 in Paneth cells of an adenoma of the rectum. A case report.
Adenoma
Expression of PRDX6 Correlates with Migration and Invasiveness of Colorectal Cancer Cells.
Adenoma
Genetic evaluation of candidate genes for the Mom1 modifier of intestinal neoplasia in mice.
Adenoma
Overexpression of the nonpancreatic secretory group II PLA2 messenger RNA and protein in colorectal adenomas from familial adenomatous polyposis patients.
Adenoma
Phospholipase A2 group IIA expression correlates with prolonged survival in gastric cancer.
Adenoma
PRDX1 and PRDX6 are repressed in papillary thyroid carcinomas via BRAF V600E-dependent and -independent mechanisms.
Adenomatous Polyposis Coli
Homeodomain-interacting protein kinase-2 restrains cytosolic phospholipase A2-dependent prostaglandin E2 generation in human colorectal cancer cells.
Adenomatous Polyposis Coli
Impact of Phospholipase A2 group IIa gene polymorphism on phenotypic features of patients with familial adenomatous polyposis.
Adenomatous Polyposis Coli
Overexpression of the nonpancreatic secretory group II PLA2 messenger RNA and protein in colorectal adenomas from familial adenomatous polyposis patients.
Adenomatous Polyposis Coli
Secretory phospholipase A2 does not appear to be associated with phenotypic variation in familial adenomatous polyposis.
Adenomatous Polyposis Coli
Three secretory phospholipase A(2) genes that map to human chromosome 1P35-36 are not mutated in individuals with attenuated adenomatous polyposis coli.
Adenomatous Polyposis Coli
Variants at the secretory phospholipase A2 (PLA2G2A) locus: analysis of associations with familial adenomatous polyposis and sporadic colorectal tumours.
Adenomatous Polyps
Group II phospholipase A2 is not a major modifier of colonic adenomatous polyps in humans.
Adenomatous Polyps
Overexpression of the nonpancreatic secretory group II PLA2 messenger RNA and protein in colorectal adenomas from familial adenomatous polyposis patients.
Adenoviridae Infections
Adenovirus-mediated transfer of the 1-cys peroxiredoxin gene to mouse lung protects against hyperoxic injury.
Adenoviridae Infections
Human group III phospholipase A2 suppresses adenovirus infection into host cells. Evidence that group III, V and X phospholipase A2s act on distinct cellular phospholipid molecular species.
Adrenoleukodystrophy
Arachidonic acid metabolism in fibroblasts from patients with peroxisomal diseases: response to interleukin 1.
Airway Obstruction
Intranasal curcumin ameliorates airway inflammation and obstruction by regulating MAPKinase activation (p38, Erk and JNK) and prostaglandin D2 release in murine model of asthma.
Alopecia
Publisher Correction: Secretory phospholipase A2-IIA overexpressing mice exhibit cyclic alopecia mediated through aberrant hair shaft differentiation and impaired wound healing response.
Alopecia
Secretory phospholipase A2-IIA overexpressing mice exhibit cyclic alopecia mediated through aberrant hair shaft differentiation and impaired wound healing response.
alpha-Thalassemia
Sickle cell trait as a limiting factor for high-level performance in a semi-marathon.
Alveolar Bone Loss
The use of live-animal micro-computed tomography to determine the effect of a novel phospholipase A2 inhibitor on alveolar bone loss in an in vivo mouse model of periodontitis.
Alzheimer Disease
A 24-week study to evaluate the effect of rilapladib on cognition and cerebrospinal fluid biomarkers of Alzheimer's disease.
Alzheimer Disease
A frontal variant of Alzheimer's disease exhibits decreased calcium-independent phospholipase A2 activity in the prefrontal cortex.
Alzheimer Disease
Acceleration of the Development of Alzheimer's Disease in Amyloid Beta-Infused Peroxiredoxin 6 Overexpression Transgenic Mice.
Alzheimer Disease
Alterations in cerebrospinal fluid glycerophospholipids and phospholipase A2 activity in Alzheimer's disease.
Alzheimer Disease
Angiotensin-converting enzyme 2 (ACE2) is upregulated in Alzheimer's disease brain.
Alzheimer Disease
Association study of interferon-?, cytosolic phospholipase A2, and cyclooxygenase-2 gene polymorphisms in Alzheimer disease.
Alzheimer Disease
Bee venom phospholipase A2 ameliorates Alzheimer's disease pathology in A? vaccination treatment without inducing neuro-inflammation in a 3xTg-AD mouse model.
Alzheimer Disease
Bee Venom Phospholipase A2 Induces Regulatory T Cell Populations by Suppressing Apoptotic Signaling Pathway.
Alzheimer Disease
Bee Venom Soluble Phospholipase A2 Exerts Neuroprotective Effects in a Lipopolysaccharide-Induced Mouse Model of Alzheimer's Disease via Inhibition of Nuclear Factor-Kappa B.
Alzheimer Disease
Cerebrospinal Fluid Secretory Ca2+-Dependent Phospholipase A2 Activity Is Increased in Alzheimer Disease.
Alzheimer Disease
Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme.
Alzheimer Disease
Conjugated linoleic acid-enriched butter improved memory and up-regulated phospholipase A2 encoding-genes in rat brain tissue.
Alzheimer Disease
Cytosolic phospholipase A2 (cPLA2) immunoreactivity is elevated in Alzheimer's disease brain.
Alzheimer Disease
Cytosolic Phospholipase A2 Facilitates Oligomeric Amyloid-? Peptide Association with Microglia via Regulation of Membrane-Cytoskeleton Connectivity.
Alzheimer Disease
Decreased phospholipase A2 activity in the brain and in platelets of patients with Alzheimer's disease.
Alzheimer Disease
Effects of Acetylcholine on ?-Amyloid-Induced cPLA2 Activation in the TB Neuroectodermal Cell Line: Implications for the Pathogenesis of Alzheimer's Disease.
Alzheimer Disease
Evidence for increased amyloid enhancing factor activity in Alzheimer brain extract.
Alzheimer Disease
Higher Levels of Oxidized Low Density Lipoproteins in Alzheimer's Disease Patients: Roles for Platelet Activating Factor Acetyl Hydrolase and Paraoxonase-1.
Alzheimer Disease
Increased iPLA2 activity and levels of phosphorylated GSK3B in platelets are associated with donepezil treatment in Alzheimer's disease patients.
Alzheimer Disease
Lithium activates brain phospholipase A2 and improves memory in rats: implications for Alzheimer's disease.
Alzheimer Disease
Low platelet iPLA2 activity predicts conversion from mild cognitive impairment to Alzheimer's disease: a 4-year follow-up study.
Alzheimer Disease
Neuroprotective effects of bee venom phospholipase A2 in the 3xTg AD mouse model of Alzheimer's disease.
Alzheimer Disease
Peroxiredoxin 6 in human brain: molecular forms, cellular distribution and association with Alzheimer's disease pathology.
Alzheimer Disease
Phospholipase A2 is involved in muscarinic receptor-mediated sAPPalpha release independently of cyclooxygenase or lypoxygenase activity in SH-SY5Y cells.
Alzheimer Disease
Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease.
Alzheimer Disease
Phospholipid-metabolizing enzymes in Alzheimer's disease: increased lysophospholipid acyltransferase activity and decreased phospholipase A2 activity.
Alzheimer Disease
PLA2G4A/cPLA2-mediated lysosomal membrane damage leads to inhibition of autophagy and neurodegeneration after brain trauma.
Alzheimer Disease
Plasmalogen-selective phospholipase A2 and its involvement in Alzheimer's disease.
Alzheimer Disease
Platelet phospholipase A(2) activity in patients with Alzheimer's disease, vascular dementia and ischemic stroke.
Alzheimer Disease
Protective effects of a selective L-type voltage-sensitive calcium channel blocker, S-312-d, on neuronal cell death.
Alzheimer Disease
Protein Expression of Angiotensin-Converting Enzyme 2 (ACE2) is Upregulated in Brains with Alzheimer's Disease.
Alzheimer Disease
Role of constitutive calcium-independent phospholipase A2 beta in hippocampo-prefrontal cortical long term potentiation and spatial working memory.
Alzheimer Disease
Role of cytosolic calcium-dependent phospholipase A2 in Alzheimer's disease pathogenesis.
Alzheimer Disease
Study of association between genetic polymorphisms of phospholipase A2 enzymes and Alzheimer's disease.
Alzheimer Disease
Synthetic and natural inhibitors of phospholipases A2: their importance for understanding and treatment of neurological disorders.
Alzheimer Disease
The cholesterol ester cycle regulates signalling complexes and synapse damage caused by amyloid-?.
Alzheimer Disease
The neurotoxic secreted phospholipase A2 from the Vipera a. ammodytes venom targets cytochrome c oxidase in neuronal mitochondria.
Alzheimer Disease
The role of phospholipase A2 in neuronal homeostasis and memory formation: implications for the pathogenesis of Alzheimer's disease.
Alzheimer Disease
The role of platelet activating factor in prion and amyloid-beta neurotoxicity.
Alzheimer Disease
The role of secretory phospholipase A2 in the central nervous system and neurological diseases.
Alzheimer Disease
Ubiquitin profile and amyloid enhancing factor activity in Alzheimer and 'normal' human brain extracts.
Alzheimer Disease
[Relevance of metabolism of membrane phospholipids for Alzheimer dementia]
Amnesia
Inhibitors of phospholipase A2 produce amnesia for a passive avoidance task in the chick.
Amyloidosis
Aggregation of Mouse Serum Amyloid A Protein Was Promoted by Amyloid-Enhancing Factors with the More Genetically Homologous Serum Amyloid A.
Amyloidosis
Amyloid enhancing factor and dietary transmission in accelerated amyloid A amyloidosis.
Amyloidosis
Attempts at suppression of amyloidogenesis in a mouse model by a variety of anti-inflammatory agents.
Amyloidosis
Classical and alternative pathway complement activation are not required for reactive systemic AA amyloid deposition in mice.
Amyloidosis
Down-regulation of the major circulating precursors of proteins deposited in secondary amyloidosis by a recombinant mouse interleukin-1 receptor antagonist.
Amyloidosis
Experimental amyloidosis in the hamster: correlation between hamster female protein levels and amyloid deposition.
Amyloidosis
Fibril amyloid enhancing factor (FAEF)-accelerated amyloidosis in the hamster is not dependent on serine esterase activity and mononuclear phagocytosis.
Amyloidosis
Long term kinetics of AA amyloidosis and effects of inflammatory restimulation after disappearance of amyloid depositions in mice.
Amyloidosis
Rapid induction of experimental AA amyloidosis in mink by intravenous injection of amyloid enhancing factor.
Amyotrophic Lateral Sclerosis
Dysregulation of stathmin, a microtubule-destabilizing protein, and up-regulation of Hsp25, Hsp27, and the antioxidant peroxiredoxin 6 in a mouse model of familial amyotrophic lateral sclerosis.
Anaphylaxis
Aspirin is an Enhancing Factor for Food-dependent Exercise-induced Anaphylaxis in Children.
Anaphylaxis
Comparative study of etidronate and SR 41319, a new diphosphonate, on passive cutaneous anaphylaxis and phospholipase A2 activity.
Anaphylaxis
Glutamine Prevents Late-Phase Anaphylaxis via MAPK Phosphatase 1-Dependent Cytosolic Phospholipase A2 Deactivation.
Anaphylaxis
Papyriflavonol A from Broussonetia papyrifera inhibits the passive cutaneous anaphylaxis reaction and has a secretory phospholipase A2-inhibitory activity.
Anaphylaxis
Phospholipase A2 Triggers Anaphylaxis to Snake Venom by Repeated Skin Sensitization-A Case Report.
Anaphylaxis
Toxoplasma gondii-derived heat shock protein 70 induces lethal anaphylactic reaction through activation of cytosolic phospholipase A2 and platelet-activating factor via Toll-like receptor 4/myeloid differentiation factor 88.
Anemia, Hemolytic
Erythroid accelerating activity of rat serum in early stage of drug induced hemolysis.
Anemia, Sickle Cell
A two-event in vitro model of acute chest syndrome: The role of secretory phospholipase A(2) and neutrophils.
Anemia, Sickle Cell
Raised neutrophil phospholipase A2 activity and defective priming of NADPH oxidase and phospholipase A2 in sickle cell disease.
Anemia, Sickle Cell
Refining the value of secretory phospholipase A2 as a predictor of acute chest syndrome in sickle cell disease: results of a feasibility study (PROACTIVE).
Anemia, Sickle Cell
Secretory phospholipase A(2) predicts impending acute chest syndrome in sickle cell disease.
Anemia, Sickle Cell
Secretory phospholipase A2 levels in patients with sickle cell disease and acute chest syndrome.
Anemia, Sickle Cell
Serum biomarkers for identifying acute chest syndrome among patients who have sickle cell disease and present to the emergency department.
Anemia, Sickle Cell
Serum C-reactive protein parallels secretory phospholipase A2 in sickle cell disease patients with vasoocclusive crisis or acute chest syndrome.
Aneurysm
Varespladib (A-002), a Secretory Phospholipase A2 Inhibitor, Reduces Atherosclerosis and Aneurysm Formation in ApoE-/- Mice.
Aneurysm, Dissecting
Group V secreted phospholipase A2 plays a protective role against aortic dissection.
Angina Pectoris
Circulating secretory type IIA phospholipase A2, lipoprotein (a) and soluble cellular adhesion molecule levels in patients with angina pectoris.
Angina, Stable
Prognostic value of plasma levels of secretory type II phospholipase A2 in patients with unstable angina pectoris.
Angina, Unstable
Circulating secretory type IIA phospholipase A2, lipoprotein (a) and soluble cellular adhesion molecule levels in patients with angina pectoris.
Angina, Unstable
Phospholipase A2 Enzymes, High-Dose Atorvastatin, and Prediction of Ischemic Events After Acute Coronary Syndromes.
Angina, Unstable
Prognostic value of plasma levels of secretory type II phospholipase A2 in patients with unstable angina pectoris.
Angina, Unstable
Secretory type II phospholipase A(2) binds to ischemic myocardium during myocardial infarction in humans.
Angina, Unstable
Serum phospholipase A2 and lysolecithin changes following myocardial infarction.
Angioedema
Association study of genetic variants in PLA2G4A, PLCG1, LAT, SYK, and TNFRS11A genes in NSAIDs-induced urticaria and/or angioedema patients.
Angioedemas, Hereditary
Secreted Phospholipases A2 in Hereditary Angioedema With C1-Inhibitor Deficiency.
Aniridia
Analysis of protein composition and protein expression in the tear fluid of patients with congenital aniridia.
Anthrax
Edema toxin impairs anthracidal phospholipase A2 expression by alveolar macrophages.
Anthrax
In vivo protective role of human group IIa phospholipase A2 against experimental anthrax.
Anthrax
Involvement of phospholipase A2 activation in anthrax lethal toxin-induced cytotoxicity.
Antiphospholipid Syndrome
Antiphospholipid antibodies inhibit prostaglandin release by decidual cells of early pregnancy: possible involvement of extracellular secretory phospholipase A2.
Aortic Aneurysm, Abdominal
Group V Secretory Phospholipase A(2) Enhances the Progression of Angiotensin II-Induced Abdominal Aortic Aneurysms but Confers Protection against Angiotensin II-Induced Cardiac Fibrosis in ApoE-Deficient Mice.
Aortic Aneurysm, Abdominal
Group X secretory phospholipase A(2) augments angiotensin II-induced inflammatory responses and abdominal aortic aneurysm formation in apoE-deficient mice.
Aortic Aneurysm, Abdominal
Serum secreted phospholipase A2 is associated with abdominal aortic aneurysm presence but not progression.
Aortic Aneurysm, Abdominal
Trans-Serosal Leakage of Proinflammatory Mediators during Abdominal Aortic Aneurysm Repair: Role of Phospholipase A2 in Activating Leukocytes.
Appendicitis
Phospholipase A2, C-reactive protein, and white blood cell count in the diagnosis of acute appendicitis.
Arteriovenous Malformations
Methylation of Phospholipase A2 Group VII Gene Is Associated with Brain Arteriovenous Malformations in Han Chinese Populations.
Arteritis
Effect of Treatment for 12 weeks with Rilapladib, a Lipoprotein-associated Phospholipase A2 Inhibitor, on Arterial Inflammation as Assessed with 18F-Fluorodeoxyglucose-PET Imaging.
Arthritis
A novel anti-inflammatory role for secretory phospholipase A(2) in immune complex-mediated arthritis.
Arthritis
Arthritis develops but fails to resolve during inhibition of cyclooxygenase 2 in a murine model of Lyme disease.
Arthritis
Bee venom phospholipase A2 alleviates collagen-induced polyarthritis by inducing Foxp3+ regulatory T cell polarization in mice.
Arthritis
Comparative efficacy of a secretory phospholipase A2 inhibitor with conventional anti-inflammatory agents in a rat model of antigen-induced arthritis.
Arthritis
Crystal structure of human cytosolic phospholipase A2 reveals a novel topology and catalytic mechanism.
Arthritis
Cytosolic phospholipase A2 alpha inhibitor, pyrroxyphene, displays anti-arthritic and anti-bone destructive action in a murine arthritis model.
Arthritis
Effect of phospholipase A2 inhibitory peptide on inflammatory arthritis in a TNF transgenic mouse model: a time-course ultrastructural study.
Arthritis
Effects of Ginkgetin from Ginkgo biloba Leaves on cyclooxygenases and in vivo skin inflammation.
Arthritis
Eicosanoid production and phospholipase A2 secretion by peritoneal macrophages from rats with adjuvant-induced arthritis.
Arthritis
Evidence for distinct mechanisms of uptake and antitumor activity of secretory phospholipase A(2) responsive liposome in prostate cancer.
Arthritis
Exacerbation of collagen antibody-induced arthritis in transgenic mice overexpressing peroxiredoxin 6.
Arthritis
Exacerbation of rat adjuvant arthritis by intradermal injection of purified mammalian 14-kDa group II phospholipase A2.
Arthritis
Fexofenadine inhibits TNF signaling through targeting to cytosolic phospholipase A2 and is therapeutic against inflammatory arthritis.
Arthritis
Inhibitors of phospholipase A2 and their therapeutic potential: an update on patents (2012-2016).
Arthritis
Measurement of human phospholipase A2 in arthritis plasma using a newly developed sandwich ELISA.
Arthritis
Phospholipase A2 from human synovial fluid: purification and structural homology to the placental enzyme.
Arthritis
Phospholipase A2 in chamber angle of normal eyes and patients with primary open angle glaucoma and exfoliation glaucoma.
Arthritis
Platelet microparticles are internalized in neutrophils via the concerted activity of 12-lipoxygenase and secreted phospholipase A2-IIA.
Arthritis
Point of care testing of phospholipase A2 group IIA for serological diagnosis of rheumatoid arthritis.
Arthritis
Posttranscriptional effect of insulin-like growth factor-I on interleukin-1beta-induced type II-secreted phospholipase A2 gene expression in rabbit articular chondrocytes.
Arthritis
Presence of secretory group IIa and V phospholipase A2 and cytosolic group IValpha phospholipase A2 in chondrocytes from patients with rheumatoid arthritis.
Arthritis
Protein kinase A-dependent stimulation of rat type II secreted phospholipase A(2) gene transcription involves C/EBP-beta and -delta in vascular smooth muscle cells.
Arthritis
Respective contribution of cytosolic phospholipase A2? and secreted phospholipase A2 IIA to inflammation and eicosanoid production in arthritis.
Arthritis
Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2.
Arthritis
Secretory synovial fluid phospholipase A2 and its role in the pathogenesis of inflammation in arthritis.
Arthritis
Small-molecule inhibitors as potential therapeutics and as tools to understand the role of phospholipases A2.
Arthritis
Structure-based grafting, mutation, and optimization of peptide inhibitors to fit in the active pocket of human secreted phospholipase A2: find new use of old Peptide agents with anti-inflammatory activity.
Arthritis
Suppressive effect of secretory phospholipase A2 inhibitory peptide on interleukin-1beta-induced matrix metalloproteinase production in rheumatoid synovial fibroblasts, and its antiarthritic activity in hTNFtg mice.
Arthritis
Synergy between 15-lipoxygenase and secreted PLA2 promotes inflammation by formation of TLR4 agonists from extracellular vesicles.
Arthritis
Synthesis and release of phospholipase A2 by unstimulated human articular chondrocytes.
Arthritis
The Acute-phase Response Is Not Predictive for the Development of Arthritis in Seropositive Arthralgia - A Prospective Cohort Study.
Arthritis, Experimental
Cytosolic group IVA phospholipase A2 inhibitors, AVX001 and AVX002, ameliorate collagen-induced arthritis.
Arthritis, Experimental
Cytosolic phospholipase A2 alpha inhibitor, pyrroxyphene, displays anti-arthritic and anti-bone destructive action in a murine arthritis model.
Arthritis, Experimental
Exacerbation of rat adjuvant arthritis by intradermal injection of purified mammalian 14-kDa group II phospholipase A2.
Arthritis, Experimental
Induction of secretory phospholipase A2 confirms the systemic inflammatory nature of adjuvant arthritis.
Arthritis, Experimental
Modulation of acute and chronic inflammatory processes by cacospongionolide B, a novel inhibitor of human synovial phospholipase A2.
Arthritis, Experimental
Reduction of cPLA2alpha overexpression: an efficient anti-inflammatory therapy for collagen-induced arthritis.
Arthritis, Experimental
[Antiphlogistic effectiveness of combinations of inhibitors of phospholipase A2, cyclooxygenase and lipoxygenases of the arachidonic acid cascade]
Arthritis, Experimental
[Simultaneous and sequential inhibition of the arachidonic acid cascade by inhibitors of phospholipase A2, cyclooxygenase and lipoxygenases in carrageenan edema and adjuvant arthritis in the rat]
Arthritis, Juvenile
Phospholipase A2 in juvenile rheumatoid arthritis: correlation to disease type and activity.
Arthritis, Psoriatic
Interleukin 15 Primes Natural Killer Cells to Kill via NKG2D and cPLA2 and This Pathway Is Active in Psoriatic Arthritis.
Arthritis, Rheumatoid
A catalytically independent physiological function for human acute phase protein group IIA phospholipase A2: cellular uptake facilitates cell debris removal.
Arthritis, Rheumatoid
A novel anti-inflammatory role for secretory phospholipase A(2) in immune complex-mediated arthritis.
Arthritis, Rheumatoid
A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis.
Arthritis, Rheumatoid
Antimalarial drugs inhibit phospholipase A2 activation and induction of interleukin 1beta and tumor necrosis factor alpha in macrophages: implications for their mode of action in rheumatoid arthritis.
Arthritis, Rheumatoid
Assay and purification of phospholipase A2 from human synovial fluid in rheumatoid arthritis.
Arthritis, Rheumatoid
Biochemical characterization of soluble phospholipase A2 from rheumatoid synovial fluid.
Arthritis, Rheumatoid
Characterisation of soluble and cell associated phospholipase A2 from rheumatoid synovial fluid.
Arthritis, Rheumatoid
Characteristics and pathophysiological roles of extracellular phospholipase A2 in inflamed sites.
Arthritis, Rheumatoid
Characterization of secretory type IIA phospholipase A2 (sPLA2-IIA) as a glycyrrhizin (GL)-binding protein and the GL-induced inhibition of the CK-II-mediated stimulation of sPLA2-IIA activity in vitro.
Arthritis, Rheumatoid
Circulating phospholipase A2 activity associated with sepsis and septic shock is indistinguishable from that associated with rheumatoid arthritis.
Arthritis, Rheumatoid
Comparative efficacy of a secretory phospholipase A2 inhibitor with conventional anti-inflammatory agents in a rat model of antigen-induced arthritis.
Arthritis, Rheumatoid
Crystal structure of human secretory phospholipase A2-IIA complex with the potent indolizine inhibitor 120-1032.
Arthritis, Rheumatoid
Cytosolic phospholipase A2 alpha inhibitor, pyrroxyphene, displays anti-arthritic and anti-bone destructive action in a murine arthritis model.
Arthritis, Rheumatoid
Effect of phospholipase A2 inhibitory peptide on inflammatory arthritis in a TNF transgenic mouse model: a time-course ultrastructural study.
Arthritis, Rheumatoid
Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis: possible contribution of phospholipase A2 to this atherogenic profile.
Arthritis, Rheumatoid
Enhanced phospholipase A2 and C activities of peripheral blood polymorphonuclear leukocytes from patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Evaluation of antirheumatic drugs for their effect in vitro on purified human synovial fluid phospholipase A2.
Arthritis, Rheumatoid
Evaluation of drug-drug interaction between the novel cPLA2 inhibitor AK106-001616 and methotrexate in rheumatoid arthritis patients.
Arthritis, Rheumatoid
Exacerbation of collagen antibody-induced arthritis in transgenic mice overexpressing peroxiredoxin 6.
Arthritis, Rheumatoid
Group II phospholipase A2 in synovial fluid and serum in acute arthritis.
Arthritis, Rheumatoid
Identification and isolation of a phospholipase A2 activating protein in human rheumatoid arthritis synovial fluid: induction of eicosanoid synthesis and an inflammatory response in joints injected in vivo.
Arthritis, Rheumatoid
Identification of inhibitors against interaction between pro-inflammatory sPLA2-IIA protein and integrin ?v?3.
Arthritis, Rheumatoid
Increased expression of human type IIa secretory phospholipase A2 antigen in arthritic synovium.
Arthritis, Rheumatoid
Induction of phospholipase A2 gene expression in human hepatoma cells by mediators of the acute phase response.
Arthritis, Rheumatoid
Induction of TNF-alpha and proinflammatory secretory phospholipase A2 by intravenous administration of CAMPATH-1H in patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Inhibition of enzymatic activity of phospholipases A2 by minocycline and doxycycline.
Arthritis, Rheumatoid
Melittin binds to secretory phospholipase A2 and inhibits its enzymatic activity.
Arthritis, Rheumatoid
Membrane-associated phospholipase A2 detected by a radioimmunoassay is a sensitive marker of inflammation in rheumatoid arthritis.
Arthritis, Rheumatoid
Metalloprotease activity, phospholipase A2 activity and cytokine concentration in osteoarthritis synovial fluids.
Arthritis, Rheumatoid
Methyltransferase and phospholipase A2 activity in the cell membrane of neutrophils and lymphocytes from patients with Behçet's disease, systemic lupus erythematosus, and rheumatoid arthritis.
Arthritis, Rheumatoid
Monosodium urate crystals stimulate phospholipase A2 enzyme activities and the synthesis of a phospholipase A2-activating protein.
Arthritis, Rheumatoid
Neutralization of Inflammation by Inhibiting In vitro and In vivo Secretory Phospholipase A2 by Ethanol Extract of Boerhaavia diffusa L.
Arthritis, Rheumatoid
Novel group V phospholipase A2 involved in arachidonic acid mobilization in murine P388D1 macrophages.
Arthritis, Rheumatoid
Novel peptide inhibitors of human secretory phospholipase A2 with antiinflammatory activity: solution structure and molecular modeling.
Arthritis, Rheumatoid
Oxysterol and 9-cis-retinoic acid stimulate the group IIA secretory phospholipase A2 gene in rat smooth-muscle cells.
Arthritis, Rheumatoid
Phospholipase A2 activity in peripheral blood cells of rheumatoid arthritis patients treated with methotrexate: a preliminary study.
Arthritis, Rheumatoid
Phospholipase A2 activity in sera and synovial fluids in rheumatoid arthritis and osteoarthritis. Its possible role as a proinflammatory enzyme.
Arthritis, Rheumatoid
Phospholipase A2 in juvenile rheumatoid arthritis: correlation to disease type and activity.
Arthritis, Rheumatoid
Phospholipase A2 modulates respiratory burst developed by neutrophils in patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Phospholipase A2 sensitivity of the dorsal root and dorsal root ganglion.
Arthritis, Rheumatoid
Phospholipid metabolism in polymorphonuclear leukocytes from rheumatoid arthritis patients: effects of non-steroidal anti-inflammatory agents and clotrimazole.
Arthritis, Rheumatoid
Point of care testing of phospholipase A2 group IIA for serological diagnosis of rheumatoid arthritis.
Arthritis, Rheumatoid
Presence of secretory group IIa and V phospholipase A2 and cytosolic group IValpha phospholipase A2 in chondrocytes from patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Pulmonary inflammation and edema induced by phospholipase A2: global gene analysis and effects on aquaporins and Na+/K+-ATPase.
Arthritis, Rheumatoid
Purification and characterization of extracellular phospholipase A2 from human synovial fluid in rheumatoid arthritis.
Arthritis, Rheumatoid
Purification of a soluble phospholipase A2 from synovial fluid in rheumatoid arthritis.
Arthritis, Rheumatoid
Regulation of synovial cell growth: basic fibroblast growth factor synergizes with interleukin 1 beta stimulating phospholipase A2 enzyme activity, phospholipase A2 activating protein production and release of prostaglandin E2 by rheumatoid arthritis synovial cells in culture.
Arthritis, Rheumatoid
Release of mast cell mediators and nitrites into knee joint fluid in osteoarthritis--comparison with articular chondrocalcinosis and rheumatoid arthritis.
Arthritis, Rheumatoid
Respective contribution of cytosolic phospholipase A2? and secreted phospholipase A2 IIA to inflammation and eicosanoid production in arthritis.
Arthritis, Rheumatoid
Reversible inhibition by protamine of human synovial and rabbit platelet secretory phospholipase A2.
Arthritis, Rheumatoid
Rheumatoid arthritis synovial fluid phospholipase A2 activating protein (PLAP) stimulates human neutrophil degranulation and superoxide ion production.
Arthritis, Rheumatoid
Secretory phospholipase A2 as an index of disease activity in rheumatoid arthritis. Prospective double blind study of 212 patients.
Arthritis, Rheumatoid
Secretory phospholipases A2 in inflammatory and allergic diseases: not just enzymes.
Arthritis, Rheumatoid
Serum phospholipase A2 activity and immunoreactive group II phospholipase A2 in rheumatoid arthritis.
Arthritis, Rheumatoid
Serum phospholipase A2 activity in patients with rheumatoid arthritis before and after treatment with methotrexate, auranofin, or combination of the two.
Arthritis, Rheumatoid
Serum phospholipase A2 correlates with disease activity in rheumatoid arthritis.
Arthritis, Rheumatoid
Simultaneous development of acute phase response and autoantibodies in preclinical rheumatoid arthritis.
Arthritis, Rheumatoid
sPLA2-IIa is an inflammatory mediator when the ocular surface is compromised.
Arthritis, Rheumatoid
Suppressive effect of secretory phospholipase A2 inhibitory peptide on interleukin-1beta-induced matrix metalloproteinase production in rheumatoid synovial fibroblasts, and its antiarthritic activity in hTNFtg mice.
Arthritis, Rheumatoid
Type IIA secretory phospholipase A2 up-regulates cyclooxygenase-2 and amplifies cytokine-mediated prostaglandin production in human rheumatoid synoviocytes.
Arthritis, Rheumatoid
Various secretory phospholipase A2 enzymes are expressed in rheumatoid arthritis and augment prostaglandin production in cultured synovial cells.
Arthritis, Rheumatoid
[Cytokines, prostaglandin E2, phospholipase A and metalloproteases in synovial fluid in osteoarthritis]
Arthritis, Rheumatoid
[Immune function of rheumatoid arthritis treated by medicated-bath therapy in Tibetan medicine]
Arthus Reaction
Time-course of phospholipase A2, eicosanoid release and cellular accumulation in rat immunological air pouch inflammation.
Asbestosis
Biochemical components of bronchoalveolar lavage in early experimental asbestosis of the sheep: phospholipase A2 activity, prostaglandin E2 and proteins.
Asthenozoospermia
Asthenozoospermia and membrane remodeling enzymes: a new role for phospholipase A2.
Asthma
85-kDa cytosolic phospholipase A2 group IValpha gene promoter polymorphisms in patients with severe asthma: a gene expression and case-control study.
Asthma
Allergen-induced proteolytic cleavage of annexin-1 and activation of cytosolic phospholipase A2 in the lungs of a mouse model of asthma.
Asthma
Bee Venom Phospholipase A2 Ameliorates House Dust Mite Extract Induced Atopic Dermatitis Like Skin Lesions in Mice.
Asthma
Bee venom phospholipase A2 suppresses allergic airway inflammation in an ovalbumin-induced asthma model through the induction of regulatory T cells.
Asthma
Bioactive lysophosphatidylcholine 16:0 and 18:0 are elevated in lungs of asthmatic subjects.
Asthma
Blockade of Human Group X Secreted Phospholipase A2 (GX-sPLA2)-induced Airway Inflammation and Hyperresponsiveness in a Mouse Asthma Model by a Selective GX-sPLA2 Inhibitor.
Asthma
Combined activities of secretory phospholipases and eosinophil lysophospholipases induce pulmonary surfactant dysfunction by phospholipid hydrolysis.
Asthma
Contribution of opioid and neurotensin receptors in the anti-inflammatory activity of PK20 hybrid compound in murine airways.
Asthma
Crystal structure of human cytosolic phospholipase A2 reveals a novel topology and catalytic mechanism.
Asthma
Emerging roles of secreted phospholipase A(2) enzymes: Lessons from transgenic and knockout mice.
Asthma
Eosinophil cysteinyl leukotriene synthesis mediated by exogenous secreted phospholipase A2 group X.
Asthma
Hydrolysis of surfactant phospholipids catalyzed by phospholipase A2 and eosinophil lysophospholipases causes surfactant dysfunction: a mechanism for small airway closure in asthma.
Asthma
Hyperoxidized peroxiredoxins in peripheral blood mononuclear cells of asthma patients is associated with asthma severity.
Asthma
Identification of Epithelial Phospholipase A2 Receptor 1 (PLA2R1) as a Potential Target in Asthma.
Asthma
Impact of a soluble phospholipase A2 inhibitor on inhaled allergen challenge in subjects with asthma.
Asthma
Importance of group X-secreted phospholipase A2 in allergen-induced airway inflammation and remodeling in a mouse asthma model.
Asthma
Increased leukocyte phospholipase A2 activity and plasma lysophosphatidylcholine levels in asthma and rhinitis and their relationship to airway sensitivity to histamine.
Asthma
Induction of group IVC phospholipase A2 in allergic asthma: transcriptional regulation by TNF? in bronchoepithelial cells.
Asthma
Mechanism of glutamine inhibition of cytosolic phospholipase A2 (cPLA2 ): Evidence of physical interaction between glutamine-induced MAPK phosphatase-1 and cPLA2.
Asthma
Negative feedback between secretory and cytosolic phospholipase A2 and their opposing roles in ovalbumin-induced bronchoconstriction in rats.
Asthma
Neutralization of Inflammation by Inhibiting In vitro and In vivo Secretory Phospholipase A2 by Ethanol Extract of Boerhaavia diffusa L.
Asthma
Phospholipase A2 and arachidonate increase in bronchoalveolar lavage fluid after inhaled antigen challenge in asthmatics.
Asthma
Phospholipase A2 in experimental allergic bronchitis: a lesson from mouse and rat models.
Asthma
Plasma phospholipase A2 activity in patients with asthma: association with body mass index and cholesterol concentration.
Asthma
Protective Effects of Intratracheally-Administered Bee Venom Phospholipase A2 on Ovalbumin-Induced Allergic Asthma in Mice.
Asthma
Regulation of Arachidonate Remodeling Enzymes Impacts Eosinophil Survival During Allergic Asthma.
Asthma
Regulation of leukotriene and platelet-activating factor synthesis in human alveolar macrophages.
Asthma
Relationship between levels of secreted phospholipase A(2) groups IIA and X in the airways and asthma severity.
Asthma
Reply to: The Intricate Web of Phospholipase A2s and Specific Features of Airway Hyperresponsiveness in Asthma.
Asthma
Secreted phospholipase A2 group X overexpression in asthma and bronchial hyperresponsiveness.
Asthma
Secretory phospholipases A2 in inflammatory and allergic diseases: not just enzymes.
Asthma
Surface properties after a simulated PLA2 hydrolysis of pulmonary surfactant's main component, DPPC.
Asthma
The Intricate Web of Phospholipase A2s and Specific Features of Airway Hyperresponsiveness in Asthma.
Asthma
The step further to understand the role of cytosolic phospholipase A2 alpha and group X secretory phospholipase A2 in allergic inflammation: pilot study.
Asthma
Toxicological effects of ambient fine (PM2.5-0.18) and ultrafine (PM0.18) particles in healthy and diseased 3D organo-typic mucocilary-phenotype models.
Asthma
Treatment of ovalbumin-induced experimental allergic bronchitis in rats by inhaled inhibitor of secretory phospholipase A(2).
Asthma
[Association of cytoplasmic phospholipase A2 gene polymorphism with bronchial asthma and response to montelukast in children].
Asthma
[Changes in activity of phospholipase A2 and its metabolic production of prostaglandins in lung tissue of asthmatic guinea pigs]
Asthma
[Changes in glucocorticoid receptor and phospholipase A2 in guinea pig asthma models]
Asthma, Aspirin-Induced
[Serum phospholipase A2 activity in patients with aspirin-induced asthma]
Astrocytoma
A dangerous liaison: Leptin and sPLA2-IIA join forces to induce proliferation and migration of astrocytoma cells.
Astrocytoma
Calcium-sensitive cytosolic phospholipase A2 (cPLA2) is expressed in human brain astrocytes.
Astrocytoma
Cytosolic phospholipase A2 and the distinct transcriptional programs of astrocytoma cells.
Astrocytoma
Cytosolic phospholipase A2 is coupled to muscarinic receptors in the human astrocytoma cell line 1321N1: characterization of the transducing mechanism.
Astrocytoma
Mepacrine treatment prevents immobilization-induced desensitization of beta-adrenergic receptors in rat hypothalamus and brain stem.
Astrocytoma
Secreted PLA2 induces proliferation in astrocytoma through the EGF receptor: another inflammation-cancer link.
Astrocytoma
Secretory phospholipase A2 activates the cascade of mitogen-activated protein kinases and cytosolic phospholipase A2 in the human astrocytoma cell line 1321N1.
Astrocytoma
Secretory phospholipase A2 induces phospholipase Cgamma-1 activation and Ca2+ mobilization in the human astrocytoma cell line 1321N1 by a mechanism independent of its catalytic activity.
Astrocytoma
Signaling mechanisms involved in the activation of arachidonic acid metabolism in human astrocytoma cells by tumor necrosis factor-alpha: phosphorylation of cytosolic phospholipase A2 and transactivation of cyclooxygenase-2.
Astrocytoma
The presence of a secretory phospholipase A2 in the nuclei of neuronal and glial cells of rat brain cortex.
Astrocytoma
Thrombin produces phosphorylation of cytosolic phospholipase A2 by a mitogen-activated protein kinase kinase-independent mechanism in the human astrocytoma cell line 1321N1.
Astrocytoma
[Expressions of peroxiredoxin 1, peroxiredoxin 6 and GFAP in human brain astrocytoma and their clinical significance].
Ataxia
Early Ataxia and Subsequent Parkinsonism: PLA2G6 Mutations Cause a Continuum Rather Than Three Discrete Phenotypes.
Ataxia
Identification of a novel mutation in PLA2G6 gene and phenotypic heterogeneity analysis of PLA2G6-related neurodegeneration.
Ataxia
New findings in a global approach to dissect the whole phenotype of PLA2G6 gene mutations.
Atherosclerosis
A Novel Genetic Approach to Investigate the Role of Plasma Secretory Phospholipase A2 (sPLA2)-V Isoenzyme in Coronary Heart Disease: A Modified Mendelian Randomization Analysis Using PLA2G5 Expression Levels.
Atherosclerosis
A-002 (Varespladib), a phospholipase A2 inhibitor, reduces atherosclerosis in guinea pigs.
Atherosclerosis
After FRANCIS: next steps in the clinical evaluation of varespladib methyl.
Atherosclerosis
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Atherosclerosis
AMPK Signaling Involvement for the Repression of the IL-1?-Induced Group IIA Secretory Phospholipase A2 Expression in VSMCs.
Atherosclerosis
Analyses of group III secreted phospholipase A2 transgenic mice reveal potential participation of this enzyme in plasma lipoprotein modification, macrophage foam cell formation, and atherosclerosis.
Atherosclerosis
Analysis of secretory group II phospholipase A2 expression in human aortic tissue in dependence on the degree of atherosclerosis.
Atherosclerosis
Atherogenic properties of LDL particles modified by human group X secreted phospholipase A2 on human endothelial cell function.
Atherosclerosis
Autocrine and paracrine transcriptional regulation of type IIA secretory phospholipase A2 gene in vascular smooth muscle cells.
Atherosclerosis
Bee Venom Phospholipase A2 Ameliorates Atherosclerosis by Modulating Regulatory T Cells.
Atherosclerosis
Biological effects of secretory phospholipase A(2) group IIA on lipoproteins and in atherogenesis.
Atherosclerosis
Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease.
Atherosclerosis
Circulating levels of secretory- and lipoprotein-associated phospholipase A2 activities: relation to atherosclerotic plaques and future all-cause mortality.
Atherosclerosis
Comparison of the Effects of Combination Atorvastatin (40 mg) + Ezetimibe (10 mg) Versus Atorvastatin (40 mg) Alone on Secretory Phospholipase A2 Activity in Patients With Stable Coronary Artery Disease or Coronary Artery Disease Equivalent.
Atherosclerosis
Comprehensive identification of novel post-translational modifications in cellular peroxiredoxin 6.
Atherosclerosis
Control of capillary formation by membrane-anchored extracellular inhibitor of phospholipase A(2).
Atherosclerosis
Cooperation between secretory phospholipase A2 and TNF-receptor superfamily signaling: implications for the inflammatory response in atherogenesis.
Atherosclerosis
Corrigendum to "Lipoprotein-associated phospholipase A2 is related to risk of subclinical atherosclerosis but is not supported by Mendelian randomization analysis in a general Japanese population." [Atherosclerosis 246 (March 2016) 141-147].
Atherosclerosis
Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, Reduces Rho Kinase Activity in Atherosclerosis.
Atherosclerosis
Darapladib, a reversible lipoprotein-associated phospholipase A2 inhibitor, for the oral treatment of atherosclerosis and coronary artery disease.
Atherosclerosis
Deficiency in sPLA(2) does not affect HDL levels or atherosclerosis in mice.
Atherosclerosis
Degeneration and atherosclerosis inducing increased deposition of type IIA secretory phospholipase A2, C-reactive protein and complement in aortic valves cause neutrophilic granulocyte influx.
Atherosclerosis
Design of Selective sPLA2-X Inhibitor (-)-2-{2-[Carbamoyl-6-(trifluoromethoxy)-1H-indol-1-yl]pyridine-2-yl}propanoic Acid.
Atherosclerosis
Discovery of a Series of Indole-2 Carboxamides as Selective Secreted Phospholipase A2 Type X (sPLA2-X) Inhibitors.
Atherosclerosis
Distinctiveness of secretory phospholipase A2 group IIA and V suggesting unique roles in atherosclerosis.
Atherosclerosis
Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial.
Atherosclerosis
Effects of crotoxin, a neurotoxin from Crotalus durissus terrificus snake venom, on human endothelial cells.
Atherosclerosis
Effects of lysophosphatidylcholine on monolayer cell permeability of human coronary artery endothelial cells.
Atherosclerosis
Elevated secretory non-pancreatic type II phospholipase A2 serum activity is associated with impaired endothelial vasodilator function in patients with coronary artery disease.
Atherosclerosis
Elevated Type II Secretory Phospholipase A2 Increases the Risk of Early Atherosclerosis in Patients with Newly Diagnosed Metabolic Syndrome.
Atherosclerosis
Emerging roles of secreted phospholipase A(2) enzymes: Lessons from transgenic and knockout mice.
Atherosclerosis
Expression of secretory phospholipase A2s in human atherosclerosis development.
Atherosclerosis
Functional Analysis of Two PLA2G2A Variants Associated with Secretory Phospholipase A2-IIA Levels.
Atherosclerosis
Ginsenosides regulation of lysophosphatidylcholine profiles underlies the mechanism of Shengmai Yin in attenuating atherosclerosis.
Atherosclerosis
Gold/Phospholipid nanoconstructs as label-free optical probes for evaluating phospholipase A2 activity.
Atherosclerosis
Group 1B phospholipase A2 in metabolic and inflammatory disease modulation.
Atherosclerosis
Group 1B phospholipase A? inactivation suppresses atherosclerosis and metabolic diseases in LDL receptor-deficient mice.
Atherosclerosis
Group IIA Secretory Phospholipase A2 Predicts Graft Failure and Mortality in Renal Transplant Recipients by Mediating Decreased Kidney Function.
Atherosclerosis
Group V and X secretory phospholipase A(2)s-induced modification of high-density lipoprotein linked to the reduction of its antiatherogenic functions.
Atherosclerosis
Group v secretory phospholipase A2 promotes atherosclerosis: evidence from genetically altered mice.
Atherosclerosis
Group X secreted phospholipase A2 limits the development of atherosclerosis in LDL receptor-null mice.
Atherosclerosis
Group X secretory phospholipase A2 negatively regulates ABCA1 and ABCG1 expression and cholesterol efflux in macrophages.
Atherosclerosis
Human Secretary Phospholipase A2 Mutations and Their Clinical Implications.
Atherosclerosis
Immune modulation of glycosaminoglycan derived from P. lewisi in TNF-? stimulated cells.
Atherosclerosis
Induction of dendritic cell-mediated T-cell activation by modified but not native low-density lipoprotein in humans and inhibition by annexin a5: involvement of heat shock proteins.
Atherosclerosis
Inflammation and atherosclerosis: Group IIa and Group V sPLA2 are not redundant.
Atherosclerosis
Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase.
Atherosclerosis
Inhibition of interleukin-1beta-induced group IIA secretory phospholipase A2 expression by peroxisome proliferator-activated receptors (PPARs) in rat vascular smooth muscle cells: cooperation between PPARbeta and the proto-oncogene BCL-6.
Atherosclerosis
Inhibition of Secretory Phospholipase A(2) in Patients with Acute Coronary Syndromes: Rationale and Design of the Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks (VISTA-16) Trial.
Atherosclerosis
Lipoprotein modification by secretory phospholipase A(2) enzymes contributes to the initiation and progression of atherosclerosis.
Atherosclerosis
Lysophosphatidylcholine and secretory phospholipase A2 in vascular disease: mediators of endothelial dysfunction and atherosclerosis.
Atherosclerosis
Lysophosphatidylcholine stimulates activator protein 1 and the c-Jun N-terminal kinase activity.
Atherosclerosis
Macrophage-expressed group IIA secretory phospholipase A2 increases atherosclerotic lesion formation in LDL receptor-deficient mice.
Atherosclerosis
Macrophage-specific expression of group IIA sPLA2 results in accelerated atherogenesis by increasing oxidative stress.
Atherosclerosis
Macrophage-specific overexpression of group IIa sPLA2 increases atherosclerosis and enhances collagen deposition.
Atherosclerosis
Mitochondrial Reactive Oxygen Species Mediate Lysophosphatidylcholine-Induced Endothelial Cell Activation.
Atherosclerosis
Modification of LDL with human secretory phospholipase A(2) or sphingomyelinase promotes its arachidonic acid-releasing propensity.
Atherosclerosis
Molecular mechanism for changes in proteoglycan binding on compositional changes of the core and the surface of low-density lipoprotein-containing human apolipoprotein B100.
Atherosclerosis
Neutrophil effector responses are suppressed by secretory phospholipase A2 modified HDL.
Atherosclerosis
Nuclear corepressors mediate the repression of phospholipase A2 group IIa gene transcription by thyroid hormone.
Atherosclerosis
Overexpression of Prdx6 reduces H2O2 but does not prevent diet-induced atherosclerosis in the aortic root.
Atherosclerosis
Oxysterol and 9-cis-retinoic acid stimulate the group IIA secretory phospholipase A2 gene in rat smooth-muscle cells.
Atherosclerosis
Pathogenic factors in vascular dementia and Alzheimer's disease. Multiple actions of heparin that probably are beneficial.
Atherosclerosis
Periodontal microbiota and phospholipases: The Oral Infections and Vascular Disease Epidemiology Study (INVEST).
Atherosclerosis
Peroxiredoxin 6 deficiency and atherosclerosis susceptibility in mice: significance of genetic background for assessing atherosclerosis.
Atherosclerosis
Peroxiredoxin 6 Is a Key Antioxidant Enzyme in Modulating the Link between Glycemic and Lipogenic Metabolism.
Atherosclerosis
Phospholipase A2 in chamber angle of normal eyes and patients with primary open angle glaucoma and exfoliation glaucoma.
Atherosclerosis
Phospholipase A2 inhibitors in the treatment of atherosclerosis: a new approach moves forward in the clinic.
Atherosclerosis
Phospholipase A2 modification of lipoproteins: potential effects on atherogenesis.
Atherosclerosis
Phospholipolyzed LDL induces an inflammatory response in endothelial cells through endoplasmic reticulum stress signaling.
Atherosclerosis
Physiological Roles of Group X-secreted Phospholipase A2 in Reproduction, Gastrointestinal Phospholipid Digestion, and Neuronal Function.
Atherosclerosis
Prognostic utility of secretory phospholipase A2 in patients with stable coronary artery disease.
Atherosclerosis
Prognostic value of plasma levels of secretory type II phospholipase A2 in patients with unstable angina pectoris.
Atherosclerosis
Protein kinase A-dependent stimulation of rat type II secreted phospholipase A(2) gene transcription involves C/EBP-beta and -delta in vascular smooth muscle cells.
Atherosclerosis
Proteolysis of Apolipoprotein A-I by Secretory Phospholipase A2: A NEW LINK BETWEEN INFLAMMATION AND ATHEROSCLEROSIS.
Atherosclerosis
PX-18 protects human saphenous vein endothelial cells under arterial blood pressure.
Atherosclerosis
Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease.
Atherosclerosis
Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2.
Atherosclerosis
Role of group II secretory phospholipase A2 in atherosclerosis: 2. Potential involvement of biologically active oxidized phospholipids.
Atherosclerosis
Secreted phospholipase A2 type IIA as a mediator connecting innate and adaptive immunity: new role in atherosclerosis.
Atherosclerosis
Secretory phospholipase A(2) elicits proinflammatory changes and upregulates the surface expression of fas ligand in monocytic cells: potential relevance for atherogenesis.
Atherosclerosis
Secretory phospholipase A(2) of group IIA: Is it an offensive or a defensive player during atherosclerosis and other inflammatory diseases?
Atherosclerosis
Secretory phospholipase a(2): a multifaceted family of proatherogenic enzymes.
Atherosclerosis
Secretory phospholipase A2 group IIA enhances the metabolic rate and increases glucose utilization in response to thyroid hormone.
Atherosclerosis
Secretory phospholipase A2 group IIA modulates insulin sensitivity and metabolism.
Atherosclerosis
Secretory phospholipase A2, group IIA is a novel serum amyloid a target gene; Activation of smooth muscle cell expression by an interleukin-1 receptor-independent mechanism.
Atherosclerosis
Secretory PLA(2) inhibitor indoxam suppresses LDL modification and associated inflammatory responses in TNFalpha-stimulated human endothelial cells.
Atherosclerosis
Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyze atherogenic lipoproteins at neutral pH. Implications for atherosclerotic lesion development.
Atherosclerosis
sPLA2-IIA Augments Oxidized LDL-Induced MCP-1 Expression in Vitro Through Activation of Akt.
Atherosclerosis
Statin therapy and secretory phospholipase A? in children with heterozygous familial hypercholesterolemia.
Atherosclerosis
Tagging SNP haplotype analysis of the secretory PLA2-V gene, PLA2G5, shows strong association with LDL and oxLDL levels, suggesting functional distinction from sPLA2-IIA: results from the UDACS study.
Atherosclerosis
The capacity of group V sPLA2 to increase atherogenicity of ApoE-/- and LDLR-/- mouse LDL in vitro predicts its atherogenic role in vivo.
Atherosclerosis
The catalytically active secretory phospholipase A2 type IIA is involved in restenosis development after PTCA in human coronary arteries and generation of atherogenic LDL.
Atherosclerosis
The secretory phospholipase A2 group IIA: a missing link between inflammation, activated renin-angiotensin system, and atherogenesis?
Atherosclerosis
The synergistic inhibition of atherogenesis in apoE-/- mice between pravastatin and the sPLA2 inhibitor varespladib (A-002).
Atherosclerosis
Thematic review series: The immune system and atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease?
Atherosclerosis
Therapeutic effect of irbesartan combined with atorvastatin calcium in the treatment of rats with coronary heart disease.
Atherosclerosis
Thyroid hormone status regulates the expression of secretory phospholipases.
Atherosclerosis
Type II secretory phospholipase A2 in cardiovascular disease: a mediator in atherosclerosis and ischemic damage to cardiomyocytes?
Atherosclerosis
Usefulness of C-reactive protein as a marker for prediction of future coronary events in the asian Indian population: Indian atherosclerosis research study.
Atherosclerosis
Val279Phe variant of Lp-PLA2 is a risk factor for a subpopulation of Indonesia patients with acute myocardial infarction.
Atherosclerosis
Varespladib (A-002), a Secretory Phospholipase A2 Inhibitor, Reduces Atherosclerosis and Aneurysm Formation in ApoE-/- Mice.
Atherosclerosis
Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial.
Atherosclerosis
[Molecular mechanisms of effects of rosuvastatin on systemic oxidative stress and endogenous inflammation in patients with atherosclerosis.]
Atherosclerosis
[Pathogenesis of myocarditis in patients with bronchial asthma and pecilomycosis].
Atherosclerosis
[Role of secreted and lipoprotein-associated phospholipase A2 in cardiovascular risk].
Atherosclerosis
[The secretory phospholipase A2 and transport of lipids by lipoproteins in patients with the risk of cardio-vascular pathology (the system "score") of lower and average degree. The diagnostic significance of the test].
Autoimmune Diseases
A Novel Insight into the Role of PLA2R and THSD7A in Membranous Nephropathy.
Autoimmune Diseases
Characterization of THSD7A-antibodies not binding to glomerular THSD7A in a patient with diabetes mellitus but no membranous nephropathy.
Autoimmune Diseases
Efficacy of low or standard rituximab-based protocols and comparison to Ponticelli's regimen in membranous nephropathy.
Autoimmune Diseases
Epigallocatechin-3-gallate modulates antioxidant and DNA repair-related proteins in exocrine glands of a primary Sjogren's syndrome mouse model prior to disease onset.
Autoimmune Diseases
Identification of an autoantigen on the surface of apoptotic human T cells as a new protein interacting with inflammatory group IIA phospholipase A2.
Autoimmune Diseases
Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab.
Autoimmune Diseases
Protective effect of cytosolic phospholipase A2 inhibition against inflammation and degeneration by promoting regulatory T cells in rats with experimental autoimmune encephalomyelitis.
Autoimmune Diseases
Recurrent Membranous Nephropathy After Kidney Transplantation Associated With Phospholipase A2 Receptor and Successfully Treated With Rituximab: A Case Report.
Autoimmune Diseases
Role of phospholipase A2 receptor 1 antibody level at diagnosis for long-term renal outcome in membranous nephropathy.
Autoimmune Diseases
Secretory phospholipases A2 in inflammatory and allergic diseases: not just enzymes.
Autoimmune Diseases
Small-molecule inhibitors as potential therapeutics and as tools to understand the role of phospholipases A2.
Autoimmune Diseases
The Genetic and Environmental Factors of Primary Membranous Nephropathy: An Overview from China.
Autoimmune Diseases
The pathogenesis of human membranous nephropathy: we are (almost) there.
Autoimmune Diseases
[Anti-phospholipase A2 receptor (anti-PLA2R) antibodies and idiopathic membranous nephropathy: which role in diagnosis and prognosis of this disease?].
Bacteremia
Contribution of interleukin-1 to activation of coagulation and fibrinolysis, neutrophil degranulation, and the release of secretory-type phospholipase A2 in sepsis: studies in nonhuman primates after interleukin-1 alpha administration and during lethal bacteremia.
Bacteremia
Cytosolic phospholipase A2? promotes pulmonary inflammation and systemic disease during Streptococcus pneumoniae infection.
Bacterial Infections
Bactericidal group IIA phospholipase A2 in serum of patients with bacterial infections.
Bacterial Infections
CD64 and Group II Secretory Phospholipase A2 (sPLA2-IIA) as Biomarkers for Distinguishing Adult Sepsis and Bacterial Infections in the Emergency Department.
Bacterial Infections
Critical role of cytosolic phospholipase a2{alpha} in bronchial mucus hyper-secretion in CFTR-deficient mice.
Bacterial Infections
Cytosolic phospholipase A2 activation in Helicobacter pylori lipopolysaccharide-induced interference with gastric mucin synthesis.
Bacterial Infections
Distinguishing septic from normal donors by detection of sPLA2-IIA from human plasma using a microsieve-based immunoassay.
Bacterial Infections
Eicosanoids in insect immunity: bacterial infection stimulates hemocytic phospholipase A2 activity in tobacco hornworms.
Bacterial Infections
Genes encoding phospholipases A2 mediate insect nodulation reactions to bacterial challenge.
Bacterial Infections
Inflammatory mediators in dengue virus infection in children: interleukin-6 and its relation to C-reactive protein and secretory phospholipase A2.
Bacterial Infections
Leptin modulates the detrimental effect of Porphyromonas gingivalis lipopolysaccharide-induced cytosolic phospholipase A2 activation on salivary mucin synthesis via ERK-signal transduction.
Bacterial Infections
Measurement of a Novel Biomarker, Secretory Phospholipase A2 Group IIA as a Marker of Sepsis: A Pilot Study.
Bacterial Infections
Methyltransferase and phospholipase A2 activity in membranes of neutrophils and lymphocytes from patients with bacterial and viral infections.
Bacterial Infections
Neutrophil response of transgenic mice expressing human group IIA phospholipase A2 in bacterial infections.
Bacterial Infections
Porphyromonas gingivalis lipopolysaccharide-induced cytosolic phospholipase A2 activation interferes with salivary mucin synthesis via platelet activating factor generation.
Bacterial Infections
Rat liver mitochondrial phospholipase A2 is an endotoxin-stimulated membrane-associated enzyme of Kupffer cells which is released during liver perfusion.
Bacterial Infections
Secretory phospholipase A(2): a marker of infection in febrile children presenting to a pediatric ED.
Bacterial Infections
Secretory phospholipase A2 in dromedary tears: a host defense against staphylococci and other gram-positive bacteria.
Bacterial Infections
Synovial-type (group II) phospholipase A2 in serum of febrile patients with haematological malignancy.
Bacterial Infections
The role of group IIA secretory phospholipase A2 (sPLA2-IIA) as a biomarker for the diagnosis of sepsis and bacterial infection in adults-A systematic review.
Bacterial Infections
The step further to understand the role of cytosolic phospholipase A2 alpha and group X secretory phospholipase A2 in allergic inflammation: pilot study.
Bacterial Infections
Thromboxane synthesis is increased by upregulation of cytosolic phospholipase A2 and cyclooxygenase-2 in peripheral polymorphonuclear leukocytes during bacterial infection in childhood.
Bacterial Infections
Type IIA Secreted Phospholipase A2 in Host Defense against Bacterial Infections.
Barrett Esophagus
Secretory Phospholipase A2 IIa Mediates Expression of Growth Factor Receptors in Esophageal Adenocarcinoma.
Barrett Esophagus
Secretory Phospholipase A2 Inhibition Attenuates Adhesive Properties of Esophageal Barrett's Cells.
Barrett Esophagus
The Secretory Phospholipase A2 Gene is Required for Gastroesophageal Reflux-Related Changes in Murine Esophagus.
Barth Syndrome
Role of calcium-independent phospholipase A2 in the pathogenesis of Barth syndrome.
Biliary Tract Neoplasms
Nutritional factors (nutritional aspects) in biliary disorders: bile acid and lipid metabolism in gallstone diseases and pancreaticobiliary maljunction.
Biliary Tract Neoplasms
Partial characterization of proapoptotic action of biliary deteriorated lipids on biliary epithelial cells in pancreaticobiliary diseases.
Blepharospasm
Quantification of muscle loss in the doxorubicin-treated orbicularis oculi of the monkey. Effect of local injection of doxorubicin into the eyelid.
Blister
Prevention of Ca(2+)-induced hepatocyte plasma membrane bleb formation by inhibitors of eicosanoid synthesis.
Blister
Production of lysophosphatidic acid in blister fluid: involvement of a lysophospholipase D activity.
Bone Diseases
Peroxiredoxin 6 Inhibits Osteogenic Differentiation and Bone Formation Through Human Dental Pulp Stem Cells and Induces Delayed Bone Development.
Bone Resorption
An essential role of cytosolic phospholipase A2alpha in prostaglandin E2-mediated bone resorption associated with inflammation.
Bone Resorption
Cytosolic phospholipase A2alpha reigns supreme in arthritis and bone resorption.
Bone Resorption
Inhibitors of cyclo-oxygenase-2 and secretory phospholipase A2 preserve bone architecture following ovariectomy in adult rats.
Bone Resorption
Interleukin-4 inhibits prostaglandin G/H synthase-2 and cytosolic phospholipase A2 induction in neonatal mouse parietal bone cultures.
Bone Resorption
Secreted phospholipase A2 type II is present in Paget's disease of bone and modulates osteoclastogenesis, apoptosis and bone resorption of human osteoclasts independently of its catalytic activity in vitro.
Bone Resorption
The use of live-animal micro-computed tomography to determine the effect of a novel phospholipase A2 inhibitor on alveolar bone loss in an in vivo mouse model of periodontitis.
Brain Edema
Activation of bradykinin B2 receptor induced the inflammatory responses of cytosolic phospholipase A2 after the early traumatic brain injury.
Brain Edema
Neuroinflammatory pathways in binge alcohol-induced neuronal degeneration: oxidative stress cascade involving aquaporin, brain edema, and phospholipase A2 activation.
Brain Edema
Release of polyunsaturated fatty acids from phospholipids and alteration of brain membrane integrity by oxygen-derived free radicals.
Brain Edema
Role of Gd-DOTA in the evaluation and imaging of experimental blood-brain barrier disruption in brain edemas and their improvement after anti-inflammatory drugs treatment.
Brain Injuries
BK-induced cytosolic phospholipase A2 expression via sequential PKC-delta, p42/p44 MAPK, and NF-kappaB activation in rat brain astrocytes.
Brain Injuries
Chronic intracerebroventricular delivery of the secretory phospholipase A2 inhibitor, 12-epi-scalaradial, does not improve outcome after focal cerebral ischemia-reperfusion in rats.
Brain Injuries
Cross-talk between oxysterols and glucocorticoids: differential regulation of secreted phopholipase A2 and impact on oligodendrocyte death.
Brain Injuries
Effects of CDP-choline on phospholipase A2 and cholinephosphotransferase activities following a cryogenic brain injury in the rabbit.
Brain Injuries
Hippocampal Gene Network Analysis in an Experimental Model of Posttraumatic Epilepsy.
Brain Injuries
Multiple mechanisms underlying neuroprotection by secretory phospholipase A2 preconditioning in a surgically induced brain injury rat model.
Brain Injuries
Neuro-Behavioral Status and the Hippocampal Expression of Metabolic Associated Genes in Wild-Type Rat Following a Ketogenic Diet.
Brain Injuries
Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A2.
Brain Injuries
Synthetic and natural inhibitors of phospholipases A2: their importance for understanding and treatment of neurological disorders.
Brain Injuries
The neuromessenger platelet-activating factor in plasticity and neurodegeneration.
Brain Injuries, Traumatic
Activation of bradykinin B2 receptor induced the inflammatory responses of cytosolic phospholipase A2 after the early traumatic brain injury.
Brain Injuries, Traumatic
Autoimmune Profiling Reveals Peroxiredoxin 6 as a Candidate Traumatic Brain Injury Biomarker.
Brain Injuries, Traumatic
PLA2G4A/cPLA2-mediated lysosomal membrane damage leads to inhibition of autophagy and neurodegeneration after brain trauma.
Brain Ischemia
Angiotensin II type 1 receptor blocker telmisartan reduces cerebral infarct volume and periinfarct cytosolic phospholipase A2 level in experimental stroke.
Brain Ischemia
CDP-choline significantly restores phosphatidylcholine levels by differentially affecting phospholipase A2 and CTP: phosphocholine cytidylyltransferase after stroke.
Brain Ischemia
Cytosolic phospholipase A2 alpha amplifies early cyclooxygenase-2 expression, oxidative stress and MAP kinase phosphorylation after cerebral ischemia in mice.
Brain Ischemia
Effects of an endothelin B receptor agonist on secretory phospholipase A2-IIA-induced apoptosis in cortical neurons.
Brain Ischemia
Induction of secretory phospholipase A2 in reactive astrocytes in response to transient focal cerebral ischemia in the rat brain.
Brain Ischemia
Lipoprotein phospholipase A2 mass and activity are not associated with the diagnosis of acute brain ischemia.
Brain Ischemia
Mice deficient in cytosolic phospholipase A2 are less susceptible to cerebral ischemia/reperfusion injury.
Brain Ischemia
Neuroprotection of early and short-time applying atorvastatin in the acute phase of cerebral ischemia: down-regulated 12/15-LOX, p38MAPK and cPLA2 expression, ameliorated BBB permeability.
Brain Ischemia
NMDA receptor-mediated arachidonic acid release in neurons: role in signal transduction and pathological aspects.
Brain Ischemia
Peroxiredoxin 6 secreted by Schwann-like cells protects neuron against ischemic stroke in rats via PTEN/PI3K/AKT pathway.
Brain Ischemia
Prdx6 Upregulation by Curcumin Attenuates Ischemic Oxidative Damage via SP1 in Rats after Stroke.
Brain Ischemia
Retraction notice to Secretory phospholipase A2 IIA is up-regulated by TNF-? and IL-1?/? after transient focal cerebral ischemia in rat [Brain res. 1134 (2007) 199-205].
Brain Ischemia
Role of cytosolic calcium-dependent phospholipase A2 in Alzheimer's disease pathogenesis.
Brain Ischemia
Role of phospholipase A2 and membrane-derived lipid second messengers in membrane function and transcriptional activation of genes: implications in cerebral ischemia and neuronal excitability.
Brain Ischemia
Role of phospholipase A2 in the release of free fatty acids during ischemia-reperfusion in the rat cerebral cortex.
Brain Ischemia
Role of the p38 mitogen-activated protein kinase/cytosolic phospholipase A2 signaling pathway in blood-brain barrier disruption after focal cerebral ischemia and reperfusion.
Brain Ischemia
Secretory phospholipase A2 IIA is up-regulated by TNF-alpha and IL-1alpha/beta after transient focal cerebral ischemia in rat.
Brain Ischemia
Secretory phospholipase A2 inhibitor PX-18 preserves microvascular reactivity after cerebral ischemia in piglets.
Brain Ischemia
Spreading depression and focal brain ischemia induce cyclooxygenase-2 in cortical neurons through N-methyl-D-aspartic acid-receptors and phospholipase A2.
Brain Ischemia
Synthetic and natural inhibitors of phospholipases A2: their importance for understanding and treatment of neurological disorders.
Brain Neoplasms
A dangerous liaison: Leptin and sPLA2-IIA join forces to induce proliferation and migration of astrocytoma cells.
Breast Neoplasms
A Panel of Tumor-associated Autoantibodies for the Detection of Early-stage Breast Cancer.
Breast Neoplasms
Anti-vascular effects of the cytosolic phospholipase A2 inhibitor AVX235 in a patient-derived basal-like breast cancer model.
Breast Neoplasms
Antitumor and antimetastatic effects of PLA2-BthTX-II from Bothrops jararacussu venom on human breast cancer cells.
Breast Neoplasms
Autophagy is involved in cytotoxic effects of crotoxin in human breast cancer cell line MCF-7 cells.
Breast Neoplasms
Bcl-x and Bcl-2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells.
Breast Neoplasms
Blockage of cytosolic phospholipase A2 alpha sensitizes aggressive breast cancer to doxorubicin through suppressing ERK and mTOR kinases.
Breast Neoplasms
BthTX-I from Bothrops jararacussu induces apoptosis in human breast cancer cell lines and decreases cancer stem cell subpopulation.
Breast Neoplasms
Cancer cells isolated from malignant pleural and peritoneal effusions inhibit phospholipase A2 activity in human polymorphonuclear leukocytes.
Breast Neoplasms
Characterization of phospholipase A2 activity in MDA-MB-435 human breast cancer cells.
Breast Neoplasms
Cigarette Smoke Regulates Calcium-Independent Phospholipase A2 Metabolic Pathways in Breast Cancer.
Breast Neoplasms
Clinical Significance of Expression Changes and Promoter Methylation of PLA2R1 in Tissues of Breast Cancer Patients.
Breast Neoplasms
Correction to: Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer.
Breast Neoplasms
Critical role of arachidonic acid-activated mTOR signaling in breast carcinogenesis and angiogenesis.
Breast Neoplasms
Cytosolic phospholipase A2 activation correlates with HER2 overexpression and mediates estrogen-dependent breast cancer cell growth.
Breast Neoplasms
Development of a cell-based bioassay for phospholipase A2-triggered liposomal drug release.
Breast Neoplasms
Dextrin-Phospholipase A(2): Synthesis and Evaluation as a Bioresponsive Anticancer Conjugate.
Breast Neoplasms
Effects of dietary fish oil on fatty acids and eicosanoids in metastasizing human breast cancer cells.
Breast Neoplasms
Epigenetic control of phospholipase A2 receptor expression in mammary cancer cells.
Breast Neoplasms
Ethanol and breast cancer: an association that may be both confounded and causal.
Breast Neoplasms
Expression of Secretory Phospholipase A2 Group IIa in Breast Cancer and Correlation to Prognosis in a Cohort of Advanced Breast Cancer Patients.
Breast Neoplasms
Genotoxic effects of BnSP-6, a Lys-49 phospholipase A2 (PLA2) homologue from Bothrops pauloensis snake venom, on MDA-MB-231 breast cancer cells.
Breast Neoplasms
Group X secreted phospholipase A2 induces lipid droplet formation and prolongs breast cancer cell survival.
Breast Neoplasms
Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer.
Breast Neoplasms
Increased expression of membrane-associated phospholipase A2 shows malignant potential of human breast cancer cells.
Breast Neoplasms
Interaction of vitamin D analogs with signaling pathways leading to active cell death in breast cancer cells.
Breast Neoplasms
Lipidomic data on lipid droplet triglyceride remodelling associated with protection of breast cancer cells from lipotoxic stress.
Breast Neoplasms
Molecular causes of the aberrant choline phospholipid metabolism in breast cancer.
Breast Neoplasms
Nipple aspirate fluids from women with breast cancer contain increased levels of group IIa secretory phospholipase A2.
Breast Neoplasms
Overexpression of group II phospholipase A2 in human breast cancer tissues is closely associated with their malignant potency.
Breast Neoplasms
Plasma phospholipase A2 activity may serve as a novel diagnostic biomarker for the diagnosis of breast cancer.
Breast Neoplasms
Polymorphisms in oxidative stress-related genes and mortality in breast cancer patients - Potential differential effects by radiotherapy?
Breast Neoplasms
Prognostic significance of PLA2G4C gene polymorphism in patients with stage II colorectal cancer.
Breast Neoplasms
Prognostic significance of three novel biologic factors in a clinical trial of adjuvant therapy for node-negative breast cancer.
Breast Neoplasms
Reprogramming lipid metabolism prevents effector T cell senescence and enhances tumor immunotherapy.
Breast Neoplasms
Secreted phospholipases A? are differentially expressed and epigenetically silenced in human breast cancer cells.
Breast Neoplasms
Synthesis and Evaluation of Cytosolic Phospholipase A(2) Activatable Fluorophores for Cancer Imaging.
Breast Neoplasms
Tetrahydrofurandiol stimulation of phospholipase A2, lipoxygenase, and cyclooxygenase gene expression and MCF-7 human breast cancer cell proliferation.
Breast Neoplasms
The anti-cancer potential of crotoxin in estrogen receptor-positive breast cancer: Its effects and mechanism of action.
Bronchial Spasm
Interaction between chloroquine and indomethacin in airways smooth muscle in vivo.
Bronchial Spasm
[Some pathogenetic mechanisms of bacterial bronchial asthma in paecilomycosis]
Bronchitis
Drastic changes in the tissue-specific expression of secreted phospholipases A2 in chicken pulmonary disease.
Bronchitis
Phospholipase A2 in experimental allergic bronchitis: a lesson from mouse and rat models.
Bronchitis
Treatment of ovalbumin-induced experimental allergic bronchitis in rats by inhaled inhibitor of secretory phospholipase A(2).
Bronchitis
[The metabolic effects of glucocorticosteroids in patients with chronic obstructive bronchitis]
Bronchopulmonary Dysplasia
Cord blood Clara cell protein CC16 predicts the development of bronchopulmonary dysplasia.
Bronchopulmonary Dysplasia
Promotion of Bronchopulmonary Dysplasia Progression Using Circular RNA circabcc4 via Facilitating PLA2G6 Expression by Sequestering miR-663a.
Brucellosis
Construction and Activity Analyses of Single Functional Mouse Peroxiredoxin 6 (Prdx6).
Brucellosis
Full-length cDNA cloning, molecular characterization and differential expression analysis of peroxiredoxin 6 from Ovis aries.
Brucellosis
Host Prdx6 contributing to the intracellular survival of Brucella suis S2 strain.
Candidemia
A Genome-Wide Functional Genomics Approach Identifies Susceptibility Pathways to Fungal Bloodstream Infection in Humans.
Candidiasis
Group V secretory phospholipase A2 modulates phagosome maturation and regulates the innate immune response against Candida albicans.
Carcinogenesis
A calcium-dependent phospholipase A2 (cPLA2) expression is regulated by MIG-6 during endometrial tumorigenesis.
Carcinogenesis
Absence of secretory phospholipase A2 gene alterations in human colorectal cancer.
Carcinogenesis
Anti-vascular effects of the cytosolic phospholipase A2 inhibitor AVX235 in a patient-derived basal-like breast cancer model.
Carcinogenesis
Characterization of phospholipase A2 activity in MDA-MB-435 human breast cancer cells.
Carcinogenesis
Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound.
Carcinogenesis
COX-2, inflammatory secreted PLA2, and cytoplasmic PLA2 protein expression in small bowel adenocarcinomas compared with colorectal adenocarcinomas.
Carcinogenesis
Cytoplasmic phospholipase A2 expression in human colon adenocarcinoma is correlated with cyclooxygenase-2 expression and contributes to prostaglandin E2 production.
Carcinogenesis
Cytoplasmic phospholipase A2 levels correlate with apoptosis in human colon tumorigenesis.
Carcinogenesis
Cytosolic Phospholipase A2 Alpha Regulates TLR Signaling and Migration in Metastatic 4T1 Cells.
Carcinogenesis
Cytosolic phospholipase A2? regulates G1 progression through modulating FOXO1 activity.
Carcinogenesis
Decreased lung tumorigenesis in mice genetically deficient in cytosolic phospholipase A2.
Carcinogenesis
Deficiency of phospholipase A2 group 7 decreases intestinal polyposis and colon tumorigenesis in Apc Min/+ mice.
Carcinogenesis
Deletion of phospholipase A2 group IVc induces apoptosis in rat mammary tumour cells by the nuclear factor-?B/lipocalin 2 pathway.
Carcinogenesis
Differential gene expression profiles of hepatocellular carcinomas associated or not with viral infection.
Carcinogenesis
Diversity in secreted PLA2-IIA activity among inbred mouse strains that are resistant or susceptible to Apc Min/+ tumorigenesis.
Carcinogenesis
Dysfunction of PLA2G6 and CYP2C44-associated network signals imminent carcinogenesis from chronic inflammation to hepatocellular carcinoma.
Carcinogenesis
Effects of dietary saturated and unsaturated fatty acids on fecal bile acids and colon carcinogenesis induced by azoxymethane in rats.
Carcinogenesis
Epigenetic control of group V phospholipase A2 expression in human malignant cells.
Carcinogenesis
Expression analysis of the group IIA secretory phospholipase A(2) in mice with differential susceptibility to azoxymethane-induced colon tumorigenesis.
Carcinogenesis
Expression of group IIA phospholipase A2 is an independent predictor of favorable outcome for patients with gastric cancer.
Carcinogenesis
Expression of group IIA secretory phospholipase A2 is elevated in prostatic intraepithelial neoplasia and adenocarcinoma.
Carcinogenesis
Expression of inflammatory secretory phospholipase A2 and cytosolic phospholipase A2 in premalignant and malignant Barrett's oesophagus.
Carcinogenesis
Expression of secretory phospholipase A2 in colon tumor cells potentiates tumor growth.
Carcinogenesis
Gene expression of cyclooxygenase-2, group II and cytosolic phospholipase A2 in human colorectal cancer.
Carcinogenesis
Group III phospholipase A2 downregulation attenuated survival and metastasis in ovarian cancer and promotes chemo-sensitization.
Carcinogenesis
Group X phospholipase A2 stimulates the proliferation of colon cancer cells by producing various lipid mediators.
Carcinogenesis
HERV-E-mediated modulation of PLA2G4A transcription in urothelial carcinoma.
Carcinogenesis
Homeodomain-interacting protein kinase-2 restrains cytosolic phospholipase A2-dependent prostaglandin E2 generation in human colorectal cancer cells.
Carcinogenesis
Identification of peroxiredoxin 6 as a direct target of withangulatin A by quantitative chemical proteomics in non-small cell lung cancer.
Carcinogenesis
Impacts of cytosolic phospholipase A2, 15-prostaglandin dehydrogenase, and cyclooxygenase-2 expressions on tumor progression in colorectal cancer.
Carcinogenesis
Increased expression and activity of group IIA and X secretory phospholipase A2 in peritumoral versus central colon carcinoma tissue.
Carcinogenesis
Increased expression of peroxiredoxin 6 and cyclophilin A in squamous cell carcinoma of the tongue.
Carcinogenesis
Inhibition of calcium-independent phospholipase A2 suppresses proliferation and tumorigenicity of ovarian carcinoma cells.
Carcinogenesis
Inhibition of cytosolic phospholipase A2 alpha increases chemosensitivity in cervical carcinoma through suppressing ?-catenin signaling.
Carcinogenesis
Interactions of platinum and ruthenium coordination complexes with pancreatic phospholipase A(2) and phospholipids investigated by MALDI TOF mass spectrometry.
Carcinogenesis
Inverse association between phospholipase A2 and COX-2 expression during mouse colon tumorigenesis.
Carcinogenesis
Lung Krüppel-like factor (LKLF) is a transcriptional activator of the cytosolic phospholipase A2 alpha promoter.
Carcinogenesis
Modulating effect of amount and types of dietary fat on colonic mucosal phospholipase A2, phosphatidylinositol-specific phospholipase C activities, and cyclooxygenase metabolite formation during different stages of colon tumor promotion in male F344 rats.
Carcinogenesis
Multifactorial hamster respiratory carcinogenesis with interdependent effects of cannula-induced mucosal wounding, saline, ferric oxide, benzo[a]pyrene and N-methyl-N-nitrosourea.
Carcinogenesis
Nipple aspirate fluids from women with breast cancer contain increased levels of group IIa secretory phospholipase A2.
Carcinogenesis
Phospholipase A2 Drives Tumorigenesis and Cancer Aggressiveness through Its Interaction with Annexin A1.
Carcinogenesis
Pla2g2a attenuates colon tumorigenesis in azoxymethane-treated C57BL/6 mice; expression studies reveal Pla2g2a target genes and pathways.
Carcinogenesis
Plasma Levels of Phospholipase A2-IIA in Patients with Different Types of Malignancies: Prognosis and Association with Inflammatory and Coagulation Biomarkers.
Carcinogenesis
Plasma phospholipase A2 activity may serve as a novel diagnostic biomarker for the diagnosis of breast cancer.
Carcinogenesis
Potential role of group X secretory phospholipase A(2) in cyclooxygenase-2-dependent PGE(2) formation during colon tumorigenesis.
Carcinogenesis
PRDX1 and PRDX6 are repressed in papillary thyroid carcinomas via BRAF V600E-dependent and -independent mechanisms.
Carcinogenesis
Presenilin Mutation Suppresses Lung Tumorigenesis via Inhibition of Peroxiredoxin 6 Activity and Expression.
Carcinogenesis
Prognostic significance of cytosolic phospholipase A2 expression in patients with colorectal cancer.
Carcinogenesis
Reduced group IVA phospholipase A2 expression is associated with unfavorable outcome for patients with gastric cancer.
Carcinogenesis
Secreted Phospholipases A2 Are Intestinal Stem Cell Niche Factors with Distinct Roles in Homeostasis, Inflammation, and Cancer.
Carcinogenesis
Secretory phospholipase A2-IIa upregulates HER/HER2-elicited signaling in lung cancer cells.
Carcinogenesis
Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis.
Carcinogenesis
Silibinin Down-regulates Expression of Secreted Phospholipase A2 Enzymes in Cancer Cells.
Carcinogenesis
Supplementation with omega fatty acids increases the mRNA expression level of PLA2G4A in patients with gastric cancer.
Carcinogenesis
The chemopreventive role of ursodeoxycholic acid in azoxymethane-treated rats: suppressive effects on enhanced group II phospholipase A2 expression in colonic tissue.
Carcinogenesis
The phospholipase A2 activity of peroxiredoxin 6 promotes cancer cell death induced by tumor necrosis factor alpha in hepatocellular carcinoma.
Carcinogenesis
Toward understanding interfacial activation of secretory phospholipase A2 (PLA2): membrane surface properties and membrane-induced structural changes in the enzyme contribute synergistically to PLA2 activation.
Carcinogenesis
Transcriptional regulation of cyclooxygenase-2 gene expression: novel effects of nonsteroidal anti-inflammatory drugs.
Carcinogenesis
Transfection of C3H10T1/2 cells with the Harvey-ras oncogene reduces cytosolic phospholipase A2 function.
Carcinogenesis
Vav3 oncogene is involved in regulation of secretory phospholipase A2-IIa expression in prostate cancer.
Carcinoma
A xenograft mouse model coupled with in-depth plasma proteome analysis facilitates identification of novel serum biomarkers for human ovarian cancer.
Carcinoma
Antitumor effects of cationic synthetic peptides derived from Lys49 phospholipase A2 homologues of snake venoms.
Carcinoma
Antitumor potential of Pllans-II, an acidic Asp49-PLA2 from Porthidium lansbergii lansbergii snake venom on human cervical carcinoma HeLa cells.
Carcinoma
Arachidonic acid, an omega-6 fatty acid, induces cytoplasmic phospholipase A2 in prostate carcinoma cells.
Carcinoma
Association of Single Nucleotide Polymorphisms in the Prostaglandin-endoperoxide Synthase 2 (PTGS2) and Phospholipase A2 Group IIA (PLA2G2A) Genes with Susceptibility to Esophageal Squamous Cell Carcinoma.
Carcinoma
Clinical significance of phospholipase A2 group IIA (PLA2G2A) expression in primary resected esophageal squamous cell carcinoma.
Carcinoma
Combined detection of serum autoantibodies as diagnostic biomarkers in esophagogastric junction adenocarcinoma.
Carcinoma
Context-dependent effect of sPLA2-IIA induced proliferation on murine hair follicle stem cells and human epithelial cancer.
Carcinoma
Crotoxin induces apoptosis and autophagy in human lung carcinoma cells in vitro via activation of the p38MAPK signaling pathway.
Carcinoma
Cyclooxygenase-2 and Cytosolic Phospholipase A2 Are Overexpressed in Mucinous Pancreatic Cysts.
Carcinoma
Cytoplasmic phospholipase A2 expression in human colon adenocarcinoma is correlated with cyclooxygenase-2 expression and contributes to prostaglandin E2 production.
Carcinoma
Cytosolic phospholipase A2 as a molecular target for the radiosensitization of ovarian cancer.
Carcinoma
Expression of cyclooxygenase-2, peroxiredoxin I, peroxiredoxin 6 and nuclear factor-?B in oral squamous cell carcinoma.
Carcinoma
Expression of cytosolic phospholipase A2 and cyclooxygenase 2 and their significance in human oral mucosae, dysplasias and squamous cell carcinomas.
Carcinoma
Expression of secretory phospholipase A2 in colon tumor cells potentiates tumor growth.
Carcinoma
Extracellular Acidity-mediated Expression of cPLA2? Confers Resistance in Gastric Cancer Cells.
Carcinoma
Group IID heparin-binding secretory phospholipase A(2) is expressed in human colon carcinoma cells and human mast cells and up-regulated in mouse inflammatory tissues.
Carcinoma
Immunohistochemical localization of group II phospholipase A2 in human pancreatic carcinomas.
Carcinoma
In vivo and in vitro studies of cytosolic phospholipase A2 expression in Helicobacter pylori infection.
Carcinoma
Increased expression and activity of group IIA and X secretory phospholipase A2 in peritumoral versus central colon carcinoma tissue.
Carcinoma
Increased expression of peroxiredoxin 6 and cyclophilin A in squamous cell carcinoma of the tongue.
Carcinoma
Inhibition of calcium-independent phospholipase A2 suppresses proliferation and tumorigenicity of ovarian carcinoma cells.
Carcinoma
Inhibition of cytosolic phospholipase A2 alpha increases chemosensitivity in cervical carcinoma through suppressing ?-catenin signaling.
Carcinoma
Localization and characterization of phospholipase A2 in mouse mammary gland-derived cells.
Carcinoma
MiR-543 Promotes Migration, Invasion and Epithelial-Mesenchymal Transition of Esophageal Cancer Cells by Targeting Phospholipase A2 Group IVA.
Carcinoma
Overexpression of Peroxiredoxin 6 (PRDX6) Promotes the Aggressive Phenotypes of Esophageal Squamous Cell Carcinoma.
Carcinoma
Overexpression of phospholipase A2 Group IIA in esophageal squamous cell carcinoma and association with cyclooxygenase-2 expression.
Carcinoma
Phospholipid patterns and phospholipase A2 activities in gastric mucosa of rats developing carcinomas after surgically induced enterogastric reflux.
Carcinoma
PRDX1 and PRDX6 are repressed in papillary thyroid carcinomas via BRAF V600E-dependent and -independent mechanisms.
Carcinoma
Proteome of Metastatic Canine Mammary Carcinomas: Similarities to and Differences from Human Breast Cancer ().
Carcinoma
Resistance to cytolysis by tumor necrosis factor alpha in malignant gynecological cell lines is associated with the expression of protein(s) that prevent the activation of phospholipase A2 by tumor necrosis factor alpha.
Carcinoma
Secretory phospholipase A2 is required to produce histologic changes associated with gastroduodenal reflux in a murine model.
Carcinoma
Secretory phospholipase A2 responsive liposomes exhibit a potent anti-neoplastic effect in vitro, but induce unforeseen severe toxicity in vivo.
Carcinoma
The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.
Carcinoma
Triosephosphate isomerase and peroxiredoxin 6, two novel serum markers for human lung squamous cell carcinoma.
Carcinoma
Urocortin affects migration of hepatic cancer cell lines via differential regulation of cPLA2 and iPLA2.
Carcinoma
[Increased phospholipase A2 and diacylglycerol lipase activities in colorectal carcinoma: possibility for carcinoma prevention or therapy?]
Carcinoma, Ductal
Deletion of phospholipase A2 group IVc induces apoptosis in rat mammary tumour cells by the nuclear factor-?B/lipocalin 2 pathway.
Carcinoma, Ehrlich Tumor
Cell swelling activates phospholipase A2 in Ehrlich ascites tumor cells.
Carcinoma, Ehrlich Tumor
Comparative characterization of two toxic phospholipases A2 from Indian cobra (Naja naja naja) venom.
Carcinoma, Ehrlich Tumor
Hypotonic cell swelling induces translocation of the alpha isoform of cytosolic phospholipase A2 but not the gamma isoform in Ehrlich ascites tumor cells.
Carcinoma, Ehrlich Tumor
The high calcium ion uptake capacity of Ehrlich ascites tumour cell mitochondria is due to inhibition of the permeability transition and phospholipase A2 activity by magnesium.
Carcinoma, Hepatocellular
85-kDa cPLA(2) plays a critical role in PPAR-mediated gene transcription in human hepatoma cells.
Carcinoma, Hepatocellular
A novel phospholipase A2 associated with nuclear matrix: stimulation of the activity and modulation of the Ca2+ dependency by polyphosphoinositides.
Carcinoma, Hepatocellular
A phase II study of oral clofazimine in unresectable and metastatic hepatocellular carcinoma.
Carcinoma, Hepatocellular
Aryl hydrocarbon receptor-mediated induction of the cytosolic phospholipase A(2)alpha gene by 2,3,7,8-tetrachlorodibenzo-p-dioxin in mouse hepatoma Hepa-1c1c7 cells.
Carcinoma, Hepatocellular
Coordinate expression of group II phospholipase A2 and the acute-phase proteins haptoglobin (HP) and alpha1-anti-chymotrypsin (ACH) by HepG2 cells.
Carcinoma, Hepatocellular
Dysfunction of PLA2G6 and CYP2C44-associated network signals imminent carcinogenesis from chronic inflammation to hepatocellular carcinoma.
Carcinoma, Hepatocellular
Elevated Expression of Cytosolic Phospholipase A2 Delta Is Associated with Lipid Metabolism Dysregulation during Hepatocellular Carcinoma Progression.
Carcinoma, Hepatocellular
Enhanced expression of group II phospholipase A2 in human hepatocellular carcinoma.
Carcinoma, Hepatocellular
Glucocorticoids inhibit oncostatin M-induced phospholipase A2 gene expression in human hepatoma cells.
Carcinoma, Hepatocellular
Glycogen synthase kinase-3beta negatively regulates group IIA phospholipase A2 expression in human aortic smooth muscle and HepG2 hepatoma cells.
Carcinoma, Hepatocellular
Identification of differentially expressed proteins between human hepatoma and normal liver cell lines by two-dimensional electrophoresis and liquid chromatography-ion trap mass spectrometry.
Carcinoma, Hepatocellular
In situ reverse transcriptase-nested polymerase chain reaction to identify intracellular nucleic acids without the necessity of DNAse pretreatment and hybridisation.
Carcinoma, Hepatocellular
Induction of phospholipase A2 gene expression in human hepatoma cells by mediators of the acute phase response.
Carcinoma, Hepatocellular
Inhibitory effects of inhibitors of arachidonic acid metabolism on the evolution of rat liver preneoplastic foci into nodules and hepatocellular carcinomas with or without phenobarbital exposure.
Carcinoma, Hepatocellular
Membrane phospholipid composition, fluidity and phospholipase A2 activity of human hepatoma cell line HepG2.
Carcinoma, Hepatocellular
Phospholipase A in the plasma membranes in ascites hepatomas and of normal livers in rat.
Carcinoma, Hepatocellular
Purification and characterization of nuclear alkaline phospholipase A2 in rat ascites hepatoma cells.
Carcinoma, Hepatocellular
Purification and properties of a membrane-bound phospholipase A2 from rat ascites hepatoma 108A cells.
Carcinoma, Hepatocellular
Significant Association Between Adiponutrin and Hepatocellular Carcinoma Risk.
Carcinoma, Hepatocellular
Statins potentiate the IFN-gamma-induced upregulation of group IIA phospholipase A2 in human aortic smooth muscle cells and HepG2 hepatoma cells.
Carcinoma, Hepatocellular
The assembly of very low density lipoproteins in rat hepatoma McA-RH7777 cells is inhibited by phospholipase A2 antagonists.
Carcinoma, Hepatocellular
The ménage à trois of autophagy, lipid droplets and liver disease.
Carcinoma, Hepatocellular
The phospholipase A2 activity of peroxiredoxin 6 promotes cancer cell death induced by tumor necrosis factor alpha in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Urocortin affects migration of hepatic cancer cell lines via differential regulation of cPLA2 and iPLA2.
Carcinoma, Non-Small-Cell Lung
A blood biomarker for monitoring response to anti-EGFR therapy.
Carcinoma, Non-Small-Cell Lung
Differential Expression And Effects Of Peroxiredoxin-6 On Drug Resistance And Cancer Stem Cell-Like Properties In Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Group IIa sPLA2 inhibition attenuates NF-?B activity and promotes apoptosis of lung cancer cells.
Carcinoma, Non-Small-Cell Lung
Identification of peroxiredoxin 6 as a direct target of withangulatin A by quantitative chemical proteomics in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Induction of cPLA2 in lung epithelial cells and non-small cell lung cancer is mediated by Sp1 and c-Jun.
Carcinoma, Non-Small-Cell Lung
Induction of cytosolic phospholipase A2 by oncogenic Ras in human non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Nucleolin regulates c-Jun/Sp1-dependent transcriptional activation of cPLA2alpha in phorbol ester-treated non-small cell lung cancer A549 cells.
Carcinoma, Non-Small-Cell Lung
Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines.
Carcinoma, Ovarian Epithelial
Elevated and secreted phospholipase A2 activities as new potential therapeutic targets in human epithelial ovarian cancer.
Carcinoma, Pancreatic Ductal
Immunohistochemical localization of group II phospholipase A2 in human pancreatic carcinomas.
Carcinoma, Squamous Cell
Context-dependent effect of sPLA2-IIA induced proliferation on murine hair follicle stem cells and human epithelial cancer.
Carcinoma, Squamous Cell
Crotoxin enhances the antitumor activity of gefinitib (Iressa) in SK-MES-1 human lung squamous carcinoma cells.
Carcinoma, Squamous Cell
Dual role of the antioxidant enzyme peroxiredoxin 6 in skin carcinogenesis.
Carcinoma, Squamous Cell
Enhancement of prostaglandin E2 production by epidermal growth factor requires the coordinate activation of cytosolic phospholipase A2 and cyclooxygenase 2 in human squamous carcinoma A431 cells.
Carcinoma, Squamous Cell
Expression of cytosolic phospholipase A2 and cyclooxygenase 2 and their significance in human oral mucosae, dysplasias and squamous cell carcinomas.
Carcinoma, Squamous Cell
Increased expression of peroxiredoxin 6 and cyclophilin A in squamous cell carcinoma of the tongue.
Carcinoma, Squamous Cell
Secretory phospholipase A(2) inhibits epidermal growth factor-induced receptor activation.
Carcinoma, Squamous Cell
Triosephosphate isomerase and peroxiredoxin 6, two novel serum markers for human lung squamous cell carcinoma.
Cardiomyopathies
HILIC-MS-based metabolomics reveal that Astragalus polysaccharide alleviates doxorubicin-induced cardiomyopathy by regulating sphingolipid and glycerophospholipid homeostasis.
Cardiomyopathies
Therapeutic potential of cPLA2 inhibitor to counteract dilated-cardiomyopathy in cholesterol-treated H9C2 cardiomyocyte and MUNO rat.
Cardiomyopathy, Dilated
Secreted Phospholipase A2-IIA Modulates Transdifferentiation of Cardiac Fibroblast through EGFR Transactivation: An Inflammation-Fibrosis Link.
Cardiotoxicity
Cardiotoxicity of Naja nigricollis phospholipase A2 is not due to alterations in prostaglandin synthesis.
Cardiotoxicity
Cobra cardiotoxin and phospholipase A2 as GAG-binding toxins: on the path from structure to cardiotoxicity and inflammation.
Cardiotoxicity
Complete amino acid sequence of an acidic, cardiotoxic phospholipase A2 from the venom of Ophiophagus hannah (King Cobra): a novel cobra venom enzyme with "pancreatic loop".
Cardiotoxicity
Crystallization and preliminary X-ray analysis of cardiotoxic phospholipase A2 from Ophiophagus hannah (king cobra).
Cardiotoxicity
Dissecting Cellular Mechanisms of Long-Chain Acylcarnitines-Driven Cardiotoxicity: Disturbance of Calcium Homeostasis, Activation of Ca2+-Dependent Phospholipases, and Mitochondrial Energetics Collapse.
Cardiotoxicity
Effect of alkylation of tryptophan residues on the enzymatic and pharmacological properties of snake venom phospholipase A2.
Cardiotoxicity
Exploring the potent inhibitors and binding modes of phospholipase A2 through in silico investigation.
Cardiotoxicity
Exploring the structural and functional aspects of the phospholipase A2 from Naja spp.
Cardiotoxicity
Inhibition of membrane-associated calcium-independent phospholipase A2 as a potential culprit of anthracycline cardiotoxicity.
Cardiotoxicity
Is direct cardiotoxicity the primary cause of death following i.v. injection of the basic phospholipase A2 from Naja nigricollis venom?
Cardiotoxicity
Orthogonal optimization of prokaryotic expression of a natural snake venom phospholipase A2 inhibitor from Sinonatrix annularis.
Cardiotoxicity
Oxidant-induced inhibition of myocardial calcium-independent phospholipase A2.
Cardiotoxicity
Pyrazolo[3,4-d]pyrimidines as inhibitor of anti-coagulation and inflammation activities of phospholipase A 2 : insight from molecular docking studies.
Cardiotoxicity
Snake venom PLA2s inhibitors isolated from Brazilian plants: synthetic and natural molecules.
Cardiovascular Diseases
A-002 (Varespladib), a phospholipase A2 inhibitor, reduces atherosclerosis in guinea pigs.
Cardiovascular Diseases
Activated platelets contribute to oxidized low-density lipoproteins and dysfunctional high-density lipoproteins through a phospholipase A2-dependent mechanism.
Cardiovascular Diseases
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Cardiovascular Diseases
Association between type II secretory phospholipase A2 plasma concentrations and activity and cardiovascular events in patients with coronary heart disease.
Cardiovascular Diseases
Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the EPIC-Norfolk study.
Cardiovascular Diseases
Elevated Type II Secretory Phospholipase A2 Increases the Risk of Early Atherosclerosis in Patients with Newly Diagnosed Metabolic Syndrome.
Cardiovascular Diseases
Expression of type IIA secretory phospholipase A2 inhibits cholesteryl ester transfer protein activity in transgenic mice.
Cardiovascular Diseases
Future role for selective phospholipase A2 inhibitors in the prevention of atherosclerotic cardiovascular disease.
Cardiovascular Diseases
Group IIA Secretory Phospholipase A2 Predicts Graft Failure and Mortality in Renal Transplant Recipients by Mediating Decreased Kidney Function.
Cardiovascular Diseases
Group IIA Secretory Phospholipase A2, Vascular Inflammation, and Incident Cardiovascular Disease.
Cardiovascular Diseases
Human Secretary Phospholipase A2 Mutations and Their Clinical Implications.
Cardiovascular Diseases
Increased type IIA secretory phospholipase A(2) expression contributes to oxidative stress in end-stage renal disease.
Cardiovascular Diseases
Inhibitors of phospholipase A2 and their therapeutic potential: an update on patents (2012-2016).
Cardiovascular Diseases
Insights into the mechanism of inhibition of phospholipase A2 by resveratrol: An extensive molecular dynamics simulation and binding free energy calculation.
Cardiovascular Diseases
Limits of Mendelian Randomization Analyses in Selection of Secretory Phospholipase A2-IIA as a Valid Therapeutic Target for Prevention of Cardiovascular Disease.
Cardiovascular Diseases
Lipoprotein-associated and secretory phospholipase A2 in cardiovascular disease: the epidemiological evidence.
Cardiovascular Diseases
Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) and Future Risk of Type 2 Diabetes: Results from the Cardiovascular Health Study.
Cardiovascular Diseases
On the present and future role of Lp-PLA2 in atherosclerosis-related cardiovascular risk prediction and management.
Cardiovascular Diseases
Phospholipase A2 inhibitors in the treatment of atherosclerosis: a new approach moves forward in the clinic.
Cardiovascular Diseases
Phospholipase A2: its role in ADP- and thrombin-induced platelet activation mechanisms.
Cardiovascular Diseases
Polymorphism of Secretary PLA2G2A gene is Associated with its Serum level in Type2 Diabetes Mellitus Patients in Northern Iran.
Cardiovascular Diseases
Possible effects of lipoprotein-associated phospholipase A2 single-nucleotide polymorphisms on cardiovascular risk in patients with preeclampsia.
Cardiovascular Diseases
Reply: Limits of Mendelian Randomization Analyses in Selection of Secretory Phospholipase A2-IIA as a Valid Therapeutic Target for Prevention of Cardiovascular Disease.
Cardiovascular Diseases
Role of secretory phospholipase A? in women with metabolic syndrome.
Cardiovascular Diseases
Secretory Phospholipase A2-IIA and Cardiovascular Disease: a Mendelian randomization study.
Cardiovascular Diseases
The Molecular Basis for the Pharmacological Activity of Anthocyans.
Cardiovascular Diseases
The synergistic inhibition of atherogenesis in apoE-/- mice between pravastatin and the sPLA2 inhibitor varespladib (A-002).
Cardiovascular Diseases
The therapeutic potential of phospholipase A2 inhibitors in cardiovascular disease.
Cardiovascular Diseases
Tracking of secretory phospholipase A2 enzyme activity levels from childhood to adulthood: a 21-year cohort.
Cardiovascular Diseases
Type II secretory phospholipase A2 in cardiovascular disease: a mediator in atherosclerosis and ischemic damage to cardiomyocytes?
Carotid Artery Diseases
Association between PNPLA3 rs738409 G variant and MRI cerebrovascular disease biomarkers.
Carotid Artery Diseases
Cell adhesion molecules and secretory type II phospholipase A2 in relation to carotid atherosclerosis in patients with hypercholesterolaemia.
Carotid Artery Diseases
Circulating levels of secretory- and lipoprotein-associated phospholipase A2 activities: relation to atherosclerotic plaques and future all-cause mortality.
Carotid Artery Diseases
Metabolic syndrome and carotid intima-media thickness in young adults: roles of apolipoprotein B, apolipoprotein A-I, C-reactive protein, and secretory phospholipase A2: the cardiovascular risk in young Finns study.
Cataract
Age-related cataracts and Prdx 6: Correlation between severity of lens opacity, age, and the level of Prdx 6 expression.
Cataract
Engineered Sumoylation-Deficient Prdx6 Mutant Protein-Loaded Nanoparticles Provide Increased Cellular Defense and Prevent Lens Opacity.
Cataract
Fatty acids modulate the efficacy of lutein in cataract prevention: Assessment of oxidative and inflammatory parameters in rats.
Cataract
Group II phospholipase A2 content of tears in patients with senile cataract and primary open-angle glaucoma.
Cataract
TAT-mediated PRDX6 protein transduction protects against eye lens epithelial cell death and delays lens opacity.
Celiac Disease
Cytosolic PLA2 is required for CTL-mediated immunopathology of celiac disease via NKG2D and IL-15.
Cellulitis
Circulating Secretory Phospholipase A2 Activity following Snakebites and Its Relationship with Envenomation Status and Progression of Local Swelling.
Central Nervous System Infections
Cysteinyl leukotrienes as novel host factors facilitating Cryptococcus neoformans penetration into the brain.
Cerebral Infarction
Angiotensin II type 1 receptor blocker telmisartan reduces cerebral infarct volume and periinfarct cytosolic phospholipase A2 level in experimental stroke.
Cerebral Infarction
Changes and significance of serum CXCL-16, GDF-15, PLA-2 levels in patients with cerebral infarction.
Cerebral Infarction
Diagnostic value of combined serological markers in the detection of acute cerebral infarction.
Cerebral Infarction
Long non-coding RNA SNHG14 promotes microglia activation by regulating miR-145-5p/PLA2G4A in cerebral infarction.
Cerebrovascular Disorders
The role of secretory phospholipase A2 in the central nervous system and neurological diseases.
Chagas Disease
A phospholipase A2 gene is linked to Jack bean urease toxicity in the Chagas' disease vector Rhodnius prolixus.
Chagas Disease
Placental alkaline phosphatase (PLAP) enzyme activity and binding to IgG in Chagas' disease.
Chagas Disease
Trypanosoma cruzi infection is enhanced by vector saliva through immunosuppressant mechanisms mediated by lysophosphatidylcholine.
Chlamydophila Infections
Relation of secretory phospholipase A(2) and high-sensitivity C-reactive protein to Chlamydia pneumoniae infection in acute coronary syndromes.
Cholangiocarcinoma
Peroxiredoxin 6 expression is inversely correlated with nuclear factor-?B activation during Clonorchis sinensis infestation.
Cholangitis
Secretory low-molecular-weight phospholipases A2 and their specific receptor in bile ducts of patients with intrahepatic calculi: factors of chronic proliferative cholangitis.
Cholecystitis
Biochemical and morphological correlations in human gallbladder with reference to membrane permeability.
Cholecystitis
Experimental study on the pathogenesis of acute acalculous cholecystitis, with special reference to the roles of microcirculatory disturbances, free radicals and membrane-bound phospholipase A2.
Cholelithiasis
Effects of long-term ursodeoxycholate administration on expression levels of secretory low-molecular-weight phospholipases A2 and mucin genes in gallbladders and biliary composition in patients with multiple cholesterol stones.
Cholelithiasis
Partial characterization of proapoptotic action of biliary deteriorated lipids on biliary epithelial cells in pancreaticobiliary diseases.
Cholelithiasis
The common adiponutrin variant p.I148M does not confer gallstone risk but affects fasting glucose and triglyceride levels.
Cholera
Activation of a keratinocyte phospholipase A2 by bradykinin and 4 beta-phorbol 12-myristate 13-acetate. Evidence for a receptor-GTP-binding protein versus a protein-kinase-C mediated mechanism.
Cholera
Cholera toxin and pertussis toxin stimulate prostaglandin E2 synthesis in a murine macrophage cell line.
Cholera
Cyclic AMP mimics, but does not mediate, interleukin-1- and tumour-necrosis-factor-stimulated phospholipase A2 secretion from rat renal mesangial cells.
Cholera
Differential effects of T-lymphocyte-derived soluble factor on virgin and primed B lymphocytes in vitro.
Cholera
GTP-binding protein mediated phospholipase A2 activation in rat liver during the progression of sepsis.
Cholera
NMDA receptor-mediated arachidonic acid release in neurons: role in signal transduction and pathological aspects.
Cholera
PDGF-stimulated cyclic AMP formation in airway smooth muscle: assessment of the roles of MAP kinase, cytosolic phospholipase A2, and arachidonate metabolites.
Cholera
Permissive stimulation of Ca(2+)-induced phospholipase A2 by an adenosine receptor agonist in a pertussis toxin-sensitive manner in FRTL-5 thyroid cells: a new 'cross-talk' mechanism in Ca2+ signalling.
Cholera
Rapid membrane responses to dihydrotestosterone are sex dependent in growth plate chondrocytes.
Cholera
Release of phospholipase A2 activity from rat vascular smooth muscle cells mediated by cAMP.
Cholera
Renal action of cholera toxin: I. Effects on urinary excretion of electrolytes and cyclic AMP.
Cholera
Role of mast cells and pro-inflammatory mediators on the intestinal secretion induced by cholera toxin.
Cholera
Stepwise iodination. A general procedure for detoxification of proteins suitable for vaccine development and antiserum production.
Cholera
Studies of the ligand binding to cholera toxin, I. The lipophilic moiety of sialoglycolipids.
Cholestasis
Protective Effects of Bee Venom-Derived Phospholipase A2 against Cholestatic Liver Disease in Mice.
Choline Deficiency
Resolution of severe hepatosteatosis in a cystic fibrosis patient with multifactorial choline deficiency: A case report.
Chondrocalcinosis
Release of mast cell mediators and nitrites into knee joint fluid in osteoarthritis--comparison with articular chondrocalcinosis and rheumatoid arthritis.
Chronic Periodontitis
Activity of platelet activating factor acetylhydrolase following phase I periodontal therapy.
Chronic Periodontitis
IPLA2 mRNA expression by human neutrophils in type 2 diabetes and chronic periodontitis.
Cleft Palate
[Observing the distribution of Annexin I and cPLA2 in the palatal process of mice by immunohistochemical staining]
Clonorchiasis
Peroxiredoxin 6 expression is inversely correlated with nuclear factor-?B activation during Clonorchis sinensis infestation.
Coinfection
A tetracycline-regulated adenoviral expression system for in vivo delivery of transgenes to lung and liver.
Coinfection
Intrinsic phospholipase A2 activity of adeno-associated virus is involved in endosomal escape of incoming particles.
Colic
D-dimer improves the prognostic value of combined clinical and laboratory data in equine gastrointestinal colic.
Colitis
A potent and selective inhibitor of group IIa secretory phospholipase A2 protects rats from TNBS-induced colitis.
Colitis
Berberine Suppresses Colonic Inflammation in Dextran Sulfate Sodium-Induced Murine Colitis Through Inhibition of Cytosolic Phospholipase A2 Activity.
Colitis
Cytosolic phospholipase A2 ? has a crucial role in the pathogenesis of DSS-induced colitis in mice.
Colitis
Deficiency of Group VIA Phospholipase A2 (iPLA2?) Renders Susceptibility for Chemical-Induced Colitis.
Colitis
Effect of putative phospholipase A2 inhibitors on acetic acid-induced acute colitis in the rat.
Colitis
Group X Secreted Phospholipase A2 Releases ?3 Polyunsaturated Fatty Acids, Suppresses Colitis, and Promotes Sperm Fertility.
Colitis
Increase in permeability and phospholipase A2 activity of colonic mucosa in Crohn's colitis.
Colitis
Increased phospholipase A2 activity in peritoneal leukocytes in rat experimental colitis.
Colitis
Prdx6 deficiency ameliorates DSS colitis: relevance of compensatory antioxidant mechanisms.
Colitis
Role of group IIA phospholipase A2 in rat colitis induced by dextran sulfate sodium.
Colitis, Ulcerative
Elevation of phospholipase A2 protein in sera of patients with Crohn's disease and ulcerative colitis.
Colitis, Ulcerative
Gene expression of group II phospholipase A2 in intestine in ulcerative colitis.
Colitis, Ulcerative
Immunohistochemical localization of group II phospholipase A2 in colonic mucosa of patients with inflammatory bowel disease.
Colitis, Ulcerative
Increased group II phospholipase A2 in colonic mucosa of patients with Crohn's disease and ulcerative colitis.
Colitis, Ulcerative
Phospholipase A2 activating protein and idiopathic inflammatory bowel disease.
Colitis, Ulcerative
Phospholipase A2 activity of colonic mucosa in patients with ulcerative colitis.
Colitis, Ulcerative
Phospholipase A2 of Microbiota as Pathogenetic Determinant to Induce Inflammatory States in Ulcerative Colitis: Therapeutic Implications of Phospholipase A2 Inhibitors.
Colitis, Ulcerative
Raised serum activity of phospholipase A2 immunochemically related to group II enzyme in inflammatory bowel disease: its correlation with disease activity of Crohn's disease and ulcerative colitis.
Colitis, Ulcerative
Serum phospholipases A2 in patients undergoing panproctocolectomy because of severe ulcerative colitis.
Colonic Neoplasms
Activation of cPLA2 is required for leukotriene D4-induced proliferation in colon cancer cells.
Colonic Neoplasms
Cytoplasmic phospholipase A2 expression in human colon adenocarcinoma is correlated with cyclooxygenase-2 expression and contributes to prostaglandin E2 production.
Colonic Neoplasms
Distinct expression pattern of the full set of secreted phospholipases A2 in human colorectal adenocarcinomas: sPLA2-III as a biomarker candidate.
Colonic Neoplasms
Emerging roles for human glycolipid transfer protein superfamily members in the regulation of autophagy, inflammation, and cell death.
Colonic Neoplasms
Group X phospholipase A2 stimulates the proliferation of colon cancer cells by producing various lipid mediators.
Colonic Neoplasms
High molecular weight phospholipase A2: its occurrence and quantification in human colon cancer and normal mucosa.
Colonic Neoplasms
Hypertonic environment elicits cyclooxygenase-2-driven prostaglandin E2 generation by colon cancer cells: role of cytosolic phospholipase A2-alpha and kinase signaling pathways.
Colonic Neoplasms
Identification of Metabolic-Associated Genes for the Prediction of Colon and Rectal Adenocarcinoma.
Colonic Neoplasms
Increased expression and activity of group IIA and X secretory phospholipase A2 in peritumoral versus central colon carcinoma tissue.
Colonic Neoplasms
Inhibition of cytosolic phospholipase A2 mRNA expression: a novel mechanism for acetylsalicylic acid-mediated growth inhibition and apoptosis in colon cancer cells.
Colonic Neoplasms
Overexpression of the nonpancreatic secretory group II PLA2 messenger RNA and protein in colorectal adenomas from familial adenomatous polyposis patients.
Colonic Neoplasms
Oxidative alterations induced in vitro by the photodynamic reaction in doxorubicin-sensitive (LoVo) and -resistant (LoVoDX) colon adenocarcinoma cells.
Colonic Neoplasms
Peroxiredoxins and Immune Infiltrations in Colon Adenocarcinoma: Their Negative Correlations and Clinical Significances, an In Silico Analysis.
Colonic Neoplasms
Potential role of group X secretory phospholipase A(2) in cyclooxygenase-2-dependent PGE(2) formation during colon tumorigenesis.
Colorectal Neoplasms
Absence of secretory phospholipase A2 gene alterations in human colorectal cancer.
Colorectal Neoplasms
Activities of phospholipase A2 and diacylglycerol lipase are increased in human colorectal cancer.
Colorectal Neoplasms
Cytoplasmic phospholipase A2 alpha overexpression in stromal cells is correlated with angiogenesis in human colorectal cancer.
Colorectal Neoplasms
Cytoplasmic phospholipase A2 expression in human colon adenocarcinoma is correlated with cyclooxygenase-2 expression and contributes to prostaglandin E2 production.
Colorectal Neoplasms
Elevated plasma phospholipase A2 and platelet-activating factor acetylhydrolase activity in colorectal cancer.
Colorectal Neoplasms
Expression of PRDX6 Correlates with Migration and Invasiveness of Colorectal Cancer Cells.
Colorectal Neoplasms
Flavonoids Identified from Korean Scutellaria baicalensis Induce Apoptosis by ROS Generation and Caspase Activation on Human Fibrosarcoma Cells.
Colorectal Neoplasms
Gene expression of cyclooxygenase-2, group II and cytosolic phospholipase A2 in human colorectal cancer.
Colorectal Neoplasms
Homeodomain-interacting protein kinase-2 restrains cytosolic phospholipase A2-dependent prostaglandin E2 generation in human colorectal cancer cells.
Colorectal Neoplasms
Impacts of cytosolic phospholipase A2, 15-prostaglandin dehydrogenase, and cyclooxygenase-2 expressions on tumor progression in colorectal cancer.
Colorectal Neoplasms
Increased lipid peroxidation in malignant tissues of patients with colorectal cancer.
Colorectal Neoplasms
Inhibition of cytosolic phospholipase A2 mRNA expression: a novel mechanism for acetylsalicylic acid-mediated growth inhibition and apoptosis in colon cancer cells.
Colorectal Neoplasms
Overexpression of the nonpancreatic secretory group II PLA2 messenger RNA and protein in colorectal adenomas from familial adenomatous polyposis patients.
Colorectal Neoplasms
Phospholipase A2 Group III and Group X Have Opposing Associations with Prognosis in Colorectal Cancer.
Colorectal Neoplasms
PLA2G4A mutants modified protective effect of tea consumption against colorectal cancer.
Colorectal Neoplasms
PLA2G4A promotes right-sided colorectal cancer progression by inducing CD39+?? Treg polarization.
Colorectal Neoplasms
Prognostic significance of cytosolic phospholipase A2 expression in patients with colorectal cancer.
Colorectal Neoplasms
Prognostic significance of PLA2G4C gene polymorphism in patients with stage II colorectal cancer.
Colorectal Neoplasms
Relationship between polymorphisms of the lipid metabolism-related gene PLA2G16 and risk of colorectal cancer in the Chinese population.
Colorectal Neoplasms
Secretory type II phospholipase A2 (PLA2G2A) expression status in colorectal carcinoma derived cell lines and in normal colonic mucosa.
Colorectal Neoplasms
Targeting cytosolic phospholipase A2 ? in colorectal cancer cells inhibits constitutively activated protein kinase B (AKT) and cell proliferation.
Colorectal Neoplasms
The expression and distribution of group IIA phospholipase A2 in human colorectal tumours.
Colorectal Neoplasms
The expression of phospholipase A2 group X is inversely associated with metastasis in colorectal cancer.
Colorectal Neoplasms
Variants at the secretory phospholipase A2 (PLA2G2A) locus: analysis of associations with familial adenomatous polyposis and sporadic colorectal tumours.
Colorectal Neoplasms
[Increased phospholipase A2 and diacylglycerol lipase activities in colorectal carcinoma: possibility for carcinoma prevention or therapy?]
Coma
Severe and fatal mass attacks by 'killer' bees (Africanized honey bees--Apis mellifera scutellata) in Brazil: clinicopathological studies with measurement of serum venom concentrations.
Communicable Diseases
Level of circulating phospholipase A2 in prediction of the prognosis of patients with suspected myocardial infarction.
Communicable Diseases
Mammalian secreted phospholipases A2 and their pathophysiological significance in inflammatory diseases.
Conjunctivitis
Suppressive effect of antiflammin-2 on compound 48/80-induced conjunctivitis. Role of phospholipase A2s and inducible nitric oxide synthase.
Conjunctivitis, Allergic
Quantification of tear proteins and sPLA2-IIa alteration in patients with allergic conjunctivitis.
Contracture
A phospholipase A2 inhibitor (Ro 31-4493) prevents protein loss associated with the calcium paradox in isolated guinea pig hearts without effect on contracture, calcium overload, or the currents through L-type calcium channels.
Contracture
Arachidonic acid and its metabolites are involved in the expression of morphine dependence in guinea-pig isolated ileum.
Contracture
Characterization of a myotoxin from the Duvernoy's gland secretion of the xenodontine colubrid Philodryas olfersii (green snake): effects on striated muscle and the neuromuscular junction.
Contracture
Contracture induction by snake venom cardiotoxin in skeletal muscle from humans and rats.
Contracture
Effects of an acidic phospholipase A2 purified from Ophiophagus hannah (king cobra) venom on rat heart.
Contracture
Functional characterization of a basic D49 phospholipase A2 (LmTX-I) from the venom of the snake Lachesis muta muta (bushmaster).
Contracture
Identification of phospholipase A2 and neurotoxic activities in the venom of the New Guinean small-eyed snake (Micropechis ikaheka).
Contracture
In vitro muscle contractures induced by halothane and suxamethonium. I: The rat diaphragm.
Contracture
In vitro muscle contractures induced by halothane and suxamethonium. II: Human skeletal muscle from normal and malignant hyperthermia susceptible patients.
Contracture
Mode of neuromuscular blocking action of toxic phospholipases A2 from Vipera ammodytes venom.
Contracture
Neuromuscular effects of nigexine, a basic phospholipase A2 from Naja nigricollis venom.
Contracture
Neurotoxic and myotoxic actions of crotoxin-like and Crotalus durissus cascavella whole venom in the chick biventer cervicis preparation.
Contracture
Neurotoxic and myotoxic effects of crotalus phospholipase A and its complex with crotapotin.
Contracture
Pharmacological and structural characterization of a novel phospholipase A2 from Micrurus dumerilii carinicauda venom.
Contracture
Possible mechanisms of action of cobra snake venom cardiotoxins and bee venom melittin.
Contracture
The role of enzyme activity and charge properties on the presynaptic neurotoxicity and the contracture-inducing activity of snake venom phospholipases A2.
Corneal Diseases
Mutation of the phospholipase catalytic domain of the Pseudomonas aeruginosa cytotoxin ExoU abolishes colonization promoting activity and reduces corneal disease severity.
Coronary Artery Disease
After FRANCIS: next steps in the clinical evaluation of varespladib methyl.
Coronary Artery Disease
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Coronary Artery Disease
Angiotensin II type 1-receptor antagonism prevents type IIA secretory phospholipase A2-dependent lipid peroxidation.
Coronary Artery Disease
Association between serum secretory phospholipase A2 and risk of ischaemic stroke.
Coronary Artery Disease
Association of biomarkers of lipid modification with functional and morphological indices of coronary stenosis severity in stable coronary artery disease.
Coronary Artery Disease
Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease.
Coronary Artery Disease
Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes.
Coronary Artery Disease
Comparison of the Effects of Combination Atorvastatin (40 mg) + Ezetimibe (10 mg) Versus Atorvastatin (40 mg) Alone on Secretory Phospholipase A2 Activity in Patients With Stable Coronary Artery Disease or Coronary Artery Disease Equivalent.
Coronary Artery Disease
Darapladib, a reversible lipoprotein-associated phospholipase A2 inhibitor, for the oral treatment of atherosclerosis and coronary artery disease.
Coronary Artery Disease
Discovery of AZD2716: A Novel Secreted Phospholipase A2 (sPLA2) Inhibitor for the Treatment of Coronary Artery Disease.
Coronary Artery Disease
Elevated secretory non-pancreatic type II phospholipase A2 serum activity is associated with impaired endothelial vasodilator function in patients with coronary artery disease.
Coronary Artery Disease
Exploring calcium ion-dependent effect on the intermolecular interaction between human secreted phospholipase A2 and its peptide inhibitors in coronary artery disease.
Coronary Artery Disease
Group X secreted phospholipase A2 limits the development of atherosclerosis in LDL receptor-null mice.
Coronary Artery Disease
Impact of a combined treatment of angiotensin II type 1 receptor blockade and 3-hydroxy-3-methyl-glutaryl-CoA-reductase inhibition on secretory phospholipase A2-type IIA and low density lipoprotein oxidation in patients with coronary artery disease.
Coronary Artery Disease
Increase in plasma levels of secretory type II phospholipase A(2) in patients with coronary spastic angina.
Coronary Artery Disease
Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase.
Coronary Artery Disease
Molecular and functional characterization of polymorphisms in the secreted phospholipase A2 group X gene: relevance to coronary artery disease.
Coronary Artery Disease
Novel insights of secretory phospholipase a(2) action in cardiology.
Coronary Artery Disease
Prognostic utility of secretory phospholipase A2 in patients with stable coronary artery disease.
Coronary Artery Disease
Prognostic value and the changes of plasma levels of secretory type II phospholipase A2 in patients with coronary artery disease undergoing percutaneous coronary intervention.
Coronary Artery Disease
Relation of secretory phospholipase A(2) and high-sensitivity C-reactive protein to Chlamydia pneumoniae infection in acute coronary syndromes.
Coronary Artery Disease
Relationship between plasma phospholipase A2 concentrations and lipoprotein subfractions in patients with stable coronary artery disease.
Coronary Artery Disease
Secretory phospholipase A2 activity in blood serum: The challenge to sense.
Coronary Artery Disease
Secretory phospholipase A2 in patients with coronary artery disease.
Coronary Artery Disease
Secretory type II phospholipase A(2) binds to ischemic myocardium during myocardial infarction in humans.
Coronary Artery Disease
Secretory type II phospholipase A2 is produced and secreted by epicardial adipose tissue and overexpressed in patients with coronary artery disease.
Coronary Artery Disease
Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study.
Coronary Artery Disease
Serum secretory phospholipase A2-IIa (sPLA2-IIA) levels in patients surviving acute myocardial infarction.
Coronary Artery Disease
Tagging-SNP haplotype analysis of the secretory PLA2IIa gene PLA2G2A shows strong association with serum levels of sPLA2IIa: results from the UDACS study.
Coronary Artery Disease
Varespladib methyl, an oral phospholipase A2 inhibitor for the potential treatment of coronary artery disease.
Coronary Disease
A Novel Genetic Approach to Investigate the Role of Plasma Secretory Phospholipase A2 (sPLA2)-V Isoenzyme in Coronary Heart Disease: A Modified Mendelian Randomization Analysis Using PLA2G5 Expression Levels.
Coronary Disease
Association between type II secretory phospholipase A2 plasma concentrations and activity and cardiovascular events in patients with coronary heart disease.
Coronary Disease
Cardiovascular and Lifestyle Risk Factors and Cognitive Function in Patients With Stable Coronary Heart Disease.
Coronary Disease
Coronary heart disease and genetic variants with low phospholipase A2 activity.
Coronary Disease
Deciphering the Causal Role of sPLA2s and Lp-PLA2 in Coronary Heart Disease.
Coronary Disease
Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial.
Coronary Disease
Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase.
Coronary Disease
Inflammatory biomarkers and the prediction of coronary events among people at intermediate risk: the EPIC-Norfolk prospective population study.
Coronary Disease
Neutralization of Inflammation by Inhibiting In vitro and In vivo Secretory Phospholipase A2 by Ethanol Extract of Boerhaavia diffusa L.
Coronary Disease
New quinoxalinone inhibitors targeting secreted phospholipase A2 and ?-glucosidase.
Coronary Disease
Phospholipase A2 inhibition and atherosclerotic vascular disease: prospects for targeting secretory and lipoprotein-associated phospholipase A2 enzymes.
Coronary Disease
Potential role of lysophosphatidic acid in hypertension and atherosclerosis.
Coronary Disease
Prediction of Residual Risk by Ceramide-Phospholipid Score in Patients With Stable Coronary Heart Disease on Optimal Medical Therapy.
Coronary Disease
Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease.
Coronary Disease
Secretory Phospholipase A2 Is Associated with the Odds of Acute Coronary Syndromes through Elevation of Serum Amyloid-A Protein.
Coronary Disease
Tagging SNP haplotype analysis of the secretory PLA2-V gene, PLA2G5, shows strong association with LDL and oxLDL levels, suggesting functional distinction from sPLA2-IIA: results from the UDACS study.
Coronary Disease
The association of PLA2G2A single nucleotide polymorphisms with type IIa secretory phospholipase A2 level but not its activity in patients with stable coronary heart disease.
Coronary Disease
The role of inflammatory biomarkers in developing targeted cardiovascular therapies: lessons from the cardiovascular inflammation reduction trials.
Coronary Disease
Type II Secretory Phospholipase A(2) and Prognosis in Patients with Stable Coronary Heart Disease: Mendelian Randomization Study.
Coronary Disease
[Elevated serum secretory type II phospholipase A2 in patients with coronary heart disease]
Coronary Occlusion
Inhibitory effect of quinacrine on myocardial reactive hyperemia in the dog.
Coronary Stenosis
Association of biomarkers of lipid modification with functional and morphological indices of coronary stenosis severity in stable coronary artery disease.
Coronavirus Infections
Coronavirus-specific antibody production in middle-aged mice requires phospholipase A2G2D.
COVID-19
Abnormal upregulation of cardiovascular disease biomarker PLA2G7 induced by proinflammatory macrophages in COVID-19 patients.
COVID-19
Group IIA secreted phospholipase A2 is associated with the pathobiology leading to COVID-19 mortality.
COVID-19
Large-Scale Plasma Analysis Revealed New Mechanisms and Molecules Associated with the Host Response to SARS-CoV-2.
COVID-19
Non-Toxic Dimeric Peptides Derived from the Bothropstoxin-I Are Potent SARS-CoV-2 and Papain-like Protease Inhibitors.
COVID-19
Secretory phospholipase A2 in SARS-CoV-2 infection and multisystem inflammatory syndrome in children (MIS-C).
COVID-19
Thymulin and peroxiredoxin 6 have protective effects against streptozotocin-induced type 1 diabetes in mice.
Cowpox
Involvement of caspase-dependent activation of cytosolic phospholipase A2 in tumor necrosis factor-induced apoptosis.
Crohn Disease
Decreased lysophospholipase and increased phospholipase A2 activity in ileal mucosa from patients with Crohn's disease.
Crohn Disease
Elevated group II phospholipase A2 mass concentration in serum and colonic mucosa in Crohn's disease.
Crohn Disease
Elevation of phospholipase A2 protein in sera of patients with Crohn's disease and ulcerative colitis.
Crohn Disease
Gene expression of group II phospholipase A2 in intestine in Crohn's disease.
Crohn Disease
Glucocorticoid treatment in ileal Crohn's disease: relief of symptoms but not of endoscopically viewed inflammation.
Crohn Disease
Immunohistochemical localization of group II phospholipase A2 in colonic mucosa of patients with inflammatory bowel disease.
Crohn Disease
In favour of prophylactic treatment for post-operative recurrence in Crohn's disease.
Crohn Disease
Increase in permeability and phospholipase A2 activity of colonic mucosa in Crohn's colitis.
Crohn Disease
Increased group II phospholipase A2 in colonic mucosa of patients with Crohn's disease and ulcerative colitis.
Crohn Disease
Initiation of anastomotic recurrence of Crohn's disease after ileocolic resection. Onset proximal to the junction and preceded by increased phospholipase A2 activity.
Crohn Disease
Neutralization of Inflammation by Inhibiting In vitro and In vivo Secretory Phospholipase A2 by Ethanol Extract of Boerhaavia diffusa L.
Crohn Disease
Paneth cell antimicrobial peptides: Topographical distribution and quantification in human gastrointestinal tissues.
Crohn Disease
Phospholipase A2 activating protein and idiopathic inflammatory bowel disease.
Crohn Disease
Phospholipase A2 gene expression and activity in histologically normal ileal mucosa and in Crohn's ileitis.
Crohn Disease
Possible Involvement of Intracellular Calcium-Independent Phospholipase A2 in the Release of Secretory Phospholipases from Mast Cells-Increased Expression in Ileal Mast Cells of Crohn's Disease.
Crohn Disease
Presence of group IIa secretory phospholipase A2 in mast cells and macrophages in normal human ileal submucosa and in Crohn's disease.
Crohn Disease
Raised serum activity of phospholipase A2 immunochemically related to group II enzyme in inflammatory bowel disease: its correlation with disease activity of Crohn's disease and ulcerative colitis.
Crohn Disease
Reduction of circulating secretory phospholipase A2 levels by anti-tumor necrosis factor chimeric monoclonal antibody in patients with severe Crohn's disease. Relation between tumor necrosis factor and secretory phospholipase A2 in healthy humans and in active Crohn's disease.
Crohn Disease
Value of blood tests including serum group IIA phospholipase A2 and bactericidal/permeability-increasing protein in Crohn's disease.
Cryptorchidism
Recessive truncating NALCN mutation in infantile neuroaxonal dystrophy with facial dysmorphism.
Cystic Fibrosis
Adenosine regulation of cystic fibrosis transmembrane conductance regulator through prostenoids in airway epithelia.
Cystic Fibrosis
Children with cystic fibrosis produce an immune response against exoenzyme S, a type III cytotoxin of Pseudomonas aeruginosa.
Cystic Fibrosis
Differential stimulation of cytosolic phospholipase A2 by bradykinin in human cystic fibrosis cell lines.
Cystic Fibrosis
Effect of allergy and inflammation on eicosanoid gene expression in CFTR deficiency.
Cystic Fibrosis
Impact of CFTR DeltaF508 mutation on prostaglandin E2 production and type IIA phospholipase A2 expression by pulmonary epithelial cells.
Cystic Fibrosis
Increase of bradykinin-stimulated arachidonic acid release in a delta F508 cystic fibrosis epithelial cell line.
Cystic Fibrosis
Pancreatic lipase and phospholipase A2 concentration in amniotic fluid and the prenatal diagnosis of cystic fibrosis.
Cystic Fibrosis
Rattlesnake Phospholipase A2 Increases CFTR-Chloride Channel Current and Corrects ?F508CFTR Dysfunction: Impact in Cystic Fibrosis.
Cystitis, Interstitial
Prostacyclin production in tryptase and thrombin stimulated human bladder endothelial cells: effect of pretreatment with phospholipase A2 and cyclooxygenase inhibitors.
Cysts
Cyclooxygenase-2 and Cytosolic Phospholipase A2 Are Overexpressed in Mucinous Pancreatic Cysts.
Cysts
LPAR2 and LPAR4 are the Main Receptors Responsible for LPA Actions in Ovarian Endometriotic Cysts.
Darier Disease
Association study of bipolar disorder at the phospholipase A2 gene (PLA2A) in the Darier's disease (DAR) region of chromosome 12q23-q24.1.
Darier Disease
Genetic association between the phospholipase A2 gene and unipolar affective disorder: a multicentre case-control study.
Dehydration
Catalytic Ca2+-binding site of pancreatic phospholipase A2: laser-induced Eu3+ luminescence study.
Dehydration
Critical role of cytosolic phospholipase a2{alpha} in bronchial mucus hyper-secretion in CFTR-deficient mice.
Dehydration
Dehydration of the lipid-protein microinterface on binding of phospholipase A2 to lipid bilayers.
Dementia
Decreased phospholipase A2 activity in cerebrospinal fluid of patients with dementia.
Dementia
Genetic deficiency of plasma lipoprotein-associated phospholipase A2 (PLA2G7 V297F null mutation) and risk of Alzheimer's disease in Japan.
Dementia
Low platelet iPLA2 activity predicts conversion from mild cognitive impairment to Alzheimer's disease: a 4-year follow-up study.
Dementia
Phenotypic spectrum of patients with PLA2G6 mutation and PARK14-linked parkinsonism.
Dementia
PRDX6 Exacerbates Dopaminergic Neurodegeneration in a MPTP Mouse Model of Parkinson's Disease.
Dementia, Vascular
Platelet phospholipase A(2) activity in patients with Alzheimer's disease, vascular dementia and ischemic stroke.
Demyelinating Diseases
Effects of phospholipase A2 on lumbar nerve root structure and function.
Demyelinating Diseases
Krabbe disease: psychosine-mediated activation of phospholipase A2 in oligodendrocyte cell death.
Demyelinating Diseases
Phospholipase A2 is involved in galactosylsphingosine-induced astrocyte toxicity, neuronal damage and demyelination.
Demyelinating Diseases
PRDX6 controls multiple sclerosis by suppressing inflammation and blood brain barrier disruption.
Dengue
Crotoxin and phospholipases A(2) from Crotalus durissus terrificus showed antiviral activity against dengue and yellow fever viruses.
Dengue
Inflammatory mediators in dengue virus infection in children: interleukin-6 and its relation to C-reactive protein and secretory phospholipase A2.
Dengue
Insights into the antiviral activity of phospholipases A2 (PLA2s) from snake venoms.
Dengue
MAP-Kinase Regulated Cytosolic Phospholipase A2 Activity Is Essential for Production of Infectious Hepatitis C Virus Particles.
Dengue
Phospholipase A2 isolated from the venom of Crotalus durissus terrificus inactivates dengue virus and other enveloped viruses by disrupting the viral envelope.
Dengue
Rapid phospholipase A2 stimulation and diacylglycerol cholinephosphotransferase inhibition in baby hamster kidney cells during initiation of dengue virus infection.
Dermatitis
Oleanonic acid, a 3-oxotriterpene from Pistacia, inhibits leukotriene synthesis and has anti-inflammatory activity.
Dermatitis, Atopic
Arachidonate release and eicosanoid generation by group IIE phospholipase A(2).
Dermatitis, Atopic
Bee Venom Phospholipase A2 Ameliorates House Dust Mite Extract Induced Atopic Dermatitis Like Skin Lesions in Mice.
Dermatitis, Atopic
CD1a presentation of endogenous antigens by group 2 innate lymphoid cells.
Dermatitis, Atopic
Cellular arachidonate-releasing function and inflammation-associated expression of group IIF secretory phospholipase A2.
Dermatitis, Atopic
Evaluation of patatin as a major cross-reactive allergen in latex-induced potato allergy.
Dermatitis, Atopic
Inhibitors of phospholipase A2 and their therapeutic potential: an update on patents (2012-2016).
Dermatitis, Atopic
Positive skin and oral challenge responses to potato and occurrence of immunoglobulin E antibodies to patatin (Sol t 1) in infants with atopic dermatitis.
Dermatitis, Atopic
The design and discovery of phospholipase A2 inhibitors for the treatment of inflammatory diseases.
Dermatitis, Atopic
The Genetics of Chronic Itch: Gene Expression in the Skin of Patients with Atopic Dermatitis and Psoriasis with Severe Itch.
Dermatitis, Atopic
[Pathobiochemical importance of phospholipases for the release of mast cell mediators]
Dermatitis, Contact
A novel treatment of contact dermatitis by topical application of phospholipase A2 inhibitor: a double-blind placebo-controlled pilot study.
Dermatitis, Contact
Lymphoid tissue phospholipase A2 group IID resolves contact hypersensitivity by driving antiinflammatory lipid mediators.
Diabetes Mellitus
A single nucleotide polymorphism (SNP) rs2072907 in the adiponutrin gene (ADPN) was not associated with obesity and type 2 diabetes in Chinese population.
Diabetes Mellitus
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Diabetes Mellitus
Association of a F479L variant in the cytosolic phospholipase A2 gene (PLA2G4A) with decreased glucose turnover and oxidation rates in Pima Indians.
Diabetes Mellitus
Comparison of the Effects of Combination Atorvastatin (40 mg) + Ezetimibe (10 mg) Versus Atorvastatin (40 mg) Alone on Secretory Phospholipase A2 Activity in Patients With Stable Coronary Artery Disease or Coronary Artery Disease Equivalent.
Diabetes Mellitus
Decreased phospholipase A2 activity in plasma and liver in uncontrolled diabetes mellitus. A defect in the early steps of prostaglandin synthesis?
Diabetes Mellitus
Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus.
Diabetes Mellitus
Eicosanoid production and phospholipase A2 activity in uterine tissue from castrated rats with non-insulin dependent diabetes mellitus.
Diabetes Mellitus
Genetic variants of PLA2G6 are associated with Type 2 diabetes mellitus and triglyceride levels in a Chinese population.
Diabetes Mellitus
Group VIA Phospholipase A2 Mediates Enhanced Macrophage Migration in Diabetes Mellitus by Increasing Expression of Nicotinamide Adenine Dinucleotide Phosphate Oxidase 4.
Diabetes Mellitus
Increased glomerular cytosolic phospholipase A2 activity of OLETF rats with early diabetes.
Diabetes Mellitus
Peroxiredoxin 6 Attenuates Alloxan-Induced Type 1 Diabetes Mellitus in Mice and Cytokine-Induced Cytotoxicity in RIN-m5F Beta Cells.
Diabetes Mellitus
Peroxiredoxin6, a Multitask Antioxidant Enzyme Involved in the Pathophysiology of Chronic Noncommunicable Diseases.
Diabetes Mellitus
Polymorphism of Secretary PLA2G2A gene is Associated with its Serum level in Type2 Diabetes Mellitus Patients in Northern Iran.
Diabetes Mellitus
Protective Effect of Peroxiredoxin 6 Against Toxic Effects of Glucose and Cytokines in Pancreatic RIN-m5F ?-Cells.
Diabetes Mellitus
Spontaneous development of endoplasmic reticulum stress that can lead to diabetes mellitus is associated with higher calcium-independent phospholipase A2 expression: a role for regulation by SREBP-1.
Diabetes Mellitus
The association of PLA2G2A single nucleotide polymorphisms with type IIa secretory phospholipase A2 level but not its activity in patients with stable coronary heart disease.
Diabetes Mellitus
Thymulin and peroxiredoxin 6 have protective effects against streptozotocin-induced type 1 diabetes in mice.
Diabetes Mellitus
[Erythrocyte lipid composition at different stages of type 1 diabetes in children].
Diabetes Mellitus
[Influence of short-term intensive insulin therapy on plasma concentration of lipoprotein-associated phospholipase A(2) and secretory phospholipase A(2) in newly diagnosed type 2 diabetic patients].
Diabetes Mellitus, Type 1
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Diabetes Mellitus, Type 1
Identification of the transcription factor ARNTL2 as a candidate gene for the type 1 diabetes locus Idd6.
Diabetes Mellitus, Type 1
Peroxiredoxin 6 Attenuates Alloxan-Induced Type 1 Diabetes Mellitus in Mice and Cytokine-Induced Cytotoxicity in RIN-m5F Beta Cells.
Diabetes Mellitus, Type 1
Protective role for cytosolic phospholipase A2alpha in autoimmune diabetes of mice.
Diabetes Mellitus, Type 1
Thymulin and peroxiredoxin 6 have protective effects against streptozotocin-induced type 1 diabetes in mice.
Diabetes Mellitus, Type 2
A single nucleotide polymorphism (SNP) rs2072907 in the adiponutrin gene (ADPN) was not associated with obesity and type 2 diabetes in Chinese population.
Diabetes Mellitus, Type 2
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Diabetes Mellitus, Type 2
Association of a F479L variant in the cytosolic phospholipase A2 gene (PLA2G4A) with decreased glucose turnover and oxidation rates in Pima Indians.
Diabetes Mellitus, Type 2
Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Distribution of Paraoxonase-1 (PON-1) and Lipoprotein Phospholipase A2 (Lp-PLA2) across Lipoprotein Subclasses in Subjects with Type 2 Diabetes.
Diabetes Mellitus, Type 2
Genetic variants of PLA2G6 are associated with Type 2 diabetes mellitus and triglyceride levels in a Chinese population.
Diabetes Mellitus, Type 2
Increased glomerular cytosolic phospholipase A2 activity of OLETF rats with early diabetes.
Diabetes Mellitus, Type 2
Insulin regulation of gene expression and concentrations of white adipose tissue-derived proteins in vivo in healthy men: relation to adiponutrin.
Diabetes Mellitus, Type 2
IPLA2 mRNA expression by human neutrophils in type 2 diabetes and chronic periodontitis.
Diabetes Mellitus, Type 2
Isolation and characterization of cytotoxic and insulin-releasing components from the venom of the black-necked spitting cobra Naja nigricollis (Elapidae).
Diabetes Mellitus, Type 2
Polymorphism of Secretary PLA2G2A gene is Associated with its Serum level in Type2 Diabetes Mellitus Patients in Northern Iran.
Diabetes Mellitus, Type 2
[Influence of short-term intensive insulin therapy on plasma concentration of lipoprotein-associated phospholipase A(2) and secretory phospholipase A(2) in newly diagnosed type 2 diabetic patients].
Diabetic Cardiomyopathies
Calcium-independent phospholipases in the heart: mediators of cellular signaling, bioenergetics, and ischemia-induced electrophysiologic dysfunction.
Diabetic Nephropathies
Enhanced expression of group IIA secreted phospholipase A2 by elevated glucose levels in cytokine-stimulated rat mesangial cells and in kidneys of diabetic rats.
Diabetic Nephropathies
Increased glomerular cytosolic phospholipase A2 activity of OLETF rats with early diabetes.
Diabetic Nephropathies
Mitogen-activated protein kinase cascade is activated in glomeruli of diabetic rats and glomerular mesangial cells cultured under high glucose conditions.
Diabetic Nephropathies
Sp1-mediated upregulation of Prdx6 expression prevents podocyte injury in diabetic nephropathy via mitigation of oxidative stress and ferroptosis.
Diabetic Nephropathies
[Effect of tangshen formula on phospholipids metabolism in diabetic nephropathy patients].
Diffuse Cerebral Sclerosis of Schilder
Insights into Lewy body disease from rare neurometabolic disorders.
Diphtheria
Inhibition of the myotoxic activity of Bothrops asper myotoxin II in mice by immunization with its synthetic 13-mer peptide 115-129.
Diphtheria
The Purification and Concentration of Diphtheria Toxin: I. Evaluation of Previous Methods; Description of a New Procedure.
Disseminated Intravascular Coagulation
Sodium oleate, arachidonate, and linoleate enhance fibrinogenolysis by Russell's viper venom proteinases and inhibit FXIIIa; a role for phospholipase A2 in venom induced consumption coagulopathy.
Down Syndrome
Evidence for increased amyloid enhancing factor activity in Alzheimer brain extract.
Dry Eye Syndromes
sPLA2-IIa amplifies ocular surface inflammation in the experimental dry eye (DE) BALB/c mouse model.
Dry Eye Syndromes
sPLA2-IIa is an inflammatory mediator when the ocular surface is compromised.
Dry Eye Syndromes
sPLA2-IIa participates in ocular surface inflammation in humans with dry eye disease.
Duodenal Ulcer
Bromophenacyl bromide, a phospholipase A(2) inhibitor attenuates chemically induced gastroduodenal ulcers in rats.
Duodenal Ulcer
Phospholipase A2 activity in gastric juice from patients with active and H. pylori-eradicated healed duodenal ulcer.
Dysarthria
Follow-up study of 25 Chinese children with PLA2G6-associated neurodegeneration.
Dyslexia
Possible relevance of phospholipid abnormalities and genetic interactions in psychiatric disorders: the relationship between dyslexia and schizophrenia.
Dyslipidemias
Global Inactivation of the Pla2g6 Gene in Mice Does Not Cause Dyslipidemia under Chow or High-fat Diet Conditions.
Dyslipidemias
Lipid-Modulating Treatments for Mixed Dyslipidemia Increase HDL-Associated Phospholipase A2 Activity with Differential Effects on HDL Subfractions.
Dystonia
Clinical heterogeneity of PLA2G6-related Parkinsonism: analysis of two Saudi families.
Dystonia
Genetic Analysis of PLA2G6 in 22 Indian Families with Infantile Neuroaxonal Dystrophy, Atypical Late-Onset Neuroaxonal Dystrophy and Dystonia Parkinsonism Complex.
Dystonia
Mitochondrial dysfunction and defects in lipid homeostasis as therapeutic targets in neurodegeneration with brain iron accumulation.
Dystonia
Phenotypic spectrum of patients with PLA2G6 mutation and PARK14-linked parkinsonism.
Dystonia
Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations.
Echinococcosis
Alveolar hydatid cyst induced amyloid enhancing factor (AEF): physicochemical properties and abolition of AEF activity by serine protease inhibitors.
Echinococcosis
Biochemical nature and cellular origin of amyloid enhancing factor (AEF) as determined by anti-AEF antibody.
Echinococcosis
Induction of amyloid enhancing factor and its biological properties in murine alveolar hydatidosis.
Eczema
Characterization and activity of phospholipase A2 in normal human epidermis and in lesion-free epidermis of patients with psoriasis or eczema.
Embolism, Fat
Catalytic activity of phospholipase A2 in serum in experimental fat embolism in pigs.
Encephalitis
BK Induces cPLA2 Expression via an Autocrine Loop Involving COX-2-Derived PGE2 in Rat Brain Astrocytes.
Encephalitis
Neuroprotective effect of apolipoprotein D against human coronavirus OC43-induced encephalitis in mice.
Encephalitis
Synthetic and natural inhibitors of phospholipases A2: their importance for understanding and treatment of neurological disorders.
Encephalomyelitis
Blockade of cytosolic phospholipase A2 alpha prevents experimental autoimmune encephalomyelitis and diminishes development of Th1 and Th17 responses.
Encephalomyelitis
Crotoxin down-modulates pro-inflammatory cells and alleviates pain on the MOG35-55-induced experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis.
Encephalomyelitis
Cytosolic phospholipase A2 alpha-deficient mice are resistant to experimental autoimmune encephalomyelitis.
Encephalomyelitis
Differing roles for members of the phospholipase A2 superfamily in experimental autoimmune encephalomyelitis.
Encephalomyelitis
Extracellular phospholipase A2 inhibitors suppress central nervous system inflammation.
Encephalomyelitis
PRDX6 controls multiple sclerosis by suppressing inflammation and blood brain barrier disruption.
Encephalomyelitis
Protective effect of cytosolic phospholipase A2 inhibition against inflammation and degeneration by promoting regulatory T cells in rats with experimental autoimmune encephalomyelitis.
Encephalomyelitis
Secreted phospholipase A2 activity in experimental autoimmune encephalomyelitis and multiple sclerosis.
Encephalomyelitis, Autoimmune, Experimental
Blockade of cytosolic phospholipase A2 alpha prevents experimental autoimmune encephalomyelitis and diminishes development of Th1 and Th17 responses.
Encephalomyelitis, Autoimmune, Experimental
Crotoxin down-modulates pro-inflammatory cells and alleviates pain on the MOG35-55-induced experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis.
Encephalomyelitis, Autoimmune, Experimental
Cytosolic phospholipase A2 alpha-deficient mice are resistant to experimental autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Differing roles for members of the phospholipase A2 superfamily in experimental autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Extracellular phospholipase A2 inhibitors suppress central nervous system inflammation.
Encephalomyelitis, Autoimmune, Experimental
Metabolic Control of Astrocyte Pathogenic Activity via cPLA2-MAVS.
Encephalomyelitis, Autoimmune, Experimental
Phospholipid metabolism in experimental allergic encephalomyelitis: activity of mitochondrial phospholipase A2 of rat brain towards specifically labelled 1,2-diacyl-, 1-alk-1'-enyl-2-acyl- and 1-alkyl-2-acyl-sn-glycero-3-phosphorylcholine.
Encephalomyelitis, Autoimmune, Experimental
PRDX6 controls multiple sclerosis by suppressing inflammation and blood brain barrier disruption.
Encephalomyelitis, Autoimmune, Experimental
Protective effect of cytosolic phospholipase A2 inhibition against inflammation and degeneration by promoting regulatory T cells in rats with experimental autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Secreted phospholipase A2 activity in experimental autoimmune encephalomyelitis and multiple sclerosis.
Endometrial Neoplasms
The significance of the altered expression of lysophosphatidic acid receptors, autotaxin and phospholipase A2 as the potential biomarkers in type 1 endometrial cancer biology.
Endometriosis
Elevation of the phospholipase A2 activity in peritoneal fluid cells from women with endometriosis.
Endometriosis
Lysophosphatidyl choline, a chemotactic factor for monocytes/T-lymphocytes is elevated in endometriosis.
Endometriosis
Macrophage activation factors and cytokines in peritoneal fluid from patients with endometriosis.
Endometriosis
Phospholipase A2 group IIA is elevated in endometriomas but not in peritoneal fluid and serum of ovarian endometriosis patients.
Endometriosis
The 763C>G Polymorphism of The Secretory PLA2IIa Gene Is Associated with Endometriosis in Iranian Women.
Endotoxemia
Involvement of a pertussis toxin-sensitive G-protein-coupled phospholipase A2 in lipopolysaccharide-stimulated prostaglandin E2 synthesis in cultured rat mesangial cells.
Enteritis
Cryptogenia multifocal ulcerous stenosing enteritis: An entity on its own as a cause of abdominal pain, iron deficiency anemia and protein-losing enteropathy.
Epilepsy
Cytosolic phospholipase A2 is a key regulator of blood-brain barrier function in epilepsy.
Epilepsy
Identification of a novel mutation in PLA2G6 gene in a Chinese pedigree with familial cortical myoclonic tremor with epilepsy.
Epilepsy
Secretory phospholipase A2 and phospholipids in neural membranes in an experimental epilepsy model.
Epstein-Barr Virus Infections
Co-existing of HSV1/2 or EBV Infection with the Presence of High-Risk HPV DNA in Cervical Lesions in the Southwest of Iran.
Erythema
Increased synthesis of high-molecular-weight cPLA2 mediates early UV-induced PGE2 in human skin.
Erythema
Intracutaneous injection of lysophosphatidylcholine induces skin inflammation and accumulation of leukocytes.
Escherichia coli Infections
Group V Phospholipase A2 in bone marrow derived myeloid cells and bronchial epithelial cells promote bacterial clearance after E. coli pneumonia.
Escherichia coli Infections
mRNA differential display of acute-phase proteins in experimental Escherichia coli infection.
Escherichia coli Infections
Resistance of transgenic mice expressing human group II phospholipase A2 to Escherichia coli infection.
Esophageal Neoplasms
Group IIA-soluble phospholipase A2 levels in patients with infections after esophageal cancer surgery.
Esophageal Neoplasms
MiR-543 Promotes Migration, Invasion and Epithelial-Mesenchymal Transition of Esophageal Cancer Cells by Targeting Phospholipase A2 Group IVA.
Esophageal Neoplasms
Secretory Phospholipase A(2) Inhibition Attenuates Intercellular Adhesion Molecule-1 Expression in Human Esophageal Adenocarcinoma Cells.
Esophageal Neoplasms
Spatially resolved metabolomics combined with multicellular tumor spheroids to discover cancer tissue relevant metabolic signatures.
Esophageal Squamous Cell Carcinoma
Association of Single Nucleotide Polymorphisms in the Prostaglandin-endoperoxide Synthase 2 (PTGS2) and Phospholipase A2 Group IIA (PLA2G2A) Genes with Susceptibility to Esophageal Squamous Cell Carcinoma.
Esophageal Squamous Cell Carcinoma
Clinical significance of phospholipase A2 group IIA (PLA2G2A) expression in primary resected esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Combined detection of serum autoantibodies as diagnostic biomarkers in esophagogastric junction adenocarcinoma.
Esophageal Squamous Cell Carcinoma
MiR-543 Promotes Migration, Invasion and Epithelial-Mesenchymal Transition of Esophageal Cancer Cells by Targeting Phospholipase A2 Group IVA.
Esophageal Squamous Cell Carcinoma
Overexpression of Peroxiredoxin 6 (PRDX6) Promotes the Aggressive Phenotypes of Esophageal Squamous Cell Carcinoma.
Esophageal Squamous Cell Carcinoma
Overexpression of phospholipase A2 Group IIA in esophageal squamous cell carcinoma and association with cyclooxygenase-2 expression.
Esophagitis
Leukotrienes in acetylcholine-induced contraction of esophageal circular smooth muscle in experimental esophagitis.
Essential Hypertension
Platelet calmodulin concentration and phospholipase A2 activity in essential hypertension.
Exfoliation Syndrome
Phospholipase A2 in chamber angle of normal eyes and patients with primary open angle glaucoma and exfoliation glaucoma.
Exophthalmos
Transdermal Delivery of Adipocyte Phospholipase A2 siRNA using Microneedles to Treat Thyroid Associated Ophthalmopathy-Related Proptosis.
Eye Diseases
Alpha-lecithin:cholesterol acyltransferase deficiency. Lack of both phospholipase A2 and acyltransferase activities characteristic of high density lipoprotein lecithin:cholesterol acyltransferase in fish eye disease.
Eye Diseases
Human secretory phospholipase A(2), group IB in normal eyes and in eye diseases.
Fatty Liver
A multi-ethnic study of a PNPLA3 gene variant and its association with disease severity in non-alcoholic fatty liver disease.
Fatty Liver
Absence of Adiponutrin (PNPLA3) and Monoacylglycerol Lipase Synergistically Increases Weight Gain and Aggravates Steatohepatitis in Mice.
Fatty Liver
Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase.
Fatty Liver
ASB14780, an Orally Active Inhibitor of Group IVA Phospholipase A2, Is a Pharmacotherapeutic Candidate for Nonalcoholic Fatty Liver Disease.
Fatty Liver
Association of glucokinase regulatory gene polymorphisms with risk and severity of non-alcoholic fatty liver disease: an interaction study with adiponutrin gene.
Fatty Liver
Dysfunction of estrogen-related receptor alpha-dependent hepatic VLDL secretion contributes to sex disparity in NAFLD/NASH development.
Fatty Liver
iPla2? deficiency in mice fed with MCD diet does not correct the defect of phospholipid remodeling but attenuates hepatocellular injury via an inhibition of lipid uptake genes.
Fatty Liver
Physical activity and sedentary behavior can modulate the effect of the PNPLA3 variant on childhood NAFLD: a case-control study in a Chinese population.
Fatty Liver
Reduction of Caloric Intake Might Override the Prosteatotic Effects of the PNPLA3 p.I148M and TM6SF2 p.E167K Variants in Patients with Fatty Liver: Ultrasound-Based Prospective Study.
Fatty Liver
Regulation of the promoter region of the human adiponutrin/PNPLA3 gene by glucose and insulin.
Fatty Liver
Tetra-primer ARMS-PCR identified four pivotal genetic variations in bovine PNPLA3 gene and its expression patterns.
Fatty Liver
The common adiponutrin variant p.I148M does not confer gallstone risk but affects fasting glucose and triglyceride levels.
Fatty Liver
The Expression of PNPLA3 Polymorphism could be the Key for Severe Liver Disease in NAFLD in Hispanic Population.
Fatty Liver
The phospholipase A2 family's role in metabolic diseases: Focus on skeletal muscle.
Fatty Liver
[Alcoholic and non-alcoholic steatohepatitis: Who is affected and what can we do for them?]
Fatty Liver
[Metformin prevents non-alcoholic fatty liver disease in rats: role of phospholipase A2/lysophosphatidylcholine lipoapoptosis pathway in hepatocytes.]
Fetal Resorption
Prophylactic Effects of Bee Venom Phospholipase A2 in Lipopolysaccharide-Induced Pregnancy Loss.
Fibrosarcoma
Evidence that porcine pancreatic phospholipase A2 via its high affinity receptor stimulates extracellular matrix invasion by normal and cancer cells.
Fibrosarcoma
MMP production in human fibrosarcoma cells and their invasiveness are regulated by group IB secretory phospholipase A2 receptor-mediated activation of cytosolic phospholipase A2.
Fibrosarcoma
Role of ceramide in stimulation of the transcription of cytosolic phospholipase A2 and cyclooxygenase 2.
Foot-and-Mouth Disease
Porcine Picornavirus 3C Protease Degrades PRDX6 to Impair PRDX6-mediated Antiviral Function.
Frontotemporal Dementia
Analysis of PLA2G6 gene mutation in sporadic early-onset parkinsonism patients from Chinese population.
Frontotemporal Dementia
Monogenic Parkinson's disease and parkinsonism: Clinical phenotypes and frequencies of known mutations.
Gallstones
Cholesterol gallstones and bile host diverse bacterial communities with potential to promote the formation of gallstones.
Gallstones
Relative contribution of bile and pancreatic juice duodenogastric reflux in gastric ulcer disease and cholelithiasis.
Gallstones
Role of phospholipase A2 in cholesterol gallstone formation is associated with biliary phospholipid species selection at the site of hepatic excretion: indirect evidence.
Gallstones
Secretory phospholipase A2 increases SR-BI-mediated selective uptake from HDL but not biliary cholesterol secretion.
Gallstones
The common adiponutrin variant p.I148M does not confer gallstone risk but affects fasting glucose and triglyceride levels.
Gastritis
In vivo and in vitro studies of cytosolic phospholipase A2 expression in Helicobacter pylori infection.
Gastroesophageal Reflux
Modulation of growth in human esophageal adenocarcinoma cells by group IIa secretory phospholipase A(2).
Gastroesophageal Reflux
Secretory phospholipase A2 is required to produce histologic changes associated with gastroduodenal reflux in a murine model.
Gastrointestinal Neoplasms
Expression of group IIA phospholipase A2 is an independent predictor of favorable outcome for patients with gastric cancer.
Gaucher Disease
Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature.
gelatinase a deficiency
Modulation of Systemic Metabolism by MMP-2: From MMP-2 Deficiency in Mice to MMP-2 Deficiency in Patients.
Glaucoma
Augmentation of Lysosomal Phospholipase A2 Activity in the Anterior Chamber in Glaucoma.
Glaucoma
Betalain exerts a protective effect against glaucoma is majorly through the association of inflammatory cytokines.
Glaucoma
Neuroprotective effect of peroxiredoxin 6 against hypoxia-induced retinal ganglion cell damage.
Glaucoma
Peroxiredoxin 6 delivery attenuates TNF-alpha-and glutamate-induced retinal ganglion cell death by limiting ROS levels and maintaining Ca(2+) homeostasis.
Glaucoma
Phospholipase A2 in chamber angle of normal eyes and patients with primary open angle glaucoma and exfoliation glaucoma.
Glaucoma
PRDX6 attenuates oxidative stress- and TGFbeta-induced abnormalities of human trabecular meshwork cells.
Glaucoma
Prdx6 retards senescence and restores trabecular meshwork cell health by regulating reactive oxygen species.
Glaucoma, Open-Angle
Group II phospholipase A2 content of tears in patients with senile cataract and primary open-angle glaucoma.
Glaucoma, Open-Angle
Phospholipase A2 in chamber angle of normal eyes and patients with primary open angle glaucoma and exfoliation glaucoma.
Glioblastoma
Expression of Cytosolic Phospholipase A2 Alpha in Glioblastoma Is Associated With Resistance to Chemotherapy.
Glioblastoma
Pharmacological inhibition of lipid droplet formation enhances the effectiveness of curcumin in glioblastoma.
Glioblastoma
PTRF/cavin-1 remodels phospholipid metabolism to promote tumor proliferation and suppress immune responses in glioblastoma by stabilizing cPLA2.
Glioblastoma
Temozolomide has anti-tumor effects through the phosphorylation of cPLA2 on glioblastoma cells.
Glioma
Benzodiazepines enhance the muscimol-dependent activation of phospholipase A2 in glioma C6 cells.
Glioma
Crotoxin from Crotalus durissus terrificus venom: In vitro cytotoxic activity of a heterodimeric phospholipase A2 on human cancer-derived cell lines.
Glioma
Dying endothelial cells stimulate proliferation of malignant glioma cells via a caspase 3-mediated pathway.
Glioma
Endothelial PKC?-MAPK/ERK-phospholipase A2 pathway activation as a response of glioma in a triple culture model. A new role for pericytes?
Glioma
Interleukin-1 beta induces cytosolic phospholipase A2 gene in rats C6 glioma cell line.
Glioma
Neoplastic and pharmacological influence on the permeability of an in vitro blood-brain barrier.
Glioma
Novel PLA2G4C polymorphism as a molecular diagnostic assay for 19q loss in human gliomas.
Glioma
Overexpression of the phospholipase A2 group V gene in glioma tumors is associated with poor patient prognosis.
Glioma
Receptor-stimulated phospholipase A2 activation is coupled to influx of external calcium and not to mobilization of intracellular calcium in C62B glioma cells.
Glioma
The selective lipoprotein-associated phospholipase A2 inhibitor darapladib triggers irreversible actions on glioma cell apoptosis and mitochondrial dysfunction.
Glomerulonephritis
Anti-neutrophil cytoplasmic antibody-associated glomerulonephritis with detection of myeloperoxidase and phospholipase A2 receptor in membranous nephropathy-lesions: report of two patients with microscopic polyangiitis.
Glomerulonephritis
Expression and localization of cyclooxygenase isoforms and cytosolic phospholipase A2 in anti-Thy-1 glomerulonephritis.
Glomerulonephritis
Group II phospholipase A2 activates mitogen-activated protein kinase in cultured rat mesangial cells.
Glomerulonephritis
[Idiopathic membranous nephropathy: Evolution in understanding the problem].
Glomerulonephritis, Membranous
A cohort study of membranous nephropathy, primary or secondary.
Glomerulonephritis, Membranous
A comparison of clinical features between idiopathic membranous nephropathy patients with and without serum antibody against phospholipase A2 receptor.
Glomerulonephritis, Membranous
A New Chemiluminescence Immunoassay for Phospholipase A2 Receptor 1 Autoantibodies Allows Early Identification of Autoantibody Recurrence in Patients With Membranous Nephropathy.
Glomerulonephritis, Membranous
A Novel Insight into the Role of PLA2R and THSD7A in Membranous Nephropathy.
Glomerulonephritis, Membranous
A novel mouse model of phospholipase A2 receptor 1-associated membranous nephropathy mimics podocyte injury in patients.
Glomerulonephritis, Membranous
A novel time-resolved fluoroimmunoassay based on magnetic microspheres method for detecting antibodies against the phospholipase A2 receptor.
Glomerulonephritis, Membranous
A novel Time-resolved Fluoroimmunoassay for the quantitative detection of Antibodies against the Phospholipase A2 Receptor.
Glomerulonephritis, Membranous
A PLA2R-IgG4 Antibody-Based Predictive Model for Assessing Risk Stratification of Idiopathic Membranous Nephropathy.
Glomerulonephritis, Membranous
A Point-of-Care Immunosensor Based on a Quartz Crystal Microbalance with Graphene Biointerface for Antibody Assay.
Glomerulonephritis, Membranous
A Proposal for a Serology-Based Approach to Membranous Nephropathy.
Glomerulonephritis, Membranous
A Rare Adult Case with Diffuse Segmental Membranous Glomerulonephritis.
Glomerulonephritis, Membranous
ADVANCES IN MEMBRANOUS NEPHROPATHY : SUCCESS STORIES OF A LONG JOURNEY.
Glomerulonephritis, Membranous
An anti-phospholipase A2 receptor quantitative immunoassay and epitope analysis in membranous nephropathy reveals different antigenic domains of the receptor.
Glomerulonephritis, Membranous
An Indirect Immunofluorescence Method Facilitates Detection of Thrombospondin Type 1 Domain-Containing 7A-Specific Antibodies in Membranous Nephropathy.
Glomerulonephritis, Membranous
Analysis of Glomerular IgG Subclasses Switch in Idiopathic Membranous Nephropathy Classified by Glomerular Phospholipase A2 Receptor Antigen and Serum Antibody.
Glomerulonephritis, Membranous
Anti-neutrophil cytoplasmic antibody-associated glomerulonephritis with detection of myeloperoxidase and phospholipase A2 receptor in membranous nephropathy-lesions: report of two patients with microscopic polyangiitis.
Glomerulonephritis, Membranous
Anti-Phospholipase A2 Receptor (PLA2R) Antibody and Glomerular PLA2R Expression in Japanese Patients with Membranous Nephropathy.
Glomerulonephritis, Membranous
Anti-phospholipase A2 receptor antibody as a prognostic marker in patients with primary membranous nephropathy.
Glomerulonephritis, Membranous
Anti-phospholipase A2 receptor antibody in membranous nephropathy.
Glomerulonephritis, Membranous
Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy.
Glomerulonephritis, Membranous
Anti-PLA2R-associated membranous nephropathy: a review with emphasis on diagnostic testing methods.
Glomerulonephritis, Membranous
Anti-PLA2R1 Antibodies Containing Sera Induce In Vitro Cytotoxicity Mediated by Complement Activation.
Glomerulonephritis, Membranous
Anti-type M phospholipase A2 receptor antibody-positive membranous nephropathy as a part of multi-system autoimmune syndrome post-allogeneic stem cell transplantation.
Glomerulonephritis, Membranous
Antibodies against M-Type Phospholipase A2 Receptor May Predict Treatment Response and Outcome in Membranous Nephropathy.
Glomerulonephritis, Membranous
Antibodies to M-type phospholipase A2 receptor (PLA2R) in membranous lupus nephritis.
Glomerulonephritis, Membranous
Antibodies to m-type phospholipase A2 receptor in children with idiopathic membranous nephropathy.
Glomerulonephritis, Membranous
Antigen identification in membranous nephropathy moves toward targeted monitoring and new therapy.
Glomerulonephritis, Membranous
Antiphospholipase 2 receptor antibody levels to predict complete spontaneous remission in primary membranous nephropathy.
Glomerulonephritis, Membranous
Antiphospholipase A2 Receptor Antibody Levels Predict the Risk of Posttransplantation Recurrence of Membranous Nephropathy.
Glomerulonephritis, Membranous
Antiphospholipase A2 Receptor Autoantibodies: A Step Forward in the Management of Primary Membranous Nephropathy.
Glomerulonephritis, Membranous
Antiphospholipase A? receptor autoantibodies: a comparison of three different immunoassays for the diagnosis of idiopathic membranous nephropathy.
Glomerulonephritis, Membranous
Association between PLA2R1 rs4664308 and susceptibility to idiopathic membranous nephropathy: Protocol for a systematic review and meta-analysis of case-control studies.
Glomerulonephritis, Membranous
Association of phospholipase A2 receptor 1 polymorphisms with idiopathic membranous nephropathy in Chinese patients in Taiwan.
Glomerulonephritis, Membranous
Association of SNPs in PLA2R1 with idiopathic and secondary membranous nephropathy in two Chinese cohorts.
Glomerulonephritis, Membranous
Autoantibodies against phospholipase A2 receptor in Brazilian patients with glomerular diseases.
Glomerulonephritis, Membranous
Autoantibodies against phospholipase A2 receptor in Korean patients with membranous nephropathy.
Glomerulonephritis, Membranous
Autoantibodies in renal diseases - clinical significance and recent developments in serological detection.
Glomerulonephritis, Membranous
Bortezomib therapy for nephrotic syndrome due to idiopathic membranous nephropathy.
Glomerulonephritis, Membranous
CD19 Targeted Low-Dose Rituximab Is Effective in the Management of Refractory Phospholipase A2 Receptor Antibody-Associated Membranous Nephropathy.
Glomerulonephritis, Membranous
Characterization of THSD7A-antibodies not binding to glomerular THSD7A in a patient with diabetes mellitus but no membranous nephropathy.
Glomerulonephritis, Membranous
Circulating anti-phospholipase A2 receptor antibodies as a diagnostic and prognostic marker in Greek patients with idiopathic membranous nephropathy - a retrospective cohort study.
Glomerulonephritis, Membranous
Circulating antibodies against M-type phospholipase A2 receptor and thrombospondin type-1 domain-containing 7A in Chinese patients with membranous nephropathy.
Glomerulonephritis, Membranous
Circulating Antibodies against Thrombospondin Type-I Domain-Containing 7A in Chinese Patients with Idiopathic Membranous Nephropathy.
Glomerulonephritis, Membranous
Circulating antibodies to ?-enolase and phospholipase A2 receptor and composition of glomerular deposits in Japanese patients with primary or secondary membranous nephropathy.
Glomerulonephritis, Membranous
Clinical and Histological Features of Phospholipase A2 Receptor-Associated and Thrombospondin Type-I Domain-containing 7A-Associated Idiopathic Membranous Nephropathy: A Single Center Retrospective Study from China.
Glomerulonephritis, Membranous
Clinical features, course and prognosis of idiopathic membranous nephropathy depending on the presence of antibodies against M-type phospholipase A2 receptor.
Glomerulonephritis, Membranous
Clinical Relevance of Domain-Specific Phospholipase A2 Receptor 1 Antibody Levels in Patients with Membranous Nephropathy.
Glomerulonephritis, Membranous
Clinical significance of autoantibodies in the assessment and treatment of idiopathic membranous nephropathy.
Glomerulonephritis, Membranous
Clinical significance of M-type phospholipase A2 receptor and thrombospondin Type 1 domain-containing 7A in primary membranous nephropathy.
Glomerulonephritis, Membranous
Clinical usefulness of anti-M-type phospholipase-A-receptor antibodies in patients with membranous nephropathy and the comparison of three quantification methods.
Glomerulonephritis, Membranous
Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN).
Glomerulonephritis, Membranous
Clinical value of renal phospholipase A2 receptor deposit in the prognosis evaluation and treatment options of idiopathic membranous nephropathy: A retrospective cohort study.
Glomerulonephritis, Membranous
Clinicopathological characteristics of M-type phospholipase A2 receptor (PLA2R)-related membranous nephropathy in Japanese.
Glomerulonephritis, Membranous
Clinicopathological features in membranous nephropathy with cancer: A retrospective single-center study and literature review.
Glomerulonephritis, Membranous
Co-occurrence of PLA2R-positive membranous nephropathy without crescents, and PR3-positive eosinophilic granulomatosis with polyangiitis?.
Glomerulonephritis, Membranous
Combined Assessment of Phospholipase A2 Receptor Autoantibodies and Glomerular Deposits in Membranous Nephropathy.
Glomerulonephritis, Membranous
Compared staining of the phospholipase A2 receptor in the glomeruli of Chinese adults and children with idiopathic membranous nephropathy.
Glomerulonephritis, Membranous
Comparison of biomarkers between PLA2RAb+ and PLA2RAb- in patients with idiopathic membranous nephropathy.
Glomerulonephritis, Membranous
Complement-induced phospholipase A2 activation in experimental membranous nephropathy.
Glomerulonephritis, Membranous
Correlation and discrepancy of phospholipase A2 receptor staining in membranous nephropathy in paraffin-embedded kidney biopsies.
Glomerulonephritis, Membranous
Cross-reactivity of anti-PLA2R1 autoantibodies to rabbit and mouse PLA2R1 antigens and development of two novel ELISAs with different diagnostic performances in idiopathic membranous nephropathy.
Glomerulonephritis, Membranous
Definition of a new cut-off for the anti-phospholipase A2 receptor (PLA2R) autoantibody immunoassay in patients affected by idiopathic membranous nephropathy.
Glomerulonephritis, Membranous
Detection and Clinical Significance of Glomerular M-type Phospholipase A2 Receptor in Patients with Idiopathic Membranous Nephropathy.
Glomerulonephritis, Membranous
Detection and monitoring PLA2R autoantibodies by LIPS in membranous nephropathy.
Glomerulonephritis, Membranous
Detection of PLA2R Autoantibodies before the Diagnosis of Membranous Nephropathy.
Glomerulonephritis, Membranous
Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies.
Glomerulonephritis, Membranous
Development and validation of a discrimination model between primary PLA2R-negative membranous nephropathy and minimal change disease confirmed by renal biopsy.
Glomerulonephritis, Membranous
Development of a Standardized Chemiluminescence Immunoassay for the Detection of Autoantibodies Against Human M-Type Phospholipase A2 Receptor in Primary Membranous Nephropathy.
Glomerulonephritis, Membranous
Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy.
Glomerulonephritis, Membranous
Diagnostic accuracy of PLA2R autoantibodies and glomerular staining for the differentiation of idiopathic and secondary membranous nephropathy: an updated meta-analysis.
Glomerulonephritis, Membranous
Diagnostic performance of glomerular PLA2R and THSD7A antibodies in biopsy confirmed primary membranous nephropathy in South Africans.
Glomerulonephritis, Membranous
Diagnostic specificity of autoantibodies to M-type phospholipase A2 receptor (PLA2R) in differentiating idiopathic membranous nephropathy (IMN) from secondary forms and other glomerular diseases.
Glomerulonephritis, Membranous
Diagnostic Test Accuracy of Serum Anti-PLA2R Autoantibodies and Glomerular PLA2R Antigen for Diagnosing Idiopathic Membranous Nephropathy: An Updated Meta-Analysis.
Glomerulonephritis, Membranous
Diagnostic value of phospholipase A2 receptor in idiopathic membranous nephropathy: a systematic review and meta-analysis.
Glomerulonephritis, Membranous
Differential analysis of urinary albumin for membranous nephropathy patients by online capillary isoelectric focusing - Mass spectrometry.
Glomerulonephritis, Membranous
Differential diagnosis of membranous nephropathy with autoantibodies to phospholipase A2 receptor 1.
Glomerulonephritis, Membranous
Effects of phospholipase A2 receptor and thrombospondin type-1 domain-containing 7A expression in glomerular basement membranes on treatment response and renal outcome in membranous nephropathy.
Glomerulonephritis, Membranous
Efficacy of low or standard rituximab-based protocols and comparison to Ponticelli's regimen in membranous nephropathy.
Glomerulonephritis, Membranous
Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy.
Glomerulonephritis, Membranous
Enigma (partially) resolved: phospholipase A2 receptor is the cause of "idiopathic" membranous glomerulonephritis.
Glomerulonephritis, Membranous
Epitope Spreading of Autoantibody Response to PLA2R Associates with Poor Prognosis in Membranous Nephropathy.
Glomerulonephritis, Membranous
Evaluation of anti-PLA2R1 as measured by a novel ELISA in patients with idiopathic membranous nephropathy: a cohort study.
Glomerulonephritis, Membranous
Evolution of antibody titre against the M-type phospholipase A2 receptor and clinical response in idiopathic membranous nephropathy patients treated with tacrolimus.
Glomerulonephritis, Membranous
Expression of phospholipase A2 receptor and IgG4 in patients with membranous nephropathy.
Glomerulonephritis, Membranous
Expression of phospholipase A2 receptor in primary cultured podocytes derived from dog kidneys.
Glomerulonephritis, Membranous
Features of phospholipase A2 receptor and thrombospondin type-1 domain-containing 7A in malignancy-associated membranous nephropathy.
Glomerulonephritis, Membranous
Fumarate modulates phospholipase A2 receptor autoimmunity-induced podocyte injury in membranous nephropathy.
Glomerulonephritis, Membranous
Glomerular Diseases Associated with Malignancies: Histopathological Pattern and Association with Circulating Autoantibodies.
Glomerulonephritis, Membranous
Glomerular IgG subclasses in idiopathic and malignancy-associated membranous nephropathy.
Glomerulonephritis, Membranous
Glomerular mannose-binding lectin deposition in intrinsic antigen-related membranous nephropathy.
Glomerulonephritis, Membranous
HLA Alleles and Prognosis of PLA2R-Related Membranous Nephropathy.
Glomerulonephritis, Membranous
HLA-DQA1 and PLA2R1 polymorphisms and risk of idiopathic membranous nephropathy.
Glomerulonephritis, Membranous
HLA-DR, and not PLA2R, is expressed on the podocytes in kidney allografts in de novo membranous nephropathy.
Glomerulonephritis, Membranous
Identification of a Major Epitope Recognized by PLA2R Autoantibodies in Primary Membranous Nephropathy.
Glomerulonephritis, Membranous
Identification of the immunodominant epitope region in phospholipase A2 receptor-mediating autoantibody binding in idiopathic membranous nephropathy.
Glomerulonephritis, Membranous
IgG subclass staining in renal biopsies with membranous glomerulonephritis indicates subclass switch during disease progression.
Glomerulonephritis, Membranous
IgG4 anti-phospholipase A2 receptor might activate lectin and alternative complement pathway meanwhile in idiopathic membranous nephropathy: an inspiration from a cross-sectional study.
Glomerulonephritis, Membranous
IgG4-Related Disease Is Not Associated with Antibody to the Phospholipase A2 Receptor.
Glomerulonephritis, Membranous
Immunohistochemical Glomerular Expression of Phospholipase A2 Receptor in Primary and Secondary Membranous Nephropathy: A Retrospective Study in an Indian Cohort with Clinicopathological Correlations.
Glomerulonephritis, Membranous
Immunological Pathogenesis of Membranous Nephropathy: Focus on PLA2R1 and Its Role.
Glomerulonephritis, Membranous
Interaction between PLA2R1 and HLA-DQA1 variants associates with anti-PLA2R antibodies and membranous nephropathy.
Glomerulonephritis, Membranous
Interaction between PLA2R1 and HLA-DQA1 Variants contributes to the increased genetic susceptibility to membranous nephropathy in Western China.
Glomerulonephritis, Membranous
Kimura's disease associated with membranous nephropathy with IgG4 and phospholipase A2 receptor-positive staining of the glomerular basement membrane.
Glomerulonephritis, Membranous
Lipid biology of the podocyte--new perspectives offer new opportunities.
Glomerulonephritis, Membranous
M-type phospholipase A2 receptor (PLA2R) glomerular staining in pediatric idiopathic membranous nephropathy.
Glomerulonephritis, Membranous
M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy.
Glomerulonephritis, Membranous
M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy.
Glomerulonephritis, Membranous
Malignancy-associated membranous nephropathy with PLA2R double-positive for glomeruli and carcinoma.
Glomerulonephritis, Membranous
Membranous Nephropathy and Nonsteroidal Anti-inflammatory Agents.
Glomerulonephritis, Membranous
Membranous nephropathy as a manifestation of graft-versus-host disease: association with HLA antigen typing, phospholipase A2 receptor, and C4d.
Glomerulonephritis, Membranous
Membranous nephropathy-one morphologic pattern with different diseases.
Glomerulonephritis, Membranous
Mercury Intoxication as a Rare Cause of Membranous Nephropathy in a Child.
Glomerulonephritis, Membranous
MHC Class II Risk Alleles and Amino Acid Residues in Idiopathic Membranous Nephropathy.
Glomerulonephritis, Membranous
Nephrotic syndrome: a watershed in the understanding of membranous nephropathy.
Glomerulonephritis, Membranous
Neural cell adhesion molecule 1 is a novel autoantigen in membranous lupus nephritis.
Glomerulonephritis, Membranous
Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab.
Glomerulonephritis, Membranous
Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies.
Glomerulonephritis, Membranous
Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy.
Glomerulonephritis, Membranous
Ofatumumab for multirelapsing membranous nephropathy complicated by rituximab-induced serum-sickness.
Glomerulonephritis, Membranous
Outcomes of primary membranous nephropathy based on serum anti-phospholipase A2 receptor antibodies and glomerular phospholipase A2 receptor antigen status: a retrospective cohort study.
Glomerulonephritis, Membranous
Pathogenesis of membranous nephropathy: recent advances and future challenges.
Glomerulonephritis, Membranous
Pathophysiological advances in membranous nephropathy: time for a shift in patient's care.
Glomerulonephritis, Membranous
Personalized phospholipase A2 receptor antibody-driven rituximab treatment strategy in membranous nephropathy.
Glomerulonephritis, Membranous
Phospholipase A2 Receptor (PLA2R) Staining Is Useful in the Determination of De Novo Versus Recurrent Membranous Glomerulopathy.
Glomerulonephritis, Membranous
Phospholipase A2 Receptor (PLA2R1) Sequence Variants in Idiopathic Membranous Nephropathy.
Glomerulonephritis, Membranous
Phospholipase A2 Receptor 1 Epitope Spreading at Baseline Predicts Reduced Likelihood of Remission of Membranous Nephropathy.
Glomerulonephritis, Membranous
Phospholipase A2 receptor and sarcoidosis-associated membranous nephropathy.
Glomerulonephritis, Membranous
Phospholipase A2 Receptor Antibodies in Membranous Nephropathy: Unresolved Issues.
Glomerulonephritis, Membranous
Phospholipase A2 Receptor Antibody IgG4 Subclass Improves Sensitivity and Specificity in the Diagnosis of Idiopathic Membranous Nephropathy.
Glomerulonephritis, Membranous
Phospholipase A2 Receptor Autoantibodies and Clinical Outcome in Patients with Primary Membranous Nephropathy.
Glomerulonephritis, Membranous
Phospholipase A2 Receptor Autoantibodies as a Novel Serological Biomarker for Autoimmune Thyroid Disease Associated Nephropathy.
Glomerulonephritis, Membranous
Phospholipase A2 receptor positive membranous nephropathy long after living donor kidney transplantation between identical twins.
Glomerulonephritis, Membranous
Phospholipase A2 receptor staining in pediatric idiopathic membranous glomerulopathy.
Glomerulonephritis, Membranous
Phospholipase A2 receptor staining is absent in many kidney biopsies with early-stage membranous glomerulonephritis.
Glomerulonephritis, Membranous
Phospholipase A2 receptor-associated membranous nephropathy in a patient with IgG4-related disease: A case report.
Glomerulonephritis, Membranous
Phospholipase A2 Receptor-Positive Idiopathic Membranous Glomerulonephritis with Onset at 95 Years: Case Report.
Glomerulonephritis, Membranous
Phospholipase A2 Receptor-Related Membranous Nephropathy and Mannan-Binding Lectin Deficiency.
Glomerulonephritis, Membranous
PLA2R and membranous nephropathy: A 3?year prospective Australian study.
Glomerulonephritis, Membranous
PLA2R antibodies, glomerular PLA2R deposits and variations in PLA2R1 and HLA-DQA1 genes in primary membranous nephropathy in South Asians.
Glomerulonephritis, Membranous
PLA2R Immunohistochemistry Staining in Membranous Glomerulopathy: A Challenging Stain to Interpret But a Potentially Useful Diagnostic Tool.
Glomerulonephritis, Membranous
PLA2R-associated membranous glomerulopathy is modulated by common variants in PLA2R1 and HLA-DQA1 genes.
Glomerulonephritis, Membranous
Podocytic Infolding Glomerulopathy in a Patient with Phospholipase A2 Receptor-Positive Membranous Nephropathy and Review of the Literature.
Glomerulonephritis, Membranous
Pre-transplant phospholipase A2 receptor autoantibody concentration is associated with clinically significant recurrence of membranous nephropathy post-kidney transplantation.
Glomerulonephritis, Membranous
Prediction of membranous nephropathy recurrence after transplantation by monitoring of anti-PLA2R1 (M-type phospholipase A2 receptor) autoantibodies: a case series of 15 patients.
Glomerulonephritis, Membranous
Pregnancy in a Patient With Primary Membranous Nephropathy and Circulating Anti-PLA2R Antibodies: A Case Report.
Glomerulonephritis, Membranous
Preparation of an epitope-based recombinant diagnostic antigen specific to anti-phospholipase A2 receptor 1 antibodies.
Glomerulonephritis, Membranous
Prevalence of serum anti M-type phospholipase A2 receptor antibody in primary membranous nephropathy: A single center experience.
Glomerulonephritis, Membranous
Prevalence, diagnostic value and clinical characteristics associated with the presence of circulating levels and renal deposits of antibodies against the M-type phospholipase A2 receptor in idiopathic membranous nephropathy.
Glomerulonephritis, Membranous
Primary Membranous Glomerulonephritis: The Role of Serum and Urine Biomarkers in Patient Management.
Glomerulonephritis, Membranous
Primary Membranous Nephropathy With Enhanced Staining of Exostosin 1/Exostosin 2 in the Glomeruli: A Report of 2 Cases.
Glomerulonephritis, Membranous
Prognostic value of phospholipase A2 receptor in primary membranous nephropathy: a systematic review and meta-analysis.
Glomerulonephritis, Membranous
Prognostic value of the dynamics of M-type phospholipase A2 receptor antibody titers in patients with idiopathic membranous nephropathy treated with two different immunosuppression regimens.
Glomerulonephritis, Membranous
Progress on the M-type phospholipase A2 receptor in idiopathic membranous nephropathy.
Glomerulonephritis, Membranous
Rapid, quantitative, and high-sensitivity detection of anti-phospholipase A2 receptor antibodies using a novel CdSe/ZnS-based fluorescence immunosorbent assay.
Glomerulonephritis, Membranous
Reappraisal of PLA2R1 in membranous nephropathy: immunostaining method influence and association with IgG4-dominant phenotype.
Glomerulonephritis, Membranous
Recurrent Membranous Nephropathy After Kidney Transplantation Associated With Phospholipase A2 Receptor and Successfully Treated With Rituximab: A Case Report.
Glomerulonephritis, Membranous
Recurrent membranous nephropathy and acute cellular rejection in a patient treated with direct anti-HCV therapy (ledipasvir/sofosbuvir).
Glomerulonephritis, Membranous
Recurrent membranous nephropathy in an allograft caused by IgG3? targeting the PLA2 receptor.
Glomerulonephritis, Membranous
Recurrent membranous nephropathy with a possible alteration in the etiology: a case report.
Glomerulonephritis, Membranous
Relationship between renal tissues phospholipase A2 receptor and its serum antibody and clinical condition and prognosis of idiopathic membranous nephropathy: a meta-analysis.
Glomerulonephritis, Membranous
Relationship between the status of phospholipase A2 receptor and prognosis of idiopathic membranous nephropathy.
Glomerulonephritis, Membranous
Renal expression of PLA2R, THSD7A, and IgG4 in patients with membranous nephropathy and correlation with clinical findings.
Glomerulonephritis, Membranous
Renal Phospholipase A2 Receptor and the Clinical Features of Idiopathic Membranous Nephropathy.
Glomerulonephritis, Membranous
Renal phospholipase A2 receptor in hepatitis B virus-associated membranous nephropathy.
Glomerulonephritis, Membranous
Response to immunosuppressive therapy in PLA2R- associated and non-PLA2R- associated idiopathic membranous nephropathy: a retrospective, multicenter cohort study.
Glomerulonephritis, Membranous
Retrospective Study of Phospholipase A2 Receptor and IgG Subclasses in Glomerular Deposits in Chinese Patients with Membranous Nephropathy.
Glomerulonephritis, Membranous
Rituximab in Patients With Phospholipase A2 Receptor-Associated Membranous Nephropathy and Severe CKD.
Glomerulonephritis, Membranous
Role of phospholipase A2 receptor 1 antibody level at diagnosis for long-term renal outcome in membranous nephropathy.
Glomerulonephritis, Membranous
Routine immunohistochemical staining in membranous nephropathy: in situ detection of phospholipase A2 receptor and thrombospondin type 1 containing 7A domain.
Glomerulonephritis, Membranous
Secondary membranous nephropathy in a patient with myasthenia gravis without thymic disease, and partial remission induced by adrenocorticotropic hormone therapy.
Glomerulonephritis, Membranous
Seropositive PLA2R-associated membranous nephropathy but biopsy-negative PLA2R staining.
Glomerulonephritis, Membranous
Serum Albumin Still of Interest to Predict Outcomes in Membranous Nephropathy in the Era of Phospholipase A2 Receptor.
Glomerulonephritis, Membranous
Serum anti-phospholipase A2 receptor (PLA2R) antibody detected at diagnosis as a predictor for clinical remission in patients with primary membranous nephropathy: a meta-analysis.
Glomerulonephritis, Membranous
Serum anti-PLA2R antibody and glomerular PLA2R deposition in Chinese patients with membranous nephropathy: A cross-sectional study.
Glomerulonephritis, Membranous
Serum anti-PLA2R antibody as a diagnostic biomarker of idiopathic membranous nephropathy: The optimal cut-off value for Chinese patients.
Glomerulonephritis, Membranous
Serum Anti-PLA2R Antibody Predicts Treatment Outcome in Idiopathic Membranous Nephropathy.
Glomerulonephritis, Membranous
Serum Antibody and Glomerular Antigen of Antiphospholipase A2 Receptor in Chinese Patients with Idiopathic Membranous Nephropathy.
Glomerulonephritis, Membranous
Serum phospholipase A2 receptor antibodies and immunoglobulin G subtypes in adult idiopathic membranous nephropathy: Clinical value assessment.
Glomerulonephritis, Membranous
Serum secretory phospholipase A2 group IB correlates with the severity of membranous nephropathy.
Glomerulonephritis, Membranous
Serum with phospholipase A2 receptor autoantibodies interferes with podocyte adhesion to collagen.
Glomerulonephritis, Membranous
Shedding new light on vasculitis: how the LAMP story unfolded.
Glomerulonephritis, Membranous
Single-nucleotide polymorphism rs4664308 in PLA2R1 gene is associated with the risk of idiopathic membranous nephropathy: a meta-analysis.
Glomerulonephritis, Membranous
sPLA2-IB and PLA2R mediate insufficient autophagy and contribute to podocyte injury in idiopathic membranous nephropathy by activation of the p38MAPK/mTOR/ULK1ser757 signaling pathway.
Glomerulonephritis, Membranous
sPLA2-IB Level Correlates with Hyperlipidemia and the Prognosis of Idiopathic Membranous Nephropathy.
Glomerulonephritis, Membranous
Spontaneous remission of proteinuria is a frequent event in phospholipase A2 receptor antibody-negative patients with membranous nephropathy.
Glomerulonephritis, Membranous
Steroid-induced Lactic Acidosis in Diffuse Large B-cell Lymphoma.
Glomerulonephritis, Membranous
Tacrolimus Prevents TWEAK-Induced PLA2R Expression in Cultured Human Podocytes.
Glomerulonephritis, Membranous
Temporal Association Between PLA2R Antibodies and Clinical Outcomes in Primary Membranous Nephropathy.
Glomerulonephritis, Membranous
The anti-PLA2R antibody in membranous nephropathy: what we know and what remains a decade after its discovery.
Glomerulonephritis, Membranous
The association between variants in PLA2R and HLA-DQA1 and renal outcomes in patients with primary membranous nephropathy in Western China.
Glomerulonephritis, Membranous
The diagnosis accuracy of PLA2R-AB in the diagnosis of idiopathic membranous nephropathy: a meta-analysis.
Glomerulonephritis, Membranous
The Evolving Role of Novel Biomarkers in Glomerular Disease: A Review.
Glomerulonephritis, Membranous
The pathogenesis of human membranous nephropathy: we are (almost) there.
Glomerulonephritis, Membranous
The prognostic value of phospholipase A2 receptor autoantibodies on spontaneous remission for patients with idiopathic membranous nephropathy: A meta-analysis.
Glomerulonephritis, Membranous
The Usefulness of Phospholipase A2 Receptor and IgG4 Detection in Differentiation Primary Membranous Nephropathy From Secondary Membranous Nephropathy in Renal Biopsy.
Glomerulonephritis, Membranous
The utility of phospholipase A2 receptor autoantibody in membranous nephropathy after kidney transplantation.
Glomerulonephritis, Membranous
THSD7A staining of membranous glomerulopathy in clinical practice reveals cases with dual autoantibody positivity.
Glomerulonephritis, Membranous
THSD7A-associated membranous nephropathy in a patient with neurofibromatosis type 1.
Glomerulonephritis, Membranous
Treatment-resistant PLA2R-negative membranous nephropathy responsive to low-density lipoprotein apheresis.
Glomerulonephritis, Membranous
Utility of Determining Autoantibodies to M-type Phospholipase A2 Receptor in Diagnosing Primary Membranous Nephropathy: An Ideal Setting.
Glomerulonephritis, Membranous
Validation of a phospholipase A2 receptor antibody ELISA in an Australian cohort with membranous glomerulonephritis.
Glomerulonephritis, Membranous
Validation of phospholipase A2 receptor direct immunofluorescence staining in the diagnosis of primary membranous glomerulonephritis.
Glomerulonephritis, Membranous
[Anti-phospholipase A2 receptor (anti-PLA2R) antibodies and idiopathic membranous nephropathy: which role in diagnosis and prognosis of this disease?].
Glomerulonephritis, Membranous
[Association of single nucleotide polymorphism in M-type phospholipase A2 receptor gene with membranous nephropathy].
Glomerulonephritis, Membranous
[Diagnostic value of renal phospholipase A2 receptor and serum anti-phospholipase A2 receptor antibody in membranous nephropathy].
Glomerulonephritis, Membranous
[Expression of renal PLA2R in patients with idiopathic membranous nephropathy and its relationship with the curative effect of immunotherapy].
Glomerulonephritis, Membranous
[Membranous nephropathy - the most commonly diagnosed glomerulopathy in patients who underwent renal biopsy in the Department of Internal Medicine, Nephrology and Endocrinology St. Queen Jadwiga Clinical District Hospital No. 2 in Rzeszow].
Glomerulonephritis, Membranous
[Membranous nephropathy: Pathophysiology and natural history].
Glomerulonephritis, Membranous
[Phospholipase A2 receptor antigen antibodies in serum and renal biopsies of patients with membranous nephropathy].
Glomerulonephritis, Membranous
[Role of M-type phospholipase A2 receptor and its antibody in hepatitis B virus-associated membranous nephropathy].
Glucose Intolerance
Pancreatic acinar cell-specific overexpression of group 1B phospholipase A(2) exacerbates diet-induced obesity and insulin resistance in mice.
Glycogen Storage Disease Type I
[Epidemiology and risk factors of hepatocellular carcinoma].
Graft vs Host Disease
Membranous nephropathy as a manifestation of graft-versus-host disease: association with HLA antigen typing, phospholipase A2 receptor, and C4d.
Granuloma
Biochemical modes of action of Cassia occidentalis and Cardiospermum halicacabum in inflammation.
Granuloma
Identification and characterization of a phospholipase A1 activity type three secreted protein, PP_ExoU from Pseudomonas plecoglossicida NB2011, the causative agent of visceral granulomas disease in large yellow croaker (Larimichthys crocea).
Granuloma
Stimulation of phospholipase A2 and vascular permeability by an extract of granuloma induced in the rat by carrageenin.
Granuloma
[Serum and ascitic phospholipase A2 activities and their heat stabilities in taurocholate induced rat acute pancreatitis]
Granulomatous Disease, Chronic
Cytosolic phospholipase A2alpha is targeted to the p47phox-PX domain of the assembled NADPH oxidase via a novel binding site in its C2 domain.
Granulomatous Disease, Chronic
iPLA2 Activation Mediates Granular Exocytosis and Corrects Microbicidal Defects in ROS-Deficient and CGD Human Neutrophils.
Granulomatous Disease, Chronic
The role of reactive oxygen species in thromboxane b2 generation by polymorphonuclear leukocytes.
Graves Disease
Immunoglobulins from Graves' disease patients stimulate phospholipase A2 and C systems in FRTL-5 and human thyroid cells.
Graves Disease
Phospholipase A2 Receptor Autoantibodies as a Novel Serological Biomarker for Autoimmune Thyroid Disease Associated Nephropathy.
Graves Ophthalmopathy
Stimulation of extraocular muscle fibroblasts by cytokines and hypoxia: possible role in thyroid-associated ophthalmopathy.
Guillain-Barre Syndrome
The effect of treatment with crotapotin on the evolution of experimental autoimmune neuritis induced in Lewis rats.
Head Injuries, Closed
Brain phospholipase A2 is activated after experimental closed head injury in the rat.
Head Injuries, Closed
Closed head injury triggers early production of TNF alpha and IL-6 by brain tissue.
Head Injuries, Closed
Superoxide dismutase activity is not affected by closed head injury in rats.
Heart Arrest
In silico identification of viper phospholipaseA2 inhibitors: validation by in vitro, in vivo studies.
Heart Diseases
The rs1051931 G>A Polymorphism in the PLA2G7 Gene Confers Resistance to Immunoglobulin Therapy in Kawasaki Disease in a Southern Chinese Population.
Heart Failure
Angiopoietins, Vascular Endothelial Growth Factors and Secretory Phospholipase A2 in Ischemic and Non-Ischemic Heart Failure.
Heart Failure
Exploring the structural and functional aspects of the phospholipase A2 from Naja spp.
Heart Failure
The role of calcium-independent phospholipase A2 in cardiolipin remodeling in the spontaneously hypertensive heart failure rat heart.
Heart Neoplasms
[Phospholipase A2, group IIa, as an earlier unknown immunohistological marker of cardiac myxoma]
Heart Rupture
Lack of phospholipase A2 receptor increases susceptibility to cardiac rupture after myocardial infarction.
Helicobacter Infections
Experimental Helicobacter felis infection in transgenic mice expressing human group IIA phospholipase A2.
Helicobacter Infections
Helicobacter infection and phospholipase A2 enzymes: effect of Helicobacter felis-infection on the expression and activity of sPLA2 enzymes in mouse stomach.
Helicobacter Infections
Mice lacking secretory phospholipase A2 show altered apoptosis and differentiation with Helicobacter felis infection.
Hemangioendothelioma
Origin of circulating group II phospholipase A2 in hepatocytes in a patient with epitheloid hemangioendothelioma of the liver.
Hematologic Diseases
[Expression of Peroxiredoxin-6 Gene in Patients with Acute Myeloid Leukemia and Its Clinical Significance].
Hemochromatosis
A possible link between genetic hemochromatosis and autoimmune thyroiditis.
Hepatic Insufficiency
[The significance of lipid peroxidation (free radical) on hepatocellular dysfunction following hepatectomy]
Hepatitis
Distribution of type V secretory phospholipase A2 expression in human hepatocytes damaged by liver disease.
Hepatitis
Diverse cellular localizations of secretory phospholipase A2 enzymes in several human tissues.
Hepatitis
PNPLA3 p.I148M and TM6SF2 p.E167K variants do not predispose to liver injury in cholestatic liver diseases: A prospective analysis of 178 patients with PSC.
Hepatitis
[Effect of phytoecdysteroids and steranobols on the activity and stability of membrane-bound enzymes of liver mitochondria in experimental hepatitis]
Hepatitis A
Hepatocyte nuclear factor 4? and downstream secreted phospholipase A2 GXIIB regulate production of infectious hepatitis C virus.
Hepatitis A
MAP-Kinase Regulated Cytosolic Phospholipase A2 Activity Is Essential for Production of Infectious Hepatitis C Virus Particles.
Hepatitis B
Expression and characterization of hepatitis B surface antigen in transgenic potato plants.
Hepatitis B
Promoting effect of hepatitis B virus on the expressoin of phospholipase A2 group IIA.
Hepatitis B
Renal phospholipase A2 receptor in hepatitis B virus-associated membranous nephropathy.
Hepatitis B
[Role of M-type phospholipase A2 receptor and its antibody in hepatitis B virus-associated membranous nephropathy].
Hepatitis B, Chronic
Distribution of type V secretory phospholipase A2 expression in human hepatocytes damaged by liver disease.
Hepatitis C
Curcumin differs from tetrahydrocurcumin for molecular targets, signaling pathways and cellular responses.
Hepatitis C
Cytosolic phospholipase A2 gamma is involved in hepatitis C virus replication and assembly.
Hepatitis C
Hepatocyte nuclear factor 4? and downstream secreted phospholipase A2 GXIIB regulate production of infectious hepatitis C virus.
Hepatitis C
MAP-Kinase Regulated Cytosolic Phospholipase A2 Activity Is Essential for Production of Infectious Hepatitis C Virus Particles.
Hepatitis C
Regioselective ?-extension of indoles with rhodium enalcarbenoids--synthesis of substituted carbazoles.
Hepatitis, Chronic
Distribution of type V secretory phospholipase A2 expression in human hepatocytes damaged by liver disease.
Hepatoblastoma
Peroxiredoxin 6 Down-Regulation Induces Metabolic Remodeling and Cell Cycle Arrest in HepG2 Cells.
Herpes Simplex
Phospholipase A2 activity is copurified together with herpes simplex virus-specified Fc receptor proteins.
Herpes Zoster
GABA, progesterone and zona pellucida activation of PLA2 and regulation by MEK-ERK1/2 during acrosomal exocytosis in guinea pig spermatozoa.
Herpes Zoster
Lysophosphatidylcholine induces changes in physicochemical, morphological, and functional properties of mouse zona pellucida: a possible role of phospholipase A2 in sperm-zona pellucida interaction.
Herpes Zoster
Progesterone primes zona pellucida-induced activation of phospholipase A2 during acrosomal exocytosis in guinea pig spermatozoa.
Herpes Zoster
Zona pellucida induces activation of phospholipase A2 during acrosomal exocytosis in guinea pig spermatozoa.
Homozygous Familial Hypercholesterolemia
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Homozygous Familial Hypercholesterolemia
Integrated analysis of microRNA and mRNA expression profiles in homozygous familial hypercholesterolemia patients and validation of atherosclerosis associated critical regulatory network.
Hyaline Membrane Disease
Secretory phospholipase A2 and neonatal respiratory distress: pilot study on broncho-alveolar lavage.
Hyaline Membrane Disease
Secretory phospholipase A2 pathway in various types of lung injury in neonates and infants: a multicentre translational study.
Hyaline Membrane Disease
Varespladib Inhibits Secretory Phospholipase A2 in Bronchoalveolar Lavage of Different Types of Neonatal Lung Injury.
Hydronephrosis
The significance of the nongenomic pathway in mediating inflammatory signaling of the dioxin-activated Ah receptor to cause toxic effects.
Hyperalgesia
Abdominal hyperalgesia in secretory phospholipase A(2)-induced rat pancreatitis: Distinct roles of NK(1) receptors.
Hyperalgesia
Activation of cytosolic phospholipase A2 in dorsal root ganglion neurons by Ca2+/calmodulin-dependent protein kinase II after peripheral nerve injury.
Hyperalgesia
Acute mechanical hyperalgesia in the rat can be produced by coactivation of spinal ionotropic AMPA and metabotropic glutamate receptors, activation of phospholipase A2 and generation of cyclooxygenase products.
Hyperalgesia
Acute thermal hyperalgesia in the rat is produced by activation of N-methyl-D-aspartate receptors and protein kinase C and production of nitric oxide.
Hyperalgesia
Analgesic Effects of Bee Venom Derived Phospholipase A(2) in a Mouse Model of Oxaliplatin-Induced Neuropathic Pain.
Hyperalgesia
Bromoenol Lactone, an Inhibitor of Calcium-Independent Phospholipase A2, Suppresses Carrageenan-Induced Prostaglandin Production and Hyperalgesia in Rat Hind Paw.
Hyperalgesia
Characterization of distinct phospholipases mediating bradykinin and noradrenaline hyperalgesia.
Hyperalgesia
Immediate inhibition of spinal secretory phospholipase A2 prevents the pain and elevated spinal neuronal hyperexcitability and neuroimmune regulatory genes that develop with nerve root compression.
Hyperalgesia
Intracerebroventricular injection of phospholipases A2 inhibitors modulates allodynia after facial carrageenan injection in mice.
Hyperalgesia
Lysophosphatidic acid and its receptor LPA1 mediate carrageenan induced inflammatory pain in mice.
Hyperalgesia
mRNA expression of interleukins, phospholipase A2, and nitric oxide synthase in the nerve root and dorsal root ganglion induced by autologous nucleus pulposus in the rat.
Hyperalgesia
Oral administration of cytosolic PLA2 inhibitor arachidonyl trifluoromethyl ketone ameliorates cauda equina compression injury in rats.
Hyperalgesia
Pathomechanism of pain-related behavior produced by allografts of intervertebral disc in the rat.
Hyperalgesia
Snake venom phospholipase A2s (Asp49 and Lys49) induce mechanical allodynia upon peri-sciatic administration: involvement of spinal cord glia, proinflammatory cytokines and nitric oxide.
Hyperalgesia
Spinal phospholipase A2 in inflammatory hyperalgesia: role of group IVA cPLA2.
Hyperalgesia
Spinal phospholipase A2 in inflammatory hyperalgesia: role of the small, secretory phospholipase A2.
Hyperalgesia
Structural determinants of the hyperalgesic activity of myotoxic Lys49-phospholipase A2.
Hyperalgesia
Suppressive Effects of Bee Venom-Derived Phospholipase A2 on Mechanical Allodynia in a Rat Model of Neuropathic Pain.
Hyperalgesia
Systemic and intrathecal effects of a novel series of phospholipase A2 inhibitors on hyperalgesia and spinal prostaglandin e2 release.
Hyperalgesia
The role of phospholipase A2 and nitric oxide in pain-related behavior produced by an allograft of intervertebral disc material to the sciatic nerve of the rat.
Hypercalcemia
Hypercalcemia stimulates expression of intrarenal phospholipase A2 and prostaglandin H synthase-2 in rats. Role of angiotensin II AT1 receptors.
Hypercholesterolemia
An in vitro model for synaptic loss in neurodegenerative diseases suggests a neuroprotective role for valproic acid via inhibition of cPLA2 dependent signalling.
Hyperemia
Inhibition of phospholipase A2 attenuates functional hyperemia in the hamster cremaster muscle.
Hyperemia
Phospholipase A2 induced diffuse alveolar damage--effect of indomethacin and dexamethasone upon morphology and plasma-histamine level.
Hypereosinophilic Syndrome
Cytosolic phospholipase A2, increased and activated in the eosinophils of patients with hypereosinophilic syndrome in vivo, is involved in the augmented release of leukotriene C4.
Hypergammaglobulinemia
IgG4-Related Disease Is Not Associated with Antibody to the Phospholipase A2 Receptor.
Hyperglycemia
Activation of the VEGF-A/ERK/PLA2 Axis Mediates Early Retinal Endothelial Cell Damage Induced by High Glucose: New Insight from an In Vitro Model of Diabetic Retinopathy.
Hyperglycemia
Adiponutrin gene is regulated by insulin and glucose in human adipose tissue.
Hyperglycemia
Gene expression of type I phospholipase A2 in pancreatic beta cells. Regulation of mRNA levels by starvation or glucose excess.
Hyperglycemia
Group 1B phospholipase A? inactivation suppresses atherosclerosis and metabolic diseases in LDL receptor-deficient mice.
Hyperglycemia
Identification of the mechanism for the inhibition of Na+,K(+)-adenosine triphosphatase by hyperglycemia involving activation of protein kinase C and cytosolic phospholipase A2.
Hyperglycemia
KLF9 regulates PRDX6 expression in hyperglycemia-aggravated bupivacaine neurotoxicity.
Hyperglycemia
Peroxiredoxin 6 Attenuates Alloxan-Induced Type 1 Diabetes Mellitus in Mice and Cytokine-Induced Cytotoxicity in RIN-m5F Beta Cells.
Hyperglycemia
Postprandial lysophospholipid suppresses hepatic fatty acid oxidation: the molecular link between group 1B phospholipase A2 and diet-induced obesity.
Hyperglycemia
The relationship between plasma asymmetrical dimethyl-L-arginine and inflammation and adhesion molecule levels in subjects with normal, impaired, and diabetic glucose tolerance.
Hyperglycemia
Therapeutic reduction of lysophospholipids in the digestive tract recapitulates the metabolic benefits of bariatric surgery and promotes diabetes remission.
Hyperinsulinism
Group 1B phospholipase A2 in metabolic and inflammatory disease modulation.
Hyperinsulinism
Insulin regulation of gene expression and concentrations of white adipose tissue-derived proteins in vivo in healthy men: relation to adiponutrin.
Hyperlipidemias
Group 1B phospholipase A2 in metabolic and inflammatory disease modulation.
Hyperlipidemias
Group 1B phospholipase A? deficiency protects against diet-induced hyperlipidemia in mice.
Hyperlipidemias
Group 1B phospholipase A? inactivation suppresses atherosclerosis and metabolic diseases in LDL receptor-deficient mice.
Hyperlipidemias
Isoproterenol, TNFalpha, and insulin downregulate adipose triglyceride lipase in 3T3-L1 adipocytes.
Hyperlipidemias
Nuclear corepressors mediate the repression of phospholipase A2 group IIa gene transcription by thyroid hormone.
Hyperlipidemias
sPLA2-IB Level Correlates with Hyperlipidemia and the Prognosis of Idiopathic Membranous Nephropathy.
Hyperlipidemias
Suppression of N-nitrosobis(2-oxopropyl)amine-induced pancreatic carcinogenesis in hamsters by pioglitazone, a ligand of peroxisome proliferator-activated receptor gamma.
Hyperlipidemias
The phospholipase A2 family's role in metabolic diseases: Focus on skeletal muscle.
Hyperlipidemias
Therapeutic reduction of lysophospholipids in the digestive tract recapitulates the metabolic benefits of bariatric surgery and promotes diabetes remission.
Hyperlipidemias
Thyroid hormone status regulates the expression of secretory phospholipases.
Hyperlipoproteinemia Type II
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Hyperlipoproteinemia Type II
Statin therapy and secretory phospholipase A? in children with heterozygous familial hypercholesterolemia.
Hypersensitivity
A murine model of wheat versus potato allergy: Patatin and 53kDa protein are the potential allergen from potato.
Hypersensitivity
Allergen-derived long peptide immunotherapy down-regulates specific IgE response and protects from anaphylaxis.
Hypersensitivity
Biologically active molecules regulating the IgE antibody system: biochemical and biological comparisons of suppressive factor of allergy (SFA) and enhancing factor of allergy (EFA).
Hypersensitivity
Cross-Linking Cellular Prion Protein Induces Neuronal Type 2-Like Hypersensitivity.
Hypersensitivity
Differential stimulation of cytosolic phospholipase A2 by bradykinin in human cystic fibrosis cell lines.
Hypersensitivity
Efficacy of a therapeutic treatment using gas-filled microbubble-associated phospholipase A2 in a mouse model of honeybee venom allergy.
Hypersensitivity
Enzymatic activity of soluble phospholipase A2 does not affect the specific IgE, IgG4 and cytokine responses in bee sting allergy.
Hypersensitivity
Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro.
Hypersensitivity
Evaluation of patatin as a major cross-reactive allergen in latex-induced potato allergy.
Hypersensitivity
Evaluation of Phototoxic and Skin Sensitization Potentials of PLA 2 -Free Bee Venom.
Hypersensitivity
FcR epsilon+ lymphocytes and regulation of the IgE antibody system. III. Suppressive factor of allergy (SFA) is produced during the in vitro FcR epsilon expression cascade and displays corollary physiologic activity in vivo.
Hypersensitivity
FcR epsilon+ lymphocytes and regulation of the IgE antibody system. V. Preliminary physicochemical characterization of the T cell-selective IgE-induced regulant EIRT.
Hypersensitivity
Group VI phospholipases A2: homeostatic phospholipases with significant potential as targets for novel therapeutics.
Hypersensitivity
Group X secretory phospholipase A2 enhances TLR4 signaling in macrophages.
Hypersensitivity
Hypersensitivity of an Arabidopsis sugar signaling mutant toward exogenous proline application.
Hypersensitivity
Identification of a B-cell epitope of hyaluronidase, a major bee venom allergen, from its crystal structure in complex with a specific Fab.
Hypersensitivity
In Vitro and In Vivo Anti-Allergic and Anti-Inflammatory Effects of eBV, a Newly Developed Derivative of Bee Venom, through Modulation of IRF3 Signaling Pathway in a Carrageenan-Induced Edema Model.
Hypersensitivity
Increased specificity of diagnostic tests with recombinant major bee venom allergen phospholipase A2.
Hypersensitivity
Loss of PLA2G6 leads to elevated mitochondrial lipid peroxidation and mitochondrial dysfunction.
Hypersensitivity
Natural and recombinant enzymatically active or inactive bee venom phospholipase A2 has the same potency to release histamine from basophils in patients with Hymenoptera allergy.
Hypersensitivity
Phospholipase A2 augments contraction and intracellular calcium mobilization through thromboxane A2 in bovine tracheal smooth muscle.
Hypersensitivity
Positive skin and oral challenge responses to potato and occurrence of immunoglobulin E antibodies to patatin (Sol t 1) in infants with atopic dermatitis.
Hypersensitivity
Prophylactic immunization of mice with phospholipase A2-loaded gas-filled microbubbles is protective against Th2-mediated honeybee venom allergy.
Hypersensitivity
Pulmonary inflammation and edema induced by phospholipase A2: global gene analysis and effects on aquaporins and Na+/K+-ATPase.
Hypersensitivity
Regulation of IgE antibody production by serum molecules. IV. Complete Freund's adjuvant induces both enhancing and suppressive activities detectable in the serum of low and high responder mice.
Hypersensitivity
Sensitivity to bee venom antigen phospholipase A2: association with specific HLA class I and class II alleles and haplotypes in beekeepers and allergic patients.
Hypersensitivity
The IgE antibody system is coordinately regulated by FcR epsilon-positive lymphoid cells and IgE-selective soluble factors.
Hypersensitivity
The roles of iPLA2, TRPM8 and TRPA1 in chemically induced cold hypersensitivity.
Hypersensitivity
Therapeutic applications of antiflammin peptides in experimental ocular inflammation.
Hypersensitivity
Toward understanding interfacial activation of secretory phospholipase A2 (PLA2): membrane surface properties and membrane-induced structural changes in the enzyme contribute synergistically to PLA2 activation.
Hypersensitivity
Treatment of ovalbumin-induced experimental allergic bronchitis in rats by inhaled inhibitor of secretory phospholipase A(2).
Hypersensitivity
[Investigations on the histology of allergic reactions of the liver to sepatotoxin and myotoxin in experimental animals.]
Hypersensitivity
[Some pathogenetic mechanisms of bacterial bronchial asthma in paecilomycosis]
Hypertension
Alterations to the vascular vasodepressor prostaglandin system in DOCA-salt hypertensive rats and their enzymatic analysis.
Hypertension
Antifibrotic activity of an inhibitor of group IIA secretory phospholipase A2 in young spontaneously hypertensive rats.
Hypertension
Correlative studies on the effects of obesity, diabetes and hypertension on gene expression in omental adipose tissue of obese women.
Hypertension
Dexamethasone attenuates reversal of hypertension in one-kidney, one-clip rats.
Hypertension
Lipid alterations in renal membrane of stoke-prone spontaneously hypertensive rats.
Hypertension
Role of Secretory Phospholipase A2 in Rhythmic Contraction of Pulmonary Arteries of Rats With Monocrotaline-Induced Pulmonary Arterial Hypertension.
Hypertension
Severe and fatal mass attacks by 'killer' bees (Africanized honey bees--Apis mellifera scutellata) in Brazil: clinicopathological studies with measurement of serum venom concentrations.
Hypertension
The study of the relationship between the activity of phospholipase A2 and acute hypoxic pulmonary arterial pressure.
Hypertension
TRPV4 activates cytosolic phospholipase A2 via Ca2+ -dependent PKC/ERK1/2 signalling in controlling hypertensive contraction.
Hypertension
[Lipid alterations in renal membrane of stroke-prone spontaneously hypertensive rats (SHRSP)]
Hypertension
[The relationship between the activity of phospholipase A2 and acute hypoxic pulmonary arterial pressure]
Hypertension, Pulmonary
Vascular endothelial growth factor, lipoporotein-associated phospholipase A2, sP-selectin and antiphospholipid antibodies, biological markers with prognostic value in pulmonary hypertension associated with chronic obstructive pulmonary disease and systemic lupus erithematosus.
Hyperthyroidism
Influence of hypo- and hyperthyroidism on rat liver glycerophospholipid metabolism.
Hyperthyroidism
[Determination of phospholipase A2 activity in liver mitochondria using fluorescent dye 1,8-anilinonaphthalene sulfonate]
Hyperthyroidism
[Effects of experimental hyperthyroidism on the phospholipase A2, lipase, cholesterolesterase and trypsin activity of the pancreatic juice and of the pancreas in rats]
Hypertriglyceridemia
Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus.
Hypertriglyceridemia
Infection and inflammation-induced proatherogenic changes of lipoproteins.
Hypertriglyceridemia
Reversal of obesity-induced hypertriglyceridemia by (R)-?-lipoic acid in ZDF (fa/fa) rats.
Hypertrophy, Left Ventricular
Antifibrotic activity of an inhibitor of group IIA secretory phospholipase A2 in young spontaneously hypertensive rats.
Hyperventilation
The effect of centrally injected CDP-choline on respiratory system; involvement of phospholipase to thromboxane signaling pathway.
Hypokinesia
Follow-up study of 25 Chinese children with PLA2G6-associated neurodegeneration.
Hypoparathyroidism
[Mechanisms of thrombocyte aggregation in experimental hypoparathyroidism]
Hypotension
Bothrops leucurus venom induces acute hypotension in rats by means of its phospholipase A2 (blD-PLA2).
Hypotension
Elevated plasma phospholipase A2 levels: correlation with the hemodynamic and pulmonary changes in gram-negative septic shock.
Hypotension
Induction of TNF-alpha and proinflammatory secretory phospholipase A2 by intravenous administration of CAMPATH-1H in patients with rheumatoid arthritis.
Hypotension
Involvement of circulating phospholipase A2 in the pathogenesis of the hemodynamic changes in endotoxin shock.
Hypotension
Pathogenesis of hypotension in septic shock: correlation of circulating phospholipase A2 levels with circulatory collapse.
Hypothyroidism
Influence of hypo- and hyperthyroidism on rat liver glycerophospholipid metabolism.
Hypothyroidism
Response of mitochondrial function to hypothyroidism in normal and regenerated rat skeletal muscle.
Hypothyroidism
Serum Phospholipase A2-IIA, hs-CRP, and Lipids in Women With Subclinical Hypothyroidism.
Ichthyosis
Sixteen novel mutations in PNPLA1 in patients with autosomal recessive congenital ichthyosis reveal the importance of an extended patatin domain in PNPLA1 that is essential for proper human skin barrier function.
Idiopathic Pulmonary Fibrosis
CREB-dependent LPA-induced signaling initiates a pro-fibrotic feedback loop between small airway basal cells and fibroblasts.
Ileitis
Phospholipase A2 gene expression and activity in histologically normal ileal mucosa and in Crohn's ileitis.
Immunoglobulin G4-Related Disease
IgG4-Related Disease Is Not Associated with Antibody to the Phospholipase A2 Receptor.
Immunoglobulin G4-Related Disease
Phospholipase A2 receptor-associated membranous nephropathy in a patient with IgG4-related disease: A case report.
Infarction, Middle Cerebral Artery
Activation of CRHR1 contributes to cerebral endothelial barrier impairment via cPLA2 phosphorylation in experimental ischemic stroke.
Infarction, Middle Cerebral Artery
Angiotensin II type 1 receptor blocker telmisartan reduces cerebral infarct volume and periinfarct cytosolic phospholipase A2 level in experimental stroke.
Infarction, Middle Cerebral Artery
Prdx6 Upregulation by Curcumin Attenuates Ischemic Oxidative Damage via SP1 in Rats after Stroke.
Infarction, Middle Cerebral Artery
The phospholipase A2 inhibitor, quinacrine, reduces infarct size in rats after transient middle cerebral artery occlusion.
Infections
A bacterially produced virus enhancing factor from an entomopoxvirus enhances nucleopolyhedrovirus infection in armyworm larvae.
Infections
A peptide derived from bee venom-secreted phospholipase A2 inhibits replication of T-cell tropic HIV-1 strains via interaction with the CXCR4 chemokine receptor.
Infections
Activation of apoptosis, but not necrosis, during Mycobacterium tuberculosis infection correlated with decreased bacterial growth: role of TNF-alpha, IL-10, caspases and phospholipase A2.
Infections
Adenovirus E3-10.4K/14.5K protein complex inhibits tumor necrosis factor-induced translocation of cytosolic phospholipase A2 to membranes.
Infections
Adenovirus type 5 exerts multiple effects on the expression and activity of cytosolic phospholipase A2, cyclooxygenase-2, and prostaglandin synthesis.
Infections
An Amperometric Biosensor for the Determination of Bacterial Sepsis Biomarker, Secretory Phospholipase Group 2-IIA Using a Tri-Enzyme System.
Infections
An antisense oligonucleotide to 1-cys peroxiredoxin causes lipid peroxidation and apoptosis in lung epithelial cells.
Infections
Antibacterial effects of human group IIA and group XIIA phospholipase A2 against Helicobacter pylori in vitro.
Infections
Association of cervicovaginal infections with increased vaginal fluid phospholipase A2 activity.
Infections
Burkholderia pseudomallei interferes with host lipid metabolism via NR1D2-mediated PNPLA2/ATGL suppression to block autophagy-dependent inhibition of infection.
Infections
Calcium-dependent phospholipase A2 Modulates Infection Induced Diaphragm Dysfunction.
Infections
Characterization by electrospray mass spectrometry of human Ca(2+)-sensitive cytosolic phospholipase A2 produced in baculovirus-infected insect cells.
Infections
Circulating inflammatory mediators predict shock and mortality in febrile patients with microbial infection.
Infections
Cleavage of RasGAP and phosphorylation of mitogen-activated protein kinase in the course of coxsackievirus B3 replication.
Infections
Club cell 10-kDa protein (CC10) inhibits cPLA2/COX2 pathway to alleviate RSV-induced airway inflammation and AHR.
Infections
Conditional knock-out of lipoic acid protein ligase 1 reveals redundancy pathway for lipoic acid metabolism in Plasmodium berghei malaria parasite.
Infections
Coordinate expression of group II phospholipase A2 and the acute-phase proteins haptoglobin (HP) and alpha1-anti-chymotrypsin (ACH) by HepG2 cells.
Infections
Critical role of phospholipase A2 group IID in age-related susceptibility to severe acute respiratory syndrome-CoV infection.
Infections
Crotoxin stimulates an M1 activation profile in murine macrophages during Leishmania amazonensis infection.
Infections
Cytosolic and Calcium-Independent Phospholipases A2 Activation and Prostaglandins E2 Are Associated with Escherichia coli-Induced Reduction of Insulin Secretion in INS-1E Cells.
Infections
Cytosolic phospholipase A2 contributes to innate immune defense against Candida albicans lung infection.
Infections
Cytosolic phospholipase A2 gamma is involved in hepatitis C virus replication and assembly.
Infections
Cytosolic phospholipase A2-alpha is necessary for platelet-activating factor biosynthesis, efficient neutrophil-mediated bacterial killing, and the innate immune response to pulmonary infection: cPLA2-alpha does not regulate neutrophil NADPH oxidase activity.
Infections
Cytosolic phospholipase a2? and eicosanoids regulate expression of genes in macrophages involved in host defense and inflammation.
Infections
Cytosolic phospholipase A2? promotes pulmonary inflammation and systemic disease during Streptococcus pneumoniae infection.
Infections
Defining Postpartum Uterine Disease and the Mechanisms of Infection and Immunity in the Female Reproductive Tract in Cattle.
Infections
Early identification of bacteremia by biochemical markers of systemic inflammation.
Infections
Effect of phospholipase A2 inhibitors during infection caused by Leishmania (Leishmania) amazonensis.
Infections
Effects of bacteriophage M13 infection upon phospholipid and fatty acid compositions of Escherichia coli.
Infections
Effects of human parvovirus B19 VP1 unique region protein on macrophage responses.
Infections
Eicosanoid mediation of immune responses at early bacterial infection stage and its inhibition by Photorhabdus temperata subsp. temperata, an entomopathogenic bacterium.
Infections
Experimental Helicobacter felis infection in transgenic mice expressing human group IIA phospholipase A2.
Infections
Functional coupling and differential regulation of the phospholipase A2-cyclooxygenase pathways in inflammation.
Infections
Genes encoding phospholipases A2 mediate insect nodulation reactions to bacterial challenge.
Infections
Group II phospholipase A2 in sera of febrile patients with microbiologically or clinically documented infections.
Infections
Group IIA-soluble phospholipase A2 levels in patients with infections after esophageal cancer surgery.
Infections
Group V and X secretory phospholipase A2 prevents adenoviral infection in mammalian cells.
Infections
Group V Phospholipase A2 in bone marrow derived myeloid cells and bronchial epithelial cells promote bacterial clearance after E. coli pneumonia.
Infections
Helicobacter infection and phospholipase A2 enzymes: effect of Helicobacter felis-infection on the expression and activity of sPLA2 enzymes in mouse stomach.
Infections
Helicobacter pylori associated phospholipase A2 activity: a factor in peptic ulcer production?
Infections
High-level production of biologically active human cytosolic phospholipase A2 in baculovirus-infected insect cells.
Infections
Host Prdx6 contributing to the intracellular survival of Brucella suis S2 strain.
Infections
Human group II phospholipase A2 expressed in Trichoplusia ni larvae--isolation and kinetic properties of the enzyme.
Infections
In vivo and in vitro studies of cytosolic phospholipase A2 expression in Helicobacter pylori infection.
Infections
Increased flexibility in the use of exogenous lipoic acid by Staphylococcus aureus.
Infections
Intrinsic phospholipase A2 activity of adeno-associated virus is involved in endosomal escape of incoming particles.
Infections
Klebsiella pneumoniae induces an inflammatory response in an in vitro model of blood-retinal barrier.
Infections
Lack of group X secreted phospholipase A2 increases survival following pandemic H1N1 influenza infection.
Infections
Leishmania donovani-Induced Prostaglandin E2 Generation Is Critically Dependent on Host Toll-Like Receptor 2-Cytosolic Phospholipase A2 Signaling.
Infections
Lipid mediators and vector infection: Trypanosoma rangeli inhibits Rhodnius prolixus hemocyte phagocytosis by modulation of phospholipase A2 and PAF-acetylhydrolase activities.
Infections
Lung cancer cell lines inhibit leukotriene B4 production by human polymorphonuclear leukocytes at the level of phospholipase A2.
Infections
Lysis of human immunodeficiency virus type 1 by a specific secreted human phospholipase A2.
Infections
Lysosomal phospholipase A2: a novel player in host immunity to Mycobacterium tuberculosis.
Infections
Mice lacking secretory phospholipase A2 show altered apoptosis and differentiation with Helicobacter felis infection.
Infections
Modification of phospholipase C and phospholipase A2 activities during poliovirus infection.
Infections
Modulation of growth in human esophageal adenocarcinoma cells by group IIa secretory phospholipase A(2).
Infections
Modulation of the activity of secretory phospholipase A2 by antimicrobial peptides.
Infections
Molecular characterization of infectious clones of the minute virus of canines reveals unique features of bocaviruses.
Infections
mRNA differential display of acute-phase proteins in experimental Escherichia coli infection.
Infections
Mutation of the phospholipase catalytic domain of the Pseudomonas aeruginosa cytotoxin ExoU abolishes colonization promoting activity and reduces corneal disease severity.
Infections
Mutational analysis of narrow pores at the fivefold symmetry axes of adeno-associated virus type 2 capsids reveals a dual role in genome packaging and activation of phospholipase A2 activity.
Infections
Peroxiredoxin 6 expression is inversely correlated with nuclear factor-?B activation during Clonorchis sinensis infestation.
Infections
Peroxiredoxin 6 phospholipid hydroperoxidase activity in the repair of peroxidized cell membranes.
Infections
Peroxiredoxin 6 Serum Levels and Risk of Neutropenic Infections in Diffuse Large B-cell Lymphoma.
Infections
Peroxiredoxin-6 Negatively Regulates Bactericidal Activity and NF-?B Activity by Interrupting TRAF6-ECSIT Complex.
Infections
Pertussis toxin-sensitive G proteins as mediators of the signal transduction pathways activated by cytomegalovirus infection of smooth muscle cells.
Infections
Phospholipases A2 in gastric juice of Helicobacter pylori--positive and negative individuals.
Infections
Porcine Fc?RI Mediates Porcine Reproductive and Respiratory Syndrome Virus Multiplication and Regulates the Inflammatory Reaction.
Infections
Preterm labor and bacterial intra-amniotic infection: arachidonic acid liberation by the action of phospholipase A2.
Infections
Preterm labor and bacterial intraamniotic infection: arachidonic acid liberation by phospholipase A2 of Fusobacterium nucleatum.
Infections
Proteomic identification of peroxiredoxin 6 for host defence against Opisthorchis viverrini infection.
Infections
Pseudolipasin A is a specific inhibitor for phospholipase A2 activity of Pseudomonas aeruginosa cytotoxin ExoU.
Infections
Pseudomonas aeruginosa eradicates Staphylococcus aureus by manipulating the host immunity.
Infections
Purification of an isoform of patatin with antimicrobial activity against Phytophthora infestans.
Infections
Regulation of cytosolic phospholipase A2 expression by cytokines in human amnion cells.
Infections
Relation of secretory phospholipase A(2) and high-sensitivity C-reactive protein to Chlamydia pneumoniae infection in acute coronary syndromes.
Infections
Renal deposits of lipoprotein-immunoglobulin complexes in Plasmodium chabaudi-infected mice.
Infections
Reprogramming of fatty acid and oxylipin synthesis in rhizobacteria-induced systemic resistance in tomato.
Infections
Resistance of transgenic mice expressing human group II phospholipase A2 to Escherichia coli infection.
Infections
Rickettsia typhi possesses phospholipase A2 enzymes that are involved in infection of host cells.
Infections
RNase 7 but not psoriasin nor sPLA2-IIA associates with Mycobacterium tuberculosis during airway epithelial cell infection.
Infections
Role of human group IIA secreted phospholipase A2 in malaria pathophysiology: Insights from a transgenic mouse model.
Infections
Role of mitogen-activated protein kinases in influenza virus induction of prostaglandin E2 from arachidonic acid in bronchial epithelial cells.
Infections
RSV-induced prostaglandin E2 production occurs via cPLA2 activation: role in viral replication.
Infections
Secreted Group IIA Phospholipase A2 Protects Humans Against the Group B Streptococcus: Experimental and Clinical Evidence.
Infections
Secreted phospholipases A(2), a new class of HIV inhibitors that block virus entry into host cells.
Infections
Secretory phospholipase A(2): a marker of infection in febrile children presenting to a pediatric ED.
Infections
Secretory phospholipase A2 in SARS-CoV-2 infection and multisystem inflammatory syndrome in children (MIS-C).
Infections
Secretory phospholipase A2 pathway in various types of lung injury in neonates and infants: a multicentre translational study.
Infections
Selective Mycobacterium avium-induced production of nitric oxide by human monocyte-derived macrophages.
Infections
Sequestration of free cholesterol in cell membranes by prions correlates with cytoplasmic phospholipase A2 activation.
Infections
Serum mannan-binding lectin (MBL) in patients with infection: clinical and laboratory correlates.
Infections
Staphylococcus aureus pneumonia in hamsters with elastase-induced emphysema--the virulence enhancing activity of mucin.
Infections
Study of the chemical nature of Frp/3 cell recognition units for hepatitis A virus.
Infections
The effect of phospholipase A2 from Crotalus durissus collilineatus on Leishmania (Leishmania) amazonensis infection.
Infections
The Prostaglandin E2-EP3 Receptor Axis Regulates Anaplasma phagocytophilum-Mediated NLRC4 Inflammasome Activation.
Infections
The role of Cryptosporidium parvum-derived phospholipase in intestinal epithelial cell invasion.
Infections
The role of group IIA secretory phospholipase A2 (sPLA2-IIA) as a biomarker for the diagnosis of sepsis and bacterial infection in adults-A systematic review.
Infections
The role of the innate immune response in hospital- versus community-acquired infection in febrile medical patients.
Infections
Toll/IMD signal pathways mediate cellular immune responses via induction of intracellular PLA 2 expression.
Infections
Transcriptomic profiling of phospholipase A2 and the role of arachidonic acid during Brucella abortus 544 infection in both in vitro and in vivo systems.
Infections
Type 1 interferon-dependent repression of NLRC4 and iPLA2 licenses down-regulation of Salmonella flagellin inside macrophages.
Infections
Tyrosine cross-linking reveals interfacial dynamics in adeno-associated viral capsids during infection.
Infections
Varespladib Inhibits Secretory Phospholipase A2 in Bronchoalveolar Lavage of Different Types of Neonatal Lung Injury.
Infections
[Effect of fish oil on intestinal Paneth cells in mouse with abdominal infection].
Infections
[Pathogenesis of myocarditis in patients with bronchial asthma and pecilomycosis].
Infections
[Platelet phospholipase A2 mRNA content changes and cDNA cloning in rat blood with bacteria infection]
Infections
[Profiles of intracellular expression, distribution, and activation of phospholipase A2 in host macrophages infected with Mycobacterium avium complex]
Infections
[Research progress in the application of necrotic cavity lavage in the treatment of infected pancreatic necrosis].
Infertility
Cytosolic phospholipase A2 and F2 isoprostanes are involved in semen quality and human infertility-A study on leucocytospermia, varicocele and idiopathic infertility.
Infertility
Effects of dialyser and dialysate on the acute phase reaction in clinical bicarbonate dialysis.
Infertility
Peroxiredoxin 6 is the primary antioxidant enzyme for the maintenance of viability and DNA integrity in human spermatozoa.
Infertility, Male
Cytosolic phospholipase A2 and F2 isoprostanes are involved in semen quality and human infertility-A study on leucocytospermia, varicocele and idiopathic infertility.
Infertility, Male
Mechanistic insights into the urea-induced denaturation of a non-seleno thiol specific antioxidant human peroxiredoxin 6.
Infertility, Male
Oxidative stress and sperm function: A systematic review on evaluation and management.
Infertility, Male
Peroxiredoxin 6 regulates the phosphoinositide 3-kinase/AKT pathway to maintain human sperm viability.
Infertility, Male
[Detection and clinical significance of phospholipase A2 in semen of male infertile patients]
Inflammatory Bowel Diseases
A potent and selective inhibitor of group IIa secretory phospholipase A2 protects rats from TNBS-induced colitis.
Inflammatory Bowel Diseases
Amelioration of TNBS-induced colon inflammation in rats by phospholipase A2 inhibitor.
Inflammatory Bowel Diseases
Cytosolic phospholipase A2 and cyclooxygenase-2 mediate release and metabolism of arachidonic acid in tumor necrosis factor-alpha-primed cultured intestinal epithelial cells (INT 407).
Inflammatory Bowel Diseases
Effect of Bacillus subtilis PB6, a natural probiotic on colon mucosal inflammation and plasma cytokines levels in inflammatory bowel disease.
Inflammatory Bowel Diseases
Elevated group II phospholipase A2 mass concentration in serum and colonic mucosa in Crohn's disease.
Inflammatory Bowel Diseases
Gene expression of group II phospholipase A2 in intestine in Crohn's disease.
Inflammatory Bowel Diseases
Gene expression of group II phospholipase A2 in intestine in ulcerative colitis.
Inflammatory Bowel Diseases
Immunohistochemical localization of group II phospholipase A2 in colonic mucosa of patients with inflammatory bowel disease.
Inflammatory Bowel Diseases
Increased group II phospholipase A2 in colonic mucosa of patients with Crohn's disease and ulcerative colitis.
Inflammatory Bowel Diseases
Increased phospholipase A2 activity of Ileal mucosa in Crohn's disease.
Inflammatory Bowel Diseases
Interleukin-6 changes tight junction permeability and intracellular phospholipid content in a human enterocyte cell culture model.
Inflammatory Bowel Diseases
Phospholipase A2 activating protein and idiopathic inflammatory bowel disease.
Inflammatory Bowel Diseases
Phospholipase A2 activity of colonic mucosa in patients with ulcerative colitis.
Inflammatory Bowel Diseases
Phospholipid-Based Prodrugs for Drug Targeting in Inflammatory Bowel Disease: Computational Optimization and In-Vitro Correlation.
Inflammatory Bowel Diseases
Phospholipid-drug conjugates as a novel oral drug targeting approach for the treatment of inflammatory bowel disease.
Inflammatory Bowel Diseases
Platelet activating factor and endotoxin increase the enzyme activity and gene expression of type II phospholipase A2 in the rat intestine. Role of polymorphonuclear leukocytes.
Inflammatory Bowel Diseases
Raised serum activity of phospholipase A2 immunochemically related to group II enzyme in inflammatory bowel disease: its correlation with disease activity of Crohn's disease and ulcerative colitis.
Inflammatory Bowel Diseases
The effect of phospholipids and fatty acids on tight-junction permeability and bacterial translocation.
Influenza, Human
Curcumin differs from tetrahydrocurcumin for molecular targets, signaling pathways and cellular responses.
Influenza, Human
Lack of group X secreted phospholipase A2 increases survival following pandemic H1N1 influenza infection.
Influenza, Human
Major Shifts in the Spatio-Temporal Distribution of Lung Antioxidant Enzymes during Influenza Pneumonia.
Influenza, Human
Production of a viral growth enhancing factor (enhancer) in eggs infected with influenza virus (PR 8).
Insulin Resistance
Adiponutrin gene is regulated by insulin and glucose in human adipose tissue.
Insulin Resistance
Adiponutrin: A new gene regulated by energy balance in human adipose tissue.
Insulin Resistance
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Insulin Resistance
Effect of lipoprotein-associated phospholipase A2 inhibitor on insulin resistance in streptozotocin-induced diabetic pregnant rats.
Insulin Resistance
Genomic Variants Associated with Resistance to High Fat Diet Induced Obesity in a Primate Model.
Insulin Resistance
Group 1B phospholipase A? inactivation suppresses atherosclerosis and metabolic diseases in LDL receptor-deficient mice.
Insulin Resistance
Inflammatory Biomarkers of Cardiometabolic Risk in Obese Egyptian Type 2 Diabetics.
Insulin Resistance
Insulin regulation of gene expression and concentrations of white adipose tissue-derived proteins in vivo in healthy men: relation to adiponutrin.
Insulin Resistance
Isoproterenol, TNFalpha, and insulin downregulate adipose triglyceride lipase in 3T3-L1 adipocytes.
Insulin Resistance
Pancreatic acinar cell-specific overexpression of group 1B phospholipase A(2) exacerbates diet-induced obesity and insulin resistance in mice.
Insulin Resistance
Peroxiredoxin 6 Confers Protection Against Nonalcoholic Fatty Liver Disease Through Maintaining Mitochondrial Function.
Insulin Resistance
Plasma adhesion and inflammation markers: asymmetrical dimethyl-L-arginine and secretory phospholipase A2 concentrations before and after laparoscopic gastric banding in morbidly obese patients.
Insulin Resistance
PNPLA3 polymorphism influences liver fibrosis in unselected patients with type 2 diabetes.
Insulin Resistance
Prostaglandin in the ventromedial hypothalamus regulates peripheral glucose metabolism.
Insulin Resistance
Secreted Phospholipase PLA2G2D Contributes to Metabolic Health by Mobilizing ?3 Polyunsaturated Fatty Acids in WAT.
Insulin Resistance
Secretory phospholipase A2 group IIA modulates insulin sensitivity and metabolism.
Insulin Resistance
Skeletal muscle expression of adipose-specific phospholipase in peripheral artery disease.
Insulin Resistance
Specifically PNPLA3-Mediated Accumulation of Liver Fat in Obese Patients with Type 2 Diabetes.
Insulin Resistance
[Alcoholic and non-alcoholic steatohepatitis: Who is affected and what can we do for them?]
Insulin Resistance
[Metformin prevents non-alcoholic fatty liver disease in rats: role of phospholipase A2/lysophosphatidylcholine lipoapoptosis pathway in hepatocytes.]
Insulinoma
Arginine vasopressin-stimulated insulin secretion and elevation of intracellular Ca++ concentration in rat insulinoma cells: influences of a phospholipase C inhibitor 1-[6-[[17 beta-methoxyestra-1,3,5(10)-trien- 17-yl]amino]hexyl]-1H-pyrrole-2,5-dione (U-73122) and a phospholipase A2 inhibitor N-(p-amylcinnamoyl)anthranilic acid.
Insulinoma
Effects of stable suppression of Group VIA phospholipase A2 expression on phospholipid content and composition, insulin secretion, and proliferation of INS-1 insulinoma cells.
Insulinoma
Evidence for association of an ATP-stimulatable Ca(2+)-independent phospholipase A2 from pancreatic islets and HIT insulinoma cells with a phosphofructokinase-like protein.
Insulinoma
Glucose-responsitivity and expression of an ATP-stimulatable, Ca(2+)-independent phospholipase A2 enzyme in clonal insulinoma cell lines.
Insulinoma
Human pancreatic islets express mRNA species encoding two distinct catalytically active isoforms of group VI phospholipase A2 (iPLA2) that arise from an exon-skipping mechanism of alternative splicing of the transcript from the iPLA2 gene on chromosome 22q13.1.
Insulinoma
Pancreatic islets and insulinoma cells express a novel isoform of group VIA phospholipase A2 (iPLA2 beta) that participates in glucose-stimulated insulin secretion and is not produced by alternate splicing of the iPLA2 beta transcript.
Insulinoma
Peroxiredoxin 6 Attenuates Alloxan-Induced Type 1 Diabetes Mellitus in Mice and Cytokine-Induced Cytotoxicity in RIN-m5F Beta Cells.
Insulinoma
Protective Effect of Peroxiredoxin 6 Against Toxic Effects of Glucose and Cytokines in Pancreatic RIN-m5F ?-Cells.
Insulinoma
Rat and human pancreatic islet cells contain a calcium ion independent phospholipase A2 activity selective for hydrolysis of arachidonate which is stimulated by adenosine triphosphate and is specifically localized to islet beta-cells.
Insulinoma
Studies of insulin secretory responses and of arachidonic acid incorporation into phospholipids of stably transfected insulinoma cells that overexpress group VIA phospholipase A2 (iPLA2beta ) indicate a signaling rather than a housekeeping role for iPLA2beta.
Insulinoma
Studies of phospholipid metabolism, proliferation, and secretion of stably transfected insulinoma cells that overexpress group VIA phospholipase A2.
Insulinoma
Studies of the role of group VI phospholipase A2 in fatty acid incorporation, phospholipid remodeling, lysophosphatidylcholine generation, and secretagogue-induced arachidonic acid release in pancreatic islets and insulinoma cells.
Insulinoma
The group VIA calcium-independent phospholipase A2 participates in ER stress-induced INS-1 insulinoma cell apoptosis by promoting ceramide generation via hydrolysis of sphingomyelins by neutral sphingomyelinase.
Intellectual Disability
Both rare and common genetic variants contribute to autism in the Faroe Islands.
Intervertebral Disc Degeneration
Effect of percutaneous nucleoplasty with coblation on phospholipase A2 activity in the intervertebral disks of an animal model of intervertebral disk degeneration: a randomized controlled trial.
Intervertebral Disc Degeneration
Phospholipase A2 activity in herniated lumbar discs. Clinical correlations and inhibition by piroxicam.
Intervertebral Disc Displacement
A controlled biochemical and immunohistochemical study of human synovial-type (group II) phospholipase A2 and inflammatory cells in macroscopically normal, degenerated, and herniated human lumbar disc tissues.
Intervertebral Disc Displacement
Comparative immunohistochemical study of group II (synovial-type) and group IV (cytosolic) phospholipases A2 in disc prolapse tissue.
Intervertebral Disc Displacement
High levels of inflammatory phospholipase A2 activity in lumbar disc herniations.
Intervertebral Disc Displacement
Human group II phospholipase A2 in normal and diseased intervertebral discs.
Intervertebral Disc Displacement
Immunocytochemical localization of immunoglobulins in disc herniations.
Intervertebral Disc Displacement
Inhibition of phospholipase A2 purified from human herniated disc.
Intervertebral Disc Displacement
Pathomechanism of pain-related behavior produced by allografts of intervertebral disc in the rat.
Intervertebral Disc Displacement
Phospholipase A2 activity in herniated lumbar discs. Clinical correlations and inhibition by piroxicam.
Intervertebral Disc Displacement
Phospholipase A2 sensitivity of the dorsal root and dorsal root ganglion.
Intervertebral Disc Displacement
Possible mechanism of painful radiculopathy in lumbar disc herniation.
Intervertebral Disc Displacement
The role of phospholipase A2 and nitric oxide in pain-related behavior produced by an allograft of intervertebral disc material to the sciatic nerve of the rat.
Intestinal Diseases
Genetic analysis is helpful for the diagnosis of small bowel ulceration.
Intestinal Polyposis
Deficiency of phospholipase A2 group 7 decreases intestinal polyposis and colon tumorigenesis in Apc Min/+ mice.
Intracranial Aneurysm
Methylation of Phospholipase A2 Group VII Gene Is Associated with Brain Arteriovenous Malformations in Han Chinese Populations.
Iron Overload
Development of esophageal metaplasia and adenocarcinoma in a rat surgical model without the use of a carcinogen.
Iron Overload
Specific roles for Group V secretory PLA? in retinal iron-induced oxidative stress. Implications for age-related macular degeneration.
Ischemic Attack, Transient
A secretory phospholipase A2-mediated neuroprotection and anti-apoptosis.
Ischemic Attack, Transient
Citicoline decreases phospholipase A2 stimulation and hydroxyl radical generation in transient cerebral ischemia.
Ischemic Attack, Transient
Phospholipase A2, hydroxyl radicals, and lipid peroxidation in transient cerebral ischemia.
Ischemic Attack, Transient
Posttreatment with EPC-K1, an inhibitor of lipid peroxidation and of phospholipase A2 activity, reduces functional deficits after global ischemia in rats.
Ischemic Stroke
Activated microglia in ischemic stroke penumbra upregulate MCP-1 and CCR2 expression in response to lysophosphatidylcholine derived from adjacent neurons and astrocytes.
Ischemic Stroke
Activation of CRHR1 contributes to cerebral endothelial barrier impairment via cPLA2 phosphorylation in experimental ischemic stroke.
Ischemic Stroke
Association between serum secretory phospholipase A2 and risk of ischaemic stroke.
Ischemic Stroke
Clinical Utility of the Serum Level of Lipoprotein-Related Phospholipase A2 in Acute Ischemic Stroke With Cerebral Artery Stenosis.
Ischemic Stroke
High-sensitivity C-reactive protein, lipoprotein-related phospholipase A2, and acute ischemic stroke.
Ischemic Stroke
Peroxiredoxin 6 secreted by Schwann-like cells protects neuron against ischemic stroke in rats via PTEN/PI3K/AKT pathway.
Ischemic Stroke
Phospholipase A2 in patients with noncardioembolic ischemic stroke and severe inflammatory reaction.
Ischemic Stroke
Platelet phospholipase A(2) activity in patients with Alzheimer's disease, vascular dementia and ischemic stroke.
Ischemic Stroke
[Lipoprotein-associated phospholipase A2: relation to development of ischemic stroke in patients with essential hypertension].
Joint Diseases
Identification and isolation of a phospholipase A2 activating protein in human rheumatoid arthritis synovial fluid: induction of eicosanoid synthesis and an inflammatory response in joints injected in vivo.
Joint Diseases
Inactivation of human synovial fluid phospholipase A2 by the marine natural product, manoalide.
Keratoconjunctivitis Sicca
Group IIA phospholipase A2 content of tears in patients with keratoconjunctivitis sicca.
Keratoconus
Corneal Oxidative Damage in Keratoconus Cells due to Decreased Oxidant Elimination from Modified Expression Levels of SOD Enzymes, PRDX6, SCARA3, CPSF3, and FOXM1.
Kidney Diseases
Altered glycosylation of IgG4 promotes lectin complement pathway activation in anti-PLA2R1-associated membranous nephropathy.
Kidney Diseases
Excessive arachidonic acid induced actin bunching remodeling and podocyte injury via a PKA-c-Abl dependent pathway.
Kidney Diseases
ROS and kidney disease in the evolution from acute phase to chronic end stage disease: A commentary on "Oxidative signaling in renal epithelium: Critical role of cPLA2 and p38SAPK".
Kidney Failure, Chronic
Increased type IIA secretory phospholipase A(2) expression contributes to oxidative stress in end-stage renal disease.
Kidney Failure, Chronic
Rituximab in Patients With Phospholipase A2 Receptor-Associated Membranous Nephropathy and Severe CKD.
Kidney Failure, Chronic
sPLA2 IB induces human podocyte apoptosis via the M-type phospholipase A2 receptor.
Kidney Neoplasms
Bee venom secretory phospholipase A2 and phosphatidylinositol-homologues cooperatively disrupt membrane integrity, abrogate signal transduction and inhibit proliferation of renal cancer cells.
Kimura Disease
Kimura's disease associated with membranous nephropathy with IgG4 and phospholipase A2 receptor-positive staining of the glomerular basement membrane.
Lecithin Cholesterol Acyltransferase Deficiency
Alpha-lecithin:cholesterol acyltransferase deficiency. Lack of both phospholipase A2 and acyltransferase activities characteristic of high density lipoprotein lecithin:cholesterol acyltransferase in fish eye disease.
Lecithin Cholesterol Acyltransferase Deficiency
Structure and function of lysosomal phospholipase A2 and lecithin:cholesterol acyltransferase.
Leiomyoma
DNA microarray data integration by ortholog gene analysis reveals potential molecular mechanisms of estrogen-dependent growth of human uterine fibroids.
Leiomyoma
The measurement of phospholipase A2 activity in human myometrium: physiological and pathological implications.
Leiomyoma
Transethnic and race-stratified genome-wide association study of fibroid characteristics in African American and European American women.
Leishmaniasis
Pentalinonsterol, a Phytosterol from Pentalinon andrieuxii, is Immunomodulatory through Phospholipase A2 in Macrophages toward its Antileishmanial Action.
Leishmaniasis, Cutaneous
The effect of phospholipase A2 from Crotalus durissus collilineatus on Leishmania (Leishmania) amazonensis infection.
Leprosy
A phase II study of oral clofazimine in unresectable and metastatic hepatocellular carcinoma.
Leukemia
A guanine nucleotide-binding protein participates in IgE receptor-mediated activation of endogenous and reconstituted phospholipase A2 in a permeabilized cell system.
Leukemia
Activation mechanism for CRAC current and store-operated Ca2+ entry: calcium influx factor and Ca2+-independent phospholipase A2beta-mediated pathway.
Leukemia
Arachidonic acid release by basophilic leukemia cells and macrophages stimulated by Ca2+ ionophores, antigen and diacylglycerol: essential role for protein kinase C and prevention by glucocorticosteroids.
Leukemia
Bothrops moojeni myotoxin-II, a Lys49-phospholipase A2 homologue: an example of function versatility of snake venom proteins.
Leukemia
Ca2+/calmodulin-dependent protein kinase II and cytosolic phospholipase A2 contribute to mitogenic signaling in myeloblastic leukemia U-937 cells.
Leukemia
Changes of phospholipase A2 inhibitory activity in the K+-sensitive actin gelation factor during the differentiation of myeloid leukemia cells.
Leukemia
Cobra venom cytotoxin free of phospholipase A2 and its effect on model membranes and T leukemia cells.
Leukemia
Differential regulation of phospholipase A2 in human leukemia cells by the etherphospholipid analogue hexadecylphosphocholine.
Leukemia
Differentiation of HL60 promyelocytic cells is promoted by a 'differentiation enhancing factor' produced by erythroleukemia cells.
Leukemia
Epigenetic regulation of the PGE2 pathway modulates macrophage phenotype in normal and pathologic wound repair.
Leukemia
Identification of novel lipid droplet factors that regulate lipophagy and cholesterol efflux in macrophage foam cells.
Leukemia
Involvement of epigenetic mechanisms in the regulation of secreted phospholipase A2 expressions in Jurkat leukemia cells.
Leukemia
Lactadherin inhibits secretory phospholipase A2 activity on pre-apoptotic leukemia cells.
Leukemia
Leukemia inhibitory factor induces the 85-kDa cytosolic phospholipase A2 gene expression in cultured human bronchial epithelial cells.
Leukemia
Nigexine, a phospholipase A2 from cobra venom with cytotoxic properties not related to esterase activity. Purification, amino acid sequence, and biological properties.
Leukemia
Phospholipase A2 stimulation during cell secretion in rat basophilic leukemia cells.
Leukemia
Potentiation of leukemogenicity and infectivity of Rauscher leukemia virus by an enhancing factor present in egg fluids.
Leukemia
Regulation of interleukin-1 and tumor necrosis factor-alpha induced granulocyte-macrophage colony-stimulating factor gene expression: potential involvement of arachidonic acid metabolism.
Leukemia
Regulation of phospholipase A2 in human leukemia cell lines: its implication for intracellular signaling.
Leukemia
Taiwan cobra phospholipase A2 suppresses ERK-mediated ADAM17 maturation, thus reducing secreted TNF-? production in human leukemia U937 cells.
Leukemia
Translocation of the 85-kDa phospholipase A2 from cytosol to the nuclear envelope in rat basophilic leukemia cells stimulated with calcium ionophore or IgE/antigen.
Leukemia
[Granulocyte-macrophage colony enhancing factor activity in supernatant from murine myelo-monocytic leukemia cell line (WEHI-3B)--studies of target cell using hydroxyurea suicide technic]
Leukemia, Erythroblastic, Acute
A vincristine-resistant murine erythroleukemia cell line secretes a differentiation enhancing factor.
Leukemia, Erythroblastic, Acute
Characterization of the biological role of murine erythroleukemia cells "differentiation enhancing factor" using antisense oligodeoxynucleotides.
Leukemia, Erythroblastic, Acute
Cytotoxicity of crotoxin on murine erythroleukemia cells in vitro.
Leukemia, Erythroblastic, Acute
Differentiation of HL60 promyelocytic cells is promoted by a 'differentiation enhancing factor' produced by erythroleukemia cells.
Leukemia, Erythroblastic, Acute
Differentiation of murine erythroleukemia cells by hexamethylenebisacetamide involves secretion and binding to membranes of a differentiation enhancing factor.
Leukemia, Erythroblastic, Acute
Extracellular release of the 'differentiation enhancing factor', a HMG1 protein type, is an early step in murine erythroleukemia cell differentiation.
Leukemia, Erythroblastic, Acute
Group II phospholipases A2 are indirectly cytolytic in the presence of exogenous phospholipid.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
JNK1/c-Jun and p38 alpha MAPK/ATF-2 pathways are responsible for upregulation of Fas/FasL in human chronic myeloid leukemia K562 cells upon exposure to Taiwan cobra phospholipase A2.
Leukemia, Myeloid
Changes of phospholipase A2 inhibitory activity in the K+-sensitive actin gelation factor during the differentiation of myeloid leukemia cells.
Leukemia, Myeloid
PLA2G4A Is a Potential Biomarker Predicting Shorter Overall Survival in Patients with Non-M3/NPM1 Wildtype Acute Myeloid Leukemia.
Leukemia, Myeloid
Purified group X secretory phospholipase A(2) induced prominent release of arachidonic acid from human myeloid leukemia cells.
Leukemia, Myeloid
Regulation of leukotriene-biosynthetic enzymes during differentiation of myelocytic HL-60 cells to eosinophilic or neutrophilic cells.
Leukemia, Myeloid, Acute
PLA2G4A Is a Potential Biomarker Predicting Shorter Overall Survival in Patients with Non-M3/NPM1 Wildtype Acute Myeloid Leukemia.
Leukemia, Myeloid, Acute
The expression of cytosolic phospholipase A2 and biosynthesis of leukotriene B4 in acute myeloid leukemia cells.
Leukemia, T-Cell
Identification of novel lipid droplet factors that regulate lipophagy and cholesterol efflux in macrophage foam cells.
Leukodystrophy, Globoid Cell
Krabbe disease: psychosine-mediated activation of phospholipase A2 in oligodendrocyte cell death.
Leukodystrophy, Globoid Cell
Role of endogenous psychosine accumulation in oligodendrocytes differentiation and survival: Implication for Krabbe disease.
Liposarcoma
Identification, cloning, expression, and purification of three novel human calcium-independent phospholipase A2 family members possessing triacylglycerol lipase and acylglycerol transacylase activities.
Liver Abscess
Vitamin supplementation increases the virulence of Entamoeba histolytica grown axenically.
Liver Cirrhosis
Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase.
Liver Cirrhosis
Distribution of type V secretory phospholipase A2 expression in human hepatocytes damaged by liver disease.
Liver Cirrhosis
Duplex High-Resolution Melting Assay for the Simultaneous Genotyping of IL28B rs12979860 and PNPLA3 rs738409 Polymorphisms in Chronic Hepatitis C Patients.
Liver Cirrhosis
Interactions of allelic variance of PNPLA3 with non genetic factors in predicting NASH and non-hepatic complications of severe obesity.
Liver Cirrhosis
PNPLA3 polymorphism influences liver fibrosis in unselected patients with type 2 diabetes.
Liver Cirrhosis
Secreted phospholipase A2 of Clonorchis sinensis activates hepatic stellate cells through a pathway involving JNK signalling.
Liver Cirrhosis
The NF-?B signalling pathway and TM7SF3 contribute to liver fibrosis caused by secreted phospholipase A2 of Clonorchis sinensis.
Liver Cirrhosis
Variant adiponutrin (PNPLA3) represents a common fibrosis risk gene: Non-invasive elastography-based study in chronic liver disease.
Liver Cirrhosis
[Effects of panax notoginseng saponins on the expression of tumor necrosis factor alpha and secretion phospholipase A2 in rats with liver fibrosis]
Liver Cirrhosis, Alcoholic
PNPLA3 genetic variation in alcoholic steatosis and liver disease progression.
Liver Diseases
A multi-ethnic study of a PNPLA3 gene variant and its association with disease severity in non-alcoholic fatty liver disease.
Liver Diseases
A nonsynonymous gene variant in adiponutrin gene is associated with nonalcoholic fatty liver disease severity.
Liver Diseases
A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity.
Liver Diseases
Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase.
Liver Diseases
ASB14780, an Orally Active Inhibitor of Group IVA Phospholipase A2, Is a Pharmacotherapeutic Candidate for Nonalcoholic Fatty Liver Disease.
Liver Diseases
Association of glucokinase regulatory gene polymorphisms with risk and severity of non-alcoholic fatty liver disease: an interaction study with adiponutrin gene.
Liver Diseases
Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
Liver Diseases
Distribution of type V secretory phospholipase A2 expression in human hepatocytes damaged by liver disease.
Liver Diseases
Genetic variants in PNPLA3 and risk of non-alcoholic fatty liver disease in a Han Chinese population.
Liver Diseases
Identification and Optimization of a Minor Allele-Specific Small Interfering RNA to Prevent PNPLA3 I148M-Driven Nonalcoholic Fatty Liver Disease.
Liver Diseases
Increased serum phospholipase A2 activity in advanced chronic liver disease as an expression of the acute phase response.
Liver Diseases
iPla2? deficiency in mice fed with MCD diet does not correct the defect of phospholipid remodeling but attenuates hepatocellular injury via an inhibition of lipid uptake genes.
Liver Diseases
Liver diseases and cancer associated with lack of lymphocytic cortisol metabolism enhancing factor.
Liver Diseases
Membranous Nephropathy Associated With Immunological Disorder-Related Liver Disease: A Retrospective Study of 10 Cases.
Liver Diseases
Peroxiredoxin 6 Confers Protection Against Nonalcoholic Fatty Liver Disease Through Maintaining Mitochondrial Function.
Liver Diseases
Peroxiredoxin 6 Is a Key Antioxidant Enzyme in Modulating the Link between Glycemic and Lipogenic Metabolism.
Liver Diseases
Peroxiredoxin 6 mediates acetaminophen-induced hepatocyte death through JNK activation.
Liver Diseases
Physical activity and sedentary behavior can modulate the effect of the PNPLA3 variant on childhood NAFLD: a case-control study in a Chinese population.
Liver Diseases
PNPLA3 p.I148M and TM6SF2 p.E167K variants do not predispose to liver injury in cholestatic liver diseases: A prospective analysis of 178 patients with PSC.
Liver Diseases
Protective Effects of Bee Venom-Derived Phospholipase A2 against Cholestatic Liver Disease in Mice.
Liver Diseases
Reduction of Caloric Intake Might Override the Prosteatotic Effects of the PNPLA3 p.I148M and TM6SF2 p.E167K Variants in Patients with Fatty Liver: Ultrasound-Based Prospective Study.
Liver Diseases
Tetra-primer ARMS-PCR identified four pivotal genetic variations in bovine PNPLA3 gene and its expression patterns.
Liver Diseases
The common adiponutrin variant p.I148M does not confer gallstone risk but affects fasting glucose and triglyceride levels.
Liver Diseases
The phospholipase A2 family's role in metabolic diseases: Focus on skeletal muscle.
Liver Diseases
The Role of Genetic Predisposition, Programing During Fetal Life, Family Conditions, and Post-natal Diet in the Development of Pediatric Fatty Liver Disease.
Liver Diseases
Variant adiponutrin (PNPLA3) represents a common fibrosis risk gene: Non-invasive elastography-based study in chronic liver disease.
Liver Diseases
[Metformin prevents non-alcoholic fatty liver disease in rats: role of phospholipase A2/lysophosphatidylcholine lipoapoptosis pathway in hepatocytes.]
Liver Diseases, Alcoholic
Adiponutrin (PNPLA3) in liver fibrogenesis: Is unaltered HepG2 cell line a better model system compared to murine models?
Liver Diseases, Alcoholic
PNPLA3 p.I148M and TM6SF2 p.E167K variants do not predispose to liver injury in cholestatic liver diseases: A prospective analysis of 178 patients with PSC.
Liver Diseases, Alcoholic
Role of cytochrome P450 in phospholipase A2- and arachidonic acid-mediated cytotoxicity.
Liver Diseases, Alcoholic
The common adiponutrin variant p.I148M does not confer gallstone risk but affects fasting glucose and triglyceride levels.
Liver Diseases, Alcoholic
Variant adiponutrin (PNPLA3) represents a common fibrosis risk gene: Non-invasive elastography-based study in chronic liver disease.
Liver Failure
Increased activity of group II phospholipase A2 in plasma in rat sodium deoxycholate induced acute pancreatitis.
Liver Failure, Acute
Mucosal expression of defensin-5, soluble phospholipase A2 and lysozyme in the intestine in a rat model of acute liver failure and its relationship to intestinal bacterial translocation.
Liver Failure, Acute
[Expression of intestinal defensin-5, soluble phospholipase A2 and lysozyme and the relation to bacterial translocation in rat models of acute liver failure].
Liver Neoplasms
PNPLA3-associated steatohepatitis: toward a gene-based classification of fatty liver disease.
Liver Neoplasms
The adiponutrin I148M variant is a risk factor for HCV-associated liver cancer in North-African patients.
Liver Neoplasms
Transforming growth factor-beta (TGF-beta) activates cytosolic phospholipase A2alpha (cPLA2alpha)-mediated prostaglandin E2 (PGE)2/EP1 and peroxisome proliferator-activated receptor-gamma (PPAR-gamma)/Smad signaling pathways in human liver cancer cells. A novel mechanism for subversion of TGF-beta-induced mitoinhibition.
Liver Neoplasms
Urocortin affects migration of hepatic cancer cell lines via differential regulation of cPLA2 and iPLA2.
Lung Diseases
Adenosine regulation of cystic fibrosis transmembrane conductance regulator through prostenoids in airway epithelia.
Lung Diseases
AdipoR-increased intracellular ROS promotes cPLA2 and COX-2 expressions via activation of PKC and p300 in adiponectin-stimulated human alveolar type II cells.
Lung Diseases
Drastic changes in the tissue-specific expression of secreted phospholipases A2 in chicken pulmonary disease.
Lung Diseases
Pathophysiologic changes induced by phospholipase A2 in the isolated, perfused guinea pig lung.
Lung Diseases
Triosephosphate isomerase and peroxiredoxin 6, two novel serum markers for human lung squamous cell carcinoma.
Lung Diseases, Obstructive
Phospholipase A2 receptor 1 promotes lung cell senescence and emphysema in obstructive lung disease.
Lung Injury
A Peptide Inhibitor of NADPH Oxidase (NOX2) Activation Markedly Decreases Mouse Lung Injury and Mortality Following Administration of Lipopolysaccharide (LPS).
Lung Injury
A Peptide Inhibitor of Peroxiredoxin 6 Phospholipase A2 Activity Significantly Protects against Lung Injury in a Mouse Model of Ventilator Induced Lung Injury (VILI).
Lung Injury
A potent inhibitor of cytosolic phospholipase A2, arachidonyl trifluoromethyl ketone, attenuates LPS-induced lung injury in mice.
Lung Injury
Abatement of bleomycin-induced pulmonary injury by cell-impermeable inhibitor of phospholipase A2.
Lung Injury
Berberine inhibits cytosolic phospholipase A2 and protects against LPS-induced lung injury and lethality independent of the alpha2-adrenergic receptor in mice.
Lung Injury
Bile acids cause secretory phospholipase A2 activity enhancement, revertible by exogenous surfactant administration.
Lung Injury
Bile acids increase alveolar epithelial permeability via MAP kinase, cytosolic phospholipase A2 , cyclooxygenase-2, PGE2 and junctional proteins.
Lung Injury
Bronchoalveolar lavage fluid phospholipase A2 activities are increased in human adult respiratory distress syndrome.
Lung Injury
Cell-specific expression of group X and group V secretory phospholipases A(2) in human lung airway epithelial cells.
Lung Injury
Clara cell secretory protein and phospholipase A2 activity modulate acute ventilator-induced lung injury in mice.
Lung Injury
Crucial role of group IIA phospholipase A(2) in oleic acid-induced acute lung injury in rabbits.
Lung Injury
Cytosolic phospholipase A2 inhibition attenuates ischemia-reperfusion injury in an isolated rat lung model.
Lung Injury
Effect of azithromycin on the LPS-induced production and secretion of phospholipase A2 in lung cells.
Lung Injury
Feasibility of extracellular competitive inhibition of phospholipase A2 in neonatal and pediatric lung injury.
Lung Injury
Group IIA phospholipase A2 mediates lung injury in intestinal ischemia-reperfusion.
Lung Injury
Gut phospholipase A2 mediates neutrophil priming and lung injury after mesenteric ischemia-reperfusion.
Lung Injury
Human meconium has high phospholipase A2 activity and induces cellular injury and apoptosis in piglet lungs.
Lung Injury
Induction of type-IIA secretory phospholipase A2 in animal models of acute lung injury.
Lung Injury
Inhibition of the phospholipase A2 activity of peroxiredoxin 6 prevents lung damage with exposure to hyperoxia.
Lung Injury
Inhibitory effects of surfactant protein A on surfactant phospholipid hydrolysis by secreted phospholipases A2.
Lung Injury
Lung injury and mortality with hyperoxia are increased in peroxiredoxin 6 gene-targeted mice.
Lung Injury
Natural disruption of group 2 phospholipase A2 gene protects against choline-deficient ethionine-supplemented diet-induced acute pancreatitis and lung injury.
Lung Injury
Neutrophils and neutrophil products do not mediate pulmonary hemodynamic effects of endotoxin on oleic acid-induced lung injury.
Lung Injury
Pancreatic phospholipase A2 contributes to lung injury in experimental meconium aspiration.
Lung Injury
Peroxiredoxin 6 gene-targeted mice show increased lung injury with paraquat-induced oxidative stress.
Lung Injury
Phospholipase A2 contamination of cobra venom factor preparations. Biologic role in complement-dependent in vivo reactions and inactivation with p-bromophenacyl bromide.
Lung Injury
Phospholipase A2 inhibition decouples lung injury from gut ischemia-reperfusion.
Lung Injury
Phospholipase A2 mediates nitric oxide production by alveolar macrophages and acute lung injury in pancreatitis.
Lung Injury
Phospholipase A2-induced lung edema and its mechanism in isolated perfused guinea pig lung.
Lung Injury
Polydatin up-regulates Clara cell secretory protein to suppress phospholipase A2 of lung induced by LPS in vivo and in vitro.
Lung Injury
Secretory phospholipase A2 and neonatal respiratory distress: pilot study on broncho-alveolar lavage.
Lung Injury
Secretory phospholipase A2 pathway during pediatric acute respiratory distress syndrome: A preliminary study.
Lung Injury
Secretory phospholipase A2 pathway in various types of lung injury in neonates and infants: a multicentre translational study.
Lung Injury
Telomere shortening activates TGF-?/Smads signaling in lungs and enhances both lipopolysaccharide and bleomycin-induced pulmonary fibrosis.
Lung Injury
The protective effect of mepacrine on acute lung edema induced by phorbol myristate acetate in rats.
Lung Injury
Therapeutic time-window of a group IIA phospholipase A2 inhibitor in rabbit acute lung injury: correlation with lung surfactant protection.
Lung Injury
Transgenic mice overexpressing peroxiredoxin 6 show increased resistance to lung injury in hyperoxia.
Lung Injury
Varespladib Inhibits Secretory Phospholipase A2 in Bronchoalveolar Lavage of Different Types of Neonatal Lung Injury.
Lung Injury
[Relationship between cytoplasmic phospholipase A2 and nuclear factor ?B in one lung ventilation-induced lung injury in rabbits].
Lung Neoplasms
Anti-cancer effect of snake venom toxin through down regulation of AP-1 mediated PRDX6 expression.
Lung Neoplasms
Anti-Cancer Effect of Thiacremonone through Down Regulation of Peroxiredoxin 6.
Lung Neoplasms
Cancer stem cell phenotype is supported by secretory phospholipase A2 in human lung cancer cells.
Lung Neoplasms
Cytosolic phospholipaseA2 inhibition with PLA-695 radiosensitizes tumors in lung cancer animal models.
Lung Neoplasms
Depletion of cytosolic phospholipase A2 in bone marrow-derived macrophages protects against lung cancer progression and metastasis.
Lung Neoplasms
Differential Expression And Effects Of Peroxiredoxin-6 On Drug Resistance And Cancer Stem Cell-Like Properties In Non-Small Cell Lung Cancer.
Lung Neoplasms
Expression of Cytosolic Phospholipase A2 (cPLA2)-Arachidonic Acid (AA)-Cyclooxygenase-2 (COX-2) Pathway Factors in Lung Cancer Patients and Its Implication in Lung Cancer Early Detection and Prognosis.
Lung Neoplasms
Group IIa secretory phospholipase A2 (sPLA2IIa) and progression in patients with lung cancer.
Lung Neoplasms
Group IIa secretory phospholipase expression correlates with group IIa secretory phospholipase inhibition-mediated cell death in K-ras mutant lung cancer cells.
Lung Neoplasms
Group IIa sPLA2 inhibition attenuates NF-?B activity and promotes apoptosis of lung cancer cells.
Lung Neoplasms
Identification of peroxiredoxin 6 as a direct target of withangulatin A by quantitative chemical proteomics in non-small cell lung cancer.
Lung Neoplasms
Induction of cPLA2 in lung epithelial cells and non-small cell lung cancer is mediated by Sp1 and c-Jun.
Lung Neoplasms
Induction of cytosolic phospholipase A2 by oncogenic Ras in human non-small cell lung cancer.
Lung Neoplasms
Inhibition of PLA2G4A Reduces the Expression of Lung Cancer-Related Cytokines.
Lung Neoplasms
Knockdown of secretory phospholipase A2 IIa reduces lung cancer growth in vitro and in vivo.
Lung Neoplasms
Long non?coding RNA SLNCR1 regulates non?small cell lung cancer migration, invasion and stemness through interactions with secretory phospholipase A2.
Lung Neoplasms
Loss of presenilin 2 is associated with increased iPLA2 activity and lung tumor development.
Lung Neoplasms
Lung cancer cell invasion and expression of intercellular adhesion molecule-1 (ICAM-1) are attenuated by secretory phospholipase A? inhibition.
Lung Neoplasms
Lung cancer cell lines inhibit leukotriene B4 production by human polymorphonuclear leukocytes at the level of phospholipase A2.
Lung Neoplasms
Nucleolin regulates c-Jun/Sp1-dependent transcriptional activation of cPLA2alpha in phorbol ester-treated non-small cell lung cancer A549 cells.
Lung Neoplasms
Pachymic acid inhibits cell growth and modulates arachidonic acid metabolism in nonsmall cell lung cancer A549 cells.
Lung Neoplasms
Peroxiredoxin 6 promotes lung cancer cell invasion by inducing urokinase-type plasminogen activator via p38 kinase, phosphoinositide 3-kinase, and Akt.
Lung Neoplasms
Phospholipase A2 activity of peroxiredoxin 6 promotes invasion and metastasis of lung cancer cells.
Lung Neoplasms
Plasma secretory phospholipase A2-IIa as a potential biomarker for lung cancer in patients with solitary pulmonary nodules.
Lung Neoplasms
PRDX6 promotes tumor development via the JAK2/STAT3 pathway in a urethane-induced lung tumor model.
Lung Neoplasms
Presenilin Mutation Suppresses Lung Tumorigenesis via Inhibition of Peroxiredoxin 6 Activity and Expression.
Lung Neoplasms
Prioritizing therapeutics for lung cancer: an integrative meta-analysis of cancer gene signatures and chemogenomic data.
Lung Neoplasms
Secretory phospholipase A2-IIa upregulates HER/HER2-elicited signaling in lung cancer cells.
Lung Neoplasms
Specific sensitivity of small cell lung cancer cell lines to the snake venom toxin taipoxin.
Lung Neoplasms
Surfactant Protein B Suppresses Lung Cancer Progression by Inhibiting Secretory Phospholipase A2 Activity and Arachidonic Acid Production.
Lung Neoplasms
Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines.
Lung Neoplasms
The future of cyclooxygenase-2 inhibitors and other inhibitors of the eicosanoid signal pathway in the prevention and therapy of lung cancer.
Lupus Erythematosus, Cutaneous
Quinacrine, an Antimalarial Drug with Strong Activity Inhibiting SARS-CoV-2 Viral Replication In Vitro.
Lupus Erythematosus, Systemic
Adenosine inhibits the release of arachidonic acid in activated human peripheral mononuclear cells. A proposed model for physiologic and pathologic regulation in systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Circulating group II phospholipase A2 activity and antilipocortin antibodies in systemic lupus erythematosus. Correlative study with disease activity.
Lupus Erythematosus, Systemic
Methyltransferase and phospholipase A2 activity in the cell membrane of neutrophils and lymphocytes from patients with Behçet's disease, systemic lupus erythematosus, and rheumatoid arthritis.
Lupus Nephritis
Antibodies to M-Type Phospholipase A2 Receptor (PLA2R) and Membranous Lupus Nephritis.
Lupus Nephritis
Antibodies to M-type phospholipase A2 receptor (PLA2R) in membranous lupus nephritis.
Lymphangioleiomyomatosis
Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis.
Lymphatic Metastasis
PRDX1 and PRDX6 are repressed in papillary thyroid carcinomas via BRAF V600E-dependent and -independent mechanisms.
Lymphoma
Evidence that porcine pancreatic phospholipase A2 via its high affinity receptor stimulates extracellular matrix invasion by normal and cancer cells.
Lymphoma
Identification of novel bioactive molecules from garlic bulbs: A special effort to determine the anticancer potential against lung cancer with targeted drugs.
Lymphoma
Identification of the transgenic integration site in 2C T cell receptor transgenic mice.
Lymphoma
Mechanisms by which elevated intracellular calcium induces S49 cell membranes to become susceptible to the action of secretory phospholipase A2.
Lymphoma
Relationship between membrane permeability and specificity of human secretory phospholipase A(2) isoforms during cell death.
Lymphoma
Role of membrane oxidation in controlling the activity of human group IIa secretory phospholipase A(2) toward apoptotic lymphoma cells.
Lymphoma
Striking Association of Lymphoid Enhancing Factor (LEF1) Overexpression and DUSP22 Rearrangements in Anaplastic Large Cell Lymphoma.
Lymphoma
Susceptibility of S49 lymphoma cell membranes to hydrolysis by secretory phospholipase A(2) during early phase of apoptosis.
Lymphoma, B-Cell
Peroxiredoxin 6 Serum Levels and Risk of Neutropenic Infections in Diffuse Large B-cell Lymphoma.
Lymphoma, Large B-Cell, Diffuse
Effects of DMSO-induced differentiation on arachidonate mobilization in the human histiocytic lymphoma cell line U937: responsiveness to sub-micromolar calcium ionophore A23187 and phorbol esters.
Lymphoma, Large B-Cell, Diffuse
Mass spectrometric analysis of arachidonyl-containing phospholipids in human U937 cells.
Lymphoma, Large B-Cell, Diffuse
Peroxiredoxin 6 Serum Levels and Risk of Neutropenic Infections in Diffuse Large B-cell Lymphoma.
Lymphoma, Large-Cell, Anaplastic
Striking Association of Lymphoid Enhancing Factor (LEF1) Overexpression and DUSP22 Rearrangements in Anaplastic Large Cell Lymphoma.
Lymphopenia
Group X Secreted Phospholipase A2 Releases ?3 Polyunsaturated Fatty Acids, Suppresses Colitis, and Promotes Sperm Fertility.
Lymphopenia
PLA2G1B is involved in CD4 anergy and CD4 lymphopenia in HIV-infected patients.
Macular Edema
Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, in Diabetic Macular Edema: A 3-Month Placebo-Controlled Study.
Malaria
Antimalarial activity of human group IIA secreted phospholipase A2 in relation with enzymatic hydrolysis of oxidized lipoproteins.
Malaria
Driving midgut-specific expression and secretion of a foreign protein in transgenic mosquitoes with AgAper1 regulatory elements.
Malaria
In vitro anti-Plasmodium falciparum properties of the full set of human secreted phospholipases A2.
Malaria
Increased serum phospholipase A2 activity in Malawian children with falciparum malaria.
Malaria
Induction of circulating group II phospholipase A2 expression in adults with malaria.
Malaria
Phospholipid organization in monkey erythrocytes upon Plasmodium knowlesi infection.
Malaria
Role of human group IIA secreted phospholipase A2 in malaria pathophysiology: Insights from a transgenic mouse model.
Malaria
Selective elimination of malaria infected erythrocytes by a modified phospholipase A2 in vitro.
Malaria
Short report: Lethal malaria in cytosolic phospholipase A2- and phospholipase A2IIA-deficient mice.
Malaria, Cerebral
Lipid metabolites of the phospholipase A2 pathway and inflammatory cytokines are associated with brain volume in paediatric cerebral malaria.
Malformations of Cortical Development
Differentially expressed proteins underlying childhood cortical dysplasia with epilepsy identified by iTRAQ proteomic profiling.
Malnutrition
Comparative changes between pancreas and pancreatic juice digestive enzyme contents during nutritional rehabilitation following severe protein malnutrition in the rat.
Malnutrition
[Effect of a protein-deficient diet (5 p. 100 gluten) and of balanced refeeding (15 p. 100 casein) on potential lipase, colipase-dependent lipase and phospholipase A2 activities. II. In the pancreatic juice of the growing rat]
Mania
Lithium and the Other Mood Stabilizers Effective in Bipolar Disorder Target the Rat Brain Arachidonic Acid Cascade.
Mastitis
Exogenous phospholipase A2 affects inflammatory gene expression in primary bovine mammary epithelial cells.
Mastocytoma
Arachidonate release and eicosanoid generation by group IIE phospholipase A(2).
Mastocytoma
Detection of secretory phospholipase A2s related but not identical to type IIA isozyme in cultured mast cells.
Mastocytoma
Distinct arachidonate-releasing functions of mammalian secreted phospholipase A2s in human embryonic kidney 293 and rat mastocytoma RBL-2H3 cells through heparan sulfate shuttling and external plasma membrane mechanisms.
Mastocytoma
Evidence that porcine pancreatic phospholipase A2 via its high affinity receptor stimulates extracellular matrix invasion by normal and cancer cells.
Mastocytoma
Redundant and segregated functions of granule-associated heparin-binding group II subfamily of secretory phospholipases A2 in the regulation of degranulation and prostaglandin D2 synthesis in mast cells.
Mastocytoma
Regulation of type V phospholipase A2 expression and function by proinflammatory stimuli.
Mastocytoma
[Activation of phospholipase hydrolysis in the process of oxidative cell damage]
Mastocytoma
[Pathobiochemical importance of phospholipases for the release of mast cell mediators]
Measles
Analysis of the molecules involved in human T-cell leukaemia virus type 1 entry by a vesicular stomatitis virus pseudotype bearing its envelope glycoproteins.
Meconium Aspiration Syndrome
Meconium aspiration syndrome: a role for phospholipase A2 in the pathogenesis?
Meconium Aspiration Syndrome
Pancreatic phospholipase A2 contributes to lung injury in experimental meconium aspiration.
Meconium Aspiration Syndrome
Secreted Phospholipase A2 is Increased in Meconium-Stained Amniotic Fluid of Term Gestations: Potential Implications for the Genesis of Meconium Aspiration Syndrome.
Meconium Aspiration Syndrome
Secretory phospholipase A2 pathway in various types of lung injury in neonates and infants: a multicentre translational study.
Meconium Aspiration Syndrome
Varespladib Inhibits Secretory Phospholipase A2 in Bronchoalveolar Lavage of Different Types of Neonatal Lung Injury.
Melanoma
Anticancer properties of phospholipase A2 from Daboia siamensis venom on human skin melanoma cells.
Melanoma
Antitumor effects of cationic synthetic peptides derived from Lys49 phospholipase A2 homologues of snake venoms.
Melanoma
Cloning of the human phospholipase A2 activating protein (hPLAP) gene on the chromosome 9p21 melanoma deleted region.
Melanoma
Comprehensive identification of novel post-translational modifications in cellular peroxiredoxin 6.
Melanoma
Cytoplasmic phospholipase A2 metabolites play a critical role in pulmonary tumor metastasis in mice.
Melanoma
Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi.
Melanoma
Identification and molecular characterization of a m5 muscarinic receptor in A2058 human melanoma cells. Coupling to inhibition of adenylyl cyclase and stimulation of phospholipase A2.
Melanoma
Increased sensitivity to TNF-mediated cytotoxicity of BL6 melanoma cells after H-2Kb gene transfection.
Melanoma
Lack of phospholipase A2 mutations in neuroblastoma, melanoma and colon-cancer cell lines.
Melanoma
New susceptibility loci for cutaneous melanoma risk and progression revealed using a porcine model.
Melanoma
Partial characterization, in vitro antioxidant and antiproliferative activities of patatin purified from potato fruit juice.
Melanoma
Peroxiredoxin 6 triggers melanoma cell growth by increasing arachidonic acid-dependent lipid signalling.
Melanoma
Phenotypic and Genotypic Analysis of Amelanotic and Hypomelanotic Melanoma Patients.
Melanoma
Polymorphisms in nevus-associated genes MTAP, PLA2G6, and IRF4 and the risk of invasive cutaneous melanoma.
Melanoma
Purification and characterization of a low molecular weight multifunctional cytotoxic phospholipase A2 from Russell's viper venom.
Melanoma
Reprogramming lipid metabolism prevents effector T cell senescence and enhances tumor immunotherapy.
Melanoma
Susceptibility to TNF in the presence of inhibitors of transcription or translation is dependent on the activity of cytosolic phospholipase A2 in human melanoma tumor cells.
Melanoma, Experimental
Cellular responses to Pyrularia thionin are mediated by Ca2+ influx and phospholipase A2 activation and are inhibited by thionin tyrosine iodination.
Meningococcal Infections
[Lipid composition of erythrocyte membranes and blood serum in meningococcal infections in children]
Meningomyelocele
Amniotic fluid levels of phospholipase A2 in fetal rats with retinoic acid induced myelomeningocele: the potential "second hit" in neurologic damage.
Menorrhagia
Phospholipase activity in the endometrium of women with normal menstrual blood loss and women with proven ovulatory menorrhagia.
Menorrhagia
The activity of calcium dependent and calcium independent phospholipase A2 in normal endometrium and in endometrium from women suffering from menorrhagia and polycystic ovary syndrome.
Mesothelioma
Intraperitoneal mesotheliomas induced in mice by a polycyclic aromatic hydrocarbon.
Metabolic Diseases
Intestinal phospholipid and lysophospholipid metabolism in cardiometabolic disease.
Metabolic Diseases
Mechanistic insights into the urea-induced denaturation of a non-seleno thiol specific antioxidant human peroxiredoxin 6.
Metabolic Diseases
Pancreatic acinar cell-specific overexpression of group 1B phospholipase A(2) exacerbates diet-induced obesity and insulin resistance in mice.
Metabolic Diseases
Peroxiredoxin 6 overexpression regulates adriamycin-induced myocardial injury, oxidative stress and immune response in rats.
Metabolic Diseases
The phospholipase A2 family's role in metabolic diseases: Focus on skeletal muscle.
Metabolic Syndrome
17? Estradiol Modulates Perfusion Pressure and Expression of 5-LOX and CYP450 4A in the Isolated Kidney of Metabolic Syndrome Female Rats.
Metabolic Syndrome
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Metabolic Syndrome
An Inhibitor of Phospholipase A2 Group IIA Modulates Adipocyte Signaling and Protects Against Diet-Induced Metabolic Syndrome in Rats.
Metabolic Syndrome
Elevated Type II Secretory Phospholipase A2 Increases the Risk of Early Atherosclerosis in Patients with Newly Diagnosed Metabolic Syndrome.
Metabolic Syndrome
Inhibitory effects of various solvent extracts from Rhamnus frangula leaves on some inflammatory and metabolic enzymes.
Metabolic Syndrome
Lipopolysaccharide promoted proliferation and adipogenesis of preadipocytes through JAK/STAT and AMPK-regulated cPLA2 expression.
Metabolic Syndrome
Metabolic syndrome and carotid intima-media thickness in young adults: roles of apolipoprotein B, apolipoprotein A-I, C-reactive protein, and secretory phospholipase A2: the cardiovascular risk in young Finns study.
Metabolic Syndrome
Utility of metabolic syndrome as a risk enhancing factor in decision of statin use.
Mevalonate Kinase Deficiency
Cytokine activation during attacks of the hyperimmunoglobulinemia D and periodic fever syndrome.
Microscopic Polyangiitis
Anti-neutrophil cytoplasmic antibody-associated glomerulonephritis with detection of myeloperoxidase and phospholipase A2 receptor in membranous nephropathy-lesions: report of two patients with microscopic polyangiitis.
Mouth Neoplasms
Butyrate inhibits oral cancer cell proliferation and regulates expression of secretory phospholipase A2-X and COX-2.
Movement Disorders
Dystonic opisthotonus: A "red flag" for neurodegeneration with brain iron accumulation syndromes?
Multiple Sclerosis
Alteration of delta-6-desaturase (FADS2), secretory phospholipase-A2 (sPLA2) enzymes by Hot-nature diet with co-supplemented hemp seed, evening primrose oils intervention in multiple sclerosis patients.
Multiple Sclerosis
Alterations in the activity of phospholipases A2 in postmortem white matter from patients with multiple sclerosis.
Multiple Sclerosis
Blockade of cytosolic phospholipase A2 alpha prevents experimental autoimmune encephalomyelitis and diminishes development of Th1 and Th17 responses.
Multiple Sclerosis
Cerebrospinal fluid secretory Ca2+-dependent phospholipase A2 activity: a biomarker of blood-cerebrospinal fluid barrier permeability.
Multiple Sclerosis
Crotoxin down-modulates pro-inflammatory cells and alleviates pain on the MOG35-55-induced experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis.
Multiple Sclerosis
Differing roles for members of the phospholipase A2 superfamily in experimental autoimmune encephalomyelitis.
Multiple Sclerosis
PRDX6 controls multiple sclerosis by suppressing inflammation and blood brain barrier disruption.
Multiple Sclerosis
Role of cytosolic calcium-dependent phospholipase A2 in Alzheimer's disease pathogenesis.
Multiple Sclerosis
Secreted phospholipase A2 activity in experimental autoimmune encephalomyelitis and multiple sclerosis.
Multiple Sclerosis
Synthetic and natural inhibitors of phospholipases A2: their importance for understanding and treatment of neurological disorders.
Multiple Sclerosis
The role of phospholipase A2 in multiple Sclerosis: A systematic review and meta-analysis.
Multiple Sclerosis
[On the activity of phospholipase A2 compared with 1-alk-1'-enyl-2-acyl- and 1-alkyl-2-acyl-glycerophosphatides in multiple sclerosis (author's transl)]
Multiple Sclerosis, Relapsing-Remitting
Alteration of delta-6-desaturase (FADS2), secretory phospholipase-A2 (sPLA2) enzymes by Hot-nature diet with co-supplemented hemp seed, evening primrose oils intervention in multiple sclerosis patients.
Multiple Sclerosis, Relapsing-Remitting
Secretory Phospholipase A2 activity in serum and cerebrospinal fluid of patients with relapsing-remitting multiple sclerosis.
Muscle Hypotonia
Cerebellar atrophy without cerebellar cortex hyperintensity in infantile neuroaxonal dystrophy (INAD) due to PLA2G6 mutation.
Muscle Spasticity
Increase in plasma levels of secretory type II phospholipase A(2) in patients with coronary spastic angina.
Muscle Weakness
Calcium-dependent phospholipase A2 Modulates Infection Induced Diaphragm Dysfunction.
Muscle Weakness
Interactions between Cytosolic Phospholipase A2 Activation and Mitochondrial Reactive Oxygen Species Production in the Development of Ventilator-Induced Diaphragm Dysfunction.
Muscle Weakness
Novel mutations in PANK2 and PLA2G6 genes in patients with neurodegenerative disorders: two case reports.
Muscular Atrophy
Genetic ablation of 12/15-lipoxygenase but not 5-lipoxygenase protects against denervation-induced muscle atrophy.
Muscular Atrophy
Inhibition of cPLA2 has neuroprotective effects on motoneuron and muscle atrophy following spinal cord injury.
Muscular Atrophy
Mechanism of attenuation of skeletal muscle atrophy by zinc-alpha2-glycoprotein.
Muscular Atrophy
Sodium fluoride induced skeletal muscle changes: Degradation of proteins and signaling mechanism.
Muscular Atrophy
Targeting cPLA2 derived lipid hydroperoxides as a potential intervention for sarcopenia.
Muscular Diseases
Loss of Function Variants in Human PNPLA8 Encoding Calcium-Independent Phospholipase A2 ? Recapitulate the Mitochondriopathy of the Homologous Null Mouse.
Muscular Diseases
Novel duplication mutation in the patatin domain of adipose triglyceride lipase (PNPLA2) in neutral lipid storage disease with severe myopathy.
Muscular Diseases
Patients with neutral lipid storage disease with myopathy (NLSDM) in Southwestern China.
Muscular Diseases
Proteome and transcriptome profiling of equine myofibrillar myopathy identifies diminished peroxiredoxin 6 and altered cysteine metabolic pathways.
Muscular Diseases
Subclinical myopathy in a child with neutral lipid storage disease and mutations in the PNPLA2 gene.
Muscular Diseases
Whole genome sequencing reveals biallelic PLA2G6 mutations in siblings with cerebellar atrophy and cap myopathy.
Muscular Dystrophies
Alternative splicing dysregulation secondary to skeletal muscle regeneration.
Muscular Dystrophies, Limb-Girdle
Alternative splicing dysregulation secondary to skeletal muscle regeneration.
Muscular Dystrophy, Duchenne
Alternative splicing dysregulation secondary to skeletal muscle regeneration.
Muscular Dystrophy, Duchenne
Group VI phospholipases A2: homeostatic phospholipases with significant potential as targets for novel therapeutics.
Myalgia
Muscle disease, HIV and zidovudine: the spectrum of muscle disease in HIV-infected individuals treated with zidovudine.
Mycoses
Group VI phospholipases A2: homeostatic phospholipases with significant potential as targets for novel therapeutics.
Mycoses
Toll/IMD signal pathways mediate cellular immune responses via induction of intracellular PLA 2 expression.
Myocardial Infarction
A decrease in plasma factor which stimulates prostaglandin I2 synthesis in patients with acute myocardial infarction.
Myocardial Infarction
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Myocardial Infarction
Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial.
Myocardial Infarction
Association of PLA2G4A with myocardial infarction is modulated by dietary PUFAs.
Myocardial Infarction
Biomarkers and Bioassays for Cardiovascular Diseases: Present and Future.
Myocardial Infarction
Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease.
Myocardial Infarction
Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes.
Myocardial Infarction
Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients.
Myocardial Infarction
Expression of type V secretory phospholipase A in myocardial remodelling after infarction.
Myocardial Infarction
Identification and characterization of human myocardial phospholipase A2 from transplant recipients suffering from end-stage ischemic heart disease.
Myocardial Infarction
Inhibition of secretory phospholipase A2 activity attenuates acute cardiogenic pulmonary edema induced by isoproterenol infusion in mice after myocardial infarction.
Myocardial Infarction
Inhibition of sPLA2-IIA, C-reactive protein or complement: new therapy for patients with acute myocardial infarction?
Myocardial Infarction
Inhibition of type 2A secretory phospholipase A(2) reduces death of cardiomyocytes in acute myocardial infarction.
Myocardial Infarction
Insights into the mechanism of inhibition of phospholipase A2 by resveratrol: An extensive molecular dynamics simulation and binding free energy calculation.
Myocardial Infarction
Lack of phospholipase A2 receptor increases susceptibility to cardiac rupture after myocardial infarction.
Myocardial Infarction
Level of circulating phospholipase A2 in prediction of the prognosis of patients with suspected myocardial infarction.
Myocardial Infarction
Neuroprotective effects of a nanocrystal formulation of sPLA(2) inhibitor PX-18 in cerebral ischemia/reperfusion in gerbils.
Myocardial Infarction
Phospholipase A2 Enzymes, High-Dose Atorvastatin, and Prediction of Ischemic Events After Acute Coronary Syndromes.
Myocardial Infarction
Phospholipase A2 expression in coronary thrombus is increased in patients with recurrent cardiac events after acute myocardial infarction.
Myocardial Infarction
Pioglitazone limits myocardial infarct size, activates Akt, and upregulates cPLA2 and COX-2 in a PPAR-?-independent manner.
Myocardial Infarction
Pioglitazone protects the myocardium against ischemia-reperfusion injury in eNOS and iNOS knockout mice.
Myocardial Infarction
Plasma phospholipase A2 activity in clinical acute myocardial infarction.
Myocardial Infarction
Reduction in myocardial ischemia/reperfusion injury in group X secretory phospholipase A2-deficient mice.
Myocardial Infarction
Secretory phospholipase A2 modified HDL rapidly and potently suppresses platelet activation.
Myocardial Infarction
Secretory type II phospholipase A(2) binds to ischemic myocardium during myocardial infarction in humans.
Myocardial Infarction
Secretory type II phospholipase A2 in culprit coronary lesions is associated with myocardial infarction.
Myocardial Infarction
Serum phospholipase A2 and lysolecithin changes following myocardial infarction.
Myocardial Infarction
Serum secretory phospholipase A2-IIa (sPLA2-IIA) levels in patients surviving acute myocardial infarction.
Myocardial Infarction
Study on the relationship of cPLA2, CK-MB, and membrane phospholipid content in acute myocardial infarction.
Myocardial Infarction
[Study on mechanisms and myocardial protective effect of Qishen Yiqi dropping pills on rats with myocardial infarction].
Myocardial Ischemia
Activation of a membrane-associated phospholipase A2 during rabbit myocardial ischemia which is highly selective for plasmalogen substrate.
Myocardial Ischemia
Activation of myocardial cAMP-dependent protein kinase by lysoplasmenylcholine.
Myocardial Ischemia
Analysis of myocardial plasmalogen and diacyl phospholipids and their arachidonic acid content using high-performance liquid chromatography.
Myocardial Ischemia
Arrhythmogenic and antiarrhythmic effects of lipolytic factors on cultured heart cells.
Myocardial Ischemia
Calcium-independent phospholipases in the heart: mediators of cellular signaling, bioenergetics, and ischemia-induced electrophysiologic dysfunction.
Myocardial Ischemia
Cardiac ischemia activates calcium-independent phospholipase A2beta, precipitating ventricular tachyarrhythmias in transgenic mice: rescue of the lethal electrophysiologic phenotype by mechanism-based inhibition.
Myocardial Ischemia
Electrospray ionization mass spectrometry analyses of nuclear membrane phospholipid loss after reperfusion of ischemic myocardium.
Myocardial Ischemia
Identification and characterization of human myocardial phospholipase A2 from transplant recipients suffering from end-stage ischemic heart disease.
Myocardial Ischemia
Increase in plasma levels of secretory type II phospholipase A(2) in patients with coronary spastic angina.
Myocardial Ischemia
Phospholipase A2 Enzymes, High-Dose Atorvastatin, and Prediction of Ischemic Events After Acute Coronary Syndromes.
Myocardial Ischemia
Purification and characterization of canine myocardial cytosolic phospholipase A2. A calcium-independent phospholipase with absolute f1-2 regiospecificity for diradyl glycerophospholipids.
Myocardial Ischemia
Recent insights pertaining to sarcolemmal phospholipid alterations underlying arrhythmogenesis in the ischemic heart.
Myocardial Ischemia
Role of phospholipase A2, C, and D activities during myocardial ischemia and reperfusion.
Myocardial Ischemia
Selected metabolic alterations in the ischemic heart and their contributions to arrhythmogenesis.
Myocardial Ischemia
Selective hydrolysis of plasmalogen phospholipids by Ca2+-independent PLA2 in hypoxic ventricular myocytes.
Myocardial Ischemia
The rapid and reversible activation of a calcium-independent plasmalogen-selective phospholipase A2 during myocardial ischemia.
Myocardial Ischemia
Thrombin activates a membrane-associated calcium-independent PLA2 in ventricular myocytes.
Myocardial Ischemia
[Effect of atorvastatin therapy on the level of secretory phospholipase A2 group IIA and on the modification of low density lipoproteins in patients with ischemic heart disease]
Myocardial Reperfusion Injury
Role of cytochrome P450 in phospholipase A2- and arachidonic acid-mediated cytotoxicity.
Myocardial Reperfusion Injury
Targeted disruption of peroxiredoxin 6 gene renders the heart vulnerable to ischemia-reperfusion injury.
Myocarditis
Deficiency of Phospholipase A2 Receptor Exacerbates Autoimmune Myocarditis in Mice.
Myocarditis
Secreted Phospholipase A2-IIA Modulates Transdifferentiation of Cardiac Fibroblast through EGFR Transactivation: An Inflammation-Fibrosis Link.
Myoglobinuria
Establishment of an animal model for myoglobinuria by use of a myotoxin from Pseudechis australis (king brown snake) venom in mice.
Myoglobinuria
Local necrotizing effect of snake venoms on skin and muscle: relationship to serum creatine kinase.
Myoglobinuria
Morphological changes induced by a generalized myotoxin (myoglobinuria-inducing toxin) from the venom of Pseudechis australis (king brown snake) in skeletal muscle and kidney of mice.
Myoglobinuria
Pathologic changes induced by phospholipase A2 isolated from the venom of Collett's snake, Pseudechis colletti: a light and electron microscopic study.
Myoglobinuria
Renal lesions in rhabdomyolysis caused by Pseudechis australis snake myotoxin.
Myotoxicity
A structure based model for liposome disruption and the role of catalytic activity in myotoxic phospholipase A2s.
Myotoxicity
Ability of antiserum to myotoxin alpha from prairie rattlesnake (Crotalus viridis viridis) venom to neutralize local myotoxicity and lethal effects of myotoxin alpha and homologous crude venom.
Myotoxicity
Ability of rabbit antiserum against crotapotin to neutralize the neurotoxic, myotoxic and phospholipase A2 activities of crotoxin from Crotalus durissus cascavella snake venom.
Myotoxicity
ACP-TX-I and ACP-TX-II, Two Novel Phospholipases A2 Isolated from Trans-Pecos Copperhead Agkistrodon contortrix pictigaster Venom: Biochemical and Functional Characterization.
Myotoxicity
Alkylation of histidine residues of Bothrops jararacussu venom proteins and isolated phospholipases A2: a biotechnological tool to improve the production of antibodies.
Myotoxicity
Amino acid sequence and biological characterization of BlatPLA2, a non-toxic acidic phospholipase A2 from the venom of the arboreal snake Bothriechis lateralis from Costa Rica.
Myotoxicity
Ammodytin L, an inactive phospholipase A2 homologue with myotoxicity in mice, binds to the presynaptic acceptor of the beta-neurotoxic ammodytoxin C in Torpedo: an indication for a phospholipase A2 activity-independent mechanism of action of beta-neurotoxins in fish?
Myotoxicity
An Evaluation of 3-Rhamnosylquercetin, a Glycosylated Form of Quercetin, against the Myotoxic and Edematogenic Effects of sPLA 2 from Crotalus durissus terrificus.
Myotoxicity
Antibody neutralization of a myotoxin from the venom of Bothrops asper (terciopelo).
Myotoxicity
Biochemical and functional studies of ColTx-I, a new myotoxic phospholipase A2 isolated from Crotalus oreganus lutosus (Great Basin rattlesnake) snake venom.
Myotoxicity
Biochemical characterization and pharmacological properties of a phospholipase A2 myotoxin inhibitor from the plasma of the snake Bothrops asper.
Myotoxicity
Both group IB and group IIA secreted phospholipases A2 are natural ligands of the mouse 180-kDa M-type receptor.
Myotoxicity
Complete amino acid sequence of an acidic, cardiotoxic phospholipase A2 from the venom of Ophiophagus hannah (King Cobra): a novel cobra venom enzyme with "pancreatic loop".
Myotoxicity
Crystal structure of a phospholipase A(2) homolog complexed with p-bromophenacyl bromide reveals important structural changes associated with the inhibition of myotoxic activity.
Myotoxicity
Crystallization and preliminary X-ray analysis of cardiotoxic phospholipase A2 from Ophiophagus hannah (king cobra).
Myotoxicity
Daboia Russelli Venom Hyaluronidase: Purification, Characterization and Inhibition by ?-3-(3-Hydroxy-4-Oxopyridyl) ?-Amino-Propionic Acid.
Myotoxicity
Detection of antibodies to myotoxin a and prairie rattlesnake (Crotalus viridis viridis) venom in three antisera using enzyme-linked immunosorbent assay and immunodiffusion.
Myotoxicity
Differences in distribution of myotoxic proteins in venoms from different Bothrops species.
Myotoxicity
Exploring the binding mechanism and kinetics of Piperine with snake venom secretory Phospholipase A2.
Myotoxicity
Gallic acid anti-myotoxic activity and mechanism of action, a snake venom phospholipase A2 toxin inhibitor, isolated from the medicinal plant Anacardium humile.
Myotoxicity
Immunochemical cross-reactivity of neurotoxic phospholipase A2 enzymes from Indian cobra (Naja naja naja) venom using polyclonal antibodies.
Myotoxicity
In vivo test of the ability of antiserum to myotoxin a from prairie rattlesnake (Crotalus viridis viridis) venom to neutralize local myonecrosis induced by myotoxin a and homologous crude venom.
Myotoxicity
Inhibition of the myotoxic and hemorrhagic activities of crotalid venoms by Eclipta prostrata (Asteraceae) extracts and constituents.
Myotoxicity
Intravascular hemolysis induced by the venom of the Eastern coral snake, Micrurus fulvius, in a mouse model: identification of directly hemolytic phospholipases A2.
Myotoxicity
Isolation and characterization of hyaluronidase a "spreading factor" from Indian cobra (Naja naja) venom.
Myotoxicity
Isolation and pharmacological characterization of a phospholipase A2 myotoxin from the venom of the Irian Jayan death adder (Acanthophis rugosus).
Myotoxicity
Isolation of a myotoxin from Bothrops asper venom: partial characterization and action on skeletal muscle.
Myotoxicity
Lapachol and synthetic derivatives: in vitro and in vivo activities against Bothrops snake venoms.
Myotoxicity
Mn(2+) ions reduce the enzymatic and pharmacological activities of bothropstoxin-I, a myotoxic Lys49 phospholipase A(2) homologue from Bothrops jararacussu snake venom.
Myotoxicity
Monoclonal antibodies to VRV-PL-VIIIa, a basic multitoxic phospholipase A2 from Vipera russelli venom.
Myotoxicity
Myotoxic activity of the toxic phospholipase, notexin, from the venom of the Australian tiger snake.
Myotoxicity
Myotoxic and cytolytic activities of dimeric Lys49 phospholipase A2 homologues are reduced, but not abolished, by a pH-induced dissociation.
Myotoxicity
Myotoxicity and physiological effects of three Trimeresurus flavoviridis phospholipases A2.
Myotoxicity
Neutralizing human anti crotoxin scFv isolated from a nonimmunized phage library.
Myotoxicity
Neutrophils do not contribute to local tissue damage, but play a key role in skeletal muscle regeneration, in mice injected with Bothrops asper snake venom.
Myotoxicity
New biological activity against phospholipase A2 by Turmerin, a protein from Curcuma longa L.
Myotoxicity
Occurrence of sulfated fucose branches in fucosylated chondroitin sulfate are essential for the polysaccharide effect preventing muscle damage induced by toxins and crude venom from Bothrops jararacussu snake.
Myotoxicity
Orthogonal optimization of prokaryotic expression of a natural snake venom phospholipase A2 inhibitor from Sinonatrix annularis.
Myotoxicity
Phase I and pharmacokinetics study of crotoxin (cytotoxic PLA(2), NSC-624244) in patients with advanced cancer.
Myotoxicity
Production and partial characterization of monoclonal antibodies to Bothrops asper (terciopelo) myotoxin.
Myotoxicity
Purification and amino acid sequence of MP-III 4R D49 phospholipase A2 from Bothrops pirajai snake venom, a toxin with moderate PLA2 and anticoagulant activities and high myotoxic activity.
Myotoxicity
Purification and primary structure of a myotoxic lysine-49 phospholipase A2 with low lipolytic activity from Trimeresurus gramineus venom.
Myotoxicity
Purification and properties of hyaluronidase from Hippasa partita (funnel web spider) venom gland extract.
Myotoxicity
Purification, characterization and cytokine release function of a novel Arg-49 phospholipase A(2) from the venom of Protobothrops mucrosquamatus.
Myotoxicity
Pyrazolo[3,4-d]pyrimidines as inhibitor of anti-coagulation and inflammation activities of phospholipase A 2 : insight from molecular docking studies.
Myotoxicity
Shared structural determinants for the calcium-independent liposome membrane permeabilization and sarcolemma depolarization in Bothropstoxin-I, a LYS49-PLA(2) from the venom of Bothrops jararacussu.
Myotoxicity
Similarities and differences in mechanisms of cardiotoxins, melittin and other myotoxins.
Myotoxicity
Skeletal muscle degeneration induced by venom phospholipases A2: insights into the mechanisms of local and systemic myotoxicity.
Myotoxicity
Snake venom PLA2s inhibitors isolated from Brazilian plants: synthetic and natural molecules.
Myotoxicity
Structural determinants of the hyperalgesic activity of myotoxic Lys49-phospholipase A2.
Myotoxicity
Systemic and local myotoxicity induced by snake venom group II phospholipases A2: comparison between crotoxin, crotoxin B and a Lys49 PLA2 homologue.
Myotoxicity
The detoxifying effects of structural elements of persimmon tannin on Chinese cobra phospholipase A2 correlated with their structural disturbing effects well.
Myotoxicity
The early expression of myotoxicity and localization of the binding sites of notexin in the soleus muscle of the rat. Notexin and muscle.
Myotoxicity
Toxicity of phospholipases A(2) D49 (6-1 and 6-2) and K49 (Bj-VII) from Bothrops jararacussu venom.
Myotoxicity
Unmasking Snake Venom of Bothrops leucurus: Purification and Pharmacological and Structural Characterization of New PLA2 Bleu TX-III.
Myotoxicity
Unveiling the elusive and exotic: Venomics of the Malayan blue coral snake (Calliophis bivirgata flaviceps).
Myxedema
Impaired inner medullary production of prostaglandin E2 in the kidney of the myxedematous rat.
Myxoma
Cell cycle and apoptosis regulatory proteins, proliferative markers, cell signaling molecules, CD209, and decorin immunoreactivity in low-grade myxofibrosarcoma and myxoma.
Myxoma
[Effect of atorvastatin therapy on the level of secretory phospholipase A2 group IIA and on the modification of low density lipoproteins in patients with ischemic heart disease]
Myxoma
[Phospholipase A2, group IIa, as an earlier unknown immunohistological marker of cardiac myxoma]
Nasal Polyps
Age dictates a steroid resistant cascade of Wnt5a, transglutaminase-2 and leukotrienes in inflamed airways.
Nasal Polyps
Group II subfamily secretory phospholipase A2 enzymes: expression in chronic rhinosinusitis with and without nasal polyps.
Nasal Polyps
Phospholipase A2-dependent release of inflammatory cytokines by superantigen-stimulated nasal polyps of patients with chronic rhinosinusitis.
Nasal Polyps
PLA2G5 regulates transglutaminase activity of human IL-4-activated M2 macrophages through PGE2 generation.
Neoplasm Metastasis
Annexin10 promotes extrahepatic cholangiocarcinoma metastasis by facilitating EMT via PLA2G4A/PGE2/STAT3 pathway.
Neoplasm Metastasis
Association of 5'UTR polymorphism of secretory phospholipase A2 group IIA (PLA2G2A) gene with prostate cancer metastasis.
Neoplasm Metastasis
Characterization of phospholipase A2 activity in MDA-MB-435 human breast cancer cells.
Neoplasm Metastasis
Cytoplasmic phospholipase A2 metabolites play a critical role in pulmonary tumor metastasis in mice.
Neoplasm Metastasis
Cytosolic Phospholipase A2 Alpha Regulates TLR Signaling and Migration in Metastatic 4T1 Cells.
Neoplasm Metastasis
Depletion of cytosolic phospholipase A2 in bone marrow-derived macrophages protects against lung cancer progression and metastasis.
Neoplasm Metastasis
Effects of dietary fish oil on fatty acids and eicosanoids in metastasizing human breast cancer cells.
Neoplasm Metastasis
Expression of PRDX6 Correlates with Migration and Invasiveness of Colorectal Cancer Cells.
Neoplasm Metastasis
Expression of Secretory Phospholipase A2 Group IIa in Breast Cancer and Correlation to Prognosis in a Cohort of Advanced Breast Cancer Patients.
Neoplasm Metastasis
Group IIa secretory phospholipase A2 (sPLA2IIa) and progression in patients with lung cancer.
Neoplasm Metastasis
Group IIa sPLA2 inhibition attenuates NF-?B activity and promotes apoptosis of lung cancer cells.
Neoplasm Metastasis
Group III phospholipase A2 downregulation attenuated survival and metastasis in ovarian cancer and promotes chemo-sensitization.
Neoplasm Metastasis
Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.
Neoplasm Metastasis
Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer.
Neoplasm Metastasis
Knockout of PRDX6 induces mitochondrial dysfunction and cell cycle arrest at G2/M in HepG2 hepatocarcinoma cells.
Neoplasm Metastasis
Liposomes Targeting P21 Activated Kinase-1 (PAK-1) and Selective for Secretory Phospholipase A2 (sPLA2) Decrease Cell Viability and Induce Apoptosis in Metastatic Triple-Negative Breast Cancer Cells.
Neoplasm Metastasis
Lung cancer cell invasion and expression of intercellular adhesion molecule-1 (ICAM-1) are attenuated by secretory phospholipase A? inhibition.
Neoplasm Metastasis
MiR-543 Promotes Migration, Invasion and Epithelial-Mesenchymal Transition of Esophageal Cancer Cells by Targeting Phospholipase A2 Group IVA.
Neoplasm Metastasis
Overexpression of Peroxiredoxin 6 (PRDX6) Promotes the Aggressive Phenotypes of Esophageal Squamous Cell Carcinoma.
Neoplasm Metastasis
Phospholipase A2 activity of peroxiredoxin 6 promotes invasion and metastasis of lung cancer cells.
Neoplasm Metastasis
Phospholipase A2 group IIA expression in gastric adenocarcinoma is associated with prolonged survival and less frequent metastasis.
Neoplasm Metastasis
PLA2G4A promotes right-sided colorectal cancer progression by inducing CD39+?? Treg polarization.
Neoplasm Metastasis
PRDX1 and PRDX6 are repressed in papillary thyroid carcinomas via BRAF V600E-dependent and -independent mechanisms.
Neoplasm Metastasis
Prognostic significance of three novel biologic factors in a clinical trial of adjuvant therapy for node-negative breast cancer.
Neoplasm Metastasis
Role of the phospholipase A2 receptor in liposome drug delivery in prostate cancer cells.
Neoplasm Metastasis
Secretory phospholipase A2-IIa upregulates HER/HER2-elicited signaling in lung cancer cells.
Neoplasm Metastasis
Sterically stabilized liposomes targeting P21 (RAC1) activated kinase-1 and secreted phospholipase A2 suppress prostate cancer growth and metastasis.
Neoplasm Metastasis
Targeting cPLA2? inhibits gastric cancer and augments chemotherapy efficacy via suppressing Ras/MEK/ERK and Akt/?-catenin pathways.
Neoplasm Metastasis
The expression of phospholipase A2 group X is inversely associated with metastasis in colorectal cancer.
Neoplasms
1,25-Dihydroxyvitamin D3 protects human leukemic cells from tumor necrosis factor-induced apoptosis via inactivation of cytosolic phospholipase A2.
Neoplasms
1H MR spectroscopic imaging of phospholipase-mediated membrane lipid release in apoptotic rat glioma in vivo.
Neoplasms
5-Lipoxygenase and endotoxin-induced microvascular albumin exchanges and leucocyte recruitment in guinea-pig lungs.
Neoplasms
A Concise Update on the Relevance of Secretory phospholipase A2 group IIA and Its Inhibitors to Cancer.
Neoplasms
A mitogen-activated protein kinase independent pathway involved in the phosphorylation and activation of cytosolic phospholipase A2 in human neutrophils stimulated with tumor necrosis factor-alpha.
Neoplasms
A phase II study of oral clofazimine in unresectable and metastatic hepatocellular carcinoma.
Neoplasms
Absence of secretory phospholipase A2 gene alterations in human colorectal cancer.
Neoplasms
Activities of phospholipase A2 and diacylglycerol lipase are increased in human colorectal cancer.
Neoplasms
Adenovirus E3-10.4K/14.5K protein complex inhibits tumor necrosis factor-induced translocation of cytosolic phospholipase A2 to membranes.
Neoplasms
Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release.
Neoplasms
Alterations in eicosanoid levels during U937 bcl-xL tumour growth suppression and recovery in NU/NU mice in vivo-Involvement of phospholipase A2.
Neoplasms
Altered glycolipid and glycerophospholipid signaling drive inflammatory cascades in adrenomyeloneuropathy.
Neoplasms
An echo-contrast agent, Levovist, lowers the ultrasound intensity required to induce apoptosis of human leukemia cells.
Neoplasms
Analysis of AGE modified proteins and RAGE expression in HER2/neu negative invasive ductal carcinoma.
Neoplasms
Anti-cancer effect of snake venom toxin through down regulation of AP-1 mediated PRDX6 expression.
Neoplasms
Antimalarial drugs inhibit phospholipase A2 activation and induction of interleukin 1beta and tumor necrosis factor alpha in macrophages: implications for their mode of action in rheumatoid arthritis.
Neoplasms
Antioxidant effects of N-acetylserotonin: possible mechanisms and clinical implications.
Neoplasms
Antisense inhibition of 85-kDa cPLA2 blocks arachidonic acid release from airway epithelial cells.
Neoplasms
Antitumor action and immune activation through cooperation of bee venom secretory phospholipase A2 and phosphatidylinositol-(3,4)-bisphosphate.
Neoplasms
Antitumor effects of cationic synthetic peptides derived from Lys49 phospholipase A2 homologues of snake venoms.
Neoplasms
Antitumor potential of the myotoxin BthTX-I from Bothrops jararacussu snake venom: evaluation of cell cycle alterations and death mechanisms induced in tumor cell lines.
Neoplasms
Arachidonic acid induces c-jun gene expression in stromal cells stimulated by interleukin-1 and tumor necrosis factor-alpha: evidence for a tyrosine-kinase-dependent process.
Neoplasms
Arachidonic acid mediates dual effect of TNF-alpha on Ca2+ transients and contraction of adult rat cardiomyocytes.
Neoplasms
Arachidonic acid mobilization is suppressed during mitosis: role of cytosolic phospholipase A2 activation.
Neoplasms
Arachidonic acid, an omega-6 fatty acid, induces cytoplasmic phospholipase A2 in prostate carcinoma cells.
Neoplasms
Arachidonic acid-selective cytosolic phospholipase A2 is crucial in the cytotoxic action of tumor necrosis factor.
Neoplasms
Artocarpin attenuates ultraviolet B-induced skin damage in hairless mice by antioxidant and anti-inflammatory effect.
Neoplasms
Association of 5'UTR polymorphism of secretory phospholipase A2 group IIA (PLA2G2A) gene with prostate cancer metastasis.
Neoplasms
Attenuation of atherosclerotic complications by modulating inflammatory responses in hypercholesterolemic rats with dietary Njavara rice bran oil.
Neoplasms
Atypical lambda/iota PKC conveys 5-lipoxygenase/leukotriene B4-mediated cross-talk between phospholipase A2s regulating NF-kappa B activation in response to tumor necrosis factor-alpha and interleukin-1beta.
Neoplasms
Autotaxin and LPA Receptors Represent Potential Molecular Targets for the Radiosensitization of Murine Glioma through Effects on Tumor Vasculature.
Neoplasms
Bactericidal/permeability-increasing protein (BPI) in sepsis correlates with the severity of sepsis and the outcome.
Neoplasms
Bee Venom Phospholipase A2, a Good "Chauffeur" for Delivering Tumor Antigen to the MHC I and MHC II Peptide-Loading Compartments of the Dendritic Cells: The Case of NY-ESO-1.
Neoplasms
Bee venom secretory phospholipase A2 and phosphatidylinositol-homologues cooperatively disrupt membrane integrity, abrogate signal transduction and inhibit proliferation of renal cancer cells.
Neoplasms
Bee Venom-A Potential Complementary Medicine Candidate for SARS-CoV-2 Infections.
Neoplasms
Biomarkers of oxidative stress are associated with frailty: the Framingham Offspring Study.
Neoplasms
Both group IB and group IIA secreted phospholipases A2 are natural ligands of the mouse 180-kDa M-type receptor.
Neoplasms
Bothrops moojeni myotoxin-II, a Lys49-phospholipase A2 homologue: an example of function versatility of snake venom proteins.
Neoplasms
Bromoenol Lactone Attenuates Nicotine-Induced Breast Cancer Cell Proliferation and Migration.
Neoplasms
BthTX-I from Bothrops jararacussu induces apoptosis in human breast cancer cell lines and decreases cancer stem cell subpopulation.
Neoplasms
Cancer cells isolated from malignant pleural and peritoneal effusions inhibit phospholipase A2 activity in human polymorphonuclear leukocytes.
Neoplasms
Cancer stem cell phenotype is supported by secretory phospholipase A2 in human lung cancer cells.
Neoplasms
Cancer: restriction of chemical energy by fatty acids as the common pathway whereby various anti-tumour procedures selectively damage malignant cells in situ.
Neoplasms
Carvedilol attenuates l-arginine induced acute pancreatitis in rats through modulation of oxidative stress and inflammatory mediators.
Neoplasms
Caspase inhibition causes hyperacute tumor necrosis factor-induced shock via oxidative stress and phospholipase A2.
Neoplasms
Cathepsin B mediates tumor necrosis factor-induced arachidonic acid release in tumor cells.
Neoplasms
Ceramide-induced enhancement of secretory phospholipase A2 expression via generation of reactive oxygen species in tumor necrosis factor-alpha-stimulated mesangial cells.
Neoplasms
Characterization and differentiation-dependent regulation of secreted phospholipases A in human keratinocytes and in healthy and psoriatic human skin.
Neoplasms
Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound.
Neoplasms
Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent.
Neoplasms
Chemopreventive Action of Anthocyanin-rich Black Soybean Fraction in APC (Min/+) Intestinal Polyposis Model.
Neoplasms
Cigarette Smoke Regulates Calcium-Independent Phospholipase A2 Metabolic Pathways in Breast Cancer.
Neoplasms
Comparative characterization of two toxic phospholipases A2 from Indian cobra (Naja naja naja) venom.
Neoplasms
Context-dependent effect of sPLA2-IIA induced proliferation on murine hair follicle stem cells and human epithelial cancer.
Neoplasms
Control of capillary formation by membrane-anchored extracellular inhibitor of phospholipase A(2).
Neoplasms
Coordinate expression of group II phospholipase A2 and the acute-phase proteins haptoglobin (HP) and alpha1-anti-chymotrypsin (ACH) by HepG2 cells.
Neoplasms
Correction to: Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer.
Neoplasms
Corticotropin-releasing hormone receptors mediate apoptosis via cytosolic calcium-dependent phospholipase A? and migration in prostate cancer cell RM-1.
Neoplasms
COX-2, inflammatory secreted PLA2, and cytoplasmic PLA2 protein expression in small bowel adenocarcinomas compared with colorectal adenocarcinomas.
Neoplasms
cPLA2a correlates with metastasis and poor prognosis of osteosarcoma by facilitating epithelial-mesenchymal transition.
Neoplasms
Crotoxin from Crotalus durissus terrificus venom: In vitro cytotoxic activity of a heterodimeric phospholipase A2 on human cancer-derived cell lines.
Neoplasms
Crotoxin Inhibits Endothelial Cell Functions in Two- and Three-dimensional Tumor Microenvironment.
Neoplasms
Curcumin differs from tetrahydrocurcumin for molecular targets, signaling pathways and cellular responses.
Neoplasms
Current insights into functions of phospholipase A2 receptor in normal and cancer cells: More questions than answers.
Neoplasms
Cyclic AMP mimics, but does not mediate, interleukin-1- and tumour-necrosis-factor-stimulated phospholipase A2 secretion from rat renal mesangial cells.
Neoplasms
Cycloheximide or nordihydroguaiaretic acid protects mice against the lethal and hepatocytolytic effects of a combined challenge with D-galactosamine and bacterial endotoxin.
Neoplasms
Cytokine activation during attacks of the hyperimmunoglobulinemia D and periodic fever syndrome.
Neoplasms
Cytokine induction of iNOS and sPLA2 in immortalized astrocytes (DITNC): response to genistein and pyrrolidine dithiocarbamate.
Neoplasms
Cytokine- and forskolin-induced synthesis of group II phospholipase A2 and prostaglandin E2 in rat mesangial cells is prevented by dexamethasone.
Neoplasms
Cytokine-stimulated secretion of group II phospholipase A2 by rat mesangial cells. Its contribution to arachidonic acid release and prostaglandin synthesis by cultured rat glomerular cells.
Neoplasms
Cytoplasmic phospholipase A2 activity and gene expression are stimulated by tumor necrosis factor: dexamethasone blocks the induced synthesis.
Neoplasms
Cytoplasmic phospholipase A2 expression in human colon adenocarcinoma is correlated with cyclooxygenase-2 expression and contributes to prostaglandin E2 production.
Neoplasms
Cytoplasmic phospholipase A2 metabolites play a critical role in pulmonary tumor metastasis in mice.
Neoplasms
Cytosolic Phospholipase A2 Alpha Regulates TLR Signaling and Migration in Metastatic 4T1 Cells.
Neoplasms
Cytosolic phospholipase A2 and cyclooxygenase-2 mediate release and metabolism of arachidonic acid in tumor necrosis factor-alpha-primed cultured intestinal epithelial cells (INT 407).
Neoplasms
Cytosolic phospholipase A2 and the distinct transcriptional programs of astrocytoma cells.
Neoplasms
Cytosolic phospholipase A2 from human monocytic cells: characterization of substrate specificity and Ca(2+)-dependent membrane association.
Neoplasms
Cytosolic phospholipase A2 is required for cytokine-induced expression of type IIA secretory phospholipase A2 that mediates optimal cyclooxygenase-2-dependent delayed prostaglandin E2 generation in rat 3Y1 fibroblasts.
Neoplasms
Cytosolic phospholipase A2 regulates alcohol-mediated astrocyte inflammatory responses in HIV-associated neurocognitive disorders.
Neoplasms
Cytosolic phospholipase A2, cyclo-oxygenases and arachidonate in human stomach tumours.
Neoplasms
Cytosolic phospholipase A2-alpha: a potential therapeutic target for prostate cancer.
Neoplasms
Cytosolic phospholipaseA2 inhibition with PLA-695 radiosensitizes tumors in lung cancer animal models.
Neoplasms
Damage to mitochondrial respiration chain is related to phospholipase A2 activation caused by tumor necrosis factor.
Neoplasms
Decreased lung tumorigenesis in mice genetically deficient in cytosolic phospholipase A2.
Neoplasms
Deletion of cytosolic phospholipase A(2) suppresses Apc(Min)-induced tumorigenesis.
Neoplasms
Deletion of phospholipase A2 group IVc induces apoptosis in rat mammary tumour cells by the nuclear factor-?B/lipocalin 2 pathway.
Neoplasms
Development of a cell-based bioassay for phospholipase A2-triggered liposomal drug release.
Neoplasms
Development- and age-associated expression pattern of peroxiredoxin 6, and its regulation in murine ocular lens.
Neoplasms
Dietary Protein and Changes in Biomarkers of Inflammation and Oxidative Stress in the Framingham Heart Study Offspring Cohort.
Neoplasms
Differential activation of keratinocyte phospholipase A2S by tumor promoters and other irritants.
Neoplasms
Differential Expression And Effects Of Peroxiredoxin-6 On Drug Resistance And Cancer Stem Cell-Like Properties In Non-Small Cell Lung Cancer.
Neoplasms
Differential regulation of phospholipase A2 by cytokines inhibiting bone formation and mineralization.
Neoplasms
Distinct expression pattern of the full set of secreted phospholipases A2 in human colorectal adenocarcinomas: sPLA2-III as a biomarker candidate.
Neoplasms
Distinct regulation of cytosolic phospholipase A2 phosphorylation, translocation, proteolysis and activation by tumour necrosis factor-receptor subtypes.
Neoplasms
Distribution of type V secretory phospholipase A2 expression in human hepatocytes damaged by liver disease.
Neoplasms
Down-regulation by prostaglandins of type-II phospholipase A2 expression in guinea-pig alveolar macrophages: a possible involvement of cAMP.
Neoplasms
Dysfunction of PLA2G6 and CYP2C44-associated network signals imminent carcinogenesis from chronic inflammation to hepatocellular carcinoma.
Neoplasms
Effect of a nonprotein bioactive agent on the reduction of cyclooxygenase-2 and tumor necrosis factor-alpha in human intervertebral disc cells in vitro.
Neoplasms
Effect of azithromycin on the LPS-induced production and secretion of phospholipase A2 in lung cells.
Neoplasms
Effect of phospholipase A2 inhibitory peptide on inflammatory arthritis in a TNF transgenic mouse model: a time-course ultrastructural study.
Neoplasms
Effect of statin and fibrate treatment on inflammation in type 2 diabetes. A randomized, cross-over study.
Neoplasms
Effect of treatment with a colloidal oatmeal lotion on the acneform eruption induced by epidermal growth factor receptor and multiple tyrosine-kinase inhibitors.
Neoplasms
Effects of a treatment with Se-rich rice flour high in resistant starch on enteric dysbiosis and chronic inflammation in diabetic ICR mice.
Neoplasms
Effects of dietary fish oil on fatty acids and eicosanoids in metastasizing human breast cancer cells.
Neoplasms
Effects of Docosahexaenoic Acid and Its Peroxidation Product on Amyloid-? Peptide-Stimulated Microglia.
Neoplasms
Effects of interleukin 1 beta, tumor necrosis factor alpha and transforming growth factor beta on group II phospholipase A2 activity in rat gingival fibroblasts.
Neoplasms
Effects of lipopolysaccharide on phospholipase A2 activity and tumor necrosis factor expression in HL-60 cells.
Neoplasms
Effects of swimming on pain and inflammatory factors in rats with lumbar disc herniation.
Neoplasms
Eicosanoid profiling in an orthotopic model of lung cancer progression by mass spectrometry demonstrates selective production of leukotrienes by inflammatory cells of the microenvironment.
Neoplasms
Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis: possible contribution of phospholipase A2 to this atherogenic profile.
Neoplasms
Elevation of serum group II phospholipase A2 in patients with cancers of digestive organs.
Neoplasms
Elevation of serum group II phospholipase A2 levels in patients with advanced cancer.
Neoplasms
Endothelial PKC?-MAPK/ERK-phospholipase A2 pathway activation as a response of glioma in a triple culture model. A new role for pericytes?
Neoplasms
Enhanced tissue expression and elevated circulating level of phospholipase A(2) receptor during murine endotoxic shock.
Neoplasms
Enhancement of experimental colon carcinogenesis by dietary 6-phenylhexyl isothiocyanate.
Neoplasms
Epigenetic control of group V phospholipase A2 expression in human malignant cells.
Neoplasms
Epigenetic control of phospholipase A2 receptor expression in mammary cancer cells.
Neoplasms
Epoxyeicosatrienoic acid ameliorates cerebral ischemia-reperfusion injury by inhibiting inflammatory factors and pannexin-1.
Neoplasms
Evaluation of cytotoxic activities of snake venoms toward breast (MCF-7) and skin cancer (A-375) cell lines.
Neoplasms
Evidence that porcine pancreatic phospholipase A2 via its high affinity receptor stimulates extracellular matrix invasion by normal and cancer cells.
Neoplasms
Examining the role of Paneth cells in the small intestine by lineage ablation in transgenic mice.
Neoplasms
Exogenous type-II phospholipase A2 stimulates prostaglandin synthesis in rat liver-derived BRL-3A cells in the presence of tumor necrosis factor alpha.
Neoplasms
Expression analysis of the group IIA secretory phospholipase A(2) in mice with differential susceptibility to azoxymethane-induced colon tumorigenesis.
Neoplasms
Expression of Cytosolic Phospholipase A2 (cPLA2)-Arachidonic Acid (AA)-Cyclooxygenase-2 (COX-2) Pathway Factors in Lung Cancer Patients and Its Implication in Lung Cancer Early Detection and Prognosis.
Neoplasms
Expression of cytosolic phospholipase A2 alpha in murine C12 cells, a variant of L929 cells, induces arachidonic acid release in response to phorbol myristate acetate and Ca2+ ionophores, but not to tumor necrosis factor-alpha.
Neoplasms
Expression of group II phospholipase A2 in Paneth cells of an adenoma of the rectum. A case report.
Neoplasms
Expression of group IIa secretory phospholipase A2 increases with prostate tumor grade.
Neoplasms
Expression of group IIA secretory phospholipase A2 is elevated in prostatic intraepithelial neoplasia and adenocarcinoma.
Neoplasms
Expression of inflammatory secretory phospholipase A2 and cytosolic phospholipase A2 in premalignant and malignant Barrett's oesophagus.
Neoplasms
Expression of peroxiredoxin 1, 2, 3, and 6 genes in cancer cells during drug resistance formation.
Neoplasms
Expression of PRDX6 Correlates with Migration and Invasiveness of Colorectal Cancer Cells.
Neoplasms
Expression of Secretory Phospholipase A2 Group IIa in Breast Cancer and Correlation to Prognosis in a Cohort of Advanced Breast Cancer Patients.
Neoplasms
Expression of secretory phospholipase A2 in colon tumor cells potentiates tumor growth.
Neoplasms
Expression of type V secretory phospholipase A in myocardial remodelling after infarction.
Neoplasms
Extracellular phospholipase A2 secretion is a common effector pathway of interleukin-1 and tumour necrosis factor action.
Neoplasms
Functional coupling between secretory and cytosolic phospholipase A2 modulates tumor necrosis factor-alpha- and interleukin-1beta-induced NF-kappa B activation.
Neoplasms
Functional screening implicates miR-371-3p and peroxiredoxin 6 in reversible tolerance to cancer drugs.
Neoplasms
Gene expression differences predict treatment outcome of merkel cell carcinoma patients.
Neoplasms
Gene expression of cyclooxygenase-2, group II and cytosolic phospholipase A2 in human colorectal cancer.
Neoplasms
Generation of ammodytoxin-anti-cathepsin B immuno-conjugate as a model for delivery of secretory phospholipase A(2) into cancer cells.
Neoplasms
Glucocorticoids inhibit oncostatin M-induced phospholipase A2 gene expression in human hepatoma cells.
Neoplasms
Group II phospholipase A2 is increased in peritoneal and pleural effusions in patients with various types of cancer.
Neoplasms
Group II phospholipase A2 mRNA synthesis is stimulated by two distinct mechanisms in rat vascular smooth muscle cells.
Neoplasms
Group IIa secretory phospholipase A2 (sPLA2IIa) and progression in patients with lung cancer.
Neoplasms
Group IVA Cytosolic Phospholipase A2 Regulates the G2-to-M Transition by Modulating the Activity of Tumor Suppressor SIRT2.
Neoplasms
Group VI phospholipases A2: homeostatic phospholipases with significant potential as targets for novel therapeutics.
Neoplasms
Group VIA phospholipase A2 in both host and tumor cells is involved in ovarian cancer development.
Neoplasms
Group X phospholipase A2 stimulates the proliferation of colon cancer cells by producing various lipid mediators.
Neoplasms
Group X secreted phospholipase A2 induces lipid droplet formation and prolongs breast cancer cell survival.
Neoplasms
Growth inhibitory effects and molecular mechanisms of crotoxin treatment in esophageal Eca-109 cells and transplanted tumors in nude mice.
Neoplasms
Half-life of interleukin-1 beta-induced group II phospholipase A2 in rat mesangial cells.
Neoplasms
High molecular weight phospholipase A2 and fatty acids in human colon tumours and associated normal tissue.
Neoplasms
High resolution mass spectrometry coupled with multivariate data analysis revealing plasma lipidomic alteration in ovarian cancer in Asian women.
Neoplasms
Homeodomain-interacting protein kinase-2 restrains cytosolic phospholipase A2-dependent prostaglandin E2 generation in human colorectal cancer cells.
Neoplasms
Hypotonic cell swelling induces translocation of the alpha isoform of cytosolic phospholipase A2 but not the gamma isoform in Ehrlich ascites tumor cells.
Neoplasms
Identification of a 27 bp 5'-flanking region element responsible for the low level constitutive expression of the human cytosolic phospholipase A2 gene.
Neoplasms
Identification of breast cancer metastasis-associated proteins in an isogenic tumor metastasis model using two-dimensional gel electrophoresis and liquid chromatography-ion trap-mass spectrometry.
Neoplasms
Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.
Neoplasms
Identification of novel cellular targets in biliary tract cancers using global gene expression technology.
Neoplasms
Identification of peroxiredoxin 6 as a direct target of withangulatin A by quantitative chemical proteomics in non-small cell lung cancer.
Neoplasms
Identification of peroxiredoxin 6 as a potential lung-adenocarcinoma biomarker for predicting chemotherapy response by proteomic analysis.
Neoplasms
Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer.
Neoplasms
Identification of the transcription factor ARNTL2 as a candidate gene for the type 1 diabetes locus Idd6.
Neoplasms
Immune modulation of glycosaminoglycan derived from P. lewisi in TNF-? stimulated cells.
Neoplasms
Immunohistochemical localization of group II phospholipase A2 in the tumours and mucosa of the colon and rectum.
Neoplasms
Impacts of cytosolic phospholipase A2, 15-prostaglandin dehydrogenase, and cyclooxygenase-2 expressions on tumor progression in colorectal cancer.
Neoplasms
In vitro and in vivo matrix metalloproteinase expression after photodynamic therapy with a liposomal formulation of aminolevulinic acid and its methyl ester.
Neoplasms
In vitro comparison of cytotoxic effects of crotoxin against three human tumors and a normal human epidermal keratinocyte cell line.
Neoplasms
Increased expression and activity of group IIA and X secretory phospholipase A2 in peritumoral versus central colon carcinoma tissue.
Neoplasms
Increased expression of membrane-associated phospholipase A2 shows malignant potential of human breast cancer cells.
Neoplasms
Increased gene expression of novel cytosolic and secretory phospholipase A(2) types in human airway epithelial cells induced by tumor necrosis factor-alpha and IFN-gamma.
Neoplasms
Increased neuroinflammatory and arachidonic acid cascade markers, and reduced synaptic proteins, in brain of HIV-1 transgenic rats.
Neoplasms
Increased resistance in splenectomized mice to a methylcholanthrene-induced tumour.
Neoplasms
Increased serum phospholipase A2 activity after non-heart-beating donor liver transplantation and association with ischemia-reperfusion injury.
Neoplasms
Increased serum phospholipase A2 activity in Malawian children with falciparum malaria.
Neoplasms
Induction of circulating group II phospholipase A2 expression in adults with malaria.
Neoplasms
Induction of circulating phospholipase A2 activity by intravenous infusion of endotoxin in patients with neoplasia.
Neoplasms
Induction of cytosolic phospholipase A2 in human leukocytes by lipopolysaccharide.
Neoplasms
Induction of release of secretory nonpancreatic phospholipase A2 from human articular chondrocytes.
Neoplasms
Induction of TNF-alpha and proinflammatory secretory phospholipase A2 by intravenous administration of CAMPATH-1H in patients with rheumatoid arthritis.
Neoplasms
Inflammatory biomarkers, physical activity, waist circumference, and risk of future coronary heart disease in healthy men and women.
Neoplasms
Inflammatory factors stimulate expression of group II phospholipase A2 in rat cultured astrocytes. Two distinct pathways of the gene expression.
Neoplasms
Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian.
Neoplasms
Influence of zero-balanced hemofiltration on the course of severe experimental pancreatitis in pigs.
Neoplasms
Inhibition of 12-O-tetradecanoyl-phorbol-13-acetate-induced tumor promotion by nordihydroguaiaretic acid, a lipoxygenase inhibitor, and p-bromophenacyl bromide, a phospholipase A2 inhibitor.
Neoplasms
Inhibition of calcium-independent phospholipase A2 suppresses proliferation and tumorigenicity of ovarian carcinoma cells.
Neoplasms
Inhibition of mitogen-activated protein kinase kinase does not impair primary activation of human platelets.
Neoplasms
Inhibition of mouse skin tumor promotion by several inhibitors of arachidonic acid metabolism.
Neoplasms
Inhibition of secretory phospholipase A2 IIa attenuates prostaglandin E2-induced invasiveness in lung adenocarcinoma.
Neoplasms
Inhibition of the platelet-aggregating activity of two human adenocarcinomas of the colon and an anaplastic murine tumor with a specific thrombin inhibitor, dansylarginine N-(3-ethyl-1,5-pentanediyl)amide.
Neoplasms
Inhibitors of phospholipase A2 and their therapeutic potential: an update on patents (2012-2016).
Neoplasms
Inhibitors of transcription and translation act synergistically with tumor necrosis factor to cause the activation of phospholipase A2.
Neoplasms
Inhibitory effects of lycopene on HMGB1-mediated pro-inflammatory responses in both cellular and animal models.
Neoplasms
Interactions of PLA2-s from Vipera lebetina, Vipera berus berus and Naja naja oxiana venom with platelets, bacterial and cancer cells.
Neoplasms
Interleukin 1 and tumor necrosis factor synergistically stimulate prostaglandin synthesis and phospholipase A2 release from rat renal mesangial cells.
Neoplasms
Interleukin-1 and tumor necrosis factor stimulate arachidonic acid release and phospholipid metabolism in human myometrial cells.
Neoplasms
Interleukin-1 beta, tumor necrosis factor and forskolin stimulate the synthesis and secretion of group II phospholipase A2 in rat mesangial cells.
Neoplasms
Interleukin-4 inhibits prostaglandin G/H synthase-2 and cytosolic phospholipase A2 induction in neonatal mouse parietal bone cultures.
Neoplasms
Interleukin-4 inhibits the gene expression and biosyntheis of cytosolic phospholipase A2 in lipopolysaccharide stimulated U937 macrophage cell line and freshly prepared adherent rheumatoid synovial cells.
Neoplasms
Intestinal secretory factor released by macrophages stimulated with Clostridium difficile toxin A: role of interleukin 1beta.
Neoplasms
Intraarticular osteoid osteoma associated with synovitis: a possible role of cyclooxygenase-2 expression by osteoblasts in the nidus.
Neoplasms
Involvement of caspase-dependent activation of cytosolic phospholipase A2 in tumor necrosis factor-induced apoptosis.
Neoplasms
Involvement of formyl peptide receptors in the stimulatory effect of crotoxin on macrophages co-cultivated with tumour cells.
Neoplasms
Involvement of lipid mediators on cytokine signaling and induction of secretory phospholipase A2 in immortalized astrocytes (DITNC).
Neoplasms
Involvement of phospholipase A2 activation in tumour cell killing by tumour necrosis factor.
Neoplasms
Ischaemic preconditioning and TNF-alpha-mediated preconditioning is associated with a differential cPLA2 translocation pattern in early ischaemia.
Neoplasms
Isolation and characterization of three inhibitors of thymidine incorporation into bovine fetal liver cells.
Neoplasms
Knockdown of secretory phospholipase A2 IIa reduces lung cancer growth in vitro and in vivo.
Neoplasms
Knockout of PRDX6 induces mitochondrial dysfunction and cell cycle arrest at G2/M in HepG2 hepatocarcinoma cells.
Neoplasms
Lack of phospholipase A2 mutations in neuroblastoma, melanoma and colon-cancer cell lines.
Neoplasms
Lactosylceramide-Induced Phosphorylation Signaling to Group IVA Phospholipase A2 via Reactive Oxygen Species in Tumor Necrosis Factor-?-Treated Cells.
Neoplasms
Lentivirus-mediated Inhibition of Tumour Necrosis Factor-? improves motor function associated with PRDX6 in spinal cord contusion rats.
Neoplasms
Liposomes containing alkylated methotrexate analogues for phospholipase A(2) mediated tumor targeted drug delivery.
Neoplasms
Liposomes Targeting P21 Activated Kinase-1 (PAK-1) and Selective for Secretory Phospholipase A2 (sPLA2) Decrease Cell Viability and Induce Apoptosis in Metastatic Triple-Negative Breast Cancer Cells.
Neoplasms
Liver diseases and cancer associated with lack of lymphocytic cortisol metabolism enhancing factor.
Neoplasms
Long non?coding RNA SLNCR1 regulates non?small cell lung cancer migration, invasion and stemness through interactions with secretory phospholipase A2.
Neoplasms
Loss of presenilin 2 is associated with increased iPLA2 activity and lung tumor development.
Neoplasms
Lung cancer cell invasion and expression of intercellular adhesion molecule-1 (ICAM-1) are attenuated by secretory phospholipase A? inhibition.
Neoplasms
Maleylated-BSA induces hydrolysis of PIP2, fluxes of Ca2+, NF-kappaB binding, and transcription of the TNF-alpha gene in murine macrophages.
Neoplasms
Mechanistic study of the sPLA2-mediated hydrolysis of a thio-ester pro anticancer ether lipid.
Neoplasms
Membrane-derived second messenger regulates x-ray-mediated tumor necrosis factor alpha gene induction.
Neoplasms
Metabolic reprogramming ensures cancer cell survival despite oncogenic signaling blockade.
Neoplasms
Metalloprotease activity, phospholipase A2 activity and cytokine concentration in osteoarthritis synovial fluids.
Neoplasms
Mitochondrial localization of cyclooxygenase-2 and calcium-independent phospholipase A2 in human cancer cells: implication in apoptosis resistance.
Neoplasms
MMP production in human fibrosarcoma cells and their invasiveness are regulated by group IB secretory phospholipase A2 receptor-mediated activation of cytosolic phospholipase A2.
Neoplasms
Modification of LDL with human secretory phospholipase A(2) or sphingomyelinase promotes its arachidonic acid-releasing propensity.
Neoplasms
Modulated mechanism of phosphatidylserine on the catalytic activity of Naja naja atra phospholipase A2 and Notechis scutatus scutatus notexin.
Neoplasms
Modulating effect of amount and types of dietary fat on colonic mucosal phospholipase A2, phosphatidylinositol-specific phospholipase C activities, and cyclooxygenase metabolite formation during different stages of colon tumor promotion in male F344 rats.
Neoplasms
Modulation of growth in human esophageal adenocarcinoma cells by group IIa secretory phospholipase A(2).
Neoplasms
Modulation of immune response and protective efficacy of recombinant outer-membrane protein F (rOmpF) of Aeromonas hydrophila in Labeo rohita.
Neoplasms
Modulation of phospholipase A2 activity by the tumour promoters phorbol esters and teleocidin.
Neoplasms
Monocyte-derived factors including PLA2G7 induced by macrophage-nasopharyngeal carcinoma cell interaction promote tumor cell invasiveness.
Neoplasms
Multivariate analysis of 9 disease-associated variables for outcome prediction in patients with sepsis.
Neoplasms
Mutagenic and genotoxic activities of Phospholipase A2 Bothropstoxin-I from Bothrops jararacussu in Drosophila melanogaster and human cell lines.
Neoplasms
MVL-PLA2, a phospholipase A2 from Macrovipera lebetina transmediterranea venom, inhibits tumor cells adhesion and migration.
Neoplasms
N-Acetylsphingosine stimulates phosphatidylglycerolphosphate synthase activity in H9c2 cardiac cells.
Neoplasms
Nanoassemblies containing a fluorouracil/zidovudine glyceryl prodrug with phospholipase A2-triggered drug release for cancer treatment.
Neoplasms
Nature of the spleen cell populations capable of releasing tumor enhancing factor.
Neoplasms
Neoplastic and pharmacological influence on the permeability of an in vitro blood-brain barrier.
Neoplasms
Neuroprotection of taurine through inhibition of 12/15 lipoxygenase pathway in cerebral ischemia of rats.
Neoplasms
Nipple aspirate fluids from women with breast cancer contain increased levels of group IIa secretory phospholipase A2.
Neoplasms
NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression.
Neoplasms
Non-Clinical Studies for Evaluation of 8-C-Rhamnosyl Apigenin Purified from Peperomia obtusifolia against Acute Edema.
Neoplasms
Novel group V phospholipase A2 involved in arachidonic acid mobilization in murine P388D1 macrophages.
Neoplasms
Novel PLA2G4C polymorphism as a molecular diagnostic assay for 19q loss in human gliomas.
Neoplasms
Nucleophosmin Regulates Intracellular Oxidative Stress Homeostasis via Antioxidant PRDX6.
Neoplasms
Nutritional factors (nutritional aspects) in biliary disorders: bile acid and lipid metabolism in gallstone diseases and pancreaticobiliary maljunction.
Neoplasms
Opiate and acetylcholine-independent analgesic actions of crotoxin isolated from crotalus durissus terrificus venom.
Neoplasms
Origin of circulating group II phospholipase A2 in hepatocytes in a patient with epitheloid hemangioendothelioma of the liver.
Neoplasms
Over-expression of caveolin-1 aggravate LPS-induced inflammatory response in AT-1 cells via up-regulation of cPLA2/p38 MAPK.
Neoplasms
Overexpression of major heat shock protein hsp70 inhibits tumor necrosis factor-induced activation of phospholipase A2.
Neoplasms
Overexpression of Peroxiredoxin 6 (PRDX6) Promotes the Aggressive Phenotypes of Esophageal Squamous Cell Carcinoma.
Neoplasms
Overexpression of Prdx6 and resistance to peroxide-induced death in Hepa1-6 cells: Prdx suppression increases apoptosis.
Neoplasms
Overexpression of secretory phospholipase A2-IIa supports cancer stem cell phenotype via HER/ERBB-elicited signaling in lung and prostate cancer cells.
Neoplasms
Overexpression of the nonpancreatic secretory group II PLA2 messenger RNA and protein in colorectal adenomas from familial adenomatous polyposis patients.
Neoplasms
Overexpression of the phospholipase A2 group V gene in glioma tumors is associated with poor patient prognosis.
Neoplasms
Pachymic acid inhibits cell growth and modulates arachidonic acid metabolism in nonsmall cell lung cancer A549 cells.
Neoplasms
Pancreatic acinar cell carcinoma. An analysis of cell lineage markers, p53 expression, and Ki-ras mutation.
Neoplasms
Pancreatic cancer cell lines can induce prostaglandin e2 production from human blood mononuclear cells.
Neoplasms
Partial characterization of proapoptotic action of biliary deteriorated lipids on biliary epithelial cells in pancreaticobiliary diseases.
Neoplasms
Partial characterization, in vitro antioxidant and antiproliferative activities of patatin purified from potato fruit juice.
Neoplasms
Peroxiredoxin 6 Serum Levels and Risk of Neutropenic Infections in Diffuse Large B-cell Lymphoma.
Neoplasms
Pharmacological inhibition of lipid droplet formation enhances the effectiveness of curcumin in glioblastoma.
Neoplasms
Phase I and pharmacokinetics study of crotoxin (cytotoxic PLA(2), NSC-624244) in patients with advanced cancer.
Neoplasms
Phase I study of VRCTC-310, a purified phospholipase A2 purified from snake venom, in patients with refractory cancer: safety and pharmacokinetic data.
Neoplasms
Phospholipase A(2) of peroxiredoxin 6 has a critical role in tumor necrosis factor-induced apoptosis.
Neoplasms
Phospholipase A2 activation and autoinduction of tumor necrosis factor gene expression by tumor necrosis factor.
Neoplasms
Phospholipase A2 activation in cultured mouse hepatocytes exposed to tumor necrosis factor-alpha.
Neoplasms
Phospholipase A2 activities with a plasmalogen substrate in brain and in neural tumor cells: a sensitive and specific assay using pyrenesulfonyl-labeled plasmenylethanolamine.
Neoplasms
Phospholipase A2 activity in 9,10-dimethyl-1,2-benzanthracene-induced mammary tumors of rats.
Neoplasms
Phospholipase A2 activity in serum is induced during treatment with recombinant human interleukin-6 in patients with cancer.
Neoplasms
Phospholipase A2 activity is not involved in the tumor necrosis factor-triggered apoptotic DNA fragmentation in bovine aortic endothelial cells.
Neoplasms
Phospholipase A2 activity of peroxiredoxin 6 promotes invasion and metastasis of lung cancer cells.
Neoplasms
Phospholipase A2 Drives Tumorigenesis and Cancer Aggressiveness through Its Interaction with Annexin A1.
Neoplasms
Phospholipase A2 from krait Bungarus fasciatus venom induces human cancer cell death in vitro.
Neoplasms
Phospholipase A2 Group III and Group X Have Opposing Associations with Prognosis in Colorectal Cancer.
Neoplasms
Phospholipase A2 is activated by tumor necrosis factor-alpha in primary hepatocytes stimulated by a deleted form of hepatocyte growth factor.
Neoplasms
Phospholipase A2 is necessary for tumor necrosis factor alpha-induced ceramide generation in L929 cells.
Neoplasms
Phospholipase A2 Isoforms as Novel Targets for Prevention and Treatment of Inflammatory and Oncologic Diseases.
Neoplasms
Phospholipases A2 in ras-transformed and immortalized human mammary epithelial cells.
Neoplasms
PLA2G4A Is a Potential Biomarker Predicting Shorter Overall Survival in Patients with Non-M3/NPM1 Wildtype Acute Myeloid Leukemia.
Neoplasms
PLA2G4A promotes right-sided colorectal cancer progression by inducing CD39+?? Treg polarization.
Neoplasms
Plasma Levels of Phospholipase A2-IIA in Patients with Different Types of Malignancies: Prognosis and Association with Inflammatory and Coagulation Biomarkers.
Neoplasms
Plasma levels of type II phospholipase A2 and nitrite/nitrate in patients with burns.
Neoplasms
Plasma membrane phospholipase A2 controls hepatocellular fatty acid uptake and is responsive to pharmacological modulation: implications for nonalcoholic steatohepatitis.
Neoplasms
Plasma secretory phospholipase A2-IIa as a potential biomarker for lung cancer in patients with solitary pulmonary nodules.
Neoplasms
Platelet activating factor (PAF) antagonists on cytokine induction of iNOS and sPLA2 in immortalized astrocytes (DITNC).
Neoplasms
Potentiation of TNF-alpha-stimulated group IIA phospholipase A(2) expression by peroxisome proliferator-activated receptor alpha activators in rat mesangial cells.
Neoplasms
Potentiation of tumor necrosis factor alpha-induced secreted phospholipase A2 (sPLA2)-IIA expression in mesangial cells by an autocrine loop involving sPLA2 and peroxisome proliferator-activated receptor alpha activation.
Neoplasms
PRDX1 and PRDX6 are repressed in papillary thyroid carcinomas via BRAF V600E-dependent and -independent mechanisms.
Neoplasms
PRDX6 Overexpression Promotes Proliferation, Invasion, and Migration of A549 Cells in vitro and in vivo.
Neoplasms
PRDX6 promotes tumor development via the JAK2/STAT3 pathway in a urethane-induced lung tumor model.
Neoplasms
Prediction of novel target genes and pathways involved in irinotecan-resistant colorectal cancer.
Neoplasms
Presenilin Mutation Suppresses Lung Tumorigenesis via Inhibition of Peroxiredoxin 6 Activity and Expression.
Neoplasms
Prognostic significance of three novel biologic factors in a clinical trial of adjuvant therapy for node-negative breast cancer.
Neoplasms
Proinflammatory mediator response in coronary bypass surgery using a centrifugal or a roller pump.
Neoplasms
Prolactin release from MtTW15 and 7315a pituitary tumors is refractory to TRH and VIP stimulation.
Neoplasms
Promoting effect of hepatitis B virus on the expressoin of phospholipase A2 group IIA.
Neoplasms
Prostaglandin E2 amplifies cytosolic phospholipase A2- and cyclooxygenase-2-dependent delayed prostaglandin E2 generation in mouse osteoblastic cells. Enhancement by secretory phospholipase A2.
Neoplasms
Prostaglandin levels in stimulated macrophages are controlled by phospholipase A2-activating protein and by activation of phospholipase C and D.
Neoplasms
Prostaglandins and cancer: further stereochemical studies on the molecule of phospholipase A2.
Neoplasms
Prostate cancer-associated autoantibodies in serum against tumor-associated antigens as potential new biomarkers.
Neoplasms
Protective effect of Alpha-Linolenic acid on Lipopolysaccharide-Induced Orchitis in mice.
Neoplasms
Protective effects and mechanisms of Baicalin and octreotide on renal injury of rats with severe acute pancreatitis.
Neoplasms
Proteomic analysis reveals changes in the liver protein pattern of rats exposed to dietary folate deficiency.
Neoplasms
PTRF/cavin-1 remodels phospholipid metabolism to promote tumor proliferation and suppress immune responses in glioblastoma by stabilizing cPLA2.
Neoplasms
Purification and characterization of a low molecular weight multifunctional cytotoxic phospholipase A2 from Russell's viper venom.
Neoplasms
Raised neutrophil phospholipase A2 activity and defective priming of NADPH oxidase and phospholipase A2 in sickle cell disease.
Neoplasms
Rapid Screening and Identification of Antitumor Ingredients from the Mangrove Endophytic Fungus Using an Enzyme-Immobilized Magnetic Nanoparticulate System.
Neoplasms
Reduced group IVA phospholipase A2 expression is associated with unfavorable outcome for patients with gastric cancer.
Neoplasms
Reduction of circulating secretory phospholipase A2 levels by anti-tumor necrosis factor chimeric monoclonal antibody in patients with severe Crohn's disease. Relation between tumor necrosis factor and secretory phospholipase A2 in healthy humans and in active Crohn's disease.
Neoplasms
Regional arterial infusion with lipoxin A4 attenuates experimental severe acute pancreatitis.
Neoplasms
Regulation of alpha 1-adrenoceptor on rat hepatocyte apoptosis induced by D-galactosamine and lipopolysaccharide.
Neoplasms
Regulation of cytosolic phospholipase A2, cyclooxygenase-1 and -2 expression by PMA, TNFalpha, LPS and M-CSF in human monocytes and macrophages.
Neoplasms
Regulation of phospholipase A2 gene expression by tumour necrosis factor alpha in human HepG2 cells.
Neoplasms
Reprogramming lipid metabolism prevents effector T cell senescence and enhances tumor immunotherapy.
Neoplasms
Resistance to cytolysis by tumor necrosis factor alpha in malignant gynecological cell lines is associated with the expression of protein(s) that prevent the activation of phospholipase A2 by tumor necrosis factor alpha.
Neoplasms
Resveratrol nanoparticle system improves dissolution properties and enhances the hepatoprotective effect of resveratrol through antioxidant and anti-inflammatory pathways.
Neoplasms
Role of phospholipase A2 and prostaglandin E in growth and differentiation of myeloid leukemic cells.
Neoplasms
Role of the Ha-ras (RasH) oncogene in mediating progression of the tumor cell phenotype (review).
Neoplasms
Role of the phospholipase A2 receptor in liposome drug delivery in prostate cancer cells.
Neoplasms
Schlafen 3 knockout mice display gender-specific differences in weight gain, food efficiency, and expression of markers of intestinal epithelial differentiation, metabolism, and immune cell function.
Neoplasms
Search of factors that intermediate cytokine-induced group IIA phospholipase A2 expression through the cytosolic phospholipase A2- and 12/15-lipoxygenase-dependent pathway.
Neoplasms
Secreted phospholipase A2 of Clonorchis sinensis activates hepatic stellate cells through a pathway involving JNK signalling.
Neoplasms
Secreted Phospholipases A2 Are Intestinal Stem Cell Niche Factors with Distinct Roles in Homeostasis, Inflammation, and Cancer.
Neoplasms
Secreted phospholipases A? are differentially expressed and epigenetically silenced in human breast cancer cells.
Neoplasms
Secretory Phospholipase A(2) Inhibition Attenuates Intercellular Adhesion Molecule-1 Expression in Human Esophageal Adenocarcinoma Cells.
Neoplasms
Secretory phospholipase A2 as a tumor-specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipids.
Neoplasms
Secretory phospholipase A2 does not appear to be associated with phenotypic variation in familial adenomatous polyposis.
Neoplasms
Secretory Phospholipase A2 IIa Mediates Expression of Growth Factor Receptors in Esophageal Adenocarcinoma.
Neoplasms
Secretory Phospholipase A2 Inhibition Attenuates Adhesive Properties of Esophageal Barrett's Cells.
Neoplasms
Secretory phospholipase A2 pathway during pediatric acute respiratory distress syndrome: A preliminary study.
Neoplasms
Secretory phospholipase A2-IIa is a target gene of the HER/HER2-elicited pathway and a potential plasma biomarker for poor prognosis of prostate cancer.
Neoplasms
Secretory phospholipase A2-IIa is involved in prostate cancer progression and may potentially serve as a biomarker for prostate cancer.
Neoplasms
Secretory phospholipase A2-IIA overexpressing mice exhibit cyclic alopecia mediated through aberrant hair shaft differentiation and impaired wound healing response.
Neoplasms
Secretory phospholipase A2-IIa upregulates HER/HER2-elicited signaling in lung cancer cells.
Neoplasms
Secretory PLA(2) inhibitor indoxam suppresses LDL modification and associated inflammatory responses in TNFalpha-stimulated human endothelial cells.
Neoplasms
Secretory type II phospholipase A2 (PLA2G2A) expression status in colorectal carcinoma derived cell lines and in normal colonic mucosa.
Neoplasms
Selective inhibition of human group IIA secreted phospholipase A2 (hGIIA) signaling reveals arachidonic acid metabolism is associated with colocalization of hGIIA to vimentin in rheumatoid synoviocytes.
Neoplasms
Serum immunoreactive pancreatic phospholipase A2 in patients with various malignant tumors.
Neoplasms
Serum mannan-binding lectin (MBL) in patients with infection: clinical and laboratory correlates.
Neoplasms
Signaling mechanisms involved in the activation of arachidonic acid metabolism in human astrocytoma cells by tumor necrosis factor-alpha: phosphorylation of cytosolic phospholipase A2 and transactivation of cyclooxygenase-2.
Neoplasms
Silibinin Down-regulates Expression of Secreted Phospholipase A2 Enzymes in Cancer Cells.
Neoplasms
Singlet-Oxygen-Induced Phospholipase A2 Inhibition: A Major Role for Interfacial Tryptophan Dioxidation.
Neoplasms
Solid and cystic pancreatic tumors. Clinical, histochemical, and electron microscopic features in ten cases.
Neoplasms
Spatially resolved metabolomics combined with multicellular tumor spheroids to discover cancer tissue relevant metabolic signatures.
Neoplasms
sPLA2 -IIA Overexpression in Mice Epidermis Depletes Hair Follicle Stem Cells and Induces Differentiation Mediated Through Enhanced JNK/c-Jun Activation.
Neoplasms
Stimulation of different phospholipase A2 isoforms by TNF-alpha and IL-1beta in adult rat ventricular myocytes.
Neoplasms
Stimulation of group II phospholipase A2 mRNA expression and release in an immortalized astrocyte cell line (DITNC) by LPS, TNF alpha, and IL-1 beta. Interactive effects.
Neoplasms
Structural and Functional Aspects of Targeting the Secreted Human Group IIA Phospholipase A2.
Neoplasms
Studies of synthetic chalcone derivatives as potential inhibitors of secretory phospholipase A2, cyclooxygenases, lipoxygenase and pro-inflammatory cytokines.
Neoplasms
Supplementation with omega fatty acids increases the mRNA expression level of PLA2G4A in patients with gastric cancer.
Neoplasms
Surfactant and Varespladib Co-Administration in Stimulated Rat Alveolar Macrophages Culture.
Neoplasms
Susceptibility to TNF in the presence of inhibitors of transcription or translation is dependent on the activity of cytosolic phospholipase A2 in human melanoma tumor cells.
Neoplasms
Synergistic Effects of Secretory Phospholipase A 2 from the Venom of Agkistrodon piscivorus piscivorus with Cancer Chemotherapeutic Agents.
Neoplasms
Synovial-type (group II) phospholipase A2 in serum of febrile patients with haematological malignancy.
Neoplasms
Synthesis and biological activity of anticancer ether lipids that are specifically released by phospholipase A2 in tumor tissue.
Neoplasms
Synthesis and catabolism of PGE2 by a nephroblastoma associated with hypercalcemia without bone metastases.
Neoplasms
Synthesis of new secretory phospholipase A2-inhibitory indole containing isoxazole derivatives as anti-inflammatory and anticancer agents.
Neoplasms
Systemic phospholipase A2 and cachectin levels in adult respiratory distress syndrome and multiple-organ failure.
Neoplasms
Targeting arachidonic acid pathway by natural products for cancer prevention and therapy.
Neoplasms
Targeting cPLA2? inhibits gastric cancer and augments chemotherapy efficacy via suppressing Ras/MEK/ERK and Akt/?-catenin pathways.
Neoplasms
Targeting the enzymes involved in arachidonic acid metabolism to improve radiotherapy.
Neoplasms
Telmisartan and N-acetylcysteine Suppress Group V Secretory Phospholipase A2 Expression in TNF?-stimulated Human Endothelial Cells and Reduce Associated Atherogenicity.
Neoplasms
Temozolomide has anti-tumor effects through the phosphorylation of cPLA2 on glioblastoma cells.
Neoplasms
The activity of cytosolic phospholipase A2 is required for the lysis of adenovirus-infected cells by tumor necrosis factor.
Neoplasms
The Acute-phase Response Is Not Predictive for the Development of Arthritis in Seropositive Arthralgia - A Prospective Cohort Study.
Neoplasms
The anti-cancer potential of crotoxin in estrogen receptor-positive breast cancer: Its effects and mechanism of action.
Neoplasms
The cytotoxicity of tumor necrosis factor depends on induction of the mitochondrial permeability transition.
Neoplasms
The expression and distribution of group IIA phospholipase A2 in human colorectal tumours.
Neoplasms
The expression of cytosolic phospholipase A2 and biosynthesis of leukotriene B4 in acute myeloid leukemia cells.
Neoplasms
The high calcium ion uptake capacity of Ehrlich ascites tumour cell mitochondria is due to inhibition of the permeability transition and phospholipase A2 activity by magnesium.
Neoplasms
The identification of a novel Paneth cell-associated antigen in a familial adenomatous polyposis mouse model.
Neoplasms
The induction of cellular group II phospholipase A2 by cytokines and its prevention by dexamethasone.
Neoplasms
The inflammatory response to vascular surgery-associated ischaemia and reperfusion in man: effect on postoperative pulmonary function.
Neoplasms
The influence of chronic ibuprofen treatment on proteins expressed in the mouse hippocampus.
Neoplasms
The intestinal epithelium and its neoplasms: genetic, cellular and tissue interactions.
Neoplasms
The metabolites in peripheral blood mononuclear cells showed greater differences between patients with impaired fasting glucose or type 2 diabetes and healthy controls than those in plasma.
Neoplasms
The modulatory properties of Si Jun Zi Tang enhancing anticancer of gefitinib by an integrating approach.
Neoplasms
The mRNA overexpression of inflammatory enzymes, phospholipase A2 and cyclooxygenase, in the large bowel mucosa and neoplasms of F344 rats treated with naturally occurring carcinogen, 1-hydroxyanthraquinone.
Neoplasms
The phospholipase A2 activity of peroxiredoxin 6 promotes cancer cell death induced by tumor necrosis factor alpha in hepatocellular carcinoma.
Neoplasms
The role of inducible nitric oxide synthase in aseptic loosening after total hip arthroplasty.
Neoplasms
The secretory phospholipase A2 gene is a candidate for the Mom1 locus, a major modifier of ApcMin-induced intestinal neoplasia.
Neoplasms
Therapeutic potential of arachidonyl trifluromethyl ketone, a cytosolic phospholipaseA2 IVA specific inhibitor, in cigarette smoke condensate-induced pathological conditions in alveolar type I & II epithelial cells.
Neoplasms
Three secretory phospholipase A(2) genes that map to human chromosome 1P35-36 are not mutated in individuals with attenuated adenomatous polyposis coli.
Neoplasms
Thrombin causes pseudopod detachment via a pathway involving cytosolic phospholipase A2 and 12/15-lipoxygenase products.
Neoplasms
TNF alpha alters mitochondrial membrane potential in L929 but not in TNF alpha-resistant L929.12 cells: relationship with the expression of stress proteins, annexin 1 and superoxide dismutase activity.
Neoplasms
TNF-? Induces Cytosolic Phospholipase A2 Expression in Human Lung Epithelial Cells via JNK1/2- and p38 MAPK-Dependent AP-1 Activation.
Neoplasms
TNF-? induces cytosolic phospholipase A2 expression via Jak2/PDGFR-dependent Elk-1/p300 activation in human lung epithelial cells.
Neoplasms
TNF-?-Induced cPLA2 Expression via NADPH Oxidase/Reactive Oxygen Species-Dependent NF-?B Cascade on Human Pulmonary Alveolar Epithelial Cells.
Neoplasms
TNF-alpha-induced endothelium-independent vasodilation: a role for phospholipase A2-dependent ceramide signaling.
Neoplasms
Towards novel radiosensitizing agents: the role of cytosolic PLA2? in combined modality cancer therapy.
Neoplasms
Transforming growth factor beta 2 differentially modulates interleukin-1 beta- and tumour-necrosis-factor-alpha-stimulated phospholipase A2 and prostaglandin E2 synthesis in rat renal mesangial cells.
Neoplasms
Transforming growth factor-beta (TGF-beta) activates cytosolic phospholipase A2alpha (cPLA2alpha)-mediated prostaglandin E2 (PGE)2/EP1 and peroxisome proliferator-activated receptor-gamma (PPAR-gamma)/Smad signaling pathways in human liver cancer cells. A novel mechanism for subversion of TGF-beta-induced mitoinhibition.
Neoplasms
Triggered activation and release of liposomal prodrugs and drugs in cancer tissue by secretory phospholipase A2.
Neoplasms
Tumor cell-induced platelet aggregation in vitro by human pancreatic cancer cell lines.
Neoplasms
Tumor necrosis factor alpha and interleukin 1beta enhance the cortisone/cortisol shuttle.
Neoplasms
Tumor necrosis factor stimulates human neutrophils to release leukotriene B4 and platelet-activating factor. Induction of phospholipase A2 and acetyl-CoA:1-alkyl-sn-glycero-3-phosphocholine O2-acetyltransferase activity and inhibition by antiproteinase.
Neoplasms
Tumor necrosis factor-alpha and interleukin-1 alpha enhance glucose utilization by astrocytes: involvement of phospholipase A2.
Neoplasms
Tumor necrosis factor-alpha induces the 85-kDa cytosolic phospholipase A2 gene expression in human bronchial epithelial cells.
Neoplasms
Tumor necrosis factor-alpha priming of phospholipase A2 activation in human neutrophils. An alternative mechanism of priming.
Neoplasms
Tumor necrosis factor-alpha stimulates prostaglandin F2alpha secretion by bovine luteal cells via activation of mitogen-activated protein kinase and phospholipase A2 pathways.
Neoplasms
Tumour necrosis factor (cachectin) induces phospholipase A2 activity and synthesis of a phospholipase A2-activating protein in endothelial cells.
Neoplasms
Tumour necrosis factor and endotoxin synergistically activate intestinal phospholipase A2 in mice. Role of endogenous platelet activating factor and effect of exogenous platelet activating factor.
Neoplasms
Tumour necrosis factor-alpha-induced phosphorylation and activation of cytosolic phospholipase A2 are abrogated by an inhibitor of the p38 mitogen-activated protein kinase cascade in human neutrophils.
Neoplasms
Urocortin affects migration of hepatic cancer cell lines via differential regulation of cPLA2 and iPLA2.
Neoplasms
Using PCR-RFLP technology to teach single nucleotide polymorphism for undergraduates.
Neoplasms
VRCTC-310--a novel compound of purified animal toxins separates antitumor efficacy from neurotoxicity.
Neoplasms
Walker 256 Tumor Growth Suppression by Crotoxin Involves Formyl Peptide Receptors and Lipoxin A?.
Neoplasms
Women with reduced ovarian reserve or advanced maternal age have an altered follicular environment.
Neoplasms
[Cytokines, prostaglandin E2, phospholipase A and metalloproteases in synovial fluid in osteoarthritis]
Neoplasms
[Diagnostic effect of bronchoalveolar lavage in early lung injury caused by enterogenic infection in rat]
Neoplasms
[Effects of panax notoginseng saponins on the expression of tumor necrosis factor alpha and secretion phospholipase A2 in rats with liver fibrosis]
Neoplasms
[Growth inhibition and induction of tumor cell death by phospholipase A2 and lipoxygenase inhibitors]
Neoplasms
[Immunologic theory investigation and discussion of pain cause by lumbar intervertebral disc herniation (LDH)]
Neoplasms
[Purification and anticancer activity of cytotoxin-14 from venom of Naja naja atra]
Neoplasms
[Some probable therapeutic effects of the treatment of malignant neoplasms with a combination of lecithinase A, gamma globulin and hyaluronidase.]
Neoplasms
[Study on mechanisms and myocardial protective effect of Qishen Yiqi dropping pills on rats with myocardial infarction].
Neoplasms
[The cytotoxic mechanism of tumor necrosis factor (TNF) in human osteosarcoma cell line TE85--(1). Implication of phospholipase A2 activity in cytotoxicity]
Neoplasms
[The peripheral blood levels of TNF alpha and PLA2 activities in dialysis and non-dialysis patients with uremia]
Neoplasms
[The relationship between opsonin, endotoxin and chemical mediators in postoperative complications after surgery]
Neoplasms
[Tumor necrosis factor induced enhancement of neutrophil chemotaxis and adhesion through mediating of phospholipase A2 activation]
Nephritis
Expression and localization of cyclooxygenase isoforms and cytosolic phospholipase A2 in anti-Thy-1 glomerulonephritis.
Nephrosis, Lipoid
[Diagnostic value of renal phospholipase A2 receptor and serum anti-phospholipase A2 receptor antibody in membranous nephropathy].
Nephrotic Syndrome
Antiphospholipase 2 receptor antibody levels to predict complete spontaneous remission in primary membranous nephropathy.
Nephrotic Syndrome
Antiphospholipase A? receptor autoantibodies: a comparison of three different immunoassays for the diagnosis of idiopathic membranous nephropathy.
Nephrotic Syndrome
Co-occurrence of PLA2R-positive membranous nephropathy without crescents, and PR3-positive eosinophilic granulomatosis with polyangiitis?.
Nephrotic Syndrome
Ofatumumab for multirelapsing membranous nephropathy complicated by rituximab-induced serum-sickness.
Nephrotic Syndrome
Role of phospholipase A2 receptor 1 antibody level at diagnosis for long-term renal outcome in membranous nephropathy.
Nephrotic Syndrome
Subfractionation, characterization, and in-depth proteomic analysis of glomerular membrane vesicles in human urine.
Nervous System Diseases
Case report of a novel homozygous splice site mutation in PLA2G6 gene causing infantile neuroaxonal dystrophy in a Sudanese family.
Nervous System Diseases
Evidence for increased amyloid enhancing factor activity in Alzheimer brain extract.
Nervous System Diseases
Inhibitors of brain phospholipase A2 activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders.
Nervous System Diseases
Inhibitors of intracellular phospholipase A2 activity: their neurochemical effects and therapeutical importance for neurological disorders.
Nervous System Diseases
Mitochondria from a mouse model of the human infantile neuroaxonal dystrophy (INAD) with genetic defects in VIA iPLA2 have disturbed Ca(2+) regulation with reduction in Ca(2+) capacity.
Nervous System Diseases
Multiplex ligation-dependent probe amplification (MLPA) analysis is an effective tool for the detection of novel intragenic PLA2G6 mutations: Implications for molecular diagnosis.
Nervous System Diseases
New potent and selective polyfluoroalkyl ketone inhibitors of GVIA calcium-independent phospholipase A2.
Nervous System Diseases
Phospholipases A2 and Inflammatory Responses in the Central Nervous System.
Nervous System Diseases
Secretory phospholipase A2 and phospholipids in neural membranes in an experimental epilepsy model.
Nervous System Diseases
Synthetic and natural inhibitors of phospholipases A2: their importance for understanding and treatment of neurological disorders.
Nervous System Neoplasms
Phospholipase A2-mediated inflammation induces regression of malignant gliomas.
Neuralgia
Activation of cytosolic phospholipase A2 in dorsal root ganglion neurons by Ca2+/calmodulin-dependent protein kinase II after peripheral nerve injury.
Neuralgia
AK106-001616, a Potent and Selective Inhibitor of Cytosolic Phospholipase A2: In Vivo Efficacy for Inflammation, Neuropathic Pain, and Pulmonary Fibrosis.
Neuralgia
Calcium-independent phospholipase A2 inhibitor produces an analgesic effect in a rat model of neuropathic pain by reducing central sensitization in the dorsal horn.
Neuralgia
Crotoxin Conjugated to SBA-15 Nanostructured Mesoporous Silica Induces Long-Last Analgesic Effect in the Neuropathic Pain Model in Mice.
Neuralgia
Evidence for de novo synthesis of lysophosphatidic acid in the spinal cord through phospholipase A2 and autotaxin in nerve injury-induced neuropathic pain.
Neuralgia
Phospholipase A2 Inhibitor-Loaded Phospholipid Micelles Abolish Neuropathic Pain.
Neuralgia
Suppressive Effects of Bee Venom-Derived Phospholipase A2 on Mechanical Allodynia in a Rat Model of Neuropathic Pain.
Neuralgia
The analgesic effect of crotoxin on neuropathic pain is mediated by central muscarinic receptors and 5-lipoxygenase-derived mediators.
Neuritis
The effect of treatment with crotapotin on the evolution of experimental autoimmune neuritis induced in Lewis rats.
Neuritis, Autoimmune, Experimental
The effect of treatment with crotapotin on the evolution of experimental autoimmune neuritis induced in Lewis rats.
Neuroaxonal Dystrophies
A new PLA2G6 mutation in a family with infantile neuroaxonal dystrophy.
Neuroaxonal Dystrophies
A novel mitofusin 2 mutation causes canine fetal-onset neuroaxonal dystrophy.
Neuroaxonal Dystrophies
Case report of a novel homozygous splice site mutation in PLA2G6 gene causing infantile neuroaxonal dystrophy in a Sudanese family.
Neuroaxonal Dystrophies
Catalytic function of PLA2G6 is impaired by mutations associated with infantile neuroaxonal dystrophy but not dystonia-parkinsonism.
Neuroaxonal Dystrophies
Cerebellar atrophy without cerebellar cortex hyperintensity in infantile neuroaxonal dystrophy (INAD) due to PLA2G6 mutation.
Neuroaxonal Dystrophies
Clinical and genetic delineation of neurodegeneration with brain iron accumulation.
Neuroaxonal Dystrophies
Clinical heterogeneity of PLA2G6-related Parkinsonism: analysis of two Saudi families.
Neuroaxonal Dystrophies
Clinical study and PLA2G6 mutation screening analysis in Chinese patients with infantile neuroaxonal dystrophy.
Neuroaxonal Dystrophies
Compound heterozygous PLA2G6 loss-of-function variants in Swaledale sheep with neuroaxonal dystrophy.
Neuroaxonal Dystrophies
Differential cerebral cortex transcriptomes of baboon neonates consuming moderate and high docosahexaenoic acid formulas.
Neuroaxonal Dystrophies
Disrupted membrane homeostasis and accumulation of ubiquitinated proteins in a mouse model of infantile neuroaxonal dystrophy caused by PLA2G6 mutations.
Neuroaxonal Dystrophies
Disturbed brain phospholipid and docosahexaenoic acid metabolism in calcium-independent phospholipase A(2)-VIA (iPLA(2)?)-knockout mice.
Neuroaxonal Dystrophies
Downbeat nystagmus as the presenting symptom of infantile neuroaxonal dystrophy: A case report.
Neuroaxonal Dystrophies
Establishment of an improved mouse model for infantile neuroaxonal dystrophy that shows early disease onset and bears a point mutation in Pla2g6.
Neuroaxonal Dystrophies
Expression of PLA2G6 in human fetal development: Implications for infantile neuroaxonal dystrophy.
Neuroaxonal Dystrophies
Extensive aggregation of ?-synuclein and tau in juvenile-onset neuroaxonal dystrophy: an autopsied individual with a novel mutation in the PLA2G6 gene-splicing site.
Neuroaxonal Dystrophies
Fetal akinesia deformation sequence and neuroaxonal dystrophy without PLA2G6 mutation.
Neuroaxonal Dystrophies
Four novel rare mutations of PLA2G6 in Chinese population with Parkinson's disease.
Neuroaxonal Dystrophies
Generation of induced pluripotent stem cells from a young-onset Parkinson's disease patient carrying the compound heterozygous PLA2G6 p.D331Y/p.M358IfsX mutations.
Neuroaxonal Dystrophies
Genetic Analysis of PLA2G6 in 22 Indian Families with Infantile Neuroaxonal Dystrophy, Atypical Late-Onset Neuroaxonal Dystrophy and Dystonia Parkinsonism Complex.
Neuroaxonal Dystrophies
Homozygous p.D331Y mutation in PLA2G6 in two patients with pure autosomal-recessive early-onset parkinsonism: Further evidence of a fourth phenotype of PLA2G6-associated neurodegeneration.
Neuroaxonal Dystrophies
Identification of the PLA2G6 c.1579G>A Missense Mutation in Papillon Dog Neuroaxonal Dystrophy Using Whole Exome Sequencing Analysis.
Neuroaxonal Dystrophies
Impaired iPLA2? activity affects iron uptake and storage without iron accumulation: an in vitro study excluding decreased iPLA2? activity as the cause of iron deposition in PLAN.
Neuroaxonal Dystrophies
Infantile and childhood onset PLA2G6-associated neurodegeneration in a large North African cohort.
Neuroaxonal Dystrophies
Infantile neuroaxonal dystrophy and PLA2G6-associated neurodegeneration: An update for the diagnosis.
Neuroaxonal Dystrophies
Infantile neuroaxonal dystrophy caused by PLA2G6 gene mutation in a Chinese patient: A case report.
Neuroaxonal Dystrophies
Infantile neuroaxonal dystrophy: what's most important for the diagnosis?
Neuroaxonal Dystrophies
Inherited neuroaxonal dystrophy in dogs causing lethal, fetal-onset motor system dysfunction and cerebellar hypoplasia.
Neuroaxonal Dystrophies
Initial survey of PLA2G6 missense variant causing neuroaxonal dystrophy in Papillon dogs in North America and Europe.
Neuroaxonal Dystrophies
Insights into Lewy body disease from rare neurometabolic disorders.
Neuroaxonal Dystrophies
iPLA2-VIA is required for healthy aging of neurons, muscle, and the female germline in Drosophila melanogaster.
Neuroaxonal Dystrophies
Iron Accumulation in Syndromes of Neurodegeneration with Brain Iron Accumulation 1 and 2 - causative or consequential?
Neuroaxonal Dystrophies
Loss of Function Variants in Human PNPLA8 Encoding Calcium-Independent Phospholipase A2 ? Recapitulate the Mitochondriopathy of the Homologous Null Mouse.
Neuroaxonal Dystrophies
Loss of PLA2G6 leads to elevated mitochondrial lipid peroxidation and mitochondrial dysfunction.
Neuroaxonal Dystrophies
Mitochondria from a mouse model of the human infantile neuroaxonal dystrophy (INAD) with genetic defects in VIA iPLA2 have disturbed Ca(2+) regulation with reduction in Ca(2+) capacity.
Neuroaxonal Dystrophies
Mitochondrial dysfunction and defects in lipid homeostasis as therapeutic targets in neurodegeneration with brain iron accumulation.
Neuroaxonal Dystrophies
Mutation screening of PLA2G6 in Japanese patients with early onset dystonia-parkinsonism.
Neuroaxonal Dystrophies
Mutations in the Drosophila homolog of human PLA2G6 give rise to age-dependent loss of psychomotor activity and neurodegeneration.
Neuroaxonal Dystrophies
Neuroaxonal dystrophy caused by group VIA phospholipase A2 deficiency in mice: a model of human neurodegenerative disease.
Neuroaxonal Dystrophies
Neuroaxonal Dystrophy in Calcium-Independent Phospholipase A2{beta} Deficiency Results from Insufficient Remodeling and Degeneration of Mitochondrial and Presynaptic Membranes.
Neuroaxonal Dystrophies
Neurodegeneration associated with genetic defects in phospholipase A(2).
Neuroaxonal Dystrophies
Neurons and astrocytes in an infantile neuroaxonal dystrophy (INAD) mouse model show characteristic alterations in glutamate-induced Ca(2+) signaling.
Neuroaxonal Dystrophies
New findings in a global approach to dissect the whole phenotype of PLA2G6 gene mutations.
Neuroaxonal Dystrophies
Novel deep intronic mutation in PLA2G6 causing early-onset Parkinson's disease with brain iron accumulation through pseudo-exon activation.
Neuroaxonal Dystrophies
Novel PLA2G6 mutations associated with an exonic deletion due to non-allelic homologous recombination in a patient with infantile neuroaxonal dystrophy.
Neuroaxonal Dystrophies
Novel splice-site mutations and a large intragenic deletion in PLA2G6 associated with a severe and rapidly progressive form of infantile neuroaxonal dystrophy.
Neuroaxonal Dystrophies
Pantothenate kinase-associated neurodegeneration is not a synucleinopathy.
Neuroaxonal Dystrophies
Phenotypic spectrum of patients with PLA2G6 mutation and PARK14-linked parkinsonism.
Neuroaxonal Dystrophies
Phospholipase PLA2G6, a Parkinsonism-Associated Gene, Affects Vps26 and Vps35, Retromer Function, and Ceramide Levels, Similar to ?-Synuclein Gain.
Neuroaxonal Dystrophies
Pla2g6 mutations associated with a continuous clinical spectrum from neuroaxonal dystrophy to hereditary spastic paraplegia.
Neuroaxonal Dystrophies
PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron.
Neuroaxonal Dystrophies
PLA2G6-associated Dystonia-Parkinsonism: Case Report and Literature Review.
Neuroaxonal Dystrophies
PLA2G6-associated neurodegeneration (PLAN): further expansion of the clinical, radiological and mutation spectrum associated with infantile and atypical childhood-onset disease.
Neuroaxonal Dystrophies
R632W mutation in PLA2G6 segregates with dystonia-parkinsonism in a consanguineous Iranian family.
Neuroaxonal Dystrophies
Reevaluating the pathogenicity of the variations c.439 G>A and c.2132 C>T in the PLA2G6 gene.
Neuroaxonal Dystrophies
Severe disturbance in the Ca2+ signaling in astrocytes from mouse models of human infantile neuroaxonal dystrophy with mutated Pla2g6.
Neuroaxonal Dystrophies
Treatment of infantile neuroaxonal dystrophy with RT001: A di-deuterated ethyl ester of linoleic acid: Report of two cases.
Neuroaxonal Dystrophies
Typical MRI features of PLA2G6 mutation-related phospholipase-associated neurodegeneration (PLAN)/infantile neuroaxonal dystrophy (INAD).
Neuroaxonal Dystrophies
Validation of the finding of hypertrophy of the clava in infantile neuroaxonal dystrophy/PLA2G6 by biometric analysis.
Neuroaxonal Dystrophies
Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations.
Neuroaxonal Dystrophies
[A novel homozygous mutation in PLA2G6 gene causes infantile neuroaxonal dystrophy in a case].
Neuroaxonal Dystrophies
[Clinical features of infantile neuroaxonal dystrophy and PLA2G6 gene testing].
Neuroaxonal Dystrophies
[PLA2G6 compound complicated mutation in an atypical neuroaxonal dystrophy pedigree].
Neuroblastoma
Activation of arachidonic acid-specific phospholipase A2 in human neuroblastoma cells after chronic alcohol exposure: prevention by GM1 ganglioside.
Neuroblastoma
Activation of phospholipases A2 and D of a human neuroblastoma cell line (LA-N-2) by N-dodecyl-L-lysine amide (compound 24), a putative G protein activator: characteristics of inhibition by (-)-nicotine.
Neuroblastoma
Antioxidant peroxiredoxin 6 protein rescues toxicity due to oxidative stress and cellular hypoxia in vitro, and attenuates prion-related pathology in vivo.
Neuroblastoma
Arachidonate release and c-fos expression in various models of hypoxia and hypoxia-hypoglycemia in retinoic acid differentiated neuroblastoma cells.
Neuroblastoma
Astrocytes regulate ?-secretase-cleaved soluble amyloid precursor protein secretion in neuronal cells: Involvement of group IIA secretory phospholipase A2.
Neuroblastoma
Bicuculline induces free fatty acid release from phospholipids in neuro-2A cells in culture.
Neuroblastoma
Clinacanthus nutans Extracts Modulate Epigenetic Link to Cytosolic Phospholipase A2 Expression in SH-SY5Y Cells and Primary Cortical Neurons.
Neuroblastoma
Cytosolic phospholipase A2 and lipoxygenase are involved in cell cycle progression in neuroblastoma cells.
Neuroblastoma
Epigenetic Regulation of Cytosolic Phospholipase A2 in SH-SY5Y Human Neuroblastoma Cells.
Neuroblastoma
Interferon-gamma induces the synthesis and activation of cytosolic phospholipase A2.
Neuroblastoma
Kainate Receptors Mediate Regulated Exocytosis of Secretory Phospholipase A(2) in SH-SY5Y Neuroblastoma Cells.
Neuroblastoma
Lack of phospholipase A2 mutations in neuroblastoma, melanoma and colon-cancer cell lines.
Neuroblastoma
Molecular analysis of the secretory phospholipase A2 gene, a candidate of Mom1 gene, in neuroblastomas.
Neuroblastoma
Nigexine, a phospholipase A2 from cobra venom with cytotoxic properties not related to esterase activity. Purification, amino acid sequence, and biological properties.
Neuroblastoma
Notexin upregulates Fas and FasL protein expression of human neuroblastoma SK-N-SH cells through p38 MAPK/ATF-2 and JNK/c-Jun pathways.
Neuroblastoma
p38 MAPK activation and mitochondrial depolarization mediate the cytotoxicity of Taiwan cobra phospholipase A2 on human neuroblastoma SK-N-SH cells.
Neuroblastoma
Regulation of the cyclooxygenase-2 system by interleukin-1beta through mitogen-activated protein kinase signaling pathways: a comparative study of human neuroglioma and neuroblastoma cells.
Neuroblastoma
Swelling-induced arachidonic acid release via the 85-kDa cPLA2 in human neuroblastoma cells.
Neuroblastoma
Taiwan cobra phospholipase A2 elicits posttranscriptional up-regulation of ADAM17 in human neuroblastoma SK-N-SH cells.
Neuroblastoma
The neuromuscular activity of Bothriopsis bilineata smaragdina (forest viper) venom and its toxin Bbil-TX (Asp49 phospholipase A2) on isolated mouse nerve-muscle preparations.
Neurodegenerative Diseases
25-hydroxycholesterol provokes oligodendrocyte cell line apoptosis and stimulates the secreted phospholipase A2 type IIA via LXR beta and PXR.
Neurodegenerative Diseases
Acceleration of the Development of Alzheimer's Disease in Amyloid Beta-Infused Peroxiredoxin 6 Overexpression Transgenic Mice.
Neurodegenerative Diseases
An in vitro model for synaptic loss in neurodegenerative diseases suggests a neuroprotective role for valproic acid via inhibition of cPLA2 dependent signalling.
Neurodegenerative Diseases
Antioxidant peroxiredoxin 6 protein rescues toxicity due to oxidative stress and cellular hypoxia in vitro, and attenuates prion-related pathology in vivo.
Neurodegenerative Diseases
Arachidonic Acid Induces ARE/Nrf2-Dependent Heme Oxygenase-1 Transcription in Rat Brain Astrocytes.
Neurodegenerative Diseases
Catalytic function of PLA2G6 is impaired by mutations associated with infantile neuroaxonal dystrophy but not dystonia-parkinsonism.
Neurodegenerative Diseases
Clinical heterogeneity of PLA2G6-related Parkinsonism: analysis of two Saudi families.
Neurodegenerative Diseases
Four novel rare mutations of PLA2G6 in Chinese population with Parkinson's disease.
Neurodegenerative Diseases
Genotype-phenotype correlations of adult-onset PLA2G6-associated Neurodegeneration: case series and literature review.
Neurodegenerative Diseases
Gold/Phospholipid nanoconstructs as label-free optical probes for evaluating phospholipase A2 activity.
Neurodegenerative Diseases
Group VI phospholipases A2: homeostatic phospholipases with significant potential as targets for novel therapeutics.
Neurodegenerative Diseases
Homozygous PLA2G6 (PARK 14) gene mutation associated neuropsychiatric phenotypes from southern India.
Neurodegenerative Diseases
Inhibition of cytosolic phospholipase A2 prevents prion peptide-induced neuronal damage and co-localisation with Beta III tubulin.
Neurodegenerative Diseases
Kainate Receptors Mediate Regulated Exocytosis of Secretory Phospholipase A(2) in SH-SY5Y Neuroblastoma Cells.
Neurodegenerative Diseases
Mitochondrial dysfunction and defects in lipid homeostasis as therapeutic targets in neurodegeneration with brain iron accumulation.
Neurodegenerative Diseases
Moving Beyond Syndromic Classifications in Neurodegenerative Disease: The Example of PLA2G6.
Neurodegenerative Diseases
Mutations in the Drosophila homolog of human PLA2G6 give rise to age-dependent loss of psychomotor activity and neurodegeneration.
Neurodegenerative Diseases
Neuroaxonal dystrophy caused by group VIA phospholipase A2 deficiency in mice: a model of human neurodegenerative disease.
Neurodegenerative Diseases
Neuroaxonal Dystrophy in Calcium-Independent Phospholipase A2{beta} Deficiency Results from Insufficient Remodeling and Degeneration of Mitochondrial and Presynaptic Membranes.
Neurodegenerative Diseases
Neuroprotection abilities of cytosolic phospholipase A2 inhibitors in kainic acid-induced neurodegeneration.
Neurodegenerative Diseases
New Insights of Phospholipase A2 Associated Neurodegeneration Phenotype Based on the Long-Term Follow-Up of a Large Hungarian Family.
Neurodegenerative Diseases
Novel deep intronic mutation in PLA2G6 causing early-onset Parkinson's disease with brain iron accumulation through pseudo-exon activation.
Neurodegenerative Diseases
Novel mutations in PANK2 and PLA2G6 genes in patients with neurodegenerative disorders: two case reports.
Neurodegenerative Diseases
Other proteins involved in Parkinson's disease and related disorders.
Neurodegenerative Diseases
Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases.
Neurodegenerative Diseases
Phospholipase PLA2G6, a Parkinsonism-Associated Gene, Affects Vps26 and Vps35, Retromer Function, and Ceramide Levels, Similar to ?-Synuclein Gain.
Neurodegenerative Diseases
Phospholipases A2 and Inflammatory Responses in the Central Nervous System.
Neurodegenerative Diseases
PLA2G4A/cPLA2-mediated lysosomal membrane damage leads to inhibition of autophagy and neurodegeneration after brain trauma.
Neurodegenerative Diseases
PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron.
Neurodegenerative Diseases
PLA2G6-Associated Neurodegeneration (PLAN): Review of Clinical Phenotypes and Genotypes.
Neurodegenerative Diseases
PRDX6 Inhibits Neurogenesis through Downregulation of WDFY1-Mediated TLR4 Signal.
Neurodegenerative Diseases
Proteome response to ochratoxin A-induced apoptotic cell death in mouse hippocampal HT22 cells.
Neurodegenerative Diseases
R632W mutation in PLA2G6 segregates with dystonia-parkinsonism in a consanguineous Iranian family.
Neurodegenerative Diseases
Role of Cytosolic Phospholipase A2 in Oxidative and Inflammatory Signaling Pathways in Different Cell Types in the Central Nervous System.
Neurodegenerative Diseases
Role of PKC and MAPK in cytosolic PLA2 phosphorylation and arachadonic acid release in primary murine astrocytes.
Neurodegenerative Diseases
Saitohin, which is nested in the tau locus and confers allele-specific susceptibility to several neurodegenerative diseases, interacts with peroxiredoxin 6.
Neurodegenerative Diseases
Secreted phospholipase A2 involvement in neurodegeneration: differential testing of prosurvival and anti-inflammatory effects of enzyme inhibition.
Neurodegenerative Diseases
Sphingomyelin Regulates the Activity of Secretory Phospholipase A2 in the Plasma Membrane.
Neurodegenerative Diseases
Validation of the finding of hypertrophy of the clava in infantile neuroaxonal dystrophy/PLA2G6 by biometric analysis.
Neuroinflammatory Diseases
Bee venom phospholipase A2 ameliorates amyloidogenesis and neuroinflammation through inhibition of signal transducer and activator of transcription-3 pathway in Tg2576 mice.
Neuroinflammatory Diseases
Botanical Polyphenols Mitigate Microglial Activation and Microglia-Induced Neurotoxicity: Role of Cytosolic Phospholipase A2.
Neuroinflammatory Diseases
Brain arachidonic acid uptake and turnover: implications for signaling and bipolar disorder.
Neuroinflammatory Diseases
Calcium-dependent cytosolic phospholipase A2 activation is implicated in neuroinflammation and oxidative stress associated with ApoE4.
Neuroinflammatory Diseases
Genetic ablation of PLA2G6 in mice leads to cerebellar atrophy characterized by Purkinje cell loss and glial cell activation.
Neuroinflammatory Diseases
Involvement of oxidative pathways in cytokine-induced secretory phospholipase A2-IIA in astrocytes.
Neuroinflammatory Diseases
Neutralization of Inflammation by Inhibiting In vitro and In vivo Secretory Phospholipase A2 by Ethanol Extract of Boerhaavia diffusa L.
Neuroinflammatory Diseases
Oleanolic acid protects against cognitive decline and neuroinflammation-mediated neurotoxicity by blocking secretory phospholipase A2 IIA-activated calcium signals.
Neuroinflammatory Diseases
PRDX6 controls multiple sclerosis by suppressing inflammation and blood brain barrier disruption.
Neuroinflammatory Diseases
Secreted phospholipase A2-IIA-induced a phenotype of activated microglia in BV-2 cells requires epidermal growth factor receptor transactivation and proHB-EGF shedding.
Neuroinflammatory Diseases
Systematic review of human post-mortem immunohistochemical studies and bioinformatics analyses unveil the complexity of astrocyte reaction in Alzheimer's disease.
Neuroinflammatory Diseases
Tracking neuroinflammation in Alzheimer's disease: the role of positron emission tomography imaging.
Neutropenia
Comparative protection against rat intestinal reperfusion injury by a new inhibitor of sPLA2, COX-1 and COX-2 selective inhibitors, and an LTC4 receptor antagonist.
Nevus
Polymorphisms in nevus-associated genes MTAP, PLA2G6, and IRF4 and the risk of invasive cutaneous melanoma.
Non-alcoholic Fatty Liver Disease
A common variant in the adiponutrin gene influences liver enzyme levels.
Non-alcoholic Fatty Liver Disease
A multi-ethnic study of a PNPLA3 gene variant and its association with disease severity in non-alcoholic fatty liver disease.
Non-alcoholic Fatty Liver Disease
A nonsynonymous gene variant in adiponutrin gene is associated with nonalcoholic fatty liver disease severity.
Non-alcoholic Fatty Liver Disease
A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity.
Non-alcoholic Fatty Liver Disease
Absence of adipose triglyceride lipase protects from hepatic ER stress.
Non-alcoholic Fatty Liver Disease
ASB14780, an Orally Active Inhibitor of Group IVA Phospholipase A2, Is a Pharmacotherapeutic Candidate for Nonalcoholic Fatty Liver Disease.
Non-alcoholic Fatty Liver Disease
Association between PNPLA3 rs738409 G variant and MRI cerebrovascular disease biomarkers.
Non-alcoholic Fatty Liver Disease
Association of glucokinase regulatory gene polymorphisms with risk and severity of non-alcoholic fatty liver disease: an interaction study with adiponutrin gene.
Non-alcoholic Fatty Liver Disease
Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
Non-alcoholic Fatty Liver Disease
Genetic variants in PNPLA3 and risk of non-alcoholic fatty liver disease in a Han Chinese population.
Non-alcoholic Fatty Liver Disease
Hepatic nucleotide binding oligomerization domain-like receptors pyrin domain-containing 3 inflammasomes are associated with the histologic severity of non-alcoholic fatty liver disease.
Non-alcoholic Fatty Liver Disease
Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease.
Non-alcoholic Fatty Liver Disease
Identification and Optimization of a Minor Allele-Specific Small Interfering RNA to Prevent PNPLA3 I148M-Driven Nonalcoholic Fatty Liver Disease.
Non-alcoholic Fatty Liver Disease
iPLA2? deficiency attenuates obesity and hepatic steatosis in ob/ob mice through hepatic fatty-acyl phospholipid remodeling.
Non-alcoholic Fatty Liver Disease
iPla2? deficiency in mice fed with MCD diet does not correct the defect of phospholipid remodeling but attenuates hepatocellular injury via an inhibition of lipid uptake genes.
Non-alcoholic Fatty Liver Disease
Pediatric non-alcoholic fatty liver disease and kidney function: Effect of HSD17B13 variant.
Non-alcoholic Fatty Liver Disease
Peroxiredoxin 6 Confers Protection Against Nonalcoholic Fatty Liver Disease Through Maintaining Mitochondrial Function.
Non-alcoholic Fatty Liver Disease
Physical activity and sedentary behavior can modulate the effect of the PNPLA3 variant on childhood NAFLD: a case-control study in a Chinese population.
Non-alcoholic Fatty Liver Disease
Plasma membrane phospholipase A2 controls hepatocellular fatty acid uptake and is responsive to pharmacological modulation: implications for nonalcoholic steatohepatitis.
Non-alcoholic Fatty Liver Disease
PNPLA3 p.I148M and TM6SF2 p.E167K variants do not predispose to liver injury in cholestatic liver diseases: A prospective analysis of 178 patients with PSC.
Non-alcoholic Fatty Liver Disease
PNPLA3-associated steatohepatitis: toward a gene-based classification of fatty liver disease.
Non-alcoholic Fatty Liver Disease
Reduction of Caloric Intake Might Override the Prosteatotic Effects of the PNPLA3 p.I148M and TM6SF2 p.E167K Variants in Patients with Fatty Liver: Ultrasound-Based Prospective Study.
Non-alcoholic Fatty Liver Disease
Severity of Nonalcoholic Fatty Liver Disease in Type 2 Diabetes Mellitus: Relationship between Nongenetic Factors and PNPLA3/HSD17B13 Polymorphisms.
Non-alcoholic Fatty Liver Disease
The common adiponutrin variant p.I148M does not confer gallstone risk but affects fasting glucose and triglyceride levels.
Non-alcoholic Fatty Liver Disease
The Expression of PNPLA3 Polymorphism could be the Key for Severe Liver Disease in NAFLD in Hispanic Population.
Non-alcoholic Fatty Liver Disease
The ménage à trois of autophagy, lipid droplets and liver disease.
Non-alcoholic Fatty Liver Disease
The Role of Genetic Predisposition, Programing During Fetal Life, Family Conditions, and Post-natal Diet in the Development of Pediatric Fatty Liver Disease.
Non-alcoholic Fatty Liver Disease
Weight loss induced by bariatric surgery restores adipose tissue PNPLA3 expression.
Non-alcoholic Fatty Liver Disease
[Metformin prevents non-alcoholic fatty liver disease in rats: role of phospholipase A2/lysophosphatidylcholine lipoapoptosis pathway in hepatocytes.]
Obesity
A collective diabetes cross in combination with a computational framework to dissect the genetics of human obesity and Type 2 diabetes.
Obesity
A dangerous liaison: Leptin and sPLA2-IIA join forces to induce proliferation and migration of astrocytoma cells.
Obesity
A Representative GIIA Phospholipase A2 Activates Preadipocytes to Produce Inflammatory Mediators Implicated in Obesity Development.
Obesity
A single nucleotide polymorphism (SNP) rs2072907 in the adiponutrin gene (ADPN) was not associated with obesity and type 2 diabetes in Chinese population.
Obesity
Activation of phospholipase A2 is associated with generation of placental lipid signals and fetal obesity.
Obesity
Adiponutrin, a transmembrane protein corresponding to a novel dietary- and obesity-linked mRNA specifically expressed in the adipose lineage.
Obesity
AdPLA ablation increases lipolysis and prevents obesity induced by high-fat feeding or leptin deficiency.
Obesity
Association between polymorphisms in SLC15A1 and PLA2G16 genes and development of obesity in Chinese subjects.
Obesity
Cold exposure down-regulates adiponutrin/PNPLA3 mRNA expression and affects its nutritional regulation in adipose tissues of lean and obese Zucker rats.
Obesity
Comprehensive identification of novel post-translational modifications in cellular peroxiredoxin 6.
Obesity
Correlative studies on the effects of obesity, diabetes and hypertension on gene expression in omental adipose tissue of obese women.
Obesity
Critical role for cytosolic group IVA phospholipase A2 in early adipocyte differentiation and obesity.
Obesity
Diet-induced obesity affects expression of adiponutrin/PNPLA3 and adipose triglyceride lipase, two members of the same family.
Obesity
Dysregulation of endocannabinoid concentrations in human subcutaneous adipose tissue in obesity and modulation by omega-3 polyunsaturated fatty acids.
Obesity
Genetic Evidence for a Role of Adiponutrin in the Metabolism of Apolipoprotein B-Containing Lipoproteins.
Obesity
Group 1B phospholipase A? deficiency protects against diet-induced hyperlipidemia in mice.
Obesity
Group 1B phospholipase A? inactivation suppresses atherosclerosis and metabolic diseases in LDL receptor-deficient mice.
Obesity
Haplotype combinations of AdPLA gene polymorphisms associate with growth traits in Chinese cattle.
Obesity
Isoproterenol, TNFalpha, and insulin downregulate adipose triglyceride lipase in 3T3-L1 adipocytes.
Obesity
Lipopolysaccharide promoted proliferation and adipogenesis of preadipocytes through JAK/STAT and AMPK-regulated cPLA2 expression.
Obesity
Mice Deficient in Group VIB Phospholipase A2 (iPLA2{gamma}) Exhibit Relative Resistance to Obesity and Metabolic Abnormalities Induced by a Western Diet.
Obesity
Pancreatic acinar cell-specific overexpression of group 1B phospholipase A(2) exacerbates diet-induced obesity and insulin resistance in mice.
Obesity
Peroxiredoxin 6 Is a Key Antioxidant Enzyme in Modulating the Link between Glycemic and Lipogenic Metabolism.
Obesity
Polymorphisms in the adiponutrin gene are associated with increased insulin secretion and obesity.
Obesity
Postprandial lysophospholipid suppresses hepatic fatty acid oxidation: the molecular link between group 1B phospholipase A2 and diet-induced obesity.
Obesity
Regulation of the promoter region of the human adiponutrin/PNPLA3 gene by glucose and insulin.
Obesity
Secreted Phospholipase PLA2G2D Contributes to Metabolic Health by Mobilizing ?3 Polyunsaturated Fatty Acids in WAT.
Obesity
Targeting of adipose tissue macrophages by bee venom phospholipase A2 attenuates high-fat diet-induced obesity.
Obesity
The adipocyte-inducible secreted phospholipases PLA2G5 and PLA2G2E play distinct roles in obesity.
Obesity
The phospholipase A(2) inhibitor methyl indoxam suppresses diet-induced obesity and glucose intolerance in mice.
Obesity
The phospholipase A2 family's role in metabolic diseases: Focus on skeletal muscle.
Obesity
The Role of Genetic Predisposition, Programing During Fetal Life, Family Conditions, and Post-natal Diet in the Development of Pediatric Fatty Liver Disease.
Obesity
Therapeutic reduction of lysophospholipids in the digestive tract recapitulates the metabolic benefits of bariatric surgery and promotes diabetes remission.
Obesity
Variation in the adiponutrin gene influences its expression and associates with obesity.
Obesity, Abdominal
Secretory Phospholipase A2 Is Associated with the Odds of Acute Coronary Syndromes through Elevation of Serum Amyloid-A Protein.
Obesity, Metabolically Benign
Dysregulation of endocannabinoid concentrations in human subcutaneous adipose tissue in obesity and modulation by omega-3 polyunsaturated fatty acids.
Obstetric Labor, Premature
Association of cervicovaginal infections with increased vaginal fluid phospholipase A2 activity.
Obstetric Labor, Premature
Elevations of group II phospholipase A2 concentrations in serum and amniotic fluid in association with preterm labor.
Obstetric Labor, Premature
Group I and group II phospholipase A2 in serum during normal and pathological pregnancy.
Obstetric Labor, Premature
Preterm labor and bacterial intra-amniotic infection: arachidonic acid liberation by the action of phospholipase A2.
Obstetric Labor, Premature
Preterm labor and bacterial intraamniotic infection: arachidonic acid liberation by phospholipase A2 of Fusobacterium nucleatum.
Obstetric Labor, Premature
Pulmonary phospholipid saturation increases with glucocorticoid receptor mRNAs in late gestation but not due to labor in the fetal rhesus monkey.
Obstetric Labor, Premature
The expression of cytosolic phospholipase A2 and prostaglandin endoperoxide synthase in ovine maternal uterine and fetal tissues during late gestation and labor.
Oligodendroglioma
Identification of novel oligodendroglioma-associated candidate tumor suppressor genes in 1p36 and 19q13 using microarray-based expression profiling.
Oligodendroglioma
Investigation of molecular factors associated with malignant transformation of oligodendroglioma by proteomic study of a single case of rapid tumor progression.
Opisthorchiasis
Proteomic identification of peroxiredoxin 6 for host defence against Opisthorchis viverrini infection.
Osteitis Deformans
Secreted phospholipase A2 type II is present in Paget's disease of bone and modulates osteoclastogenesis, apoptosis and bone resorption of human osteoclasts independently of its catalytic activity in vitro.
Osteoarthritis
Increased expression of human type IIa secretory phospholipase A2 antigen in arthritic synovium.
Osteoarthritis
Metalloprotease activity, phospholipase A2 activity and cytokine concentration in osteoarthritis synovial fluids.
Osteoarthritis
Multiple phospholipase A2 enzymes participate in the inflammatory process in osteoarthritic cartilage.
Osteoarthritis
Phospholipase A2 activity in sera and synovial fluids in rheumatoid arthritis and osteoarthritis. Its possible role as a proinflammatory enzyme.
Osteoarthritis
Phospholipase A2 inhibitor-loaded micellar nanoparticles attenuate inflammation and mitigate osteoarthritis progression.
Osteoarthritis
Presence of secretory group IIa and V phospholipase A2 and cytosolic group IValpha phospholipase A2 in chondrocytes from patients with rheumatoid arthritis.
Osteoarthritis
Release of mast cell mediators and nitrites into knee joint fluid in osteoarthritis--comparison with articular chondrocalcinosis and rheumatoid arthritis.
Osteoarthritis
Suppressive effect of secretory phospholipase A2 inhibitory peptide on interleukin-1beta-induced matrix metalloproteinase production in rheumatoid synovial fibroblasts, and its antiarthritic activity in hTNFtg mice.
Osteoarthritis
The contribution of synovial fluid lipoproteins to the chronic synovitis of rheumatoid arthritis.
Osteoarthritis
[Cytokines, prostaglandin E2, phospholipase A and metalloproteases in synovial fluid in osteoarthritis]
Osteosarcoma
Acetone immersion enhanced MALDI-MS imaging of small molecule metabolites in biological tissues.
Osteosarcoma
Stimulation of matrix vesicle enzyme activity in osteoblast-like cells by 1,25(OH)2D3 and transforming growth factor beta (TGF beta).
Osteosarcoma
[The cytotoxic mechanism of tumor necrosis factor (TNF) in human osteosarcoma cell line TE85--(1). Implication of phospholipase A2 activity in cytotoxicity]
Otitis
Tissue Damage Signaling Is a Prerequisite for Protective Neutrophil Recruitment to Microbial Infection in Zebrafish.
Ovarian Neoplasms
Acquired cisplatin resistance in human ovarian A2780 cancer cells correlates with shift in taurine homeostasis and ability to volume regulate.
Ovarian Neoplasms
Caspase-3-dependent Activation of Calcium-independent Phospholipase A2 Enhances Cell Migration in Non-apoptotic Ovarian Cancer Cells.
Ovarian Neoplasms
Combination therapy of an inhibitor of group VIA phospholipase A2 with paclitaxel is highly effective in blocking ovarian cancer development.
Ovarian Neoplasms
Constitutive and lysophosphatidic acid (LPA)-induced LPA production: role of phospholipase D and phospholipase A2.
Ovarian Neoplasms
Cytosolic phospholipase A2 as a molecular target for the radiosensitization of ovarian cancer.
Ovarian Neoplasms
Epidermal growth factor induces platelet-activating factor production through receptors transactivation and cytosolic phospholipase A2 in ovarian cancer cells.
Ovarian Neoplasms
Group III phospholipase A2 downregulation attenuated survival and metastasis in ovarian cancer and promotes chemo-sensitization.
Ovarian Neoplasms
Group VIA phospholipase A2 in both host and tumor cells is involved in ovarian cancer development.
Ovarian Neoplasms
Inhibition of calcium-independent phospholipase A2 suppresses proliferation and tumorigenicity of ovarian carcinoma cells.
Ovarian Neoplasms
Peroxiredoxin 6 overexpression attenuates cisplatin-induced apoptosis in human ovarian cancer cells.
Ovarian Neoplasms
Phorbol 12-myristate 13-acetate stimulates lysophosphatidic acid secretion from ovarian and cervical cancer cells but not from breast or leukemia cells.
Pancreatic Cyst
Cyclooxygenase-2 and Cytosolic Phospholipase A2 Are Overexpressed in Mucinous Pancreatic Cysts.
Pancreatic Diseases
Clinical usefulness of serum phospholipase A2 determination in patients with pancreatic diseases.
Pancreatic Diseases
Serum levels of six pancreatic enzymes as related to the degree of renal dysfunction.
Pancreatic Diseases
Simultaneous determinations of pancreatic phospholipase A2 and prophospholipase A2 in various pancreatic diseases.
Pancreatic Diseases
The diagnostic value of serum pancreatic phospholipase A2 (PLA2) in pancreatic diseases.
Pancreatic Diseases
[Usefulness of serum pancreatic phospholipase A2 determination in patients with various pancreatic diseases]
Pancreatic Neoplasms
Activation of MAP kinase cascade induced by human pancreatic phospholipase A2 in a human pancreatic cancer cell line.
Pancreatic Neoplasms
Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts.
Pancreatic Neoplasms
Crotoxin from Crotalus durissus terrificus venom: In vitro cytotoxic activity of a heterodimeric phospholipase A2 on human cancer-derived cell lines.
Pancreatic Neoplasms
Expression analysis of the prostaglandin E2 production pathway in human pancreatic cancers.
Pancreatic Neoplasms
Flavonoids Identified from Korean Scutellaria baicalensis Induce Apoptosis by ROS Generation and Caspase Activation on Human Fibrosarcoma Cells.
Pancreatic Neoplasms
Human pancreatic phospholipase A2 stimulates the growth of human pancreatic cancer cell line.
Pancreatic Neoplasms
Immunoreactive phospholipase A2 in serum in acute pancreatitis and pancreatic cancer.
Pancreatic Neoplasms
Suppression of N-nitrosobis(2-oxopropyl)amine-induced pancreatic carcinogenesis in hamsters by pioglitazone, a ligand of peroxisome proliferator-activated receptor gamma.
Pancreatic Pseudocyst
Characterization of phospholipase A2 activity in aspirates of human pancreatic pseudocysts after isolation by reversed-phase high performance liquid chromatography.
Pancreaticobiliary Maljunction
Nutritional factors (nutritional aspects) in biliary disorders: bile acid and lipid metabolism in gallstone diseases and pancreaticobiliary maljunction.
Pancreaticobiliary Maljunction
Partial characterization of proapoptotic action of biliary deteriorated lipids on biliary epithelial cells in pancreaticobiliary diseases.
Pancreatitis
A randomized double-blind study using CaNa2EDTA, a phospholipase A2 inhibitor, in the management of human acute pancreatitis.
Pancreatitis
Abdominal hyperalgesia in secretory phospholipase A(2)-induced rat pancreatitis: Distinct roles of NK(1) receptors.
Pancreatitis
Acute lung injury in experimental pancreatitis in rats: pulmonary protective effects of crotapotin and N-acetylcysteine.
Pancreatitis
Acute lung injury induced by phospholipase A2. Structural and functional changes.
Pancreatitis
Acute pancreatitis in transgenic mice expressing human group IIA phospholipase A2.
Pancreatitis
Application of a new monoclonal antibody for time-resolved fluoroimmunoassay of human pancreatic phospholipase A2.
Pancreatitis
Bactericidal/permeability-increasing protein and group I and II phospholipase A2 during the induction phase of human acute pancreatitis.
Pancreatitis
Behavior of plasma phospholipase A2 activity in experimental acute pancreatitis according to diet.
Pancreatitis
Beneficial effect of iloprost on the course of acute taurocholate pancreatitis in rats and its limitation by antecedent acute ethanol intake.
Pancreatitis
C-reactive protein (CRP) and serum phospholipase A2 in the assessment of the severity of acute pancreatitis.
Pancreatitis
Catalytic activity of phospholipase A2 in blood plasma and pancreatic tissue perfusion in early experimental acute pancreatitis.
Pancreatitis
Changes of gastric and intestinal blood flow, serum phospholipase A2 and interleukin-1beta in rats with acute necrotizing pancreatitis.
Pancreatitis
Changes of Inflammation and Apoptosis in Adrenal Gland After Experimental Injury in Rats with Acute Necrotizing Pancreatitis.
Pancreatitis
Characterization of two phospholipases A2 in serum of patients with sepsis and acute pancreatitis.
Pancreatitis
Crucial role of group IIA phospholipase A2 in pancreatitis-associated adrenal injury in acute necrotizing pancreatitis.
Pancreatitis
Dexamethasone Affects Inflammation but Not Trypsinogen Activation in Experimental Acute Pancreatitis.
Pancreatitis
Diagnostic and prognostic utility of phospholipase A activity in patients with acute pancreatitis: comparison with amylase and lipase.
Pancreatitis
Differentiation of human phospholipase A2 isoenzymes in serum and other body fluids with use of monoclonal antibodies.
Pancreatitis
Duodenal secretion of phospholipase A2, amylase, and bicarbonate in chronic pancreatitis.
Pancreatitis
Early assessment of acute pancreatitis. A comparative study of computed tomography and laboratory tests.
Pancreatitis
Early bacterial infection of the pancreas and course of disease in cerulein-induced acute pancreatitis in rats.
Pancreatitis
Effect of a new inhibitor of type II phospholipase A2 on experimental acute pancreatitis in rats.
Pancreatitis
Effect of a selective inhibitor of secretory phospholipase A2, S-5920/LY315920Na, on experimental acute pancreatitis in rats.
Pancreatitis
Effect of IS-741 (a new synthetic antiinflammatory agent) on acute necrotizing pancreatitis in dogs. Significance of its inhibitory effect on cytosolic phospholipase A2.
Pancreatitis
Effect of procainhydrochloride on phospholipase A2 catalytic activity in sodium taurocholate-induced acute experimental pancreatitis in rats.
Pancreatitis
Effects of gabexate mesilate (FOY) on amylase and phospholipase A2 in human serum and pancreatic juice.
Pancreatitis
Effects of Snake-Derived Phospholipase A2 Inhibitors on Acute Pancreatitis: In vitro and in vivo Characterization.
Pancreatitis
Effects of the serine protease inhibitor gabexate mesilate on purified pancreatic phospholipase A2.
Pancreatitis
Effects of urinary trypsin inhibitor on pancreatic enzymes and experimental acute pancreatitis.
Pancreatitis
Evaluation of phospholipase A2 measurement for early prediction of the severity of acute pancreatitis.
Pancreatitis
Experimental pancreatitis in the rat. Changes in pulmonary phospholipids during sodium taurocholate-induced acute pancreatitis.
Pancreatitis
Experimental pancreatitis in the rat. Light and electron microscopical observations on early pancreatic lesions induced by intraductal injection of trypsin, phospholipase A2, lysolecithin and non-ionic detergent.
Pancreatitis
Experimental study of a novel phospholipase A2 inhibitor in acute pancreatitis.
Pancreatitis
Gabexate mesilate and camostate: new inhibitors of phospholipase A2 and their influence on the alpha-amylase activity in serum of patients with acute pancreatitis.
Pancreatitis
Hydrolytic activities of human pancreatic phospholipase A2 and endotoxin-stimulated endogenous phospholipase A2 toward membrane phospholipids of erythrocytes.
Pancreatitis
Immunoreactive pancreatic phospholipase A2 and catalytically active phospholipases A2 in serum from patients with acute pancreatitis.
Pancreatitis
Immunoreactive phospholipase A2 in serum in acute pancreatitis and pancreatic cancer.
Pancreatitis
Improved method for the determination of phospholipase A2 catalytic activity concentration in human serum and ascites.
Pancreatitis
In vivo effect of pancreatic phospholipase A2 on the arachidonic acid cascade.
Pancreatitis
Increased activity of group II phospholipase A2 in plasma in rat sodium deoxycholate induced acute pancreatitis.
Pancreatitis
Increased concentrations of synovial-type phospholipase A2 in serum and pulmonary and renal complications in acute pancreatitis.
Pancreatitis
Inhibition of enzymatic activity of phospholipases A2 by minocycline and doxycycline.
Pancreatitis
Inhibition of inducible nitric oxide synthase-derived nitric oxide as a therapeutical target for acute pancreatitis induced by secretory phospholipase A2.
Pancreatitis
Involvement of oxygen radicals and phospholipase A2 in acute pancreatitis of the rat.
Pancreatitis
Kinetics of group IB and IIA phospholipase A2 during low-volume continuous hemodiafiltration in severe acute pancreatitis.
Pancreatitis
Long-term ethanol ingestion causes an increase of phospholipase A2 activity in acute experimental pancreatitis in rats.
Pancreatitis
Lysophosphatidylcholine activates transcription factor NF-kappaB and AP-1 in AR42J cells.
Pancreatitis
Natural disruption of group 2 phospholipase A2 gene protects against choline-deficient ethionine-supplemented diet-induced acute pancreatitis and lung injury.
Pancreatitis
Oxidative stress as an early prognostic factor in acute pancreatitis (AP): its correlation with serum phospholipase A2 (PLA2) and plasma polymorphonuclear elastase (PMN-E) in different-severity forms of human AP.
Pancreatitis
Pancreatic and synovial type phospholipases A2 in serum samples from patients with severe acute pancreatitis.
Pancreatitis
Pancreatic phospholipase A2 activity in acute pancreatitis: a prognostic marker for early identification of patients at risk.
Pancreatitis
Pancreatic phospholipase A2 in proximal tubules of rat kidney in experimental acute pancreatitis and after intravenous injection of the enzyme.
Pancreatitis
Pancreaticobiliary maljunction-associated pancreatitis: an experimental study on the activation of pancreatic phospholipase A2.
Pancreatitis
Pathophysiological role of secretory type I and II phospholipase A2 in acute pancreatitis: an experimental study in rats.
Pancreatitis
Phospholipase A2 activity and concentration in several body fluids in patients with acute pancreatitis.
Pancreatitis
Phospholipase A2 activity in body fluids and pancreatic tissue in patients with acute necrotising pancreatitis.
Pancreatitis
Phospholipase A2 activity in taurocholate-induced acute pancreatitis in the rat model.
Pancreatitis
Phospholipase A2 as a point of care alternative to serum amylase and pancreatic lipase.
Pancreatitis
Phospholipase A2 in acute pancreatitis: new biochemical and pathological aspects.
Pancreatitis
Phospholipase A2 in chamber angle of normal eyes and patients with primary open angle glaucoma and exfoliation glaucoma.
Pancreatitis
Phospholipase A2 in serum and ascitic exudate in experimental acute haemorrhagic pancreatitis in pigs.
Pancreatitis
Phospholipase A2 inhibitors and their possible clinical use in the treatment of acute pancreatitis.
Pancreatitis
Phospholipase A2 is associated with albumin in patients with acute pancreatitis.
Pancreatitis
Phospholipase A2 mediates nitric oxide production by alveolar macrophages and acute lung injury in pancreatitis.
Pancreatitis
Purification and characterization of human pancreatic phospholipase A2 and development of a radioimmunoassay.
Pancreatitis
Rectal indomethacin versus placebo to reduce the incidence of pancreatitis after endoscopic retrograde cholangiopancreatography: results of a controlled clinical trial.
Pancreatitis
Renal tubular cell injury and serum phospholipase A2 activity in acute pancreatitis.
Pancreatitis
Role of pancreatic enzymes and their substrates in autodigestion of the pancreas. In vitro studies with isolated rat pancreatic acini.
Pancreatitis
Role of phospholipase A2 in pancreatic acinar cell damage and possibilities of inhibition: studies with isolated rat pancreatic acini.
Pancreatitis
Role of platelet-activating factor in pancreatitis-associated acute lung injury in the rat.
Pancreatitis
Role of substance P and bradykinin in acute pancreatitis induced by secretory phospholipase A2.
Pancreatitis
Secretory phospholipase A2 in patients with infected pancreatic necroses in acute pancreatitis.
Pancreatitis
Serum pancreatic phospholipase A2 and prophospholipase A2 in acute pancreatitis and after endoscopic retrograde pancreatography.
Pancreatitis
Serum phospholipase A2 activity in acute pancreatitis: an early guide to severity.
Pancreatitis
Serum phospholipase A2 in intensive care patients with peritonitis, multiple injury, and necrotizing pancreatitis.
Pancreatitis
Serum phospholipase A2, amylase, lipase, and urinary amylase activities in relation to the severity of acute pancreatitis.
Pancreatitis
Serum phospholipase A2, immunoreactive trypsin, and trypsin inhibitors during human acute pancreatitis.
Pancreatitis
Severe acute pancreatitis is related to increased early urinary levels of the activation Peptide of pancreatic phospholipase A(2).
Pancreatitis
The effects of a thromboxane A2 synthesis inhibitor and a prostaglandin I2 analogue on experimental acute necrotizing pancreatitis in rats.
Pancreatitis
The role of ascites and phospholipase A2 on peritoneal permeability changes in acute experimental pancreatitis.
Pancreatitis
The role of phospholipase A2 in the pathogenesis of respiratory damage in hemorrhagic necrotizing pancreatitis--assessment of a new experimental model.
Pancreatitis
Toward routine use of nonsteroidal anti-inflammatory drugs for patients undergoing endoscopic retrograde cholangiopancreatography.
Pancreatitis
Toxic effects of human pancreatic and snake and bee venom phospholipases A2 on MCF-7 cells in culture.
Pancreatitis
Usefulness of determination of serum immunoreactive pancreatic phospholipase A2 content for early identification of severe acute pancreatitis.
Pancreatitis
What is the best biochemical test to diagnose acute pancreatitis? A prospective clinical study.
Pancreatitis
Zerumbone attenuates the severity of acute necrotizing pancreatitis and pancreatitis-induced hepatic injury.
Pancreatitis
[Biochemical diagnostics in acute pancreatitis recognition and outcome predicition]
Pancreatitis
[Effect of phospholipase A2 on pancreatic parenchymal necrosis in acute pancreatitis in rats]
Pancreatitis
[Experimental studies on pathophysiology of acute pancreatitis, with special reference to pancreatic phospholipase A2 and the effect of CDP-choline]
Pancreatitis
[In vitro examination of the influence of lipase and amylase on dog's pancreas tissue incubated with endotoxins, phospholipase A2 or cytokines]
Pancreatitis
[Influences of BN50739 on neutrophil elastase and phospholipase A2 in lung and tracheal mucosa of pigs with acute severe pancreatitis]
Pancreatitis
[Phospholipase A2 inhibitors in hemorrhagic-necrotizing pancreatitis. Animal experiment evaluation of a new treatment concept]
Pancreatitis
[Role of phospholipase A2 in injury of lung complicated by acute pancreatitis and the therapeutic effect and mechanism of verapamil on it]
Pancreatitis
[Serum and ascitic phospholipase A2 activities and their heat stabilities in taurocholate induced rat acute pancreatitis]
Pancreatitis
[Study of phospholipase A2 in serum, ascitic exudate and pancreatic tissue in acute pancreatitis in rats]
Pancreatitis
[Therapy of acute pancreatitis with a synthetic protease and phospholipase A2 inhibitor gabexate mesilate]
Pancreatitis, Acute Hemorrhagic
Phospholipase A2 in sodium taurocholate-induced experimental hemorrhagic pancreatitis in the rat.
Pancreatitis, Acute Hemorrhagic
The effect of gabexate mesilate on the outcome of acute hemorrhagic pancreatitis in pigs.
Pancreatitis, Acute Necrotizing
Acute lung injury in experimental pancreatitis in rats: pulmonary protective effects of crotapotin and N-acetylcysteine.
Pancreatitis, Acute Necrotizing
Changes of gastric and intestinal blood flow, serum phospholipase A2 and interleukin-1beta in rats with acute necrotizing pancreatitis.
Pancreatitis, Acute Necrotizing
Crucial role of group IIA phospholipase A2 in pancreatitis-associated adrenal injury in acute necrotizing pancreatitis.
Pancreatitis, Acute Necrotizing
Effect of IS-741 (a new synthetic antiinflammatory agent) on acute necrotizing pancreatitis in dogs. Significance of its inhibitory effect on cytosolic phospholipase A2.
Pancreatitis, Acute Necrotizing
Human pancreatic phospholipase A2 in acute necrotizing pancreatitis.
Pancreatitis, Acute Necrotizing
Pathomorphological study of the pancreas during phospholipase A2-induced experimental pancreatic necrosis.
Pancreatitis, Acute Necrotizing
Phospholipase A2 in acute pancreatitis: new biochemical and pathological aspects.
Pancreatitis, Acute Necrotizing
Role of pancreatic enzymes and their substrates in autodigestion of the pancreas. In vitro studies with isolated rat pancreatic acini.
Pancreatitis, Acute Necrotizing
Secretory phospholipase A2 in patients with infected pancreatic necroses in acute pancreatitis.
Pancreatitis, Acute Necrotizing
The effects of a thromboxane A2 synthesis inhibitor and a prostaglandin I2 analogue on experimental acute necrotizing pancreatitis in rats.
Pancreatitis, Acute Necrotizing
[Preventive therapy with mexidol in toxic damage to the heart].
Pancreatitis, Alcoholic
Immunoreactive phospholipase A2 in serum in acute pancreatitis and pancreatic cancer.
Pancreatitis, Chronic
Duodenal secretion of phospholipase A2, amylase, and bicarbonate in chronic pancreatitis.
Pancreatitis, Chronic
Immunocytochemical evidence of phospholipase A2 in pancreatic tumors--diagnostic values.
Pancreatitis, Chronic
Immunohistochemical localization of group II phospholipase A2 in human pancreatic carcinomas.
Pancreatitis, Chronic
Immunohistochemical localization of phospholipase A2 in human pancreas in acute and chronic pancreatitis.
Pancreatitis, Chronic
[A new pathophysiologic concept in chronic pancreatitis: tissue destruction induced via inflammatory mediators]
Pancreatitis, Chronic
[The role of phospholipase A2 in pathogenesis of acute and chronic pancreatitis, its significance in diagnosis of the disease]
Pantothenate Kinase-Associated Neurodegeneration
Childhood disorders of neurodegeneration with brain iron accumulation (NBIA).
Pantothenate Kinase-Associated Neurodegeneration
Disorders of phospholipids, sphingolipids and fatty acids biosynthesis: toward a new category of inherited metabolic diseases.
Pantothenate Kinase-Associated Neurodegeneration
Emerging Disease-Modifying Therapies in Neurodegeneration With Brain Iron Accumulation (NBIA) Disorders.
Pantothenate Kinase-Associated Neurodegeneration
Extensive aggregation of ?-synuclein and tau in juvenile-onset neuroaxonal dystrophy: an autopsied individual with a novel mutation in the PLA2G6 gene-splicing site.
Pantothenate Kinase-Associated Neurodegeneration
Iron Accumulation in Syndromes of Neurodegeneration with Brain Iron Accumulation 1 and 2 - causative or consequential?
Pantothenate Kinase-Associated Neurodegeneration
Neurodegeneration with brain iron accumulation.
Papilledema
Epac2-deficiency leads to more severe retinal swelling, glial reactivity and oxidative stress in transient middle cerebral artery occlusion induced ischemic retinopathy.
Papilloma
Elevated prostaglandin E2 level via cPLA2--COX-2--mPGES-1 pathway involved in bladder carcinogenesis induced by terephthalic acid-calculi in Wistar rats.
Papilloma
Type II phospholipase A2 recombinant overexpression enhances stimulated arachidonic acid release.
Paralysis
Ammonium chloride and methylamine hydrochloride antagonize clostridial neurotoxins.
Paralysis
An agonist of the CXCR4 receptor accelerates the recovery from the peripheral neuroparalysis induced by Taipan snake envenomation.
Paralysis
Facial diplegia, pharyngeal paralysis, and ophthalmoplegia after a timber rattlesnake envenomation.
Paralysis
Heparin at low concentration acts as antivenom against Bothrops jararacussu venom and bothropstoxin-I neurotoxic and myotoxic actions.
Paralysis
Influence of temperature upon paralyzing and myotoxic effects of bothropstoxin-I on mouse neuromuscular preparations.
Paralysis
Inhibition of vacuolar adenosine triphosphatase antagonizes the effects of clostridial neurotoxins but not phospholipase A2 neurotoxins.
Paralysis
Neuromuscular paralysis by the basic phospholipase A2 subunit of crotoxin from Crotalus durissus terrificus snake venom needs its acid chaperone to concurrently inhibit acetylcholine release and produce muscle blockage.
Paralysis
Progress in understanding the pathophysiology of cerebral ischemia: the almitrine-raubasine approach.
Paralysis
Quantification of crotamine, a small basic myotoxin, in South American rattlesnake (Crotalus durissus terrificus) venom by enzyme-linked immunosorbent assay with parallel-lines analysis.
Paralysis
Reversible skeletal neuromuscular paralysis induced by different lysophospholipids.
Paralysis
Study of crotoxin on the induction of paralysis in extraocular muscle in animal model.
Paralysis
Understanding Biological Roles of Venoms Among the Caenophidia: The Importance of Rear-Fanged Snakes.
Paraplegia
PLA2G6-associated neurodegeneration presenting as a complicated form of hereditary spastic paraplegia.
Parkinson Disease
A Han Chinese Family With Early-Onset Parkinson's Disease Carrying Novel Frameshift Mutation and Compound Heterozygous Mutation of PRKN Appearing Incompatible With MDS Clinical Diagnostic Criteria.
Parkinson Disease
Association between PLA2G6 gene polymorphisms and Parkinson's disease in the Chinese Han population.
Parkinson Disease
Association of rare heterozygous PLA2G6 variants with the risk of Parkinson's disease.
Parkinson Disease
Bee venom phospholipase A2 ameliorates motor dysfunction and modulates microglia activation in Parkinson's disease alpha-synuclein transgenic mice.
Parkinson Disease
Bee Venom Phospholipase A2, a Novel Foxp3+ Regulatory T Cell Inducer, Protects Dopaminergic Neurons by Modulating Neuroinflammatory Responses in a Mouse Model of Parkinson's Disease.
Parkinson Disease
Comparison of Administration Routes on the Protective Effects of Bee Venom Phospholipase A2 in a Mouse Model of Parkinson's Disease.
Parkinson Disease
Comparison of the Protective Effects of Bee Venom Extracts with Varying PLA2 Compositions in a Mouse Model of Parkinson's Disease.
Parkinson Disease
Dose-Dependent Neuroprotective Effect of Standardized Bee Venom Phospholipase A2 Against MPTP-Induced Parkinson's Disease in Mice.
Parkinson Disease
Early-Onset Parkinson's Disease Caused by PLA2G6 Compound Heterozygous Mutation, a Case Report and Literature Review.
Parkinson Disease
Elevated activity of phospholipid biosynthetic enzymes in substantia nigra of patients with Parkinson's disease.
Parkinson Disease
Four novel rare mutations of PLA2G6 in Chinese population with Parkinson's disease.
Parkinson Disease
Generation of induced pluripotent stem cells from a young-onset Parkinson's disease patient carrying the compound heterozygous PLA2G6 p.D331Y/p.M358IfsX mutations.
Parkinson Disease
Genes Implicated in Familial Parkinson's Disease Provide a Dual Picture of Nigral Dopaminergic Neurodegeneration with Mitochondria Taking Center Stage.
Parkinson Disease
Genetic analysis of ATP13A2, PLA2G6 and FBXO7 in a cohort of Chinese patients with early-onset Parkinson's disease.
Parkinson Disease
Heterozygous PLA2G6 Mutation Leads to Iron Accumulation Within Basal Ganglia and Parkinson's Disease.
Parkinson Disease
iPLA2? knockout mouse, a genetic model for progressive human motor disorders, develops age-related neuropathology.
Parkinson Disease
Lack of Association Between PLA2G6 Genetic Variation and Parkinson's Disease: A Systematic Review.
Parkinson Disease
Lipoprotein-Associated Phospholipase A2 Is a Risk Factor for Patients With Parkinson's Disease.
Parkinson Disease
Mice deficient in group IV cytosolic phospholipase A2 are resistant to MPTP neurotoxicity.
Parkinson Disease
Novel deep intronic mutation in PLA2G6 causing early-onset Parkinson's disease with brain iron accumulation through pseudo-exon activation.
Parkinson Disease
Novel therapeutic approaches for Parkinson's disease by targeting brain cholesterol homeostasis.
Parkinson Disease
PARK14 (D331Y) PLA2G6 Causes Early-Onset Degeneration of Substantia Nigra Dopaminergic Neurons by Inducing Mitochondrial Dysfunction, ER Stress, Mitophagy Impairment and Transcriptional Dysregulation in a Knockin Mouse Model.
Parkinson Disease
Phenotypic spectrum of patients with PLA2G6 mutation and PARK14-linked parkinsonism.
Parkinson Disease
Phospholipase iPLA2? averts ferroptosis by eliminating a redox lipid death signal.
Parkinson Disease
PLA2G6 accumulates in Lewy bodies in PARK14 and idiopathic Parkinson's disease.
Parkinson Disease
Pla2g6 Deficiency in Zebrafish Leads to Dopaminergic Cell Death, Axonal Degeneration, Increased ?-Synuclein Expression, and Defects in Brain Functions and Pathways.
Parkinson Disease
PLA2G6 mutations in PARK14-linked young-onset parkinsonism and sporadic Parkinson's disease.
Parkinson Disease
PLA2G6 variants associated with the number of affected alleles in Parkinson's disease in Japan.
Parkinson Disease
Pluripotent Stem Cell Derived Neurons as In Vitro Models for Studying Autosomal Recessive Parkinson's Disease (ARPD): PLA2G6 and Other Gene Loci.
Parkinson Disease
PRDX6 Exacerbates Dopaminergic Neurodegeneration in a MPTP Mouse Model of Parkinson's Disease.
Parkinson Disease
Reprogramming of a human induced pluripotent stem cell (iPSC) line (IBMSi012-A) from an early-onset Parkinson's disease patient harboring a homozygous p.D331Y mutation in the PLA2G6 gene.
Parkinson Disease
Role of cytosolic calcium-dependent phospholipase A2 in Alzheimer's disease pathogenesis.
Parkinson Disease
Structural and Aggregation Properties of Alpha-Synuclein Linked to Phospholipase A2 Action.
Parkinson Disease
Synthetic and natural inhibitors of phospholipases A2: their importance for understanding and treatment of neurological disorders.
Parkinson Disease
The role of genetics in Parkinson's disease: a large cohort study in Chinese mainland population.
Parkinsonian Disorders
A clinical and genetic study of early-onset and familial parkinsonism in taiwan: An integrated approach combining gene dosage analysis and next-generation sequencing.
Parkinsonian Disorders
Analysis of PLA2G6 gene mutation in sporadic early-onset parkinsonism patients from Chinese population.
Parkinsonian Disorders
Aripiprazole in a Patient of PLA2G6-Associated Neurodegeneration With Psychosis.
Parkinsonian Disorders
Clinical heterogeneity of PLA2G6-related Parkinsonism: analysis of two Saudi families.
Parkinsonian Disorders
Early Ataxia and Subsequent Parkinsonism: PLA2G6 Mutations Cause a Continuum Rather Than Three Discrete Phenotypes.
Parkinsonian Disorders
Early-onset L-dopa-responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations.
Parkinsonian Disorders
Early-Onset Parkinson's Disease Caused by PLA2G6 Compound Heterozygous Mutation, a Case Report and Literature Review.
Parkinsonian Disorders
Genetic Analysis of PLA2G6 in 22 Indian Families with Infantile Neuroaxonal Dystrophy, Atypical Late-Onset Neuroaxonal Dystrophy and Dystonia Parkinsonism Complex.
Parkinsonian Disorders
Homozygous p.D331Y mutation in PLA2G6 in two patients with pure autosomal-recessive early-onset parkinsonism: Further evidence of a fourth phenotype of PLA2G6-associated neurodegeneration.
Parkinsonian Disorders
Imaging striatal dopaminergic function in phospholipase A2 group VI-related parkinsonism.
Parkinsonian Disorders
Loss of PLA2G6 leads to elevated mitochondrial lipid peroxidation and mitochondrial dysfunction.
Parkinsonian Disorders
Mitochondrial dysfunction and defects in lipid homeostasis as therapeutic targets in neurodegeneration with brain iron accumulation.
Parkinsonian Disorders
Monogenic Parkinson's disease and parkinsonism: Clinical phenotypes and frequencies of known mutations.
Parkinsonian Disorders
MPP+ induced SH-SY5Y apoptosis is potentiated by cyclosporin A and inhibited by aristolochic acid.
Parkinsonian Disorders
Mutation screening of PLA2G6 in Japanese patients with early onset dystonia-parkinsonism.
Parkinsonian Disorders
Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature.
Parkinsonian Disorders
New endemic familial parkinsonism in south Moravia, Czech Republic and its genetical background.
Parkinsonian Disorders
Phenotypic spectrum of patients with PLA2G6 mutation and PARK14-linked parkinsonism.
Parkinsonian Disorders
Phospholipase PLA2G6, a Parkinsonism-Associated Gene, Affects Vps26 and Vps35, Retromer Function, and Ceramide Levels, Similar to ?-Synuclein Gain.
Parkinsonian Disorders
PLA2G6 gene mutation in autosomal recessive early-onset parkinsonism in a Chinese cohort.
Parkinsonian Disorders
PLA2G6 mutations and Parkinsonism: Long-term follow-up of clinical features and neuropathology.
Parkinsonian Disorders
PLA2G6 mutations in PARK14-linked young-onset parkinsonism and sporadic Parkinson's disease.
Parkinsonian Disorders
PLA2G6 Mutations Related to Distinct Phenotypes: A New Case with Early-onset Parkinsonism.
Parkinsonian Disorders
Progressive Axonal Degeneration of Nigrostriatal Dopaminergic Neurons in Calcium-Independent Phospholipase A2? Knockout Mice.
Parkinsonian Disorders
Protective effect of quinacrine on striatal dopamine levels in 6-OHDA and MPTP models of Parkinsonism in rodents.
Parkinsonian Disorders
Severe Early-Onset Parkinsonian Syndrome Caused by PLA2G6 Heterozygous Variants.
Parkinsonian Disorders
Structural and Aggregation Properties of Alpha-Synuclein Linked to Phospholipase A2 Action.
Parkinsonian Disorders
Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations.
Pectus Carinatum
Recessive truncating NALCN mutation in infantile neuroaxonal dystrophy with facial dysmorphism.
Peptic Ulcer
Effect of quinacrine, a phospholipase A2 inhibitor on stress and chemically induced gastroduodenal ulcers.
Peptic Ulcer
Helicobacter pylori associated phospholipase A2 activity: a factor in peptic ulcer production?
Peptic Ulcer
PH-activated phospholipase A2: an important mucosal barrier breaker in peptic ulcer disease.
peptidylprolyl isomerase deficiency
Uterine FK506-binding protein 52 (FKBP52)-peroxiredoxin-6 (PRDX6) signaling protects pregnancy from overt oxidative stress.
Periodontal Diseases
IPLA2 mRNA expression by human neutrophils in type 2 diabetes and chronic periodontitis.
Periodontitis
The use of live-animal micro-computed tomography to determine the effect of a novel phospholipase A2 inhibitor on alveolar bone loss in an in vivo mouse model of periodontitis.
Peripheral Nerve Injuries
Activation of cytosolic phospholipase A2 in dorsal root ganglion neurons by Ca2+/calmodulin-dependent protein kinase II after peripheral nerve injury.
Peripheral Nerve Injuries
Intracellular phospholipase A2 group IVA and group VIA play important roles in Wallerian degeneration and axon regeneration after peripheral nerve injury.
Peripheral Nervous System Diseases
Disorders of phospholipids, sphingolipids and fatty acids biosynthesis: toward a new category of inherited metabolic diseases.
Peritonitis
Ac2-26 Mimetic Peptide of Annexin A1 Inhibits Local and Systemic Inflammatory Processes Induced by Bothrops moojeni Venom and the Lys-49 Phospholipase A2 in a Rat Model.
Peritonitis
Alterations of the composition and metabolism of pulmonary surfactant phospholipids induced by experimental peritonitis in rats.
Peritonitis
Are phospholipase A2 and nitric oxide involved in the alterations in peritoneal transport during CAPD peritonitis?
Peritonitis
Characterization and pharmacological modulation of soluble phospholipase A2 generated during glycogen-induced rat peritonitis.
Peritonitis
Extracellular phospholipase A2 activity in cell free peritoneal lavage fluid from mice with zymosan peritonitis.
Peritonitis
Kinetics of phospholipase A2, arachidonic acid, and eicosanoid appearance in mouse zymosan peritonitis.
Peritonitis
Opuntia dillenii cladode: Opuntiol and opuntioside attenuated cytokines and eicosanoids mediated inflammation.
Peritonitis
Phospholipase-resistant phosphatidylcholine reduces intra-abdominal adhesions induced by bacterial peritonitis.
Peritonitis
Pro-inflammatory activity of phospholipase A2 in CAPD patients with and without peritonitis.
Peritonitis
Reduction of cPLA2alpha overexpression: an efficient anti-inflammatory therapy for collagen-induced arthritis.
Peritonitis
Serum phospholipase A2 in intensive care patients with peritonitis, multiple injury, and necrotizing pancreatitis.
Peritonitis
[Changes in phospholipase A2 activity and lipid peroxidation in endotoxicosis during experimental peritonitis]
Persistent Infection
Cytosolic and Calcium-Independent Phospholipases A2 Activation and Prostaglandins E2 Are Associated with Escherichia coli-Induced Reduction of Insulin Secretion in INS-1E Cells.
Persistent Infection
Role of cytosolic and calcium independent phospholipases A2 in insulin secretion impairment of INS-1E cells infected by S. aureus.
Pheochromocytoma
Arachidonic acid release and prostaglandin F2alpha formation induced by phenylarsine oxide in PC12 cells: possible involvement of secretory phospholipase A2 activity.
Pheochromocytoma
Function of type II phospholipase A2 in dopamine secretion by rat neuronal PC12 cells.
Pheochromocytoma
Influence of phospholipases A2 from snake venoms on survival and neurite outgrowth in pheochromocytoma cell line PC12.
Pheochromocytoma
Inhibition by protein kinase C activation of melittin-induced arachidonic acid release in PC12 pheochromocytoma cells.
Pheochromocytoma
Release of secretory phospholipase A2 from rat neuronal cells and its possible function in the regulation of catecholamine secretion.
Pheochromocytoma
Secretory phospholipases A2 induce neurite outgrowth in PC12 cells through lysophosphatidylcholine generation and activation of G2A receptor.
Pheochromocytoma
The perturbed membrane of cells undergoing apoptosis is susceptible to type II secretory phospholipase A2 to liberate arachidonic acid.
phosphatidylinositol deacylase deficiency
Group X secretory phospholipase A2 can induce arachidonic acid release and eicosanoid production without activation of cytosolic phospholipase A2 alpha.
phospholipase a2 deficiency
Choline and choline-related nutrients in regular and preterm infant growth.
phospholipase a2 deficiency
Curcumin abates hypoxia-induced oxidative stress based-ER stress-mediated cell death in mouse hippocampal cells (HT22) by controlling Prdx6 and NF-?B regulation.
phospholipase a2 deficiency
Deficiency in sPLA(2) does not affect HDL levels or atherosclerosis in mice.
phospholipase a2 deficiency
Deficiency of Prdx6 in lens epithelial cells induces ER stress-response-mediated impaired homeostasis and apoptosis.
phospholipase a2 deficiency
Detection of secretory phospholipase A2s related but not identical to type IIA isozyme in cultured mast cells.
phospholipase a2 deficiency
Disorders of phospholipids, sphingolipids and fatty acids biosynthesis: toward a new category of inherited metabolic diseases.
phospholipase a2 deficiency
Dual Roles of Group IID Phospholipase A2 in Inflammation and Cancer.
phospholipase a2 deficiency
Group IVA phospholipase A2 deficiency prevents CCl4-induced hepatic cell death through the enhancement of autophagy.
phospholipase a2 deficiency
Group V Secretory Phospholipase A(2) Enhances the Progression of Angiotensin II-Induced Abdominal Aortic Aneurysms but Confers Protection against Angiotensin II-Induced Cardiac Fibrosis in ApoE-Deficient Mice.
phospholipase a2 deficiency
Group VIA phospholipase A2 deficiency in mice chronically fed with high-fat-diet attenuates hepatic steatosis by correcting a defect of phospholipid remodeling.
phospholipase a2 deficiency
Group X Secreted Phospholipase A2 Releases ?3 Polyunsaturated Fatty Acids, Suppresses Colitis, and Promotes Sperm Fertility.
phospholipase a2 deficiency
Group X secretory phospholipase A2 negatively regulates ABCA1 and ABCG1 expression and cholesterol efflux in macrophages.
phospholipase a2 deficiency
Inherited human group IVA cytosolic phospholipase A2 deficiency abolishes platelet, endothelial, and leucocyte eicosanoid generation.
phospholipase a2 deficiency
Neuroaxonal dystrophy caused by group VIA phospholipase A2 deficiency in mice: a model of human neurodegenerative disease.
phospholipase a2 deficiency
Peroxiredoxin 6 deficiency and atherosclerosis susceptibility in mice: significance of genetic background for assessing atherosclerosis.
phospholipase a2 deficiency
Pla2g6 Deficiency in Zebrafish Leads to Dopaminergic Cell Death, Axonal Degeneration, Increased ?-Synuclein Expression, and Defects in Brain Functions and Pathways.
phospholipase a2 deficiency
Prdx6 deficiency ameliorates DSS colitis: relevance of compensatory antioxidant mechanisms.
phospholipase a2 deficiency
Restoration of On-Time Embryo Implantation Corrects the Timing of Parturition in Cytosolic Phospholipase A2 Group IVA Deficient Mice.
phospholipase a2 deficiency
The capacity of group V sPLA2 to increase atherogenicity of ApoE-/- and LDLR-/- mouse LDL in vitro predicts its atherogenic role in vivo.
Pick Disease of the Brain
Saitohin, which is nested in the tau locus and confers allele-specific susceptibility to several neurodegenerative diseases, interacts with peroxiredoxin 6.
Pick Disease of the Brain
Saitohin, which is nested within the tau gene, interacts with tau and Abl and its human-specific allele influences Abl phosphorylation.
Picornaviridae Infections
Porcine Picornavirus 3C Protease Degrades PRDX6 to Impair PRDX6-mediated Antiviral Function.
Pituitary Neoplasms
12-O-tetradecanoyl-phorbol-13-acetate-induced ACTH secretion in pituitary tumor cells.
Pituitary Neoplasms
Evidence supporting a correlation between arachidonic acid release and prolactin secretion from GH3 cells.
Pituitary Neoplasms
Inhibitors of the arachidonic acid metabolism attenuate the thyroliberin (TRH) stimulated prolactin production without modifying the production of inositolphosphates in GH4C1 pituitary cells.
Pituitary Neoplasms
Somatostatin stimulates BKCa channels in rat pituitary tumor cells through lipoxygenase metabolites of arachidonic acid.
Pityriasis
Phospholipase A2 enzymes represent a shared pathogenic pathway in psoriasis and pityriasis rubra pilaris.
Pityriasis Rubra Pilaris
Phospholipase A2 enzymes represent a shared pathogenic pathway in psoriasis and pityriasis rubra pilaris.
Pleural Effusion
Detection and characterization of extracellular phospholipase A2 in pleural effusion of patients with tuberculosis.
Pleural Effusion
Group II phospholipase A2 is increased in peritoneal and pleural effusions in patients with various types of cancer.
Pleurisy
A novel role for phospholipase A2 isoforms in the checkpoint control of acute inflammation.
Pleurisy
Antiinflammatory action of thielocin A1 beta, a group II phospholipase A2 specific inhibitor, in rat carrageenan-induced pleurisy.
Pleurisy
Dynamics and participation of type II phospholipase A2 in rat zymosan-induced pleurisy.
Pleurisy
Role of type II phospholipase A2 in the inflammatory process of carrageenan-induced pleurisy in rats.
Pleurisy
Sequential release of TNFalpha and phospholipase A(2) in a rat model of LPS-induced pleurisy.
Pneumonia
AdipoR-increased intracellular ROS promotes cPLA2 and COX-2 expressions via activation of PKC and p300 in adiponectin-stimulated human alveolar type II cells.
Pneumonia
Critical role of cytosolic phospholipase a2{alpha} in bronchial mucus hyper-secretion in CFTR-deficient mice.
Pneumonia
Cytosolic phospholipase A2? promotes pulmonary inflammation and systemic disease during Streptococcus pneumoniae infection.
Pneumonia
Deficiency of phospholipase A2 receptor exacerbates ovalbumin-induced lung inflammation.
Pneumonia
Drastic changes in the tissue-specific expression of secreted phospholipases A2 in chicken pulmonary disease.
Pneumonia
Effects of inflammatory stimuli on responses of macrophages to Mycoplasma bovis infection.
Pneumonia
Expression of secretory phospholipase A2 enzymes in lungs of humans with pneumonia and their potential prostaglandin-synthetic function in human lung-derived cells.
Pneumonia
Factors controlling vascular permeability: transmitting mechanical signals. Focus on "mechanical induction of group V phospholipase A2 causes lung inflammation and acute lung injury".
Pneumonia
Genetic inactivation of the phospholipase A2 activity of peroxiredoxin 6 in mice protects against LPS-induced acute lung injury.
Pneumonia
Group V Phospholipase A2 in bone marrow derived myeloid cells and bronchial epithelial cells promote bacterial clearance after E. coli pneumonia.
Pneumonia
Group V secretory phospholipase A2 is involved in macrophage activation and is sufficient for macrophage effector functions in allergic pulmonary inflammation.
Pneumonia
Group V secretory phospholipase A2 reveals its role in house dust mite-induced allergic pulmonary inflammation by regulation of dendritic cell function.
Pneumonia
Increased group IV cytosolic phospholipase A2 activity in lungs of sheep after smoke inhalation injury.
Pneumonia
Lack of group X secreted phospholipase A2 increases survival following pandemic H1N1 influenza infection.
Pneumonia
Mechanical induction of Group V phospholipase A2 causes lung inflammation and acute lung injury.
Pneumonia
Peroxiredoxin 6 differentially regulates acute and chronic cigarette smoke–mediated lung inflammatory response and injury.
Pneumonia
Polydatin up-regulates Clara cell secretory protein to suppress phospholipase A2 of lung induced by LPS in vivo and in vitro.
Pneumonia
Pseudomonas aeruginosa cytotoxin ExoU is injected into phagocytic cells during acute pneumonia.
Pneumonia
Pulmonary inflammation and edema induced by phospholipase A2: global gene analysis and effects on aquaporins and Na+/K+-ATPase.
Pneumonia
Reduction of pulmonary surfactant in patients with human immunodeficiency virus infection and Pneumocystis carinii pneumonia.
Pneumonia
Secreted Phospholipase A2 is Increased in Meconium-Stained Amniotic Fluid of Term Gestations: Potential Implications for the Genesis of Meconium Aspiration Syndrome.
Pneumonia
Secretory Phospholipase A2-IIA Protein and mRNA Pools in Extracellular Vesicles of Bronchoalveolar Lavage Fluid from Patients with Early Acute Respiratory Distress Syndrome: A New Perception in the Dissemination of Inflammation?
Pneumonia
Serum ferritin elevation and acute lung injury in rats subjected to hemorrhage: reduction by mepacrine treatment.
Pneumonia
Surface properties after a simulated PLA2 hydrolysis of pulmonary surfactant's main component, DPPC.
Pneumonia
Surfactant phospholipids and lavage phospholipase A2 in experimental Pneumocystis carinii pneumonia.
Pneumonia
Varespladib Inhibits Secretory Phospholipase A2 in Bronchoalveolar Lavage of Different Types of Neonatal Lung Injury.
Pneumonia, Pneumocystis
Surfactant phospholipids and lavage phospholipase A2 in experimental Pneumocystis carinii pneumonia.
Pneumonia, Ventilator-Associated
Secretion of Pseudomonas aeruginosa type III cytotoxins is dependent on pseudomonas quinolone signal concentration.
Polycystic Kidney Diseases
Alterations in renal cytosolic phospholipase A2 and cyclooxygenases in polycystic kidney disease.
Polycystic Kidney Diseases
Dietary soy protein selectively reduces renal prostanoids and cyclooxygenases in polycystic kidney disease.
Polycystic Ovary Syndrome
A nontargeted proteomic study of the influence of androgen excess on human visceral and subcutaneous adipose tissue proteomes.
Polycystic Ovary Syndrome
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Polycystic Ovary Syndrome
The activity of calcium dependent and calcium independent phospholipase A2 in normal endometrium and in endometrium from women suffering from menorrhagia and polycystic ovary syndrome.
Polycystic Ovary Syndrome
The platelet activating factor acetyl hydrolase, oxidized low-density lipoprotein, paraoxonase 1 and arylesterase levels in treated and untreated patients with polycystic ovary syndrome.
Porphyria Cutanea Tarda
Hepatic arachidonic acid metabolism is disrupted after hexachlorobenzene treatment.
Porphyrias
Hepatic arachidonic acid metabolism is disrupted after hexachlorobenzene treatment.
Pre-Eclampsia
Activities of phospholipase A2, cyclooxygenase, and PGI2 synthase of umbilical venous endothelial cells in preeclamptic women.
Pre-Eclampsia
Differential proteomic analysis of highly purified placental cytotrophoblasts in preeclampsia demonstrates a state of increased oxidative stress and reduced cytotrophoblast antioxidant defense.
Pre-Eclampsia
Group I and group II phospholipase A2 in serum during normal and pathological pregnancy.
Pre-Eclampsia
Increased placental phospholipase A2 gene expression and free F2-isoprostane levels in response to oxidative stress in preeclampsia.
Pre-Eclampsia
Plasma and urinary 8-iso-prostane as an indicator of lipid peroxidation in pre-eclampsia and normal pregnancy.
Pre-Eclampsia
Plasma from preeclamptic women increases human endothelial cell prostacyclin production without changes in cellular enzyme activity or mass.
Pre-Eclampsia
The role of the endogenous anti-inflammatory compound gravidin in pre-eclampsia.
Premature Birth
Associations of maternal PLA2G4C and PLA2G4D polymorphisms with the risk of spontaneous preterm birth in a Chinese population.
Premature Birth
Primate-specific evolution of noncoding element insertion into PLA2G4C and human preterm birth.
Prion Diseases
Antioxidant peroxiredoxin 6 protein rescues toxicity due to oxidative stress and cellular hypoxia in vitro, and attenuates prion-related pathology in vivo.
Progeria
The role of lipid metabolism in aging, lifespan regulation, and age-related disease.
Prostatic Hyperplasia
Expression of group IIa secretory phospholipase A2 increases with prostate tumor grade.
Prostatic Hyperplasia
Phospholipase A2 degradation products modulate epithelial and stromal 5alpha-reductase activity of human benign prostatic hyperplasia in vitro.
Prostatic Intraepithelial Neoplasia
Expression of group IIA secretory phospholipase A2 is elevated in prostatic intraepithelial neoplasia and adenocarcinoma.
Prostatic Neoplasms
Association of 5'UTR polymorphism of secretory phospholipase A2 group IIA (PLA2G2A) gene with prostate cancer metastasis.
Prostatic Neoplasms
Cytosolic phospholipase A2-alpha: a potential therapeutic target for prostate cancer.
Prostatic Neoplasms
Diverse effects of phospholipase A2 receptor expression on LNCaP and PC-3 prostate cancer cell growth in vitro and in vivo.
Prostatic Neoplasms
Evidence for distinct mechanisms of uptake and antitumor activity of secretory phospholipase A(2) responsive liposome in prostate cancer.
Prostatic Neoplasms
Expression of group IIA secretory phospholipase A2 is elevated in prostatic intraepithelial neoplasia and adenocarcinoma.
Prostatic Neoplasms
Increased Peroxiredoxin 6 Expression Predicts Biochemical Recurrence in Prostate Cancer Patients After Radical Prostatectomy.
Prostatic Neoplasms
Inhibition of calcium-independent phospholipase A2 activates p38 MAPK signaling pathways during cytostasis in prostate cancer cells.
Prostatic Neoplasms
Liposomes Targeting P21 Activated Kinase-1 (PAK-1) and Selective for Secretory Phospholipase A2 (sPLA2) Decrease Cell Viability and Induce Apoptosis in Metastatic Triple-Negative Breast Cancer Cells.
Prostatic Neoplasms
Overexpression of secretory phospholipase A2-IIa supports cancer stem cell phenotype via HER/ERBB-elicited signaling in lung and prostate cancer cells.
Prostatic Neoplasms
Phospholipase A2-Responsive Phosphate Micelle-Loaded UCNPs for Bioimaging of Prostate Cancer Cells.
Prostatic Neoplasms
Role of the phospholipase A2 receptor in liposome drug delivery in prostate cancer cells.
Prostatic Neoplasms
Secretory phospholipase A2-IIa is a target gene of the HER/HER2-elicited pathway and a potential plasma biomarker for poor prognosis of prostate cancer.
Prostatic Neoplasms
Secretory phospholipase A2-IIa is involved in prostate cancer progression and may potentially serve as a biomarker for prostate cancer.
Prostatic Neoplasms
Selenium- or Vitamin E-Related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECT.
Prostatic Neoplasms
Sterically stabilized liposomes targeting P21 (RAC1) activated kinase-1 and secreted phospholipase A2 suppress prostate cancer growth and metastasis.
Prostatic Neoplasms
The arachidonic Acid pathway and its role in prostate cancer development and progression.
Prostatic Neoplasms
Vav3 oncogene is involved in regulation of secretory phospholipase A2-IIa expression in prostate cancer.
Protein-Energy Malnutrition
[Comparative study of the effects of 2 types of protein-energy malnutrition followed by a balanced refeeding, on the lipase, phospholipase A2 and amylase activities of the pancreas and pancreatic juice in the growing rat]
Proteinuria
M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy.
Proteinuria
PLA2R antibody levels and clinical outcome in patients with membranous nephropathy and non-nephrotic range proteinuria under treatment with inhibitors of the renin-angiotensin system.
Proteinuria
Secondary membranous nephropathy in a patient with myasthenia gravis without thymic disease, and partial remission induced by adrenocorticotropic hormone therapy.
Proteinuria
Serum secretory phospholipase A2 group IB correlates with the severity of membranous nephropathy.
Proteinuria
sPLA2-IB and PLA2R mediate insufficient autophagy and contribute to podocyte injury in idiopathic membranous nephropathy by activation of the p38MAPK/mTOR/ULK1ser757 signaling pathway.
Proteinuria
sPLA2-IB Level Correlates with Hyperlipidemia and the Prognosis of Idiopathic Membranous Nephropathy.
Proteinuria
Spontaneous remission of proteinuria is a frequent event in phospholipase A2 receptor antibody-negative patients with membranous nephropathy.
Pruritus
TRPV1 mediates histamine-induced itching via the activation of phospholipase A2 and 12-lipoxygenase.
Psoriasis
A randomized, double-blind, placebo-controlled, dose-escalation first-in-man study (phase 0) to assess the safety and efficacy of topical cytosolic phospholipase A2 inhibitor, AVX001, in patients with mild to moderate plaque psoriasis.
Psoriasis
Autoantigens ADAMTSL5 and LL37 are significantly upregulated in active Psoriasis and localized with keratinocytes, dendritic cells and other leukocytes.
Psoriasis
Characterization and activity of phospholipase A2 in normal human epidermis and in lesion-free epidermis of patients with psoriasis or eczema.
Psoriasis
Characterization and differentiation-dependent regulation of secreted phospholipases A in human keratinocytes and in healthy and psoriatic human skin.
Psoriasis
Confirmation of raised phospholipase A2 activity in the uninvolved skin of psoriasis.
Psoriasis
Dermal and ocular safety of the new phospholipase A2 inhibitors PX-18 and PX-13 formulated as drug nanosuspension.
Psoriasis
Epidermal phospholipase A2 activity is raised in the uninvolved skin of psoriasis.
Psoriasis
Inhibition of phospholipases suppresses progression of psoriasis through modulation of inflammation.
Psoriasis
Inhibitors of phospholipase A2 and their therapeutic potential: an update on patents (2012-2016).
Psoriasis
Phospholipase A2 activity of peripheral-blood mononuclear leukocytes in psoriasis.
Psoriasis
Phospholipase A2 enzymes represent a shared pathogenic pathway in psoriasis and pityriasis rubra pilaris.
Psoriasis
Secretory and cytosolic phospholipase A(2)regulate the long-term cytokine-induced eicosanoid production in human keratinocytes.
Psoriasis
Structure of Human GIVD Cytosolic Phospholipase A2 Reveals Insights into Substrate Recognition.
Psoriasis
The design and discovery of phospholipase A2 inhibitors for the treatment of inflammatory diseases.
Psoriasis
The Genetics of Chronic Itch: Gene Expression in the Skin of Patients with Atopic Dermatitis and Psoriasis with Severe Itch.
Psoriasis
The level of phospholipase A2 activity is raised in the uninvolved epidermis of psoriasis.
Pulmonary Arterial Hypertension
Role of Secretory Phospholipase A2 in Rhythmic Contraction of Pulmonary Arteries of Rats With Monocrotaline-Induced Pulmonary Arterial Hypertension.
Pulmonary Arterial Hypertension
The study of the relationship between the activity of phospholipase A2 and acute hypoxic pulmonary arterial pressure.
Pulmonary Arterial Hypertension
[The relationship between the activity of phospholipase A2 and acute hypoxic pulmonary arterial pressure]
Pulmonary Atelectasis
Transgenic expression of group V, but not group X, secreted phospholipase A2 in mice leads to neonatal lethality because of lung dysfunction.
Pulmonary Disease, Chronic Obstructive
A novel polymorphism in secretory phospholipase A2-IID is associated with body weight loss in chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Gly80Ser Polymorphism of Phospholipase A2-IID Is Associated with Cytokine Inducibility in A549 Cells.
Pulmonary Disease, Chronic Obstructive
Molecular modeling of Gly80 and Ser80 variants of human group IID phospholipase A2 and their receptor complexes: potential basis for weight loss in chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Peroxiredoxins and Immune Infiltrations in Colon Adenocarcinoma: Their Negative Correlations and Clinical Significances, an In Silico Analysis.
Pulmonary Disease, Chronic Obstructive
Toxicological effects of ambient fine (PM2.5-0.18) and ultrafine (PM0.18) particles in healthy and diseased 3D organo-typic mucocilary-phenotype models.
Pulmonary Disease, Chronic Obstructive
Vascular endothelial growth factor, lipoporotein-associated phospholipase A2, sP-selectin and antiphospholipid antibodies, biological markers with prognostic value in pulmonary hypertension associated with chronic obstructive pulmonary disease and systemic lupus erithematosus.
Pulmonary Edema
Acute lung injury by sepsis and acid aspiration: a key role for cytosolic phospholipase A2.
Pulmonary Edema
Berberine inhibits cytosolic phospholipase A2 and protects against LPS-induced lung injury and lethality independent of the alpha2-adrenergic receptor in mice.
Pulmonary Edema
Inhibition of secretory phospholipase A2 activity attenuates acute cardiogenic pulmonary edema induced by isoproterenol infusion in mice after myocardial infarction.
Pulmonary Edema
Phospholipase A2 induced diffuse alveolar damage--effect of indomethacin and dexamethasone upon morphology and plasma-histamine level.
Pulmonary Edema
[Effects of phospholipase A2 on the etiology of pulmonary edema hemodynamics of lesser circulation in intact and vagotomized animals]
Pulmonary Edema
[Experimental study on the pathogenesis of pulmonary insufficiency in acute pancreatitis and changes in the pulmonary surfactant]
Pulmonary Eosinophilia
Acidic Calcium-Independent Phospholipase A2 Regulates Eosinophil-Mediated Pathology during Filarial Manifestation of Tropical Pulmonary Eosinophilia.
Pulmonary Fibrosis
AK106-001616, a Potent and Selective Inhibitor of Cytosolic Phospholipase A2: In Vivo Efficacy for Inflammation, Neuropathic Pain, and Pulmonary Fibrosis.
Pulmonary Fibrosis
Telomere shortening activates TGF-?/Smads signaling in lungs and enhances both lipopolysaccharide and bleomycin-induced pulmonary fibrosis.
Radiculopathy
Immediate inhibition of spinal secretory phospholipase A2 prevents the pain and elevated spinal neuronal hyperexcitability and neuroimmune regulatory genes that develop with nerve root compression.
Radiculopathy
The role of steroids and their effects on phospholipase A2. An animal model of radiculopathy.
Rectal Neoplasms
Identification of Metabolic-Associated Genes for the Prediction of Colon and Rectal Adenocarcinoma.
Rectal Neoplasms
PLA2G2A overexpression is associated with poor therapeutic response and inferior outcome in rectal cancer patients receiving neoadjuvant concurrent chemoradiotherapy.
Rectal Neoplasms
PLA2G4A mutants modified protective effect of tea consumption against colorectal cancer.
Renal Insufficiency, Chronic
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Renal Insufficiency, Chronic
Rituximab in Patients With Phospholipase A2 Receptor-Associated Membranous Nephropathy and Severe CKD.
Reperfusion Injury
Attenuation of ischemia and reperfusion injury of canine livers by inhibition of type II phospholipase A2 with LY329722.
Reperfusion Injury
Calcium in renal cells. Modulation of calcium-dependent activation of phospholipase A2.
Reperfusion Injury
Comparative protection against rat intestinal reperfusion injury by a new inhibitor of sPLA2, COX-1 and COX-2 selective inhibitors, and an LTC4 receptor antagonist.
Reperfusion Injury
Cytosolic phospholipase A2 inhibition attenuates ischemia-reperfusion injury in an isolated rat lung model.
Reperfusion Injury
Differential regulation of activator protein-1 and heat shock factor-1 in myocardial ischemia and reperfusion injury: role of poly(ADP-ribose) polymerase-1.
Reperfusion Injury
In vitro studies on the influence of L-ascorbic acid 2-[3,4-dihydro- 2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6yl-hy drogen phosphate] potassium salt on lipid peroxidation and phospholipase A2 activity.
Reperfusion Injury
Increased serum phospholipase A2 activity after non-heart-beating donor liver transplantation and association with ischemia-reperfusion injury.
Reperfusion Injury
Mice deficient in cytosolic phospholipase A2 are less susceptible to cerebral ischemia/reperfusion injury.
Reperfusion Injury
Phospholipase A2 is activated in the kidney, but not in the liver during ischemia-reperfusion.
Reperfusion Injury
Protective effect of mepacrine on hypoxia-reoxygenation-induced acute lung injury in rats.
Reperfusion Injury
Protective effect of N-(p-amylcinnamoyl) anthranilic acid, phospholipase A2 enzyme inhibitor, and transient receptor potential melastatin-2 channel blocker against renal ischemia-reperfusion injury.
Reperfusion Injury
Protective role of exogenous recombinant peroxiredoxin 6 under ischemia-reperfusion injury of kidney.
Reperfusion Injury
Regulation of Prdx6 by Nrf2 Mediated Through aiPLA2 in White Matter Reperfusion Injury.
Reperfusion Injury
Reperfusion mucosal damage after complete intestinal ischemia in the dog: the effects of antioxidant and phospholipase A2 inhibitor therapy.
Reperfusion Injury
Retraction. Targeted disruption of peroxiredoxin 6 gene renders the heart vulnerable to ischemia-reperfusion injury.
Reperfusion Injury
Targeted disruption of peroxiredoxin 6 gene renders the heart vulnerable to ischemia-reperfusion injury.
Reperfusion Injury
The contribution of phospholipase A2 to the cochlear dysfunction induced by transient ischemia.
Reperfusion Injury
Tissular prostanoid release, phospholipase A2 activity, and lipid peroxidation in pancreas transplantation.
Reproductive Tract Infections
Association of cervicovaginal infections with increased vaginal fluid phospholipase A2 activity.
Respiratory Distress Syndrome
A diether phosphonolipid surfactant analog, DEPN-8, is resistant to phospholipase-C cleavage.
Respiratory Distress Syndrome
Bronchoalveolar lavage fluid phospholipase A2 activities are increased in human adult respiratory distress syndrome.
Respiratory Distress Syndrome
Clinical and biological role of secretory phospholipase A2 in acute respiratory distress syndrome infants.
Respiratory Distress Syndrome
Cord blood Clara cell protein CC16 predicts the development of bronchopulmonary dysplasia.
Respiratory Distress Syndrome
Crucial role of group IIA phospholipase A(2) in oleic acid-induced acute lung injury in rabbits.
Respiratory Distress Syndrome
Effect of cooling on lung secretory phospholipase A2 activity in vitro, ex vivo, and in vivo.
Respiratory Distress Syndrome
Endotoxin induces expression of type II phospholipase A2 in macrophages during acute lung injury in guinea pigs: involvement of TNF-alpha in lipopolysaccharide-induced type II phospholipase A2 synthesis.
Respiratory Distress Syndrome
Ex vivo effect of varespladib on secretory phospholipase A2 alveolar activity in infants with ARDS.
Respiratory Distress Syndrome
Interaction of secreted phospholipase A2 and pulmonary surfactant and its pathophysiological relevance in acute respiratory distress syndrome.
Respiratory Distress Syndrome
Lidocaine attenuates acute lung injury induced by a combination of phospholipase A2 and trypsin.
Respiratory Distress Syndrome
Lysophosphatidylcholine sensitizes lipid extracts of pulmonary surfactant to inhibition by serum proteins.
Respiratory Distress Syndrome
Phospholipase A2 is present in meconium and inhibits the activity of pulmonary surfactant: an in vitro study.
Respiratory Distress Syndrome
Potential role of Clara cell protein, an endogenous phospholipase A2 inhibitor, in acute lung injury.
Respiratory Distress Syndrome
Pulmonary Secretory Phospholipase A(2) in Infants with Respiratory Distress Syndrome Stimulates in vitro Neutrophil Migration.
Respiratory Distress Syndrome
Secretory phospholipase A2 pathway during pediatric acute respiratory distress syndrome: A preliminary study.
Respiratory Distress Syndrome
Secretory Phospholipase A2-IIA Protein and mRNA Pools in Extracellular Vesicles of Bronchoalveolar Lavage Fluid from Patients with Early Acute Respiratory Distress Syndrome: A New Perception in the Dissemination of Inflammation?
Respiratory Distress Syndrome
Secretory Phospholipase A2-Mediated Depletion of Phosphatidylglycerol in Early Acute Respiratory Distress Syndrome.
Respiratory Distress Syndrome
Systemic phospholipase A2 and cachectin levels in adult respiratory distress syndrome and multiple-organ failure.
Respiratory Distress Syndrome
Therapeutic use of a group IIA phospholipase A2 inhibitor in acute respiratory distress syndrome: time is of the essence.
Respiratory Distress Syndrome
Thymulin and peroxiredoxin 6 have protective effects against streptozotocin-induced type 1 diabetes in mice.
Respiratory Distress Syndrome
Transgenic expression of group V, but not group X, secreted phospholipase A2 in mice leads to neonatal lethality because of lung dysfunction.
Respiratory Distress Syndrome
Varespladib Inhibits Secretory Phospholipase A2 in Bronchoalveolar Lavage of Different Types of Neonatal Lung Injury.
Respiratory Insufficiency
Crotoxin-Induced Mice Lung Impairment: Role of Nicotinic Acetylcholine Receptors and COX-Derived Prostanoids.
Respiratory Insufficiency
Frequency-dependent neuromuscular blockade by textilotoxin in vivo.
Respiratory Insufficiency
Secretory phospholipase A2 pathway in various types of lung injury in neonates and infants: a multicentre translational study.
Respiratory Insufficiency
The role of phospholipase A2 in respiratory failure of acute pancreatitis.
Respiratory Insufficiency
The role of phospholipase A2 in the pathogenesis of respiratory damage in hemorrhagic necrotizing pancreatitis--assessment of a new experimental model.
Respiratory Insufficiency
Tourniquet ineffectiveness to reduce the severity of envenoming after Crotalus durissus snake bite in Belo Horizonte, Minas Gerais, Brazil.
Respiratory Insufficiency
Transgenic expression of group V, but not group X, secreted phospholipase A2 in mice leads to neonatal lethality because of lung dysfunction.
Respiratory Insufficiency
[Experimental study on the pathogenesis of pulmonary insufficiency in acute pancreatitis and changes in the pulmonary surfactant]
Respiratory Paralysis
Anticrotalic and antitumoral activities of gel filtration fractions of aqueous extract from Tabernaemontana catharinensis (Apocynaceae).
Respiratory Syncytial Virus Infections
Secretory phospholipase A2 pathway during pediatric acute respiratory distress syndrome: A preliminary study.
Respiratory Tract Infections
Critical role of phospholipase A2 group IID in age-related susceptibility to severe acute respiratory syndrome-CoV infection.
Retinal Degeneration
Specific roles for Group V secretory PLA? in retinal iron-induced oxidative stress. Implications for age-related macular degeneration.
Retinal Neovascularization
The Role of Cytosolic Phospholipase A2 in Retinal Neovascularization.
Retinoblastoma
Identification of novel lipid droplet factors that regulate lipophagy and cholesterol efflux in macrophage foam cells.
Retinopathy of Prematurity
The Role of Cytosolic Phospholipase A2 in Retinal Neovascularization.
Rhabdomyolysis
Phospholipases A2 From Viperidae Snake Venoms: How do They Induce Skeletal Muscle Damage?
Rhabdomyolysis
Renal lesions in rhabdomyolysis caused by Pseudechis australis snake myotoxin.
Rhabdomyolysis
Severe and fatal mass attacks by 'killer' bees (Africanized honey bees--Apis mellifera scutellata) in Brazil: clinicopathological studies with measurement of serum venom concentrations.
Rheumatic Heart Disease
[Changes of lipid metabolism in cardiac failure patients with rheumatic heart disease]
Rhinitis
Increased leukocyte phospholipase A2 activity and plasma lysophosphatidylcholine levels in asthma and rhinitis and their relationship to airway sensitivity to histamine.
Rhinitis
The role of mast cell-derived secreted phospholipases A(2) in respiratory allergy.
Rhinitis, Allergic, Seasonal
Phospholipase A2 mRNA expression in the nasal mucosa of healthy subjects and patients with seasonal allergic rhinitis.
Salmonella Infections
Calcium-independent phospholipase A2 beta is dispensable in inflammasome activation and its inhibition by bromoenol lactone.
Sarcoma
Antitumor effects of cationic synthetic peptides derived from Lys49 phospholipase A2 homologues of snake venoms.
Sarcoma
Evidence that porcine pancreatic phospholipase A2 via its high affinity receptor stimulates extracellular matrix invasion by normal and cancer cells.
Sarcoma
Identification of novel lipid droplet factors that regulate lipophagy and cholesterol efflux in macrophage foam cells.
Sarcoma, Avian
Enhancing factor for Rous sarcoma virus: in vitro assay and action on both cells and virus.
Sarcoma, Avian
The tyrosine phosphorylation substrate p36 is developmentally regulated in embryonic avian limb and is induced in cell culture.
Sarcoma, Yoshida
Influence of charge on the inactivation of membrane bound (Na+ + K+)-ATPase of Yoshida sarcoma cells by inhibitor proteins from cobra venom.
Sarcopenia
Prdx6 Plays a Main Role in the Crosstalk Between Aging and Metabolic Sarcopenia.
Sarcopenia
Targeting cPLA2 derived lipid hydroperoxides as a potential intervention for sarcopenia.
Sciatica
A controlled biochemical and immunohistochemical study of human synovial-type (group II) phospholipase A2 and inflammatory cells in macroscopically normal, degenerated, and herniated human lumbar disc tissues.
Sciatica
Chymopapain-induced reduction of proinflammatory phospholipase A2 activity and amelioration of neuropathic behavioral changes in an in vivo model of acute sciatica.
Sciatica
Phospholipase A2 activity in herniated lumbar discs. Clinical correlations and inhibition by piroxicam.
Scoliosis
Recessive truncating NALCN mutation in infantile neuroaxonal dystrophy with facial dysmorphism.
Seizures
Cytosolic phospholipase A2 is a key regulator of blood-brain barrier function in epilepsy.
Seizures
Hippocampal Gene Network Analysis in an Experimental Model of Posttraumatic Epilepsy.
Seizures
Ketogenic diet change cPLA2/clusterin and autophagy related gene expression and correlate with cognitive deficits and hippocampal MFs sprouting following neonatal seizures.
Seizures
Leptin-regulated autophagy plays a role in long-term neurobehavioral injury after neonatal seizures and the regulation of zinc/cPLA2 and CaMK II signaling in cerebral cortex.
Seizures
Modulation of DL-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid/quisqualate receptors by phospholipase A2: a necessary step in long-term potentiation?
Seizures
Neuro-Behavioral Status and the Hippocampal Expression of Metabolic Associated Genes in Wild-Type Rat Following a Ketogenic Diet.
Seizures
Secreted phospholipase A2-induced neurotoxicity and epileptic seizures after intracerebral administration: an unexplained heterogeneity as emphasized with paradoxin and crotoxin.
Seizures
Secretory phospholipase A2 and phospholipids in neural membranes in an experimental epilepsy model.
Seizures
The accumulation of free arachidonic acid, diacylglycerols, prostaglandins, and lipoxygenase reaction products in the brain during experimental epilepsy.
Sepsis
A continuous fluorescence assay for the determination of calcium-dependent secretory phospholipase A2 activity in serum.
Sepsis
Acute lung injury by sepsis and acid aspiration: a key role for cytosolic phospholipase A2.
Sepsis
Alteration of Lysophosphatidylcholine-Related Metabolic Parameters in the Plasma of Mice with Experimental Sepsis.
Sepsis
An Amperometric Biosensor for the Determination of Bacterial Sepsis Biomarker, Secretory Phospholipase Group 2-IIA Using a Tri-Enzyme System.
Sepsis
Antisense inhibition of secretory and cytosolic phospholipase A2 reduces the mortality in rats with sepsis*.
Sepsis
Bactericidal/permeability-increasing protein (BPI) in sepsis correlates with the severity of sepsis and the outcome.
Sepsis
CD64 and Group II Secretory Phospholipase A2 (sPLA2-IIA) as Biomarkers for Distinguishing Adult Sepsis and Bacterial Infections in the Emergency Department.
Sepsis
Characterization of cellular and elevated serum phospholipase A2 activities with a comparison of two methods.
Sepsis
Characterization of two phospholipases A2 in serum of patients with sepsis and acute pancreatitis.
Sepsis
Circulating inflammatory mediators predict shock and mortality in febrile patients with microbial infection.
Sepsis
Circulating phospholipase A2 activity associated with sepsis and septic shock is indistinguishable from that associated with rheumatoid arthritis.
Sepsis
Contribution of interleukin-1 to activation of coagulation and fibrinolysis, neutrophil degranulation, and the release of secretory-type phospholipase A2 in sepsis: studies in nonhuman primates after interleukin-1 alpha administration and during lethal bacteremia.
Sepsis
Effect of azithromycin on the LPS-induced production and secretion of phospholipase A2 in lung cells.
Sepsis
Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure.
Sepsis
Enhancement of leukocyte response to lipopolysaccharide by secretory group IIA phospholipase A2.
Sepsis
Evidence for distinct mechanisms of uptake and antitumor activity of secretory phospholipase A(2) responsive liposome in prostate cancer.
Sepsis
Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis.
Sepsis
Group II phospholipase A2 gene expression is transcriptionally regulated in rat liver during sepsis.
Sepsis
Group II phospholipase A2 in sera of febrile patients with microbiologically or clinically documented infections.
Sepsis
Group IIA secretory phospholipase 2 independently predicts mortality and positive blood culture in emergency department sepsis patients.
Sepsis
GTP-binding protein mediated phospholipase A2 activation in rat liver during the progression of sepsis.
Sepsis
Heterogeneous models for an early discrimination between sepsis and non-infective SIRS in medical ward patients: a pilot study.
Sepsis
High sPLA2-IIA level is associated with eicosanoid metabolism in patients with bacterial sepsis syndrome.
Sepsis
Increased serum phospholipase A2 activity in Malawian children with falciparum malaria.
Sepsis
Induction of group II phospholipase A2 expression and pathogenesis of the sepsis syndrome.
Sepsis
Is circulating phospholipase A2 removed by large-pore continuous venovenous hemodiafiltration in septic acute renal failure?
Sepsis
LY315920NA/S-5920, a selective inhibitor of group IIA secretory phospholipase A2, fails to improve clinical outcome for patients with severe sepsis.
Sepsis
Measurement of a Novel Biomarker, Secretory Phospholipase A2 Group IIA as a Marker of Sepsis: A Pilot Study.
Sepsis
Modulation of lipid and protein mediators of inflammation by cytosolic phospholipase A2alpha during experimental sepsis.
Sepsis
Nitrite/nitrate (NOX) and type II phospholipase A2, leukotriene B4, and platelet-activating factor levels in patients with septic shock.
Sepsis
Opinion paper on innovative approach of biomarkers for infectious diseases and sepsis management in the emergency department.
Sepsis
Phospholipase A in acute lung injury after trauma and sepsis: its relation to the inflammatory mediators PMN-elastase, C3a, and neopterin.
Sepsis
Phospholipase A2 activities are decreased during early but increased during late phases of sepsis in rat heart.
Sepsis
Phospholipids and their inhibitors: a critical evaluation of their role in the treatment of sepsis.
Sepsis
Plasma secretory phospholipase A2 as an early marker for late-onset sepsis in preterm infants-a pilot study.
Sepsis
Platelet-activating factor (PAF) acetylhydrolase activity, type II phospholipase A2, and cytokine levels in patients with sepsis.
Sepsis
Relationships between plasma levels of type-II phospholipase A2, PAF-acetylhydrolase, leukotriene B4, complements, endothelin-1, and thrombomodulin in patients with sepsis.
Sepsis
Secretory non-pancreatic phopholipase A2 in severe sepsis: relation to endotoxin, cytokines and thromboxane B2.
Sepsis
Suppression of murine endotoxic shock by sPLA2 inhibitor, indoxam, through group IIA sPLA2-independent mechanisms.
Sepsis
Surgical trauma induces group II phospholipase A2 production by neutrophils at a local site after surgery.
Sepsis
The role of group IIA secretory phospholipase A2 (sPLA2-IIA) as a biomarker for the diagnosis of sepsis and bacterial infection in adults-A systematic review.
Sepsis
Transcriptional Regulation of the Group IIA Secretory Phospholipase A2 Gene by C/EBP? in Rat liver and its Relationship to Hepatic Gluconeogenesis during Sepsis.
Sepsis
[Research progress in the application of necrotic cavity lavage in the treatment of infected pancreatic necrosis].
Sepsis
[Secreted phospholipases A2 (sPLA2): friends or foes? Are they actors in antibacterial and anti-HIV resistance?]
Severe Dengue
Inflammatory mediators in dengue virus infection in children: interleukin-6 and its relation to C-reactive protein and secretory phospholipase A2.
Shock, Septic
A predictive model for the clearance of soluble phospholipase A2 during septic shock.
Shock, Septic
Altered ryanodine receptor of canine cardiac sarcoplasmic reticulum and its underlying mechanism in endotoxin shock.
Shock, Septic
Association of type II secretory phospholipase A2 and surfactant protein D with the pulmonary oxygenation potential in patients with septic shock during polymyxin-B immobilized fiber-direct hemoperfusion.
Shock, Septic
Circulating inflammatory mediators predict shock and mortality in febrile patients with microbial infection.
Shock, Septic
Circulating phospholipase A2 activity associated with sepsis and septic shock is indistinguishable from that associated with rheumatoid arthritis.
Shock, Septic
Comparison of the enterotoxigenic types, toxic shock syndrome toxin I (TSST-1) strains and antibiotic susceptibilities for enterotoxigenic Staphylococcus aureus strains isolated from food and clinical samples.
Shock, Septic
Concordance of endogenous cortisol and phospholipase A2 levels in gram-negative septic shock: a prospective study.
Shock, Septic
Crystal structure of human secretory phospholipase A2-IIA complex with the potent indolizine inhibitor 120-1032.
Shock, Septic
Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure.
Shock, Septic
Elevated plasma phospholipase A2 levels: correlation with the hemodynamic and pulmonary changes in gram-negative septic shock.
Shock, Septic
Enhanced expression of group II phospholipase A2 gene in the tissues of endotoxin shock rats and its suppression by glucocorticoid.
Shock, Septic
Glutamine inhibits lipopolysaccharide-induced cytoplasmic phospholipase A2 activation and protects against endotoxin shock in mouse.
Shock, Septic
Group II phospholipases A2 are indirectly cytolytic in the presence of exogenous phospholipid.
Shock, Septic
Increased activity of group II phospholipase A2 in plasma in rat sodium deoxycholate induced acute pancreatitis.
Shock, Septic
Increased concentrations of synovial-type phospholipase A2 in serum and pulmonary and renal complications in acute pancreatitis.
Shock, Septic
Induction of cytosolic phospholipase A2 and prostaglandin H2 synthase-2 by lipopolysaccharide in human polymorphonuclear leukocytes.
Shock, Septic
Induction of phospholipase A2 gene expression in human hepatoma cells by mediators of the acute phase response.
Shock, Septic
Involvement of circulating phospholipase A2 in the pathogenesis of the hemodynamic changes in endotoxin shock.
Shock, Septic
Nitrite/nitrate (NOX) and type II phospholipase A2, leukotriene B4, and platelet-activating factor levels in patients with septic shock.
Shock, Septic
Novel group V phospholipase A2 involved in arachidonic acid mobilization in murine P388D1 macrophages.
Shock, Septic
Pathogenesis of hypotension in septic shock: correlation of circulating phospholipase A2 levels with circulatory collapse.
Shock, Septic
PCR detection of Staphylococcal enterotoxins (SEs) N, O, P, Q, R, U, and survey of SE types in Staphylococcus aureus isolates from food-poisoning cases in Taiwan.
Shock, Septic
Phospholipase A2 from plasma of patients with septic shock is associated with high-density lipoproteins and C3 anaphylatoxin: some implications for its functional role.
Shock, Septic
Phospholipase A2-induced hypotension in the rat and its pharmacological modulation.
Shock, Septic
Platelet activating factor and endotoxin increase the enzyme activity and gene expression of type II phospholipase A2 in the rat intestine. Role of polymorphonuclear leukocytes.
Shock, Septic
Platelet-activating factor and phospholipase A2 in patients with septic shock and trauma.
Shock, Septic
Potential therapeutic efficacy of inhibitors of human phospholipase A2 in septic shock.
Shock, Septic
Rat liver mitochondrial phospholipase A2 is an endotoxin-stimulated membrane-associated enzyme of Kupffer cells which is released during liver perfusion.
Shock, Septic
SB 203347, an inhibitor of 14 kDa phospholipase A2, alters human neutrophil arachidonic acid release and metabolism and prolongs survival in murine endotoxin shock.
Shock, Septic
Serum phospholipase A2 enzyme activity and immunoreactivity in a prospective analysis of patients with septic shock.
Shock, Septic
Subcellular membrane impairment and application of phospholipase A2 inhibitors in endotoxic shock.
Shock, Septic
Toxic effects of human pancreatic and snake and bee venom phospholipases A2 on MCF-7 cells in culture.
Shock, Septic
[The effect of Staphylococcus aureus toxic shock exotoxin on whole blood cell chemiluminescence in vitro and in vivo]
Shock, Septic
[The effect of the protease inhibitor FUT-175 on phospholipase A2, complement, prostaglandins and prekallikrein during endotoxin shock]
Shwartzman Phenomenon
Differentiation of the anti-shock effect of ulinastatin from steroid hormone, by the continuous observation of microcirculation dynamics.
Skin Diseases
A randomized, double-blind, placebo-controlled, dose-escalation first-in-man study (phase 0) to assess the safety and efficacy of topical cytosolic phospholipase A2 inhibitor, AVX001, in patients with mild to moderate plaque psoriasis.
Skin Diseases
A unique phospholipase A2 in human epidermis: its physiologic function and its level in certain dermatoses.
Skin Diseases
Secretory and cytosolic phospholipase A(2)regulate the long-term cytokine-induced eicosanoid production in human keratinocytes.
Skin Neoplasms
Context-dependent effect of sPLA2-IIA induced proliferation on murine hair follicle stem cells and human epithelial cancer.
Small Cell Lung Carcinoma
Cytosolic phospholipaseA2 inhibition with PLA-695 radiosensitizes tumors in lung cancer animal models.
Small Cell Lung Carcinoma
Specific sensitivity of small cell lung cancer cell lines to the snake venom toxin taipoxin.
Solitary Pulmonary Nodule
Combination diagnosis of multi-slice spiral computed tomography and secretary phospholipase A2-IIa for solitary pulmonary nodules.
Solitary Pulmonary Nodule
Plasma secretory phospholipase A2-IIa as a potential biomarker for lung cancer in patients with solitary pulmonary nodules.
Spasm
Increase in plasma levels of secretory type II phospholipase A(2) in patients with coronary spastic angina.
Spastic Paraplegia, Hereditary
Defective FA2H leads to a novel form of neurodegeneration with brain iron accumulation (NBIA).
Spastic Paraplegia, Hereditary
Pla2g6 mutations associated with a continuous clinical spectrum from neuroaxonal dystrophy to hereditary spastic paraplegia.
Spastic Paraplegia, Hereditary
PLA2G6-associated neurodegeneration presenting as a complicated form of hereditary spastic paraplegia.
Sphincter of Oddi Dysfunction
Toward routine use of nonsteroidal anti-inflammatory drugs for patients undergoing endoscopic retrograde cholangiopancreatography.
Spinal Cord Injuries
A novel role of phospholipase A2 in mediating spinal cord secondary injury.
Spinal Cord Injuries
Annexin A1 reduces inflammatory reaction and tissue damage through inhibition of phospholipase A2 activation in adult rats following spinal cord injury.
Spinal Cord Injuries
Characterizing Phospholipase A2-Induced Spinal Cord Injury-A Comparison with Contusive Spinal Cord Injury in Adult Rats.
Spinal Cord Injuries
Computational Exploration of Natural Compounds to Target Cytosolic Phospholipase A 2 Protein: A Novel Therapeutic Target for Spinal Cord Injury.
Spinal Cord Injuries
cPLA2 activation contributes to lysosomal defects leading to impairment of autophagy after spinal cord injury.
Spinal Cord Injuries
Cytosolic phospholipase A2 protein as a novel therapeutic target for spinal cord injury.
Spinal Cord Injuries
Differential expression of sPLA(2) following spinal cord injury and a functional role for sPLA(2)-IIA in mediating oligodendrocyte death.
Spinal Cord Injuries
Immunocytochemical localization of cPLA2 in rat and monkey spinal cord.
Spinal Cord Injuries
Inhibition of cPLA2 has neuroprotective effects on motoneuron and muscle atrophy following spinal cord injury.
Spinal Cord Injuries
Lentivirus-mediated Inhibition of Tumour Necrosis Factor-? improves motor function associated with PRDX6 in spinal cord contusion rats.
Spinal Cord Injuries
Neuroprotection and its molecular mechanism following spinal cord injury.
Spinal Cord Injuries
Oral administration of cytosolic PLA2 inhibitor arachidonyl trifluoromethyl ketone ameliorates cauda equina compression injury in rats.
Spinal Cord Injuries
Phospholipase A2 superfamily members play divergent roles after spinal cord injury.
Spinal Cord Injuries
RhoA/Rho Kinase Mediates Neuronal Death Through Regulating cPLA2 Activation.
Spinal Cord Injuries
Role of phospholipase A2s and lipid mediators in secondary damage after spinal cord injury.
Spinal Cord Injuries
Role of secretory phospholipase a(2) in CNS inflammation: implications in traumatic spinal cord injury.
Spinal Cord Injuries
The effects of myelin on macrophage activation are phenotypic specific via cPLA2 in the context of spinal cord injury inflammation.
Spinocerebellar Ataxias
Ataxin-1 regulates the cerebellar bioenergetics proteome through the GSK3?-mTOR pathway which is altered in Spinocerebellar ataxia type 1 (SCA1).
Spinocerebellar Degenerations
Monogenic Parkinson's disease and parkinsonism: Clinical phenotypes and frequencies of known mutations.
Spondylolisthesis
Human group II phospholipase A2 in normal and diseased intervertebral discs.
Spotted Fever Group Rickettsiosis
Rickettsial phospholipase A2 as a pathogenic mechanism in a model of cell injury by typhus and spotted fever group rickettsiae.
Squamous Cell Carcinoma of Head and Neck
A novel read-through transcript JMJD7-PLA2G4B regulates head and neck squamous cell carcinoma cell proliferation and survival.
Squamous Cell Carcinoma of Head and Neck
Context-dependent effect of sPLA2-IIA induced proliferation on murine hair follicle stem cells and human epithelial cancer.
Squamous Cell Carcinoma of Head and Neck
Expression of cyclooxygenase-2, peroxiredoxin I, peroxiredoxin 6 and nuclear factor-?B in oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Immunological network analysis in HPV associated head and neck squamous cancer and implications for disease prognosis.
Squamous Cell Carcinoma of Head and Neck
Prognostic value of lipid metabolism-related genes in head and neck squamous cell carcinoma.
Starvation
Gene expression of type I phospholipase A2 in pancreatic beta cells. Regulation of mRNA levels by starvation or glucose excess.
Starvation
Interaction of vitamin D analogs with signaling pathways leading to active cell death in breast cancer cells.
Starvation
Starvation decreases insulin secretion, prostaglandin E2 production and phospholipase A2 activity in rat pancreatic islets.
Starvation
[Oxidative phosphorylation and the activity of the polyenzyme systems of rat liver mitochondrial membranes in starvation]
Status Epilepticus
Cytosolic phospholipase A2 is a key regulator of blood-brain barrier function in epilepsy.
Status Epilepticus
Matrix Metalloproteinase-Mediated Blood-Brain Barrier Dysfunction in Epilepsy.
Status Epilepticus
The accumulation of free arachidonic acid, diacylglycerols, prostaglandins, and lipoxygenase reaction products in the brain during experimental epilepsy.
Stomach Diseases
Cytosolic phospholipase A2 activation in Helicobacter pylori lipopolysaccharide-induced interference with gastric mucin synthesis.
Stomach Neoplasms
Expression of group IIA phospholipase A2 is an independent predictor of favorable outcome for patients with gastric cancer.
Stomach Neoplasms
Flavonoids Identified from Korean Scutellaria baicalensis Induce Apoptosis by ROS Generation and Caspase Activation on Human Fibrosarcoma Cells.
Stomach Neoplasms
Group II phospholipase A2 in invasive gastric cancer cell line is induced by interleukin 6.
Stomach Neoplasms
Phospholipase A2 group IIA expression correlates with prolonged survival in gastric cancer.
Stomach Neoplasms
Reduced group IVA phospholipase A2 expression is associated with unfavorable outcome for patients with gastric cancer.
Stomach Neoplasms
Supplementation with omega fatty acids increases the mRNA expression level of PLA2G4A in patients with gastric cancer.
Stomach Neoplasms
The effect of ?-fatty acids on the expression of phospholipase A2 group 2A in human gastric cancer patients.
Stomach Neoplasms
[Expression of peroxiredoxin 6 in gastric cancer and its clinical significance].
Stomach Ulcer
Antioxidant and gastric cytoprotective prostaglandins properties of Cassia sieberiana roots bark extract as an anti-ulcerogenic agent.
Stomach Ulcer
Relative contribution of bile and pancreatic juice duodenogastric reflux in gastric ulcer disease and cholelithiasis.
Stroke
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Stroke
Angiotensin II type 1 receptor blocker telmisartan reduces cerebral infarct volume and periinfarct cytosolic phospholipase A2 level in experimental stroke.
Stroke
CDP-choline significantly restores phosphatidylcholine levels by differentially affecting phospholipase A2 and CTP: phosphocholine cytidylyltransferase after stroke.
Stroke
Human group IIA secretory phospholipase A2 induces neuronal cell death via apoptosis.
Stroke
Identification of pleiotropic genes between risk factors of stroke by multivariate metaCCA analysis.
Stroke
Insights into the mechanism of inhibition of phospholipase A2 by resveratrol: An extensive molecular dynamics simulation and binding free energy calculation.
Stroke
Phospholipase A2 of Peroxiredoxin 6 Plays a Critical Role in Cerebral Ischemia/Reperfusion Inflammatory Injury.
Stroke
Prdx6 Upregulation by Curcumin Attenuates Ischemic Oxidative Damage via SP1 in Rats after Stroke.
Stroke
Protective effects of a selective L-type voltage-sensitive calcium channel blocker, S-312-d, on neuronal cell death.
Stroke
Reduction of lipoxidative load by secretory phospholipase A2 inhibition protects against neurovascular injury following experimental stroke in rat.
Stroke
S1PR2 antagonist alleviates oxidative stress-enhanced brain endothelial permeability by attenuating p38 and Erk1/2-dependent cPLA2 phosphorylation.
Stroke
Secretory phospholipase A2 IIA is up-regulated by TNF-alpha and IL-1alpha/beta after transient focal cerebral ischemia in rat.
Stroke
Secretory phospholipase A2 modified HDL rapidly and potently suppresses platelet activation.
Subacute Sclerosing Panencephalitis
On the activity of brain phospholipase A2 towards specifically labelled glycerophospholipids during subacute sclerosing panencephalitis.
Subacute Sclerosing Panencephalitis
Phospholipid metabolism in subacute sclerosing panencephalitis: activity of brain phospholipase A2 towards specifically labelled 1,2-diacyl-,1-alk-1'-enyl-2-acyl- and 1-alkyl-2-acyl-sn-glycero-3-phosphorycholine.
Subarachnoid Hemorrhage
Endothelins activate phospholipase A2 in brain capillary endothelial cells.
Sunburn
Effect of Artocarpus communis Extract on UVB Irradiation-Induced Oxidative Stress and Inflammation in Hairless Mice.
Synovitis
Cytosolic phospholipase A2 regulates TNF-induced production of joint destructive effectors in synoviocytes.
Synovitis
Effect of phospholipase A2 inhibitory peptide on inflammatory arthritis in a TNF transgenic mouse model: a time-course ultrastructural study.
Synovitis
The synovial-like membrane at the bone interface in loose total hip replacements contains high levels of extracellular group II phospholipase A2.
Tachycardia, Ventricular
Cardiac ischemia activates calcium-independent phospholipase A2beta, precipitating ventricular tachyarrhythmias in transgenic mice: rescue of the lethal electrophysiologic phenotype by mechanism-based inhibition.
Tangier Disease
Pseudomonas aeruginosa and sPLA2 IB stimulate ABCA1-mediated phospholipid efflux via ERK-activation of PPARalpha-RXR.
Tetanus
Characterization of enhancing factor (EF) prepared from spleen of mice immunized with tetanus toxoid.
Tetanus
Inhibition of vacuolar adenosine triphosphatase antagonizes the effects of clostridial neurotoxins but not phospholipase A2 neurotoxins.
Tetanus
Nordihydroguaiaretic acid blocks the synaptic component of long-term potentiation and the associated increases in release of glutamate and arachidonate: an in vivo study in the dentate gyrus of the rat.
Tetanus
Selective restimulation of antigen or allergen preactivated T cells using OKT3 F(ab)2 results in the secretion of TH-1 or TH-2-like cytokine patterns.
Tetanus
Some general rules governing fate and action of polypeptide and protein drugs, as derived from investigations with staphylococcal alpha-toxin, tetanus toxin, and so-calledd crotoxin.
Tetanus
Stepwise iodination. A general procedure for detoxification of proteins suitable for vaccine development and antiserum production.
Thrombocythemia, Essential
Drug-induced interstitial pneumonitis in essential thrombocythemia treated with anagrelide.
Thrombocythemia, Essential
Phospholipase A2 activity in platelets of patients with primary thrombocythemia.
Thrombocytopenia
Comparative proteomes, immunoreactivities and neutralization of procoagulant activities of Calloselasma rhodostoma (Malayan pit viper) venoms from four regions in Southeast Asia.
Thrombocytopenia
Hemolytic anemia, spherocytosis, and thrombocytopenia associated with honey bee envenomation in a dog.
Thromboembolism
[Preventive effect of liquemin depot in thromboembolism; experimental proof with myotoxin thrombokinase test.]
Thrombophilia
Anticoagulant and membrane-degrading effects of secretory (non-pancreatic) phospholipase A2 are inhibited in plasma.
Thrombophilia
Revealing the mechanisms and the material basis of Rubia cordifolia L. on abnormal uterine bleeding with uniting simultaneous determination of four components and systematic pharmacology approach-experimental validation.
Thrombosis
Crotoxin, a neurotoxin from Crotalus durissus terrificus snake venom, as a potential tool against thrombosis development.
Thrombosis
Derrone Inhibits Platelet Aggregation, Granule Secretion, Thromboxane A2 Generation, and Clot Retraction: An In Vitro Study.
Thrombosis
Fractionation of Bothrops jararacussu snake venom: partial chemical characterization and biological activity of bothropstoxin.
Thrombosis
Group V secretory phospholipase A2 impairs endothelial protein C receptor-dependent protein C activation and accelerates thrombosis in vivo.
Thrombosis
Group VIB calcium-independent phospholipase A2 (iPLA2?) regulates platelet activation, hemostasis and thrombosis in mice.
Thrombosis
Inhibition by Ethanol of Shear Stress-Induced Formation of Platelet Thrombi in Whole Blood.
Thrombosis
Phospholipase A2 expression in coronary thrombus is increased in patients with recurrent cardiac events after acute myocardial infarction.
Thrombosis
[The secretory phospholipase A2 and transport of lipids by lipoproteins in patients with the risk of cardio-vascular pathology (the system "score") of lower and average degree. The diagnostic significance of the test].
Thyroid Cancer, Papillary
PRDX1 and PRDX6 are repressed in papillary thyroid carcinomas via BRAF V600E-dependent and -independent mechanisms.
Thyroid Diseases
A possible link between genetic hemochromatosis and autoimmune thyroiditis.
Thyroid Diseases
Phospholipase A2 Receptor Autoantibodies as a Novel Serological Biomarker for Autoimmune Thyroid Disease Associated Nephropathy.
Thyroid Diseases
PRDX1 and PRDX6 are repressed in papillary thyroid carcinomas via BRAF V600E-dependent and -independent mechanisms.
Thyroiditis
Phospholipase A2 Receptor Autoantibodies as a Novel Serological Biomarker for Autoimmune Thyroid Disease Associated Nephropathy.
Thyroiditis
PRDX1 and PRDX6 are repressed in papillary thyroid carcinomas via BRAF V600E-dependent and -independent mechanisms.
Toxemia
In vivo protective role of human group IIa phospholipase A2 against experimental anthrax.
Toxoplasmosis
Evaluation of two inhibitors of invasion: LY311727 [3-(3-acetamide-1-benzyl-2-ethyl-indolyl-5-oxy)propane phosphonic acid] and AEBSF [4-(2-aminoethyl)-benzenesulphonyl fluoride] in acute murine toxoplasmosis.
Tremor
Identification of a novel mutation in PLA2G6 gene in a Chinese pedigree with familial cortical myoclonic tremor with epilepsy.
Tremor
Role of calcium-independent phospholipase A2 in cortex striatum thalamus cortex circuitry-enzyme inhibition causes vacuous chewing movements in rats.
triacylglycerol lipase deficiency
Alpha-lecithin:cholesterol acyltransferase deficiency. Lack of both phospholipase A2 and acyltransferase activities characteristic of high density lipoprotein lecithin:cholesterol acyltransferase in fish eye disease.
Triple Negative Breast Neoplasms
Antitumor and antimetastatic effects of PLA2-BthTX-II from Bothrops jararacussu venom on human breast cancer cells.
Triple Negative Breast Neoplasms
Cigarette smoke induces cell motility via platelet-activating factor accumulation in breast cancer cells: a potential mechanism for metastatic disease.
Triple Negative Breast Neoplasms
Liposomes Targeting P21 Activated Kinase-1 (PAK-1) and Selective for Secretory Phospholipase A2 (sPLA2) Decrease Cell Viability and Induce Apoptosis in Metastatic Triple-Negative Breast Cancer Cells.
Triple Negative Breast Neoplasms
Synthesis and Evaluation of Cytosolic Phospholipase A(2) Activatable Fluorophores for Cancer Imaging.
Trypanosomiasis
The effects of bee (Apis mellifera) venom phospholipase A2 on Trypanosoma brucei brucei and enterobacteria.
Tuberculosis
Activation of apoptosis, but not necrosis, during Mycobacterium tuberculosis infection correlated with decreased bacterial growth: role of TNF-alpha, IL-10, caspases and phospholipase A2.
Tuberculosis
Comparative roles of free fatty acids with reactive nitrogen intermediates and reactive oxygen intermediates in expression of the anti-microbial activity of macrophages against Mycobacterium tuberculosis.
Tuberculosis
Cytosolic Phospholipase A2 Enzymes Are Not Required by Mouse Bone Marrow-Derived Macrophages for the Control of Mycobacterium tuberculosis In Vitro.
Tuberculosis
Cytosolic phospholipase A2 participates with TNF-alpha in the induction of apoptosis of human macrophages infected with Mycobacterium tuberculosis H37Ra.
Tuberculosis
Detection and characterization of extracellular phospholipase A2 in pleural effusion of patients with tuberculosis.
Tuberculosis
Lysosomal phospholipase A2: a novel player in host immunity to Mycobacterium tuberculosis.
Tuberculosis
Redox chemistry of Mycobacterium tuberculosis alkylhydroperoxide reductase E (AhpE): Structural and mechanistic insight into a mycoredoxin-1 independent reductive pathway of AhpE via mycothiol.
Tuberculosis
RNase 7 but not psoriasin nor sPLA2-IIA associates with Mycobacterium tuberculosis during airway epithelial cell infection.
Tuberculosis
Rv0807, a putative phospholipase A2 of Mycobacterium tuberculosis; Elucidation through sequence analysis, homology modeling, molecular docking and molecular dynamics studies of potential substrates and inhibitors.
Tuberculosis
Secretory phospholipase A(2) plays an essential role in microglial inflammatory responses to Mycobacterium tuberculosis.
Tuberculosis
[Profiles of the expression of phospholipase A2 family mRNAs by macrophages infected with Mycobacterium tuberculosis]
Tuberculosis
[Role of phospholipase A2 in regulating lipid peroxidation and the respiratory chain in experimental tuberculosis]
Tuberous Sclerosis
Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis.
Typhus, Epidemic Louse-Borne
Rickettsial phospholipase A2 as a pathogenic mechanism in a model of cell injury by typhus and spotted fever group rickettsiae.
unspecific monooxygenase deficiency
Disorders of phospholipids, sphingolipids and fatty acids biosynthesis: toward a new category of inherited metabolic diseases.
Urinary Bladder Neoplasms
Suppressive Effect of Matrine on Tumor Invasion in N-Butyl-N-(4-Hydroxybutyl)Nitrosamine-Induced Urinary Bladder Carcinogenesis.
Urinary Bladder Neoplasms
Targeted inhibition of p38alpha MAPK suppresses tumor-associated endothelial cell migration in response to hypericin-based photodynamic therapy.
Urticaria
Association study of genetic variants in PLA2G4A, PLCG1, LAT, SYK, and TNFRS11A genes in NSAIDs-induced urticaria and/or angioedema patients.
Uterine Cervical Neoplasms
Inhibition of cytosolic phospholipase A2 alpha increases chemosensitivity in cervical carcinoma through suppressing ?-catenin signaling.
Uterine Cervical Neoplasms
Overexpression and biological function of PRDX6 in human cervical cancer.
Uterine Diseases
Defining Postpartum Uterine Disease and the Mechanisms of Infection and Immunity in the Female Reproductive Tract in Cattle.
Uterine Inertia
[The influence of nitric oxide generation on the production of interleukins and processes of prostaglandin synthesis in fetal membranes in spontaneous parturition and uterine inertia]
Uveitis
Fluctuation of lysosomal phospholipase A2 in experimental autoimmune uveitis in rats.
Uveitis
Phospholipase A2, leukotriene C4 and prostaglandin E2 levels in aqueous humour of guinea pigs with experimental S-antigen induced autoimmune uveitis.
Uveitis
Suppression of experimental autoimmune uveitis in guinea-pigs by inhibition of phospholipase A2.
Vaginosis, Bacterial
Association of cervicovaginal infections with increased vaginal fluid phospholipase A2 activity.
Vaginosis, Bacterial
The determination of phospholipase A2 enzyme activity in the vaginal secretions of pregnant and non-pregnant women with bacterial vaginosis-and in culture exudates of its causative organisms.
Varicocele
Cytosolic phospholipase A2 and F2 isoprostanes are involved in semen quality and human infertility-A study on leucocytospermia, varicocele and idiopathic infertility.
Varicocele
Fatty Acid Profile and Metabolism Are Related to Human Sperm Parameters and Are Relevant in Idiopathic Infertility and Varicocele.
Vascular Calcification
Systems biology identifies cytosolic PLA2 as a target in vascular calcification treatment.
Vascular Diseases
Functional coupling expression of COX-2 and cPLA2 induced by ATP in rat vascular smooth muscle cells: role of ERK1/2, p38 MAPK, and NF-kappaB.
Vascular Diseases
Lysophosphatidylcholine and secretory phospholipase A2 in vascular disease: mediators of endothelial dysfunction and atherosclerosis.
Vascular Diseases
Phospholipase A2 inhibition and atherosclerotic vascular disease: prospects for targeting secretory and lipoprotein-associated phospholipase A2 enzymes.
Vascular Diseases
Plasma levels of the lyso-derivative of platelet-activating factor are related to age.
Vascular Diseases
Role of PI3K/AKT, cPLA2 and ERK1/2 signaling pathways in insulin regulation of vascular smooth muscle cells proliferation.
Vascular Diseases
Variation of lipoprotein associated phospholipase A2 across demographic characteristics and cardiovascular risk factors: A systematic review of the literature.
Vascular System Injuries
Potential role for mast cell tryptase in recruitment of inflammatory cells to endothelium.
Vasospasm, Intracranial
Endothelins activate phospholipase A2 in brain capillary endothelial cells.
Ventilator-Induced Lung Injury
A Peptide Inhibitor of Peroxiredoxin 6 Phospholipase A2 Activity Significantly Protects against Lung Injury in a Mouse Model of Ventilator Induced Lung Injury (VILI).
Ventilator-Induced Lung Injury
Clara cell secretory protein and phospholipase A2 activity modulate acute ventilator-induced lung injury in mice.
Ventilator-Induced Lung Injury
Cytosolic phospholipase A2 and arachidonic acid metabolites modulate ventilator-induced permeability increases in isolated mouse lungs.
Virus Diseases
Distribution of type V secretory phospholipase A2 expression in human hepatocytes damaged by liver disease.
Virus Diseases
Genetic and pharmacologic evidence that calcium-independent phospholipase A2beta regulates virus-induced inducible nitric-oxide synthase expression by macrophages.
Virus Diseases
Inflammatory mediators in dengue virus infection in children: interleukin-6 and its relation to C-reactive protein and secretory phospholipase A2.
Virus Diseases
Methyltransferase and phospholipase A2 activity in membranes of neutrophils and lymphocytes from patients with bacterial and viral infections.
Virus Diseases
Phospholipase A2 isolated from the venom of Crotalus durissus terrificus inactivates dengue virus and other enveloped viruses by disrupting the viral envelope.
Virus Diseases
Porcine Picornavirus 3C Protease Degrades PRDX6 to Impair PRDX6-mediated Antiviral Function.
Virus Diseases
Rapid phospholipase A2 stimulation and diacylglycerol cholinephosphotransferase inhibition in baby hamster kidney cells during initiation of dengue virus infection.
Virus Diseases
Secretory phospholipase A(2): a marker of infection in febrile children presenting to a pediatric ED.
Virus Diseases
Secretory phospholipase A2 pathway during pediatric acute respiratory distress syndrome: A preliminary study.
Vitamin E Deficiency
Vitamin E differentially regulates the expression of peroxiredoxin-1 and -6 in alveolar type II cells.
Vitamin E Deficiency
[Non-antioxidative mechanism of cytochrome P-450 stabilization by alpha-tocopherol: the effectiveness in avitaminosis E]
Wasting Syndrome
The significance of the nongenomic pathway in mediating inflammatory signaling of the dioxin-activated Ah receptor to cause toxic effects.
West Nile Fever
High-mobility group box-1, promising serological biomarker for the distinction of human WNV disease severity.
Whooping Cough
A single species of A1 adenosine receptor expressed in Chinese hamster ovary cells not only inhibits cAMP accumulation but also stimulates phospholipase C and arachidonate release.
Whooping Cough
Activation of a keratinocyte phospholipase A2 by bradykinin and 4 beta-phorbol 12-myristate 13-acetate. Evidence for a receptor-GTP-binding protein versus a protein-kinase-C mediated mechanism.
Whooping Cough
Activation of phospholipases A2 and D of a human neuroblastoma cell line (LA-N-2) by N-dodecyl-L-lysine amide (compound 24), a putative G protein activator: characteristics of inhibition by (-)-nicotine.
Whooping Cough
Agonist-mediated activation of PLA2 initiates Ca2+ mobilization in intestinal longitudinal smooth muscle.
Whooping Cough
Agonist-specific alterations in receptor-phospholipase coupling following inactivation of Gi2alpha gene.
Whooping Cough
Alpha 2-adrenergic receptor stimulation of phospholipase A2 and of adenylate cyclase in transfected Chinese hamster ovary cells is mediated by different mechanisms.
Whooping Cough
Alpha adrenergic receptor subtypes involved in prostaglandin synthesis are coupled to Ca++ channels through a pertussis toxin-sensitive guanine nucleotide-binding protein.
Whooping Cough
Angiogenin stimulates endothelial cell prostacyclin secretion by activation of phospholipase A2.
Whooping Cough
Angiotensin II directly increases rabbit renal brush-border membrane sodium transport: presence of local signal transduction system.
Whooping Cough
Arachidonic acid mediates interferon-gamma-induced sphingomyelin hydrolysis and monocytic marker expression in HL-60 cell line.
Whooping Cough
ATP produces potassium currents via P3 purinoceptor in the follicle cell layer of Xenopus oocytes.
Whooping Cough
Basic fibroblast growth factor stimulates cytosolic phospholipase A2, phospholipase C-gamma1 and phospholipase D through distinguishable signaling mechanisms.
Whooping Cough
Basic fibroblast growth factor-stimulated endothelial cell movement is mediated by a pertussis toxin-sensitive pathway regulating phospholipase A2 activity.
Whooping Cough
beta2-Adrenergic signaling in human heart: shift from the cyclic AMP to the arachidonic acid pathway.
Whooping Cough
Bradykinin activates protein kinase C in cultured cortical collecting tubular cells.
Whooping Cough
Cholera toxin and pertussis toxin stimulate prostaglandin E2 synthesis in a murine macrophage cell line.
Whooping Cough
Coupling of expressed alpha 1B- and alpha 1D-adrenergic receptor to multiple signaling pathways is both G protein and cell type specific.
Whooping Cough
Direct dopamine D2-receptor-mediated modulation of arachidonic acid release in transfected CHO cells without the concomitant administration of a Ca2+-mobilizing agent.
Whooping Cough
Effects of ATP on phosphoinositide hydrolysis and prostaglandin E2 generation in rabbit astrocytes.
Whooping Cough
Endothelial cell thrombin receptors and PAR-2. Two protease-activated receptors located in a single cellular environment.
Whooping Cough
Enhancement of HIV-1 replication in human macrophages is induced by CD8+ T cell soluble factors.
Whooping Cough
Enhancement of stress-induced synthesis of stress proteins by mastoparan in C6 rat glioma cells.
Whooping Cough
Evidence for a beta2-adrenergic/arachidonic acid pathway in ventricular cardiomyocytes. Regulation by the beta1-adrenergic/camp pathway.
Whooping Cough
Evidence for coupling of bradykinin receptors to a guanine-nucleotide binding protein to stimulate arachidonate liberation in the osteoblast-like cell line, MC3T3-E1.
Whooping Cough
Evidence that the ATP-induced increase in vasomotion of guinea-pig mesenteric lymphatics involves an endothelium-dependent release of thromboxane A2.
Whooping Cough
Further evidence that the CCK2 receptor is coupled to two transduction pathways using site-directed mutagenesis.
Whooping Cough
Glucose transport stimulation by bradykinin in Swiss 3T3 fibroblasts: a pertussis toxin-sensitive mechanism operates without involvement of arachidonic acid and cyclic AMP.
Whooping Cough
GTP-binding protein mediated phospholipase A2 activation in rat liver during the progression of sepsis.
Whooping Cough
GVI phospholipase A2 role in the stimulatory effect of sphingosine-1-phosphate on TRPC5 cationic channels.
Whooping Cough
Heterotrimeric G proteins containing G alpha i3 regulate multiple effector enzymes in the same cell. Activation of phospholipases C and A2 and inhibition of adenylyl cyclase.
Whooping Cough
High-density lipoprotein stimulates endothelial cell movement by a mechanism distinct from basic fibroblast growth factor.
Whooping Cough
Histamine activates a background, arachidonic acid-sensitive K channel in embryonic chick dorsal root ganglion neurons.
Whooping Cough
Histamine-stimulated and GTP-binding proteins-mediated phospholipase A2 activation in rabbit platelets.
Whooping Cough
Increase in cytosolic free Ca2+ in corticotropin-stimulated white adipocytes.
Whooping Cough
Indirect inhibition by bradykinin of cyclic AMP generation in isolated rat glomeruli and mesangial cells.
Whooping Cough
Induction of microvascular leakage and histamine release by promutoxin, an Arg49 phospholipase A2.
Whooping Cough
Intestinal secretory factor released by macrophages stimulated with Clostridium difficile toxin A: role of interleukin 1beta.
Whooping Cough
Intracellular calcium mobilization and phospholipid degradation in sphingosylphosphorylcholine-stimulated human airway epithelial cells.
Whooping Cough
Involvement of a pertussis toxin-sensitive G protein-coupled phospholipase A2 in agonist-stimulated arachidonic acid release in membranes isolated from bovine iris sphincter smooth muscle.
Whooping Cough
Involvement of a pertussis toxin-sensitive G-protein-coupled phospholipase A2 in lipopolysaccharide-stimulated prostaglandin E2 synthesis in cultured rat mesangial cells.
Whooping Cough
Lipocortin 1 and the control of cPLA2 activity in A549 cells. Glucocorticoids block EGF stimulation of cPLA2 phosphorylation.
Whooping Cough
LPA is a novel lipid regulator of mesangial cell hexokinase activity and HKII isoform expression.
Whooping Cough
LysoPC and PAF Trigger Arachidonic Acid Release by Divergent Signaling Mechanisms in Monocytes.
Whooping Cough
Mastoparan elicits prostaglandin E2 generation and inhibits inositol phosphate accumulation via different mechanisms in rabbit astrocytes.
Whooping Cough
Mechanism of arachidonic acid liberation in platelet-activating factor-stimulated human polymorphonuclear neutrophils.
Whooping Cough
Mechanism of induction of prostaglandin E2 production by endothelin 1 in cultured rat mesangial cells.
Whooping Cough
Mechanism of N-formyl-methionyl-leucyl-phenylalanine- and platelet-activating factor-induced arachidonic acid release in guinea pig alveolar macrophages: involvement of a GTP-binding protein and role of protein kinase A and protein kinase C.
Whooping Cough
Multiple signal transduction pathways lead to extracellular ATP-stimulated mitogenesis in mammalian cells: II. A pathway involving arachidonic acid release, prostaglandin synthesis, and cyclic AMP accumulation.
Whooping Cough
Muscarinic regulation of phospholipase A2 and iodide fluxes in FRTL-5 thyroid cells.
Whooping Cough
Niacin induces PPARgamma expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways.
Whooping Cough
NMDA receptor-mediated arachidonic acid release in neurons: role in signal transduction and pathological aspects.
Whooping Cough
No direct correlation between Ca2+ mobilization and dissociation of Gi during platelet phospholipase A2 activation.
Whooping Cough
Permissive stimulation of Ca(2+)-induced phospholipase A2 by an adenosine receptor agonist in a pertussis toxin-sensitive manner in FRTL-5 thyroid cells: a new 'cross-talk' mechanism in Ca2+ signalling.
Whooping Cough
Pertussis toxin-sensitive activation of phospholipase A2 can be resolved from phosphoinositidase C in primary cultures of mouse osteoblasts using indomethacin.
Whooping Cough
Pertussis toxin-sensitive GTP-binding proteins may regulate phospholipase A2 in response to thrombin in rabbit platelets.
Whooping Cough
Pertussis toxin-sensitive secretory phospholipase A2 expression and motility in activated primary human keratinocytes.
Whooping Cough
Pharmacological comparison of UTP- and thapsigargin-induced arachidonic acid release in mouse RAW 264.7 macrophages.
Whooping Cough
Phospholipase A2 and phospholipase C are activated by distinct GTP-binding proteins in response to alpha 1-adrenergic stimulation in FRTL5 thyroid cells.
Whooping Cough
Platelet-activating factor stimulates multiple signaling pathways in cultured rat mesangial cells.
Whooping Cough
Potential role for local luminal angiotensin II in proximal tubule sodium transport.
Whooping Cough
Prostaglandin E2-induced arachidonic acid release and catecholamine secretion from cultured bovine adrenal chromaffin cells.
Whooping Cough
Proteolytic activation of protein kinase Calpha by peroxynitrite in stimulating cytosolic phospholipase A2 in pulmonary endothelium: involvement of a pertussis toxin sensitive protein.
Whooping Cough
Purinergic P2Y receptors on astrocytes are directly coupled to phospholipase A2.
Whooping Cough
Rapid membrane responses to dihydrotestosterone are sex dependent in growth plate chondrocytes.
Whooping Cough
Release of calcium from inositol 1,4,5-trisphosphate receptor-regulated stores by HIV-1 Tat regulates TNF-alpha production in human macrophages.
Whooping Cough
Role of an aprotinin-sensitive protease in protein kinase Calpha-mediated activation of cytosolic phospholipase A2 by calcium ionophore (A23187) in pulmonary endothelium.
Whooping Cough
Role of endothelin-1 in regulating proliferation of cultured rabbit airway smooth muscle cells.
Whooping Cough
Secretory phospholipase A2 activates the cascade of mitogen-activated protein kinases and cytosolic phospholipase A2 in the human astrocytoma cell line 1321N1.
Whooping Cough
Secretory phospholipase A2 induces phospholipase Cgamma-1 activation and Ca2+ mobilization in the human astrocytoma cell line 1321N1 by a mechanism independent of its catalytic activity.
Whooping Cough
Signal transduction by tumor necrosis factor alpha is mediated through a guanine nucleotide-binding protein in osteoblast-like cell line, MC3T3-E1.
Whooping Cough
Signalling pathways regulating human neutrophil migration induced by secretory phospholipases A2.
Whooping Cough
Stimulation of phospholipase A2 activity in bovine rod outer segments by the beta gamma subunits of transducin and its inhibition by the alpha subunit.
Whooping Cough
Stimulation of reactive oxidant production in neutrophils by soluble and insoluble immune complexes occurs via different receptors/signal transduction systems.
Whooping Cough
Studies on opsonized zymozan, FMLP, carbachol, PMA and A23187 stimulated respiratory burst of human PMNLs.
Whooping Cough
The coupling of pertussis toxin-sensitive G proteins to phospholipase A2 and adenylyl cyclase in CHO cells expressing bovine rhodopsin.
Whooping Cough
The guanine-nucleotide-binding protein subunit G alpha i2 is involved in calcium activation of phospholipase A2. Effects of the dominant negative G alpha i2 mutant, [G203T]G alpha i2, on activation of phospholipase A2 in Chinese hamster ovary cells.
Whooping Cough
Tumour necrosis factor (cachectin) induces phospholipase A2 activity and synthesis of a phospholipase A2-activating protein in endothelial cells.
Wound Infection
Relationship between plasma levels of type II phospholipase A2, PAF acetylhydrolase, endothelin-1, and thrombomodulin in patients with infected burns.
Yellow Fever
Crotoxin and phospholipases A(2) from Crotalus durissus terrificus showed antiviral activity against dengue and yellow fever viruses.
Yellow Fever
Phospholipase A2 isolated from the venom of Crotalus durissus terrificus inactivates dengue virus and other enveloped viruses by disrupting the viral envelope.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
pH RANGE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
5.5 - 7
at 50°C, pH 5.5: about 75% of maximal activity, pH 7.0: about 65% of maximal activity, recombinant enzyme
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
TEMPERATURE RANGE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
35 - 65
35°C: about 70% of maximal activity, 65°C: about 70% of maximal activity, enzyme expressed in Pichia pastoris
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
pI VALUE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
5.9
enzyme expressed in Pichia pastoris, isoelectric focusing
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ORGANISM
COMMENTARY
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY
GeneOntology No.
LITERATURE
SOURCE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
UNIPROT
ENTRY NAME
ORGANISM
NO. OF AA
NO. OF TRANSM. HELICES
MOLECULAR WEIGHT[Da]
SOURCE
SEQUENCE
LOCALIZATION PREDICTION
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable).
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PDB
SCOP
CATH
UNIPROT
ORGANISM
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBUNIT
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
additional information
additional information
three-dimensional structure and homology modeling, overview
additional information
-
three-dimensional structure and homology modeling, overview
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
POSTTRANSLATIONAL MODIFICATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
glycoprotein
the enzyme expressed in Pichia pastoris is post-translational modified, while the enzyme secreted by prokaryotes does not occur glycosylation
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
pH STABILITY
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
4.5 - 6.2
at 20°C, 5 h, the recombinant enzyme is stable at a pH range of 4.5-6.2
749606
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
TEMPERATURE STABILITY
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
35
1 h, pH 6, about 35% loss of activity, recombinant enzyme
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PURIFICATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CLONED (Commentary)
ORGANISM
UNIPROT
LITERATURE
expression in Pichia pastoris GS115 under the control of AOX1 promoter
secreted phospholipase A2, DNA and amino acid sequence determination and analysis
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
EXPRESSION
ORGANISM
UNIPROT
LITERATURE
high concentration of Ca2+ is necessary for the expression of the enzyme activity
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
APPLICATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
industry
application in oil degumming. In the enzymatic degumming process, the phosphorus content is reduced to 20.74 mg/kg within 6 h, which is promising for the industrial application
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REF.
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
Jovel, S.R.; Kumagai, T.; Danshiitsoodol, N.; Matoba, Y.; Nishimura, M.; Sugiyama, M.
Purification and characterization of the second Streptomyces phospholipase A2 refolded from an inclusion body
Protein Expr. Purif.
50
82-88
2006
Streptomyces coelicolor, Streptomyces violaceoruber (Q6UV28), Streptomyces violaceoruber, Streptomyces coelicolor A3(2), Streptomyces violaceoruber A-2688 (Q6UV28), Streptomyces violaceoruber A-2688
brenda
Liu, A.; Yu, X.W.; Sha, C.; Xu, Y.
Streptomyces violaceoruber phospholipase A2 expression in Pichia pastoris, properties, and application in oil degumming
Appl. Biochem. Biotechnol.
175
3195-3206
2015
Streptomyces violaceoruber (Q6UV28), Streptomyces violaceoruber
brenda
EXTERNAL LINKS (specific for EC-Number 3.1.1.4)
Transporter Classification Database (TCDB): 1.N.2.1.6, 1.B.84.1.6, 1.B.84.1.5, 1.B.84.1.3, 1.B.84.1.1, 1.B.84.1.4, 1.B.84.1.2
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
About BRENDA
Social media
Help
Survey
Download
Contribution
Legal
Curated at
Member of
